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Abstract
This thesis describes the production of antibodies for the detection of cephalexin and their 
application in ELISA and Biacore ‘real-time’ surface plasmon resonance (SPR)-based 
biosensor assays. The use of antibiotics in food-producing animals has many beneficial 
effects (e.g. treatment of mastitis in dairy cattle). However, their use and misuse has also been 
implicated in the increased incidence of resistant microbial strains with the associated public 
health risks and economic losses for food processors. Antibiotic residues can adversely affect 
bacterial starter cultures used in the production of milk-based products such as cheese and 
yoghurts. The P-lactam antibiotic cephalexin was chosen as the target for the production of 
antibodies due to its generic cephem-based structure, solubility, and, in particular its use of 
this antibiotic in treatment of udder infections (e.g. mastitis).
Cephalexin-protein conjugates were produced and used for the generation of polyclonal and 
monoclonal antibodies that were then purified and characterised by SDS-PAGE, Western 
blotting and ELISA. The specificity of these antibodies was determined and they were used in 
displacement immunoassays for the detection of the relevant antibiotic in ‘spiked’ samples of 
PBS and whole milk.
Recombinant single chain Fv (scFv) antibody fragments were produced using phage-display 
technology. Naive and immune phage-display libraries were panned using cephalexin 
conjugates. In addition, a monoclonal antibody-secreting hybridoma cell line was used in the 
production of a phage-displayed recombinant scFv. The recombinant scFv (wild type) derived 
from the parental hybridoma cell was purified and characterised by SDS-PAGE, Western 
blotting and ELISA. Wild type scFv was subsequently used as a template for the production 
of a mutant scFv phage-displayed library using random mutagenesis and error-prone PCR. 
Mutant scFv antibodies were isolated, expressed and then purified using immobilised metal 
affinity chromatography (IMAC). Two mutant clones expressing scFv antibodies selected 
showed improved functional expression and assay performance when compared to wild type 
scFv. Comparative gene and amino-acid sequence analysis and protein modelling was carried 
out on wild type and selected mutant recombinant scFv antibodies and confirmed the presence 
of mutations in the framework and variable heavy chain complemetarity determining region 
amino acid sequences.
All antibodies were evaluated in ELISA and Biacore assay formats for the detection of 
cephalexin in milk samples. The polyclonal, monoclonal and recombinant scFv antibody- 
based assays demonstrated varying sensitivity and reproducibility but achieved cephalexin
detection below the legislated European Union maximum residue limit (EUMRL) in milk
(1 0 0  Mgflig).
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Chapter 1 
Introduction
1
1.1 Project Overview
The main aim of this work was the production of antibodies to cephalexin and their 
subsequent use in the development of assays for its specific detection in milk. This 
introductory chapter reviews aspects of the general project background, including detection of 
small molecule contaminants in foods, mastitis and antibiotic residues in milk, and the P- 
lactam antibiotics with a focus on cephalosporins. In addition, public health concerns with 
regard to the use of antimicrobials in food-producing animals, current detection methods, the 
immune system, antibody production and engineering techniques are also described. 
Introductions are presented at the beginning of each of the relevant chapters which describe 
the particular technologies relevant to that section.
1.2 Detection of contaminants in foods
Contaminants may be introduced into food by industrial or environmental pollution, during 
growth or at any stage in the processing leading to the final packaged product. For example 
reports in the media about Sudan Red, a known carcinogen detected in different foods and 
ingredients highlighted the overall amplified awareness of such contaminants in public, 
industrial and legislative domains. Food contamination arising from antibiotics used in 
veterinary medicine is an increasingly important public health issue. Antibiotic use in food- 
producing animals is associated with potential direct (i.e. allergic reactions) and indirect 
hazards (i.e. increased occurrence of antibiotic resistance pathogenic bacteria). Food ingestion 
is considered to be a major route of exposure to many of these contaminants. Small molecules 
such as antibiotics with molecular weight < 5000 Daltons are called haptens. They are 
molecules that are too small to elicit a direct immune response without being first conjugated 
to a larger carrier (e.g. protein). Many publications describe the production of antibodies that 
are capable of detecting very small quantities of hapten contaminants in an appropriate 
immunoassay format (Stanker et al., 1989; Daly et al., 2001; Dillon et al., 2003; Miura et al., 
2003; Baeumner, 2003; Oi et al., 2005).
The European Union has significant legislation with regard to small molecule food 
contaminants. The legislation covers a broad range including, for example, veterinary 
medicines (e.g. antibiotic residues in milk), food additives and environmental or industrial 
pollutants, for example, plant mycotoxins, which may include aflatoxins (potent carcinogens) 
in grain and nut products that are poorly stored (Anadón et al., 1999; Stolker et al., 2005). 
The use of most pharmacologically active substances in food-producing animals (i.e. 
veterinary medicines) is governed by the EU Council Regulation 2377/90/EC. This regulation
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describes the procedure for the establishment of maximum residue limits (MRL’s) for 
veterinaiy medicinal product residues in foodstuffs of animal origin. Veterinary medicine 
residue problems are addressed in reports from the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA), the Working Group on the Safety of Residues (WGSR) of the 
Committee for Veterinary Medicinal Products (CVMP) of the European Medicines 
Evaluation Agency (EMEA). The CVMP are responsible for the establishment of maximum 
residue limits (MRL’s). EU council regulation 2377/90/EC contains four Annexes that 
classify each potential contaminant relative to its potential exposure risk. Annex I includes 
substances for which final MRL’s (e.g. cephalexin, appendix 1) have been established. Annex
II includes those substances where the establishment of MRL values for the protection of 
public health it is not considered necessary. The use of this group of substances is permitted 
in certain food-producing animals under defined conditions. Annex III includes compounds 
for which provisional MRL’s have been set out, yet not all requirements for the establishment 
of the MRL have been met. Finally, Annex IV lists substances that have no MRL established, 
for the simple reason that their presence in foods at whatever limit constitutes a hazard to 
public health. Included in the legislation are other substances (i.e. originating from sources 
other than veterinary medicine) that are required to be monitored for public health reasons 
(i.e. aflatoxins) and other plant-associated toxins (Than et al, 2005).
Overall, there is a myriad of potential hapten contaminants that may be present in a vast 
number of different foodstuffs. For each contaminant with a listed MRL, a value was 
established for a particular foodstuff. For example, P-Lactam antibiotics, include many 
different compounds and have MRL’s in kidney tissue ranging from 25-300 pg/kg. However, 
in milk the MRL’s range from 4-100 pg/kg. This highlights the need for an extremely 
flexible, sensitive and rapid analytical methodology capable of multi-analyte detection with 
high-throughput. Such systems should be capable of detecting residues of the parent 
compound and its metabolites in diverse sample matrices (e.g. milk, tissue, plant material or 
honey).
The sample matrix is usually determined by the point in production at which testing is 
performed, i.e. from the final end food product (e.g. milk) to the actual food-producing animal 
(e.g. animal tissue, feed, water or urine). Analytical techniques must be capable of 
specifically detecting a multitude of different compounds (Table 1.1). Antibody-based 
analytical techniques meet such requirements, being highly specific, available in many 
different flexible assay formats and are very robust.
3
Current techniques employed for the detection of such contaminants almost always involves 
LC-MS-based techniques. This usually involves extensive sample pre-treatment and 
extraction processes. Due to the bulky nature of the equipment, relatively low throughput and 
the expertise required to carry out such analyses, they are not suitable for ‘in the field’ or 
‘user-friendly’ measurement by untrained persons. Such techniques are carried out as 
confirmatory tests, with certain rapid detection technologies available for particular 
compound types. However, within the EU there is no obligation to use standardised methods 
in the residue control of food-producing animals. Techniques are required to satisfy 
performance characteristics, limits and other criteria which encourage the development of 
new analytical approaches (e.g. antibody micro-arrays) (Christiansen, 2002).
Table 1.1. Examples of some potential contaminants, the respective MRL ranges for that 
foodstuff and the foods in which they may be found.
Contaminant
Specific 
MRL (jig/kg)
Foodstuff
Antibiotics
Aminoglycosides 50-750 Meat & milk
(e.g. gentamycin)
ß-Lactams (e.g. cephalexin) 4-100 Milk
Macrolides 40-2000 Meat, Milk & Eggs
Sulphonamides 10 0 Milk & Eggs
Tetracyclines 100-600 Meat
Quinolones 30-600 Fish
Chloramphenicol 0.3 Meat & Seafood
Toxins
Aflatoxins 1-8 Nuts & Grains
1.3 Mastitis and antibiotic residues in milk
Antimicrobial agents, generally referred to as antibiotics, are used in food-producing animals 
for three main reasons. Firstly, in the treatment of diseases, secondly as a prophylactic to 
prevent disease and finally as feed additives to promote beneficial effects such as increased 
body mass. In dairy cattle worldwide, one of the most prevalent and costly diseases is 
mastitis. This is an inflammation of the mammary gland caused by micro-organisms, usually
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bacteria, that invade the cows’ udder, proliferate, and produce toxins that are harmful to 
surrounding tissues. Mastitis may be sub-clinical, i.e. no visible signs of disease, or clinical 
displaying mild or severe signs of infection which include clots present in the milk, swelling 
of infected udder quarters, fever and the potential death of infected animal. Mastitis may be 
caused by a multitude of micro-organisms classified as environmental or contagious. The 
latter resulting from infection by various Streptococci (e.g. S. agalactiae) and Staphylococci 
(e.g. S. aureus) species, environmental causative micro-organisms include various coliforms 
(e.g. E. coli) and environmental Streptococci (e.g. S. dysgalactiae).
1.3.1 Diagnosis o f mastitis
Cows already infected with contagious bacteria are the main source of infection within herds 
and hence early detection and treatment is of the utmost importance. Clinical mastitis is easy 
to detect for veterinarians and trained dairy personnel, but detection of sub-clinical cases of 
mastitis can be a challenge. Diagnostic methods are focused on detection of inflammatory 
products, somatic cell count (SCC), and bacterial growth. The International Dairy Federation 
(International Dairy Federation, 1971), have decided that milk SCC and bacteriological 
examination are the main parameters that define whether or not an animal should be regarded 
as infected. Hamann (2002) suggested that a SCC of 100,000 cells/ml in raw milk represents a 
‘normal’ physiological limit in an udder quarter. A SCC of approximately >200,000 cells/ml 
may be taken as an indicative (i.e. 250,000 to 1,000,000 cells/ml) of udder quarter infection. 
The specific identification of the causative agent is critical to the subsequent treatment of 
infected animal udder quarter, as this dictates if the use of particular anti-microbial treatment 
(e.g. antibiotics) is necessaiy.
1.3.2 Effects on Milk Production, Composition and Quality
Mastitis reduces yield and alters milk composition resulting in a very negative economic 
impact on producers. Mastitis-causing pathogens produce toxins that can directly damage 
milk-producing tissue of the mammary gland and the presence of bacteria initiates 
inflammation within the mammary tissue in an attempt to eliminate the invading micro­
organisms (see innate immune system, section 1.9.1). The inflammatory immune response 
contributes to the decreased production and altered compositional changes observed in milk 
from infected animals. In sub-clinical mastitis there are significant changes in the types of 
proteins present. The major milk protein is casein. Casein has a high nutritional value and 
contains most of the milk calcium within its structure. It is also very important in cheese 
manufacturing. The casein content of milk from mastitic cows is reduced, while the content of
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relatively lower quality (in terms of food production) whey proteins or blood serum proteins, 
such as serum albumin and immunoglobulins, increases in the milk. Increased concentration 
of certain enzymes in mastitic milk released as a result of mammary tissue damage can also 
negatively affect milk quality in terms of flavour. For example, an increase in the enzyme 
lipase results in an elevated level of free fatty acids that can produce ‘off-flavours’ in milk. 
This can result in significant economic loss to the producer, from direct milk production and 
the production of value-added milk products (e.g. cheese and yoghurt). The prevalence of 
mastitis in dairy cattle worldwide and the bacterial nature (in most cases) of the disease is 
used as a major justification for the legal application of anti-microbials in milk-producing 
animals.
1.3.3 Mastitis treatment
Mastitis may be best prevented using hygienic farming/milking procedures. Treatment of 
mastitis when it does occur invariably involves using antibiotics at various stages of the 
disease (i.e. sub-clinical or clinical mastitis). Antibiotics should ideally only be administered 
during ‘dry’ as opposed to lactation periods, where the potential for contamination of milk is 
removed. Sub-therapeutic treatment of lactating cows can result in milk containing antibiotic 
residues unless the animal is removed from milking schedules. Cows with mammary bacterial 
infections are usually treated with intra-mammary antibiotic infusions.
There are a host of potential antibiotics available for treatment. Infusions usually contain high 
levels of penicillins, cephalosporins and cloxacillins and some others found to be the most 
effective therapeutic agents. In general, the beta (P)-lactam antibiotics (i.e. penicillins, 
cephalosporins etc.) are the most widely used antibiotics in both human and animal medicine. 
There are a range of cephalexin monohydrate suspensions marketed for the treatment of 
mastitis in bovines, ovines and caprines, for example, Cefa-Milk ® (www.engormix.com). 
Antibiotic preparations are usually in the form of slow release bases, allowing them to remain 
in the udder for extended periods of time. Preparations are also available as combination 
therapies, for example, Cefa-milk ® Forte, a suspension of cephalexin monohydrate and 
gentomycin sulphate.
Efflux of the antibiotic is directly affected by milking frequency and may vary from cow-to- 
cow, so animals receiving treatment outside recommended dry periods should remain off 
milking for an extended period post-treatment. If this is not adhered to or the antibiotic 
persists within a particular cow potential contamination of resulting milk with residues is 
greatly enhanced. Milking of cows while undergoing treatment is also counterproductive to
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antibiotic therapy as effectively the antibiotic will be removed from infected udder quarters 
which may result in development of chronic mastitis.
1.4 The beta (P)-lactam antibiotics and mechanism of antimicrobial activity
P-lactam antibiotics are a very large family of antimicrobial drugs containing reactive beta 
lactam ring systems. The ring systems contained within this class of antibiotics represent the 
bio-active components. Encompassed in their chemical structure are ring systems found in 
five distinct conformations or sub-groups (figure 1.1). The sub-groups are termed penam (i.e. 
penicillins), cephem (i.e. cephalosporins), penem, carbapenem and monobactam depending 
on their respective ring structures. In general, beta lactam bacteriocidal activity is attributed to 
their ability to bind a group of bacterial proteins, loosely referred to as penicillin binding 
proteins (PBP). PBPs are enzymatic proteins that function in bacterial cell wall synthesis. 
Irreversible-binding of such PBPs is facilitated by the highly strained and reactive nature of P- 
lactam ring structures with variety of stable leaving groups. PBPs bind irreversibly to p- 
lactams, as their respective ring structures spatial arrangements closely resemble the 
conformation of certain PBP natural peptidoglycan substrates (e.g. D-alanine-D-alanine). A 
generalised binding mechanism of natural substrate and generic beta-lactam is shown in 
Figure 1.2. This results in reduced or inhibited cross-linking and disruption of bacterial wall 
synthesis, which is followed by inhibition of cell division or cell lysis and death.
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Figure 1.1. The core P-lactam ring structures for each of the five beta-lactam antibiotic sub­
groups, penam, penem, carbapenem, cephem and monobactam are shown. Atoms are 
numbered with respect to nitrogen at position one.
The biochemical makeup of the bacterial cell wall is a distinguishing feature. Cells can be 
visually classified by cell wall make up, as Gram (after the Danish biologist Hans Christian 
Gram) positive or negative using established staining methods. Cell walls have provided a 
target for the development of specific antimicrobial agents to combat various infections that 
bacteria cause. Overall, cell walls serve three main purposes within bacteria. They provide (i) 
a semi-permeable barrier through which only certain substances may pass (ii) a barrier against 
osmotic stress, and (iii) prevent digestion by host enzymes.
There are various PBPs implicated in cell wall synthesis although their functions are not fully 
understood. Various P-lactam antibiotics bind in a dissimilar manner to different PBPs 
producing a variety of effects. Binding to PBP-1 (transpeptidase or transamidase) produces 
cell lysis. Binding to PBP-2 (transpeptidase) leads to irregular oval cells that are incapable of 
cell division, while binding to PBP-4-6 (carboxypeptidases) have no lethal effects.
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PBP binding natural substrate (D-Ala-D-Ala)
PBP irreversible binding beta-lactam substrate
Figure 1.2. Overview of a penicillin-binding protein (PBP) binding to its natural substrate 
(top of figure) and to a generic beta-lactam antibiotic (bottom of figure). Binding of PBP to 
the D-alanine-D-alanine (D-Ala) portion of peptidoglycan moieties (R, represents the 
remaining molecule) which is the natural substrate, is reversible and results in formation of a 
reactive intermediate complex (I), shown in square brackets. This intermediate complex 
subsequently undergoes further reaction, as dictated by the particular PBP, during bacterial 
cell wall synthesis. In contrast, binding of PBP to the beta-lactam ring on the antibiotic 
(generic antibiotic structure shown, where R, represents functional group) is irreversible and 
results in formation of a stable PBP-beta-lactam conjugate, thus inhibiting PBP function in 
bacterial cell wall synthesis. Red arrows represent the movement of electrons in bond 
formation from nucleophilic to corresponding electrophilic participants.
COOH
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The cell walls of the Gram negative organisms are the more complex than Gram positive and 
both types are sensitive to beta-lactams due to presence of PBPs. The Gram positive cell wall 
serves as a good generic model for explanatory purposes. Gram positive cell walls consist of a 
characteristic set of carbohydrates and proteins on the external surface (e.g. antigenic 
determinants) and inside this is a layer comprised of repeating units of N-acetylglucosamine 
(NAG) and N-acetylmuramic acid (NAM) peptidoglycans arranged in polymeric chain form. 
This layer of the cell wall is highly cross-linked lending greater intrinsic stability to the 
barrier. Cross-linking is catalysed by a cell wall transamidase (CWT) also known as PBP-1. 
Each NAM unit is covalently linked to an oligopeptide chain that contains both L and D- 
amino acids (i.e. alanine [Ala], lysine [Lys], glycine [Gly] and glutamic acid [Glu]). CWT 
transiently binds a single oligopeptide on strand one through a surface serine residue and this 
bond is subsequently attacked by an amino terminus of a free glycine residue on strand two 
oligopeptide (Figure 1.3).
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Figure 13. Cell wall transamidase (CWT) or PBP-1-catalysed cross-linking of N- 
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) polymeric (denoted by small n 
above) peptidoglycans. Each NAM unit is covalently linked to an oligopeptide (R-L-ala-D- 
glu-L-lys-D-ala-D-ala) chain containing both L- and D-amino acids. CWT transiently binds to 
a single NAG-NAM polymeric unit (strand 1) via R-D-Ala-D-Ala oligopeptide (red arrows 
depict the movement of electrons from nucleophilic to electrophilic moiety). Binding occurs 
through a CWT surface serine residue (-OH) and this intermediate bond is subsequently 
attacked by a free glycine residue amino terminus (red arrow) of an adjacent strand 
oligopeptide (strand 2). This results in covalently cross-linked strands with the release of D- 
alanine and a proton. CWT is regenerated and is ready for a new catalytic cycle.
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1.5 Introduction to Cephalexin and Cephalosporins
Cephalexin is a member of the cephalosporin sub-family of p-lactam antibiotics. It contains a 
cephem P-lactam ring system that is characteristic of these antibiotics and once intact confers 
their antimicrobial activity. Four generations of cephalosporin-based antimicrobials have 
evolved since their discovery by Guiseppe Brotzu, in the 1940’s. The various cephalosporins 
contain the core cephem P-lactam ring structure substituted with different side chain groups 
that affects their antimicrobial activity and resistance to hydrolysis mediated by (3-lactamase 
enzymes. This classification may be further elaborated by their relative activity against 
various pathogenic microbes into limited-, intermediate-, and broad-spectrum cephalosporins. 
Cephalexin may be described as a semi-synthetic first-generation cephalosporin with a 
limited-spectrum of activity. Cephalexin hydrate (Figure 1.4) was chosen as the test 
compound for the production of antibodies in this work. This was due to its relative stability, 
availability and it also serves as a generic model for the cephalosporin (cephem) sub-group. 
The target analyte is unmodified cephalexin, i.e. no secondary metabolite is produced. The 
current MRL for cephalexin is 100 |xg/kg of milk (Appendix 1).
A few first- and second-generation P-lactams including cephalexin have strictly regulated 
approval for use worldwide for the treatment of mastitis infections in dairy cattle. 
Consequently, this group of antimicrobials are most frequently analysed in milk quality 
assurance programs globally. FEDESA, the European Animal Health Association, a body that 
actively promotes the responsible use of animal health products to ensure the health and 
welfare of European animal populations, estimated that the usage of antibiotics in animals, as 
opposed to humans, in the EU accounted for 48% of the overall total usage. This 48% figure 
is further broken down into therapeutic use (33%) and the remaining 15% as feed additive 
(FEDESA Antibiotics for Animals, 1999). The efficiency of antibiotics in general as growth 
promoters is reflected by their use as animal food additives.
Figure 1.4. The chemical structure of cephalexin (Cephalexin hydrate contains an associated 
water molecule).
O OH
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1.6 Public Health issues regarding use of antibiotics in animals
The use of antibiotics in food-producing animals has had many beneficial effects (e.g. longer 
life expectancy, increase body mass, economic gain from healthier livestock). However, their 
use and misuse has also been implicated in the increased incidence of resistant microbial 
strains. The generally accepted mechanism by which antibiotic resistance is acquired involves 
the antibiotic itself exerting a selective pressure upon microorganisms. During the 1990’s 
several scientists raised concerns regarding fluoroquinolone-resistant food borne pathogens. 
These concerns were compounded by the temporal association between the approval of 
fluoroquinolone for therapeutic use in poultry in Europe and the emergence of 
fluoroquinolone-resistant Campylobacter spp. in humans (US Food and Drug Administration, 
FDA, URL: www.fda.gov/cvm A and B). In December 1998 EU health ministers voted to ban 
four specific antimicrobials that were widely used at sub-therapeutic levels (i.e. as 
prophylactics or to promote animal growth). Although none of these antimicrobials were from 
the (3-lactam family they were widely used in the treatment of human disease. This highlights 
the general lack of data and understanding regarding the potential risks associated with the 
use of antimicrobials in food-producing animals.
Similar action was sought in the United States whereby a citizen’s petition was made to the 
FDA’s Centre for Veterinary Medicine (CVM) on behalf of the Centre for Science in the 
Public Interest (CSPI), the Environmental Defence Fund, the Food Animal Concerns Trust, 
the Public Citizens Health Research Group, and the Union of Concerned Scientists. The 
petition requested the withdrawal of approvals for the sub-therapeutic use of medically 
important antibiotics in livestock feeds. The CSPI specified a priority list, seven antibiotics 
were requested to be withdrawn, penicillin included. However, although no specific action 
was taken with regard to the petition, the FDA released updated guidelines for industry 
regarding the use of anti-microbial drugs for food animals. The guidelines set out a 
framework for the qualitative risk assessment to be carried out by prospective drug sponsors 
seeking approval for their drug for use in food-producing animals.
Within these guidelines, anti-microbial drugs are classified into three categories based on 
their perceived risk. Category 1 (high risk estimate) are for strictly limited use and include 
third generation cephalosporins (e.g. cefataxime) among others. Category 2 (medium risk 
estimate) require intermediate restriction on use and include fourth-generation 
cephalosporins. Finally, category 3 (low risk estimate) have the least restricted use, which 
includes the fist and second-generation cephalosporins (e.g. cephalexin) (FDA, Guidance for 
Industry (GFI) #152 ("Evaluating the Safety of Antimicrobial New Animal Drugs with
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Regard to their Microbiological Effects on Bacteria of Human Health Concern") October 
2003). All of the categories (1-3) are further classified with regard to their relative importance 
in human medicine. High-risk estimate drugs are considered critically important, medium 
risks are highly important, and low risk is considered important.
The limitations placed on the usage of certain antibiotics by the US and EU regulatory bodies 
and general guidelines regarding the responsible use of such drugs are based largely on the 
assumption that selective pressure is the only mechanism by which resistance is gained. 
However, recent work (Beaber et al., 2004) carried out by researchers at the Howard Hughes 
Medical Institute (HHMI) and Tufts University School of Medicine suggests a more direct 
involvement by the antibiotic itself. The work focused on a set of antibiotic resistance genes 
designated SXT. This is a 100-kb self-transmissible, conjugative, chromosomally integrating 
element, which confers resistance to four different antibiotics (i.e. chloramphenicol, 
sulphamethoxazole, trimethoprim, and streptomycin).
The SXT genetic element was derived from Vibrio cholerae in 1993 and is found in almost all 
clinical isolates of the strain in Asia. When they sequenced this region of the bacterial 
chromosome they discovered it contained a gene (setR) encoding a repressor protein (SetR). 
This protein was similar to one found in lambdoid phage viruses. It is responsible for the 
maintenance of the viral genes in an inactive state. Damage to the bacterial chromosome 
activates an “SOS response”. Hence, the repressor is in effect ‘turned off, triggering the virus 
to replicate and spread from the damaged bacteria. During the course of their work they found 
that the SetR protein did act as a repressor to two other genes, setC and setD, which are 
transcriptional activators of excision and transfer processes of the SXT genes. They also 
found that another protein, RecA, renders SetR inactive via proteolysis which gives rise to the 
‘SOS response’. The ‘SOS response’ may be activated by different stimuli, e.g. UV light. 
However, more importantly the stimuli also include antibiotics. They found that the ‘SOS 
response’ was activated by the fluoroquinolone antibiotic ciprfloxacin (Beaber et al., 2003). 
This work and other such studies (Jerman et al., 2005; Maiques et al., 2006) demonstrate an 
alternative means by which dissemination of antibiotic resistance can occur and highlights the 
need for more stringent controls on the general use of antimicrobials especially with regard to 
their use in food-producing animals.
Risk assessment reviews on penicillin hypersensitivity revealed a very small number of 
previously sensitised individuals from whom there is reasonable clinical and documentary 
evidence that penicillin residues in milk triggered an allergic reaction, usually a rash. 
Although these cases are veiy rare (less than 10 cases reported in the last 25 years), this
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illustrates the continuing need to control antibiotic residues vigilantly (Dewdney et al., 1991). 
Anaphylactic reactions to mainly penicillin-based (3-lactams are sometimes reported. 
However, in cephalosporins such cases are very rare indeed occurring in approximately 2 
cases per 10,000. In these instances, the dosage required to cause reactions is of a therapeutic 
order, yet, for the development of hypersensitivity the levels may be much lower.
1.7 Public and Industrial concerns about food safety and its implications
There are also economic concerns, along with the health risks associated with the presence of 
antibiotic residues in the food chain. Antibiotic residues can affect bacterial starter cultures 
used in the production of milk-based products such as cheese and yoghurts. This can cost 
considerable amounts of money in lost, reduced or spoiled production, which is of concern to 
large and small-scale producers alike.
Public concern with regard to food safety (i.e. the presence of veterinary medicine residues, 
such as antibiotics in foods) has become a major factor in the establishment of testing 
programmes. A recent study by the Food Safety Authority of Ireland (FSAI) reported that 
from a list of unrelated issues that worry consumers, food safety ranked fourth with 53% of 
the people surveyed. The specific worries that they tended to have were primarily with regard 
to the presence of pesticide and herbicide residues (70%) and Bovine Spongiform 
Encephalopathy (BSE) (67%). However, 63% of the people who took part in the survey 
report having concerns regarding antibiotic residues in foodstuffs. These results were based 
on a list of prompted responses (FSAI, Consumer Attitudes to Food Safety in Ireland, 2003). 
A similar study also carried out by the FSAI on industry attitudes to food safety in Ireland 
placed antibiotic residues sixth on a list of prompted concerns (FSAI, Industry Attitudes to 
Food Safety in Ireland, 2003).
Consumers are now increasingly aware of potential contaminants in food (e.g. antibiotic 
residues, pesticides, hormones etc.) and, as a consequence, some of the larger supermarket 
chains now include a record of the animal origin and statements like “Antibiotic free” on the 
packaging in the case of certain meat products.
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1.8 Current testing techniques for the detection of antibiotics in milk
Within the EU countries, national testing and control programs are compulsory in order to 
ensure that all foods from animal origin remain free from veterinary drug residues. The EU 
reference method for the determination of antibiotic and sulphonamide residues in raw and 
heat-treated milk is the International Dairy Federation (IDF) microbial inhibition test method. 
This method uses Bacillus stearothermophilus var. calidolactis, ATCC 10149 as the test 
organism due to its relatively high sensitivity to inhibitory substances (IDF 1991). The test 
involves a colour change that is dependant on the growth of B. stearothermophilus. However, 
it is quite complex and time-consuming. Current test kits based on the IDF microbial 
inhibition test with improved performance characteristics (e.g. Delvotest® SP (Gist- 
brocades/DSM), Charm Farm Test (Charm Sciences)) are routinely used that utilise B. 
stearothermophilus. The Delvotest® SP test is a broad spectrum test i.e. non-specific 
detection of a range of P-lactams, tetracyclines, sulphonamides, macrolides and 
aminoglycosides to name but a few. This test is presently the standard method required by the 
Department of Agriculture and Food (DAF) in Ireland. The Delvo® SP test is capable of 
detecting a range of antimicrobial drugs in milk at or below their respective MRL, for 
example manufacturers declare a sensitivity range of 40-60 (ig/kg for cephalexin (FSAI, 
2002).
In addition to the above assay kits, so called ‘rapid’ test methods are also available. In 
contrast to microbial inhibition tests that are relatively lengthy and used to test for a broad 
spectrum of antimicrobials, rapid test methods generally require less time and detect specific 
families of antibiotics. At pasteurising plants rapid antibiotic screening tests are often used 
prior to the standard Delvo® SP test to avoid delays. Rapid screening methods are based on a 
variety of assay techniques for example, immunoassays (IDEXX Parallux™ Antibiotic test 
kit, IDEXX Inc.). This test kit is a solid-phase fluorescent immunoassay (Kumar et al., 1997) 
for determination of P-lactams, sulphonamides and tetracyclines in milk. It is a laboratory- 
based test that requires trained staff and expensive equipment (e.g. Parallux Processor). 
Different families of antimicrobial residues are detected using a variety of available 
cartridges. There is no sensitivity quoted by the manufacturer for cephalexin. This method is 
employed as a tanker release test throughout the UK and Northern Ireland (FSAI, 2002) and 
by a number of companies in the Republic of Ireland. IDEXX also produce the SNAP® Beta- 
lactam test, which detects a range of beta-lactam antibiotics in raw bovine milk. The kit is 
more conducive to ‘on-site’ or farm testing as it is more user friendly than the Parallux™ kit. 
The SNAP® Beta-lactam test is an enzyme-linked receptor-binding assay, as yet the 
manufactures state sensitivity to cephalexin is to be confirmed.
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Immunoassay-based detection methods for P-lactams have been reported in the literature 
(Meyer et al., 1999; Gaudin et al., 2001) along with other methods describing various 
methods for determining penicillin and cephalosporin sub-families. These include UV-vis- 
spectroscopy (Martinez et al., 2002), High Performance Liquid Chromatography (HPLC) 
(Samanidou et al., 2003), matrix solid phase dispersion (MSPD) (O’ Keeffe, 1999), Liquid 
Chromatography (LC) (Suhren and Knappstein, 2003) and Capillaiy Electrophoresis (CE) 
(Hernandez et al., 2003). Such techniques require extensive sample preparation or extraction 
steps (Fedeniuk and Shand, 1998). Some researchers have also developed novel biosensors in 
order to detect various [3-Lactams. In such cases the antibiotic is detected using an 
immobilised P-Lactamase enzyme that converts P-Lactams (e.g. penicillin) in the sample to 
the requisite acid (i.e. penicilloic acid) thus increasing the pH, which can be detected using a 
glass-pH electrode in situ (Patel, 2002).
Overall, immunoassay techniques for the detection of beta-lactams are more conducive to the 
production of a portable ‘user-friendly’ device and offer many advantages including, 
increased specificity, sensitivity and flexibility, in terms of potential target analyte by the 
incorporation of different specific antibodies for each analyte.
1.9 The Immune system
1.9.1 Innate immunity
The innate immune system is characterised by its ‘non-specific’ nature and consists of two 
main components. Firstly, the physical barriers including, the skin, self-cleaning barriers (e.g. 
mucus membranes), stomach acid and non-pathogenic bacterial flora. These represent the first 
line of external defence. Secondly, the internal innate immune system via the inflammatory 
response which results in increased blood flow and vascular permeability to affected areas, 
followed by an localised accumulation of leukocytes (e.g. monocytes and neutrophils) and 
certain soluble factors. Neutrophils, monocytes and natural killer (NK) cells migrate to 
affected areas guided by chemotactic factors. Monocytes that exit the circulatory system and 
enter tissues mature to become macrophages. Neutrophils and macrophages are the functional 
phagocytes of the body (Paape et al., 2002), whereas NK-cells recognise cells that fail to 
express major histocompatibility complex (MHC) class I molecules, and lyse these cells 
through various killing mechanisms.
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Phagocytosis is the ingestion of large bodies (e.g. micro-organisms, cellular debris) by 
formation of endocytic vesicles termed phagosomes. In order for phagocytosis to occur the 
body must first be bound to the phagocyte surface via specialised cell-surface receptors. In 
effect this triggers the phagocyte to begin engulfing the body using its plasma membrane, 
thereby enclosing it in a phagosome. The phagosome then fuses with a lysosome (intra­
cellular body containing digestive enzymes) upon which the ingested particle is broken down. 
Material that can be utilised (e.g. antigenic determinants) is transported initially to the cytosol 
and indigestible material remains in the lysosome forming residual bodies. Macrophages 
carry out phagocytosis and play an important role as antigen-presenting cells (APC) by 
presenting processed antigenic material in association with MHC class II molecule on the 
cells plasma membrane surface. APC’s, including B-lymphocytes and dendritic cells, present 
surface bound antigen to T-lymphocytes which in turn trigger further cascades via various 
cytokines. Macrophages also ingest damaged cells, connective tissue matrix and neutrophils 
that have become apoptotic from phagocytosis.
1.9.2 Acquired immunity
If an invading micro-organism survives the external and internal innate immune barriers the 
adapted or acquired immune response comes into play. The main distinguishing feature of 
acquired immunity with regard to innate immunity is its high specificity. Acquired immunity 
can be sub-divided into two discriminate types, humoral and cell-mediated responses. The 
cell-mediated response, involves only T-lymphocytes, where the active agent is the T-cells. T- 
cells can be further distinguished into at least four distinct varieties i.e. CD4+ helper (THi and 
Tin), CD8+ cytotoxic (Tc), Natural Killer (Tnk) and regulatoiy (TR) cells.
The humoral or antibody response involves the concerted action of both B- and T- 
lymphocytes resulting in the production of soluble immunoglobulins (Ig) or antibodies into 
the blood stream. B-lymphocytes mature in the bone marrow, whereas, T-lymphocytes mature 
in the thymus gland. Following maturation both cell types migrate to secondary lymphoid 
organs (e.g. spleen and lymph nodes). Lymphocytes may be naive or ‘primed’ (i.e. exposed to 
specific antigen). Naive and ‘primed’ lymphocytes are partly differentiated or fully 
differentiated, respectively, as triggered by specific antigen binding. Lymphocytes 
continuously re-circulate in the body ‘patrolling’ for their respective antigen. Primed 
lymphocytes home back to their predilection organ, which is the tissue or the draining lymph 
node of that tissue, where they first encountered their specific antigen (Mackay, 1992). Naive 
lymphocytes only traffic the route from blood to peripheral lymph nodes and back to blood 
via efferent lymph. Lymphocyte trafficking is directed by homing receptors, i.e. cell-surface
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molecules that selectively interact with molecules on endothelial cells, and these receptors 
may be locally up-regulated during inflammation (Dailey, 1998).
Upon binding with their specific epitope (i.e. minimum portion of antigen to which the 
antibody binds), B-cells with membrane bound antibody will multiply and differentiate with 
the aid of CD4+ TH-cells. The humoral response requires various similar cell-to-cell 
interactions to select ideal complementary B-cell clones (with respect to optimum antigen 
binding). This is mediated by MHC class II. MHC class II molecules are glycoproteins that 
are exclusively expressed by APC’s. They function in the presentation of antigen on plasma 
membranes of APC including B-cells to the CD4+ TH cells. This triggers a signalling cascade 
within TH-cells resulting in the release of various cytokines which initiate rapid cell 
proliferation and differentiation (Figure 1.5). B-cells may differentiate into two main variants 
i.e. ‘plasma’ and ‘memory’. ‘Plasma’ B-cells are short-lived, characterised by a large 
endoplasmic reticulum and continuously secret specific soluble antibody. Memory clones 
persist and confer protection from a particular antigen (i.e. pathogenic bacteria) for extended 
periods of time. A main function of Igs is to facilitate phagocytosis by acting as opsonins. 
Moreover, they can activate complement and mediate inflammatory reactions, prevent 
bacterial colonisation, neutralize toxins, and trigger NK-cells to kill antibody-coated cells 
(Leibson, 1997; Sanchez-Mejorada and Rosales, 1998; Perussia, 2000; Tizard, 2000; Vivier et 
al., 2004).
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Figure 1.5. A schematic diagram representing a generic overview of the adaptive immune 
response. Lymphocytes are produced in the bone marrow, where B-cells mature and T-cells 
migrate to the thymus gland prior to maturation and formation of four distinct cell types (T- 
Helper CD4+ (THi+h2), T-Cytotoxic CD8+ (Tc), Natural killer-T (Tnk) and T-Regulator (TR)). 
Invading bacteria are identified as foreign and are engulfed by phagocytosis (e.g. by a 
macrophage) where they are systematically dismantled. Macrophages then display processed 
bacterial antigens (represented as red triangles and yellow squares in above key) in 
association with MHC class II complex (blue rectangles, above key) on their outer surface for 
binding of complementary Ig-containing B- or T-cells. B-cells may also act as APC. B-cells 
containing complementary Ig and TH CD4+ cells bind to MHC class II antigen and stimulate 
the generation of a signalling cascade of cytokines. Cytokines direct the T-cell activation and
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B-cell differentiation. Tc CD8+ cells may also degrade host cells that display foreign antigens 
on their surface in complex with MHC class I molecules (represented as black rectangles, as 
shown in the key).
1.9.3 Antigens and antibody structure
Antigens may be of various different chemical classes ranging from biological 
macromolecules (e.g. peptides, carbohydrates, and nucleotides) to non-biological molecules. 
The relative molecular mass of the antigen plays an important role in the subsequent immune 
response, if it has a relatively low (<5 kDa) molecular mass (e.g. illicit drugs, pesticides, 
antibiotics) it may not be recognised by the organism’s immune system. Such compounds are 
known as haptens. In the production of antibodies this obstacle is overcome by coupling such 
haptens to larger protein carrier. Antibodies will be generated that are specific to the desired 
hapten and also the carrier protein. Bovine serum albumin (BSA), ovalbumin (OVA), 
thyroglobulin (THY), and non-protein polymers e.g. dextran, are generally used for coupling 
to haptens to elicit an immune response. Antibodies are produced and circulated within the 
blood of the organism as already stated; such antibody populations are heterogeneous in 
nature and are termed as polyclonal (i.e. mixture of antibodies reactive to many different 
epitopes produced by a variety of parental cells). Monoclonal or monospecific antibodies (i.e. 
specific to a single epitope) can be produced by somatic cell fusion, isolating B-cells and 
fusing them with a myeloma cell line to produce hybridomas.
Antibodies are globular glycoproteins that are generally referred to as immunoglobulins (Ig). 
In humans there are five different classes of Ig or isotypes. These can be distinguished 
biochemically (i.e. each contains its own particular type of heavy chain) and functionally as 
IgM, IgA, IgD, IgG and IgE. IgG represents a good generic model to use to describe antibody 
structure since it is most common in serum (70-75% of the total Ig population) and most 
frequently utilised in immunoassay and biosensor applications (Fitzpatrick et al., 2000). It is 
stable during isolation, purification and chemical coupling. The IgG class consists of 4 
polypeptide chains i.e. two 50 kDa heavy (H) chains each approximately 440 amino acids 
long and two 25 kDa light (L) chains about 220 amino acids long. There are repeating 
domains, each with about 110 amino acid residues within both of these chains (Zubay, 1993). 
Each heavy chain is covalently linked to the corresponding light chain via disulphide bonds. 
The two heavy chains also linked via disulphide bonds in close proximity to the hinge axis 
(Figure 1.6).
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Figure 1.6. The basic IgG structure is shown. The IgG class consists of 4 polypeptide chains 
i.e. two heavy (H) and two light (L). On the IgG molecule the H and L chains are sub-divided 
into constant (C) (represented in gold) and variable (V) domains relative to their amino acid 
sequence. The L chain has both a variable (VL) (represented in red) and a constant (CL) and 
the H chain has a single variable domain (VH) (represented in blue) and three constant 
domains (CHi, CH2, Cm). The antigen-binding region containing the complementarity- 
determining (CDR) loop regions (indicated by 6 blue circles (3X VH and 3X VL) within 
antigen binding site). The antibody specificity and relative affinity (binding strength) to its 
complementary antigen is determined by the CDRs.
The basic IgG structure may be cleaved using proteases. Papain digestion yields two separate 
univalent Fab fragments as it cuts the IgG above the hinge axis. The Fc portion of the 
molecule is so called as it readily crystallises. It carries out important effector functions 
within the humoral immune response (e.g. triggering phagocytosis of pathogens). Proteolytic 
digests using the enzyme pepsin have yielded divalent F(ab’ )2 fragments indicating the cut 
occurs below the disulphide bonds proximal to the hinge region.
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In the IgG molecule the H and L chains are sub-divided into constant (C) and variable (V) 
domains determined by their amino acid sequences. The L chain has a variable (VL) domain 
at the N-terminus end and a constant (CL) domain at the C-terminal end. The H chain has a 
single variable domain (VH) and three constant domains (CH1, CH2, CH3), at N- and C- 
terminals, respectively. VH and VL domains each contain three localised areas of high- 
sequence variability (hypervariable regions) within the three-dimensional structure form the 
antigen-binding site. These areas are termed the complementarity-determining (CDR) regions 
and determine the specificity and relative affinity (binding strength) of the antibody to its 
complementary antigen. The remaining amino acid sequences of each variable domain are 
relatively conserved and are referred to as framework regions.
Heavy chains are classified according to amino acid sequence and confer different functional 
and effector capabilities to resulting immunoglobulins. The four different isotypes of Ig in 
humans are IgA, IgD, IgE, IgG and IgM. Each contains its own type of heavy chain; 
designated a, 8 , s, y, and p, respectively. The IgG class is further divided into sub-classes 
IgGl, IgG2a, IgG2b, IgG3 in mice and IgGl, IgG2, IgG3, IgG4 in humans, depending on the 
number and distribution of disulphide bonds. Antibodies also contain one of two possible 
light chain forms, designated k  or X, which differ appreciably in the constant region sequence.
1.9.4 Antibody synthesis and diversity
The mammalian humoral immune response has vast potential antibody diversity, expressing 
as many as 1011 distinct antibody binding capacities. The antibody repertoire or binding- 
diversity is so vast as to make an individual antibody germ-line hypothesis highly 
implausible. In fact no complete antibody genes exist in germ-line cells; antibody diversity is 
generated via the two distinct processes of somatic recombination and somatic point hyper­
mutation. All antibody polypeptide chains are derived from split genes encoded in separate 
sections. Antibody genes are assembled during B-cell maturation by somatic recombination, 
whereby the genes are constructed from various different basal genetic elements or clusters. 
In humans the chromosomes 2, 22, and 14 encode gene clusters associated with the k  light 
chains, the X light chains and the heavy chains, respectively (Zubay, 1993). Elegant studies 
(Tonegwa, 1983) have demonstrated that antibody gene construction requires the splicing of 
non-sequential germ-line clusters including variable (V), joining (J) and constant (C) exons to 
form compete heavy (i.e. VH, CHi, Ch2 etc.) and light chain (i.e. VL and VH) genes. Heavy 
chain gene synthesis also involves a diversity (D) element located between (J) and (C) exons. 
During initial B-cell differentiation, light chain genes are assembled by somatic 
recombination of germ-line Vl (encoding approximately 95 amino acids on the Vl
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polypeptide domain) and J (encoding the remaining VL domain amino acids) exons. This 
process is referred to as V-J joining, and occurs by random joining of a single Vl exon (from 
approximately 300 distinct variations in murine germ-line cells) with one J exon (of a 
possible 5). Heavy chain genes are constructed in an analogous manner. However, further 
diversity is introduced into heavy chains via the D genetic element. During the somatic 
recombination event, heavy chain gene synthesis proceeds by D-J joining followed by V-DJ 
joining (Figure 1.7). Diversity is initially generated by one of a potential 15 active D 
segments recombining with one of four possible J segments, followed by recombination with 
any one of potentially 200-1000 VH segments. During V-J, D-J and V-DJ gene recombination 
events, sequence diversity is also promoted by modifications to nucleic acid sequence within 
these regions termed ‘junctional diversity’.
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Figure 1.7. This is a representation of the variable light and heavy chain gene construction 
from germ-line gene segments by somatic recombination. Each respective exon is represented 
by a coloured box and introns are represented by lines. Light chain variable region genes are 
constructed by VJ joining, from two sets of distinct segments, variable (V) and joining (J), as 
shown above on the left. Each constant region is encoded by a spatially separated exon, that is 
joined by post-translational mRNA splicing to remove introns, in the process forming a 
complete light chain gene. Heavy chain variable genes are constructed by initial D-J joining 
followed by V-DJ joining, from three segment groups (V), diversity (D) and (J), as shown 
above (right). Regions encoding alternative heavy chain constant domains are spatially 
separated from variable regions by large introns and are joined to variable exons by 
processing of primary RNA transcript. Light and heavy chain genes are translated into large 
polypeptide chains that associate to form a complete antibody (IgG depicted above). The 
diagram presented was adapted from Janeway et al. (1999).
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The second process mediating generation of antibody-binding diversity is somatic point 
hyper-mutation. The mechanism of somatic point hyper-mutation of Ig genes is still not fully 
understood. A variety of models have been put forward that suggest the involvement of DNA 
polymerase(s), as reviewed by Jacobs and Bross (2001). The hyper-mutation process also 
requires various other factors as suggested by Storb el al. (1998). They proposed the 
involvement of a mutator factor that loads onto an initiating RNA polymerase. They later 
report (Longacre et al., 2003) that this mutator factor is possibly a recently discovered 
activation-induced deaminase (Revy et al., 2000; Muramatsu et al., 2000). Following the 
hyper-mutation process the repair phase may involve naturally error-prone DNA polymerases 
(Storb and Stavnezer, 2002; Longacre et al., 2003). Various comparative studies of germ-line 
and somatic antibody genes have demonstrated that Vl -Jl and Vh-Dh-Jh segments were 
subject to high frequency mutations during somatic differentiation. The density of observed 
mutations is about three fold higher within the CDR encoded regions. During the humoral 
response beneficial mutations within these gene regions are selected for by the presence of 
antigen. In effect somatic hyper-mutation and junctional diversity gives the immune system 
the ability to produce antibodies that are progressively ‘engineered’ to have higher affinity to 
their respective antigen.
1.10 Monoclonal antibody production by somatic cell fusion
Kohler and Milstein in 1975 (Kohler and Milstein, 1975) first reported the Nobel Prize- 
winning method of somatic cell fusion between a myeloma and an immune lymphoblast. 
Each individual resultant hybridoma (hybrid-myeloma) combines the immortality of the 
myeloma with the antibody production capabilities of the lymphocyte, thus serving as a stable 
source of mono-specific antibody. The technique has been refined and many alternative 
protocols developed. However, all are based on the same core elements.
The technique involves the extraction of lymphocytes from the spleen or lymph nodes of an 
immunised animal (e.g. mouse) subsequent to their fusion with relevant myeloma cells (non- 
Ig secretory immortalised cells). The myeloma-lymphocyte fusion product contains two 
different nuclei, termed heterokaryons, which in due course form a cell containing a single 
fused nucleus (hybridoma) with genetic information from both parent cells. Hybridomas 
continue to grow and divide indefinitely compared to lymphocytes, which only grow and 
divide for a short period of time in vitro. The cell fusion process is facilitated using for 
example, a polywax such as polyethylene glycol (PEG) that enhances the cell fusion process 
and the transfer of nuclei. Originally the somatic cell fusion was facilitated using Sendai 
virus, but this was problematic (Sikora and Smedley, 1984). Hybridoma cells secrete a single
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antibody type into the growth media or supernatant at a concentration range of 1 to 10 0  fAg/ml 
(Falkenberg, 1998). Specific antibody activity is identified using a suitable assay. Positive 
fractions may then be further separated by limited dilution until the expressed antibody is 
monospecific, or monoclonal, derived from a single parent hybridoma (Figure 1.8). The 
technique makes it possible to produce and maintain indefinitely homogenous populations of 
monoclonal antibodies with defined specificities and affinities. Monoclonal antibodies are 
finding ever-diversifying applications including environmental and food immunodiagnostics 
and as clinical therapeutics (Fitzpatrick et ah, 2000; Jessup et ah, 2000).
Increasingly monoclonal antibody production techniques have been coupled with or 
superseded by recombinant phage-display technologies (Siegel et ah, 1997; Burioni et ah, 
1998; Yoo etah, 2002).
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Figure 1.8. Schematic overview of key steps involved in the production of monoclonal 
antibody-secreting murine hybridoma cells by somatic cell fusion. Initially, immunised mice 
are screened for specific antibody activity using an appropriate assay technique. Once 
sufficient antibody titre is obtained lymphocytes are extracted from the animal’s spleen or 
lymph nodes. Lymphocytes are then fused with myeloma cells to produce hybridoma cells 
that are subsequently screened and cloned out to isolate a single cell type in culture secreting 
a single antibody idiotype.
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1.11 Recombinant Antibody production
1.11.1 Introduction
Monoclonal antibody fragments i.e. single chain Fv (scFv) and Fab are now routinely 
produced using combinatorial library-display technologies. Protein-display technologies 
including phage-, ribosomal-, and cell surface-display-based methods have revolutionised 
affinity protein research in general. Such methodologies have accelerated the production, 
screening and selection of high-affinity monoclonal antibodies to a myriad of different 
targets. Various antibody libraries have been produced by isolating genetic material encoding 
antibodies obtained from a variety sources, including hybridoma cell lines, spleenocytes or 
lymph tissues isolated from pre-immunised (immune) or naïve sources (non-immune). In 
addition, antibody libraries have been constructed from fully synthetic antibody or antibody 
‘like’ genes yielding novel antigen-binding proteins or ‘affibodies’ (Fernández, 2004; Nygren 
and Skerra, 2004). Synthetic antibody libraries consist of stable protein structural framework 
regions based on Ig domains with an affinity function grafted onto it, thus, yielding novel 
synthetic binding proteins.
The key factors of display systems are the vast library sizes obtained (i.e. binding function 
diversity) and the direct link between phenotype (binding function) and genotype (encoding 
gene), that facilitates the selection and amplification of antibodies with desired characteristics. 
This technology permits relatively rapid production, identification and isolation of 
monoclonal antibody fragments with diversity of antigen binding function, novel binding 
affinities and specificities from vast library repertoires and subsequent engineering to further 
improve desired characteristics.
The main advantage of recombinant antibody production is its inherent capacity for molecular 
biology-based manipulations. Using established recombinant techniques antibodies are now 
routinely produced incorporating affinity tags (e.g. polyhistidine, strepavidin) to aid 
subsequent purification and detection or immobilisation (i.e. on a biosensor chip). In addition, 
antibody genes can be expressed in a range of plasmid vectors that enable expression as 
fusion proteins in bacterial hosts yielding bifunctional or bispecific antibodies. Bifunctional 
antibodies contain a single antigen-binding capacity covalently linked to a specific biological 
function, for example an enzyme (e.g. alkaline phosphatase). Bispecific antibodies contain 
two distinctly different antigen-binding capacities. Recombinant protein-display technologies 
also facilitate engineering or evolution of proteins. This has enabled enhanced antibody 
expression, stability and binding characteristics by selection. In effect it is possible to ‘tailor-
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make’ and screen vast numbers of monoclonal antibodies to obtain the optimum 
characteristics for use as diagnostic or therapeutic agents. Combinatorial antibody library 
display and selection processes are also conducive to automation that permits the 
development of high-throughput production and isolation systems.
1.11.2 Protein display technology
Overall, protein display technologies can be sub-divided into three main categories, 
bacteriophage (phage), ribosomal (i.e. mRNA-protein complex) and cell surface (i.e. 
bacterial) based. All three methods permit the simultaneous selection of high-affinity 
antibodies and the genetic material that encodes it. Phage-display is by far the most widely 
used in vitro technique for the display of large antibody fragment repertoires and selection of 
high-affinity clones against many different types of targets. This method will be discussed in 
greater detail in this thesis. A brief description of ribosomal and cell-surface display 
techniques will be given. All three techniques are used to produce scFv and Fab antibody 
fragments as opposed to whole IgG molecules (Figure 1.6).
Ribosomal display methods exploit the cellular role of ribosomes in the synthesis of proteins 
and are based on the formation of stable antibody, ribosome and mRNA complexes (ARM 
complex) in vitro. This system maintains the link between antibody (phenotype) and mRNA 
(genotype) together with the ribosome (basal protein-production machinery). A diagrammatic 
overview of the technique is presented in figure 1.9. One of the main advantages of ribosomal 
over other display technologies is that it is cell-free thus it permits the production of 
potentially very large antibody repertoires (< 1014) (Hudson and Souriau, 2003). Vast 
repertoires are facilitated as the technique is not limited by microbial cell transformations, 
does not require any cloning and mRNA products of selection are utilised directly as 
templates for reverse-transcription polymerase chain reaction (RT-PCR). Since it is a cell-free 
method it also facilitates the production of antibodies that may be toxic to cellular expression 
hosts or prone to degradation by intra-cellular proteolytic enzymes. Ribosomal display is 
limited in that it requires ribonuclease-free environments and optimisation of buffer 
composition to allow formation of stable ARM complexes with correctly folded antibody. 
The technique has been extensively reviewed (He and Taussig, 2002).
29
A)0 0 <
Figure 1.9. Diagrammatic representation of the main steps involved in ribosome-display 
library production and panning (blue coloured arrows). Firstly, it involves the transcription of 
antibody genetic diversity yielding mRNA followed by translation mRNA sequences into 
properly folded antibody by formation of stable ARM complex with large (LRS) and small 
(SRS) ribosomal subunits under optimised buffer conditions. Panning is carried out on 
immobilised antigen to select for specific scFv-ARM complexes. Subsequently, the ARM 
complexes are disrupted and mRNA used as the template for RT-PCR. The resulting cDNA 
can be subjected to further rounds of selection by repeating the process or used for in vitro 
expression of antibody.
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The third recombinant-based selection platform is cell surface display. In this technique 
proteins or antibodies are displayed on the surface of intact cells, including yeast (e.g. 
Saccharomyces cerevisiae), bacteria (e.g. Escherichia coli) and even some mammalian cell 
types. This method is more analogous to phage-display in that it is a cell-based technique and 
requires cloning of antibody gene repertoires into cell-based expression systems. Cell-surface 
display has been found to be less applicable to the generation of large antibody libraries (in 
the order of <108 clones). A yeast-display-based method used in conjunction with random 
mutagenesis techniques to diversify variable heavy (VH) and light (VL) domain genes has 
yielded a very high affinity (48 fM) antibody (Boder et al., 2000).
1.11.3 Combinatorial phage-display libraries
A combinatorial phage display library consists of a heterogeneous mix of phage clones each 
displaying a different functional antibody, typically of the order of 109 clones. In the reported 
literature, phage displayed antibody libraries almost always consist of either single chain Fv 
(scFv) or Fab fragments. Since the discovery of the technique as a means of displaying 
peptides on the surface of a bacteriophage (Smith et al., 1980 and Smith, 1985), it has proven 
to be a robust and powerful means of selecting high-quality antibody fragments. Phage- 
display was successfully applied to existing hybridoma cell lines, as a means of cloning and 
expressing their respective antibodies in a recombinant bacterial host, and in the production of 
combinatorial antibody libraries. Phages (Bacteriophage) are viruses that infect bacterial cells, 
introducing their genetic material in the process. This permits the introduction of foreign 
DNA (i.e. natural or synthetic antibody genes) into host bacterial cells (e.g. E. coli) and the 
expression and replication of both protein and genetic material encoding it, as shown in 
Figure 1.10.
Bacteriophage fd and M l3 are filamentous non-lytic bacteriophage, which are the most 
commonly used phages for antibody phage-display (Hoogenboom, 2005). Phage-display 
DNA vector systems are usually truncated phage plasmids (termed phagemids) with phage 
and E.coli origins of replication and contain the inserted DNA (i.e. antibody gene) adjacent to 
a phage coat protein gene (e.g. glllp). When expressed within bacterial hosts it produces a 
hybrid antibody-gHIp fusion protein. Phagemid vectors do not contain all the requisite genes 
encoding proteins for complete phage replication and, therefore, helper phage are required in 
order to produce and package complete virions displaying antibody fragments as fusion 
partners with coat proteins.
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Figure 1.10. Schematic overview of major steps involved in production of phage-display 
libraries (blue coloured arrows), from initial cloning of genetic diversity and production of 
antibody gene pool by extraction of mRNA from populations of hybridomas (black arrows) or 
from B-cells taken from the spleen of a naive / pre-immunised animal. Antibody (i.e. Fab or 
scFv) cDNA gene constructs are then ligated into a phagemid vector and transfected into 
competent bacterial cells (e.g. E. coli XL1 blue). The antibody fragment is co-expressed with 
phage coat protein and preferentially packaged into phage particles using a helper phage (e.g. 
M13-K007), in effect coupling genotype and phenotype. Phage-displayed antibodies are then 
subjected to a panning selection cycle. Subsequently, the required antibody is obtained by 
isolating infected single E. coli colonies on selective agar. The basic steps involved in the 
production of mutant libraries are also shown (grey arrows).
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Successful phage-display-based methods require very stringent control over the expression of 
scFv-coat protein due to two main reasons. Firstly, the antibody coat protein fusion is 
potentially very toxic to the host cell and secondly, as a consequence of the need for 
subsequent infection with helper phage (superinfection). Superinfection is inhibited by the 
intrinsic expression of phage coat proteins. Expression is invariably controlled by 
transcriptional regulation via the lac promoter. Alternatively, other regulatory systems, for 
example the tetA promoter (Rau et al., 2002), have been used. Upon infection with helper 
phage hybrid antibody coat protein fusions are incorporated into the phage particles as they 
are assembled in the hosts’ periplasmic space and then released from the cell. As helper phage 
contains its own copies of wild type coat proteins (e.g. glllp) they will compete with 
antibody-coat protein fusion for incorporation into the newly forming phage particles. This 
has been overcome by researchers in various ways, for example, by producing helper phage 
that are deficient in gHlp gene and preferentially package insert-containing phagemid into 
infectious virions (Rondot et al., 2001 and Soltes el al., 2003).
The key advantage of this technique is the link between phenotype (i.e. scFv or Fab displayed 
on phage surface) and genotype (i.e. the genetic information encoding scFv or Fab contained 
within the infectious phage virions). Once the phage displaying the antibody infects a new 
bacterial host, it produces multiple progeny each an identical copy containing the displayed 
antibody on the surface and genes encoding it within. Heterogeneous polyclonal libraiy 
populations of phage-displayed antibodies can be ‘enriched’ for desired binding 
characteristics by affinity selection or ‘panning’. Library panning can be carried out in several 
ways, as will be discussed in section 1.11.3.2 and can play a major role in obtaining high 
quality antibodies. Panning strategies are usually user defined and dependant on two main 
criteria, the pan stringency and desired yield. Increased panning stringency will result in a 
lower yield of phage; however, increased stringency will yield more optimum clones (i.e. of 
higher affinity to target antigen). Therefore, a balance between these two factors must be 
found in the development of a successful panning strategy.
1.11.3.1 Phage-display library production
Over the past ten years many different methods and approaches have been described for the 
production of phage display libraries. Libraries have been produced containing antibody gene 
repertoires (of the order of 10u individual clones) from immune, non-immune (naive) and 
semi- or fully synthetic origins (i.e. based on synthetic PCR products). A number of synthetic 
scFv and Fab libraries have been reported in the literature (Azriel-Rosenfeld et al., 2004; Lee
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et al., 2004; Sidhu et al., 2004) Library quality is generally evaluated in terms of the size (i.e. 
the number of clones) usually presented as the transformation efficiency and, more 
importantly, the quantity of different functional clones (i.e. true library diversity).
Although phage-display technology has to a degree negated the need for animals in the 
production of antibodies, display libraries are commonly produced from immunised 
organisms. Organisms used as genetic donors in phage libraiy production include mice, 
human and recently chickens (Finlay et al., 2005). Each organism should be taken on their 
individual merits (e.g. number of primers required to amplify all potential antibody variants 
from germline sequences) with regard to what is required by the user. Generally the 
underlying principles of library synthesis remain the same. Methodologies mainly differ in:
(i) The number and types of primers used for VH and VL gene amplification (dependant on 
consensus antibody germline families).
(ii) DNA vectors (e.g. phagemid or phage) may contain different affinity tags and sites for 
binding restriction enzymes, used to introduce antibody genes into vectors in the correct 
orientation.
(iii) Phage coat protein used for fusion partner to antibody.
(iv) Helper phage used for library rescue (e.g. selectively infective as opposed to non- 
selective helper phage).
Overall antibody gene constructs are assembled using PCR. The VH and VL domain genes 
may be intersected by encoded linker sequence of various lengths (scFv format) or contain 
terminal cysteine residues for disulphide bridge formation (dsFv format). Fab antibody 
fragments are produced by the inclusion of a constant domain gene into the construct. The 
majority of libraries produced utilise the scFv format. However, many Fab libraries are also 
reported. Phage-display systems also incorporate various polypeptide tags into the expressed 
antibody to aid in downstream purification and detection. A comprehensive evaluation of 
affinity tags is presented by Lichty et al. (2005). Antibodies are almost invariably screened by 
ELISA using commercial labelled secondary antibodies specific to M l3 phage or FLAG 
polypeptide tag for example. The appropriate system is defined by the specific users’ 
requirements.
A good representative example system for phage-display library production is described by 
Krebber et al. (1997). This work describes the production of a murine single chain Fv (scFv) 
antibody library from initial RNA extraction and cDNA synthesis to scFv gene construction 
by a splicing by overlap extension (SOE) PCR. The technique was used to develop
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recombinant scFv antibodies from hybridomas and immunised mice spleenocytes. The system 
lists a full set of murine antibody gene primers (designed to cover all known potential VH and 
VL genes) based on consensus sequence analysis. Primers also incorporated the necessary 
restriction sites required for the incorporation into compatible DNA vectors. The protocol 
utilised Sfi 1, a single rare cutting restriction enzyme. The scFv gene constructs consist of VH 
and Vi, domains joined by a region encoding a flexible 20 amino acid glycine serine repeat 
linker.
In initial library production antibody gene constructs are cloned in frame with a glllp gene, 
for expression as fusions with glllp minor phage coat protein using the pAKlOO phagemid 
vector. Expression is tightly controlled using the lac promoter system. Transcription may be 
inhibited by culturing transformed E. coli cells in growth media supplemented with glucose. 
Alternatively, transcription may be induced by removal of glucose and addition of 
isopropylthiogalactoside (IPTG). Once suitable monoclonal scFv has been identified the 
system allows scFv expression as a single entity (i.e. not as a fusion with glllp) by 
transferring into an E. coli strain that recognises amber stop codons. The amber stop codon is 
present between scFv and gHIp genes on the pAKlOO phagemid. Alternatively enhanced 
soluble expression is facilitated using the compatible vector series. The scFv construct can be 
excised using Sfi 1 restriction sites and can be sub-cloned into the pAK.400 vector. This vector 
contains no glllp gene downstream of inserted scFv and soluble expression is enhanced by 
incorporation of a Shine-Dalgamo translational initiation sequence. The authors also 
expressed scFv in dimeric form using the pAK500 vector that introduces a protein helix 
(leucine zipper) into the scFv structure that promotes dimérisation by association. The 
pAK600 vector permits the production of bifunctional scFv by expression of a scFv-alkaline 
phosphatase fusion hybrid. Purification and detection of scFv is facilitated by incorporation of 
FLAG, six histidine residues and myc polypeptide tags.
In addition to generating combinatorial libraries from immunised source organisms, so called 
‘single-pot’, universal or naïve phage-display libraries have been produced and offer 
alternative vast antibody repertoires for panning with potential target antigens. There are a 
range of universal naïve antibody libraries currently available including n-CoDeR™, a Fab 
library from Bioinvent (www.bioinvent.com), BMV, a scFv library from Cambridge 
Antibody Technology (www.cambridgeantibody.com'). HuMade™, a scFv libraiy from 
Crucell (www.crucell.com) and the HuCAL*Gold Fab library from MorphoSys 
(www.morphosvs.com). Due to their commercial nature little information regarding their 
exact production methods is made public.
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The Human Combinatorial Antibody Library (HuCal) (Knappik et al., 2000) is a fully 
synthetic library. Library production was performed by analyzing the human antibody 
repertoire in terms of structure, amino acid sequence diversity and germline usage. Knappik 
and co-workers found that 95% of human antibody diversity was represented by seven 
variable heavy (VH) and seven variable light (VL) framework germline gene families. 
Framework consensus sequences for each family were derived and optimised for expression 
in E. coli. Synthetic genes were modular by construction and mutually compatible by design 
which facilitated introduction of different complementarity determining regions (CDRs). 
Hence the library binding diversity was increased using CDR gene regions diversified by 
randomising CDR3 regions of both VH and VL domain master genes. The randomised CDR3 
regions were generated from mixed trinucleotides and introduced into the modular framework 
genes using optimised restriction sites. The modular nature of this library facilitated rapid 
evolution of binders by selection and modification with pre-built CDR cassette libraries. This 
work was applied to scFv and Fab antibody fragment formats.
1.11.3.2 Library panning strategies
Phage-display technology is tailored for the selection of antibodies with the optimum 
expression and affinity from vast antibody repertoires. Selection of the highest affinity 
antibodies is largely determined by the panning process. The simplest method of panning a 
library is based on ELISA, where immobilised antigen is incubated with prepared polyclonal 
phages (Figure 1.11). Non-specifically bound phages are removed by multiple washing steps 
and specific scFv-phage eluted using a gentle acidic or basic solutions. Alternatively, phage 
antibodies may be eluted using excess antigen in solution or by successively lowering soluble 
antigen concentration after each round of panning thereby increasing the selective pressure 
toward high affinity clones. Following this, retained phages are used to infect E.coli in 
logarithmic growth phase, in effect multiplying up the specific binding population. Polyclonal 
phage-antibody populations may be subjected to successive rounds of panning to greatly 
enrich the specific binding population. Typically, three or four rounds of panning are carried 
out on library populations depending on the library quality. This is necessary due to non­
specific binding limiting the enrichment of optimum antibody binders.
Monoclonal antibodies (i.e. scFv or Fab) can be obtained simply by isolating single phage 
infected E. coli colonies on selective agar after successive rounds of the panning process. On 
the whole, the panning strategy should take into account the potential function of the desired 
antibody. For example, if the antibody is going to be used to detect a protein target in aqueous
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solution, it should be selected for under those conditions, as solid phase immobilisation or 
adsorption conditions may alter the true epitope conformation.
(vi) Eluted specific phage 
rescued from E. coli
(v) Eluted phage 
amplified by
reinfecting E. coli
Expressed 
monoclonal 
scFv antibody
(ii) Specific phage 
selected for on 
immobilised antigen
(iii) Non-specific 
phage removed by 
washing
(i) Phage displayed 
antibody repertoire
(iv) Bound phage 
eluted from 
immobilised antigen
Figure 1.11. Diagrammatic representation of typical steps involved in basic panning of 
combinatorial phage-displayed libraries, (i) The polyclonal phage-displayed antibodies are 
packaged and isolated from E. coli. (ii) Phages are the subjected to selective pressure on 
immobilised antigen, (iii) Non-specific phages are removed by repetitive washing using 
appropriate buffer, (iv) Specific bound phages are eluted from immobilised antigen using 
specific conditions (i.e. acidic or basic solutions) (v) Exponential growth phase E. coli 
containing F’ plasmid are infected by eluted phages. Following infection monoclonal phage- 
antibodies can be obtained by isolating single infected colonies on selective agar (represented 
by black block arrow), (vi) Panned phages amplified in E. coli are purified from bacteria and 
subjected to subsequent rounds of panning.
If, however, target antigen is a hapten i.e. small molecules (<5 kDa) higher affinity clones can 
be selected for by successively limiting both the concentration of free antigen over subsequent 
panning rounds and the contact time between phages antibodies and target. Panning with 
complex antigen preparations (e.g. whole cells, cell extracts or hapten-protein conjugates) can 
utilise subtractive panning. This involves removing potential non-specific binding phage 
antibodies from the library population by panning with the non-target components of the
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mixture and discarding the panned phage. This reduces the non-specific phage scFvs in the 
population. Novel panning strategies have included combining cell display and phage display 
libraries, as reported by (Benhar el al., 2000). The “delayed infectivity panning” or DIP 
technology described used bacterial cells to display the target antigen on their surface. These 
cells were used for capture of specific-phage and as subsequent hosts for scFv-displaying 
phages. A reverse variation of the DIP method was also applied to an epitope mapping 
technique (Mazor et al., 2005), by displaying a characterised scFv on a bacterial cell surface 
and using this to capture phage-displayed polypeptide variants of the epitope region.
In the first instance phage-displayed antibodies are generally screened for potential antigen 
binding by phage ELISA in microtitre immunoplates. Subsequent to expression and 
purification, soluble antibody fragments (i.e. scFv or Fab) may be further characterised in 
displacement or affinity assays using biosensors (e.g. Biacore™ series of surface plasmon 
resonance (SPR)-based biosensors). Novel library screening systems have been developed 
based on engineered display systems that facilitate arraying. The phage antibodies are 
expressed as cellulose-binding domain (CBD) fusions with immobilisation onto cellulose- 
based filters followed by probing with appropriately labelled antigen (Azriel-Rosenfeld et al.,
2004).
1.11.3.3 Antibody engineering
The potential application of antibodies as analytical and therapeutic tools has been greatly 
enhanced as a direct consequence of recombinant display technology and protein engineering 
techniques. Using established molecular biology-based methods it is now possible to improve 
or alter antibody characteristics in terms of binding affinity or avidity, stability or cross­
reactivity and intrinsic immunogenic properties (i.e. ‘humanised’ antibodies). Antibodies can 
be manipulated by linking them in vivo to moieties that allow enhanced signal transduction or 
improved immobilisation strategies to facilitate application in novel assay formats or bio­
sensing devices (Killard et al., 1995; Darmanin Sheehan et al., 2003; O’Kennedy et al.,
2005).
There are two basic ways in which antibodies can be engineered using recombinant methods 
(Figure 1.12). Firstly, antibodies may be produced in multimeric form, as bispecific entities or 
as fusion proteins with biologically active moieties. Antibody functional affinity (avidity) 
may be enhanced by expressing scFv monomers as a ‘diabody’ (dimeric scFv with divalent 
binding capacity), ‘triabody’ (trivalent) or ‘tetrabody’ (tetravalent). Multiple binding domains 
and dual specificities (bispecific antibodies (bsAbs)) have been readily combined to yield
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novel binding constructs (Lu et al., 2003), Antibody gene sequences may be also mutated to 
beneficially alter binding characteristics, expression profile and stability. Antibody 
engineering, in combination with phage-display, removes the requirement for extensive 
theoretical-based binding site design approaches, as nascent antibodies can be quickly 
identified and enriched by panning. This combined technology has been successfully applied 
to ‘humanise’ murine antibodies (Mazor et al., 2005) by grafting murine heavy and light 
chain CDRs into human framework regions. Antibody engineering will have profound 
implications on the use of antibodies as therapeutic agents and the potential applications of 
immunodiagnostic devices.
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Figure 1.12. Illustration of potential antibody fragments produced by enzymatic cleavage and 
recombinant methods. Chemical and enzymatic cleavage methods have yielded several 
antibody-derived fragments including the Fab monomer (antigen-binding) by digestion using 
papain and F(ab)2 dimer using pepsin, and readily ctystallisable Fc fragments. Recombinant 
production techniques have yielded Fv fragments (VH and VL with the CDR region), Fab and 
single chain Fv (scFv) fragments consisting of an Fv with a linker peptide. Antibody 
engineering has led to the production of bispecific and bifunctional antibodies. Multimeric 
scFvs have been produced by altering linker length. Diabodies, triabodies and tetrabodies, 
consist of two, three and four associated scFv monomers, respectively. Molecular-biology 
techniques also permit mutation of individual CDR regions followed by incorporation into 
stable framework regions. The multiple domain structure of antibodies facilitates chemical, 
enzymatic and genetic manipulations to yield novel antibody derivatives or fragments that are 
stable and retain strong affinity towards the relative antigen.
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Various methods described permit two antibody specificities to be combined in single 
molecules in the process forming ‘bispecific’ antibodies (Lu et al., 2003 & 2004). Work in 
this field has mainly focused on the development of dual targets for tumour associated 
antigens (TAA) and immune effector cell surface receptors. The potential of bispecific 
antibodies as cancer therapeutics is extremely promising with clinical trials for cancer 
treatment being carried out on a number of bsAbs. Traditional means of producing bsAbs 
used complex chemistries (chemically cross-linking two F (ab') fragments at hinge region) or 
using hybrid-hybridoma or quadroma production using tissue culture techniques (Nolan and 
O’Kennedy, 1993; Segal et al., 2001). These methods invariably resulted in poor yields of 
heterogeneous product, as well as being problematic and expensive.
Bifunctional antibodies have been produced by expressing antibodies as chimeric fusion 
proteins with reporter moieties or affinity ligands in vivo, using phage-display techniques. 
Hence, scFvs can be expressed as a fusion partner with biologically significant domains while 
retaining biological function (Berdichevsky et al., 1999; Cloutier et al., 2000; Brennan et al., 
2003; Santala and Lamminmaki, 2004). Cloutier and co-workers described the production and 
application of an expression vector that permits in vivo biotinylation of scFv antibodies by 
subsequent expression in E. coli of scFv-BAD (biotin acceptor domain) fusion. The BAD 
domain is a 15 amino acid long peptide that is biotinylated in the presence of BirA enzyme. 
Thus, they produced in vivo biotinylated-scFv that was then purified using affinity 
chromatography. Biotinylated-scFv subsequently was tetramerised on strepavidin molecules 
to create what they termed a StAb or ‘streptabody’. Competitive assays using StAbs showed 
an avidity improvement of one log in comparison to the relevant monomer-scFv.
A cellulose binding domain (CBD) is another example of high-affinity tag that was 
successfully expressed as a scFv fusion partner. Berdichevsky and colleagues (1999) reported 
a phage-display method that utilises the high affinity of CBD to cellulose as a novel means of 
phage capture and elution, demonstrating in the process that scFv-CBD fusion was expressed 
as monomer and retained both antibody and cellulose binding functions. This system offers an 
alternative enrichment step during the library panning process that reduces the potential 
capture of ‘insert loss’ virions. It may prove advantageous over more commonly used affinity 
tags as cellulose is cheap and readily available in pure form.
Other workers have developed expression systems for producing in vivo fluorescently labelled 
scFvs in prokaiyotic (Griep et al., 1999; Morino et al., 2001) and eukaryotic cells. One report 
(Piepp et al., 2004) describes the production of two sets of eukaryotic expression vectors that 
permit the expression of scFv fusions with mutant form of green fluorescent protein (GFP+)
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and red fluorescent protein (DsRed) in insect and mammalian cells. The scFv-fluorescent 
protein fusions were applied in fluorescence activated cell sorting (FACS). The advantages of 
such in vivo methods for covalently linking individual components over more traditional 
chemistry-based ones are numerous. They typically yield more homogenous product and 
remove the need for laborious optimisation of chemical approaches and separation 
techniques.
The second main approach to antibody engineering is carried out by random or site-directed 
mutagenesis, or variable chain ‘shuffling’ techniques. These techniques have been used on 
scFv or Fab gene sequences to beneficially alter binding characteristics, expression profile or 
intrinsic stability. Researchers have taken many different approaches to what is in essence the 
‘evolution’ of antibodies to obtain desired characteristics. Recombinant display technologies 
facilitate antibody evolution and selection, by mimicking, to an extent, the natural acquired 
immune system. Random or point mutations can be introduced into various antibody genes or 
particular gene regions followed by mutant antibody phage library construction and panning. 
Work in this area has focused on a variety of obstacles to ideal antibody design. This 
includes, for example, overcoming problems associated with transfer from eukaryotic (i.e. 
hybridomas) to prokaryotic (i.e. Escherichia coli) expression systems, detrimental immune 
responses to potential immunotherapeutics and generally improving the overall antibody 
affinity or specificity characteristics.
In vitro affinity maturation has been successfully achieved by numerous researchers yielding 
antibodies with increased affinity in comparison to the original or ‘wild type’ antibody. One 
such study (Schier et al., 1996) describes the mutation of VH and VL CDR3 regions found in a 
human anti-c-erbB-2 tumour antigen scFv, previously isolated from a naive phage-display 
library. Mutations were introduced stepwise, firstly into wild type VL CDR3 gene sequences 
using a designed oligonucleotide which partially randomised 9 amino acid residues located in 
this region. A phage-display library of the resulting mutant clones was constructed and 
subsequently panned for c-erbB-2-specific scFv. The highest affinity clone obtained was 
found to have a 16-fold lower dissociation rate constant (Kj) with respect to wild type. 
Following this VH CDR3 mutant libraries were constructed from the new mutant clone. 
Panning of these libraries yielded clones with a further 9-fold decrease in Kj. They obtained a 
scFv with 1230-fold overall increase in affinity compared to original wild type by combining 
the mutations isolated from the individual VhCDR3 libraries.
Alternative methods of producing mutated phage-display antibody libraries have yielded 
different antibody improvements. Random mutagenesis of wild-type antibody genes
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combined with cleverly designed panning strategies have yielded antibodies with improved 
affinity and cross-reactive characteristics (Zhang et a l 2003). Other studies utilised random 
mutation of the entire scFv gene by error-prone PCR to produce antibodies with increased or 
broader specificity ranges (Korpimaki et al., 2002). In this work a phage-displayed scFv was 
produced from monoclonal antibody-secreting hybridoma cells specific to sulphonamide 
antimicrobials and used to construct a mutant scFv library. Mutant scFv gene sequences were 
produced using wild type scFv gene as template for error-prone PCR (Fromant et al., 1995, 
Cadwell and Joyce, 1998). Mutant scFv obtained was capable of detecting a broader range of 
sulphonamide compounds in comparison to the wild type antibody. The authors of this work 
later reported further improvement of the scFv obtained in terms of its sulphonamide 
specificity range, by using a site-directed mutagenesis approach (Korpimaki et al., 2004).
Antibodies with increased as opposed to broader specificity, have been successfully obtained 
using variations of this technique. Saviranta et al., (1998), used an anti-17p-estradiol Fab that 
was previously isolated and characterised, to fabricate a mutant phage-display library. Mutant 
Fab genes were produced using error-prone PCR to amplify VH domains and subsequently 
used to construct Fab genes. The library was selected for decreased testosterone (TES) cross­
reactivity by the addition of a large excess TES as a competitor to the panning reaction. 
Resulting mutant Fab clones retained their anti-17P-estradiol activity and displayed a 20-fold 
improvement over original wild type Fab with regard to their potential to cross-react with 
TES. Random point mutation and variable chain shuffling (discussed later in this section) 
techniques were combined to alter antibody specificity and assay sensitivity to similar 
antigens. The original scFv antibody was s-triazine specific and following manipulations 
clones were isolated with a 22-fold lower IC50 to the related pesticide atrazine (Rau et al., 
2002).
Random mutations may also be introduced in vivo by transforming mutator strains of E. coli. 
Such cells, introduce point mutations at a substantially higher rate in comparison to normal 
strains following transformation. An example protocol (Coia et al., 2001) was reported that 
utilises various mutator strains of E. coli to facilitate the introduction of a random point 
mutation per kilobase of target DNA sequences, by adjustment of bacterial growth conditions. 
The authors have used this method in parallel with phage-display and selection to obtain scFv 
antibodies with enhanced affinities and increased expression levels.
Another observable benefit of antibody engineering, in conjunction with recombinant display 
technologies is the selection of clones with improved expression levels. Mutant antibodies 
may gain advantage from engineering by, for example, point mutations contained within
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framework regions that have little or no effect on affinity and permit elevated expression in 
prokaryotic cells. Enhanced expression results in greater antibody yields and is directly 
selected for during the panning process.
In contrast to methods based on random or site-directed mutagenesis within variable heavy 
and light chains some workers have focused on exploring the potential of chain shuffling. 
This involves cross-pairing VH and VL chains isolated from different antibodies. One report 
(Collet et al., 1992) describes using a binary system of replicon-compatible plasmids to test 
potential promiscuous recombination of VH and VL chains within sets of human Fab 
fragments isolated from combinatorial antibody libraries. The results of this work found that 
VH chain could recombine with multiple VL chains while retaining antigen binding. Although 
crosses showed similar apparent binding constants, they mainly differed in amount of active 
Fab expressed in the bacterial host. This work implicated VH chain dominance in antigen- 
binding by exploring several further direct chain crosses using VH and VL chains derived from 
antigen-specific and nonrelated Fab clones. They found that only crosses containing VH 
derived from antigen-specific clones retained binding activity. This work illustrates a method 
for potentially improving the stability of antibody obtained from bacterial cultures and 
implicates the VH chain as an optimum site for mutagenesis with regard to engineering 
binding characteristics. Antibody stability is a key factor in their performance as potential 
biopharmaceuticals and analytical tools. Stability of scFv antibody fragments depends largely 
on the intrinsic stability of its constituent VH and VL domains as well as the stability of the 
interface between each domain (VH and VL). These are properties dependant on particular 
individual sequences. Worn and Pluckthun (2001) have extensively reviewed scFv stability 
engineering. A range of engineering techniques have been successfully applied to overcome 
poor stability. These include, for example, antigen-specific CDR grafting onto stable 
framework regions and variable light-chain shuffling (Rojas et al., 2004).
1.12 Thesis outline
The aim of the work presented in this thesis was the production of polyclonal, monoclonal 
and genetically-derived scFv antibody fragments for the detection of the beta-lactam 
antibiotic residue, cephalexin, in milk. The work describes the production and 
characterisation of polyclonal (Chapter 3) and monoclonal antibodies, using hybridoma 
(Chapter 4) and recombinant phage-display technologies (Chapter 5). Antibodies were used in 
the development of ELISA and biosensor-based immunoassays capable of detection of 
cephalexin below its listed maximum residue limit (MRL) in milk.
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A polyclonal antibody was generated from cephalexin-bovine serum albumin (BSA) 
conjugate, cephalexin conjugates were produced by covalently binding it to various proteins 
for use as immunogens and analytical reagents. A panel of monoclonal antibodies was 
produced by somatic cell fusion procedures.
Recombinant antibody production techniques included the production of phage-display 
libraries from pre-immunised mice, the phage-display of scFv constructed from hybridoma 
cells and panning of a naive human combinatorial library (BMV library). A mutant phage- 
display library was generated using positive scFv-secreting clone using random mutagenesis 
and error-prone PCR. Phage-display libraries were panned using cephalexin conjugates and 
bound phages were retained by competitive cephalexin elution and with mild acid shock 
elution strategies. Soluble scFv antibodies were isolated, expressed and purified from mutant 
libraries. Selected clones were sequenced and point mutations were identified in CDR and 
structural framework regions.
All antibodies were purified and characterised by ELISA, SDS-PAGE and Western blotting. 
Subsequently, antibodies were evaluated in the development of inhibition immunoassays for 
the detection of cephalexin ‘spiked’ samples of PBS and whole milk (pasteurised and 
homogenised). Assays were initially carried out by ELISA and transferred to the SPR-based 
BIAcore 3000™ ‘real-time’ biosensor. The research encompassed the development of ELISA, 
and BIAcore-based displacement assays for the detection of cephalexin in milk. Working 
assays with desired performance characteristics (i.e. sensitivity and reproducibility) were 
validated. A range of semi-quantitative ELISA and Biacore-based assays were developed for 
the specific detection of cephalexin in milk. Antibodies produced were generally capable of 
detecting cephalexin at and below the MRL in milk, in ELISA and BIAcore-based assays.
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Chapter 2 
Materials & Methods
2.1 General Formulations
2.1.1 Reagents and chemicals
All standard laboratory reagents were purchased from Sigma Chemical Co., Poole, Dorset, 
England and were research grade unless stated otherwise.
Table 2.1. Reagents used and suppliers.
Reagent Supplier
Acetic acid 
Hydrochloric acid
Riedel de-Haen AG, Wunstorfer, Strabe 40, D-30926, 
Hannover, Germany.
Blue Ranger® pre-stained 
molecular weight markers 
BCA protein assay kit
Pierce, 3747 North Meridian Rd., PO box 117, Rockford, 
IL 61105, USA.
Amine coupling kit BIAcore AB, 2 Meadway Court, Meadway Technology 
Park, Stevenage, Herts SGI 2EF, UK.
DNA ligase Boehringer-Mannheim Ltd., East Sussex, UK.
Briclone Archport Ireland Ltd., Dublin City University, Glasnevin, 
Dublin 9, Ireland.
Bacteriological Agar
Tiyptone
Yeast Extract
Phosphate buffered saline tablets
Oxoid, Basingstoke, Hampshire, RG24 8PW, UK.
Trizol
Foetal calf serum 
L-Glutamine (lOOx) (200mM) 
Non-essential amino acids (lOOx) 
Sodium pyruvate (lOOmM)
Gibro BRL, Renfew Rd., Paisley PA49RF, Scotland.
PCR Optimizer kit Invitrogen, 9704-CH-Groningen, Netherlands.
PCR Primers MWG-Biotech Ltd, Milton Keynes, MK12 5RD, UK.
Perfectprep* gel cleanup kit Eppendorf AG, 22331, Hamburg, Germany.
Wizard® Plus Mini-prep kit 
PCR prep DNA purification kit 
Reverse-Transcription kit 
RQ1 RNase-Free DNase 1 
and buffer
Promega Corporation, 2800 Wood Hollow Rd., Madison, 
W1 53711-5399, USA.
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Restriction enzymes and relevant
buffers
New England Biolabs, Hitchin, Herts., England.
VCSM13 Bacteriophage Stratagene, North Torrey Pines Rd. La Jolla, USA.
2.1.2 Consumables
Table 2.2. Consumables used and suppliers.
Consumable Supplier
1.5 ml and 0.5 ml micro-centrifuge 
tubes, 50 ml (falcon) polypropylene 
tubes, pipette tips, Sterile 96-well 
plates
Sarstedt Ltd., Sinnottstown lane, Drinagh, Wexford, 
Ireland.
Sterile 20 ml universals Medical Supply Company, Damastown, Mulhuddart, 
Dublin 15, Ireland.
Nunc Maxisorp™ 96-well plates 
Tissue culture plastic-ware
Nunc, Kamstrup, DK, Roskilde, Denmark.
Nitrocellulose membrane Schleicher and Schuell Bioscience GmbH, Hahnestrasse 
3, D-37586, Dassel, Germany.
Acrodisc* 0.2 pm syringe filters 
Omega™ 10 and 50 kDa membrane 
filters
PALL Corp., Newquay, Cornwall, UK. (Distributed by 
VWR International Ltd., Rath Business Park, Ashbourne, 
Co. Meath, Ireland.)
Durapore® 0.2 (xm and 0.45 pm 
membrane filters
Millipore, 290 Concord Rd., Billerica, MA 01821, USA. 
(Distributed by AGB Scientific Ltd., Dublin Industrial 
Estate, Dublin 11, Ireland.)
BIAcore CM5 sensor chip BIAcore AB, 2 Meadway Court, Meadway Technology 
Park, Stevenage, Herts SGI 2EF, UK.
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2.1.3 Equipment
Table 2.3. Equipment used and suppliers.
Equipment Supplier
BIAcore 1000™ 
BIAcore 3000™
BIAcore AB, 2 Meadway Court, Meadway Technology 
Park, Stevenage, Herts SGI 2EF, UK.
SB 1 Blood tube rotator Stuart Scientific, Holmthorpe Industrial Estate, Redhill, 
Surrey, UK.
Heraeus Christ Labofuge 6000 
Biofuge A Microcentrifuge
Heraeus Instruments Inc, 111-A Corporate Boulevard, 
South Plainfield, New Jersey, USA.
Beckman J2-J21 centrifuge Beckman-Coulter Inc., 4300N Harbour Boulevard, South 
Plainfield, New Jersey, 07080, USA.
Sorvall RC-5B refrigerated 
centrifuge
Du Pont instruments, Newtown, Connecticut, USA.
Titretek Twinreader Plus Medical Supply Company, Damastown, Mulhuddart, 
Dublin 12, Ireland.
3015 pH meter Jenway Ltd., Essex, England.
Orbital incubator Sanyo Gallenkamp PLC., Monarch Way, Belton Park, 
Loughborough, Leicester, UK.
RM6 Lauda waterbath 
T-Gradient BIOMETRA-PCR 
Millipore Filtration Apparatus 
(250 ml)
AGB Scientific Ltd., Dublin Industrial Estate, Glasnevin, 
Dublin 9, Ireland.
Stirred Ultrafiltration Cell 8400 Amicon Inc., Beverly, Massachusetts 01915, USA.
Stuart Platform Shaker STR6 Lennox, P.O. Box 212A, John F. Kennedy Drive, Naas 
Rd., Dublin 12, Ireland.
UV-160A spectrophotometer Shimadzu Corp., 1 Nishinokyo-Kuwabaracho, Nakagyo- 
ku, Kyoto 604, Japan.
IJVP ImageStore 7500 gel 
documentation system
Ultra Violet Products, Upland, CA., USA.
C 02 Tissue culture incubator 
Thermoforma series II 3110 
FASTER BH2000 Laminar air 
flow unit
Biosciences, 3 Charlemont Terrace, Crofton Rd., Dun 
Laoghaire, Dublin, Ireland.
Laminar Flow Unit Holten 2448K Holten Laminar, A/S Gydevang 17, DK 3450 Allerod, 
Denmark.
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2.1.4 Microbiological culture media formulations
2.1.4.1 Bacterial culture medium
Table 2.4. Bacterial growth media used and components with amounts used. (Solid medium 
was made by adding 15 g/1 bacteriological agar to the media below).
Media Type
2 x Tiyptone and yeast extract (TY) medium
Components and amounts
Tiyptone 
Yeast Extract 
NaCl
16 g/1 
10 g/1 
5 g/1
Luria Bertani broth (LB) medium Tryptone
Yeast Extract 
NaCl
10 g/1
5 g/1 
5 g/1
Non-expression medium (NE) Tryptone 
Yeast Extract 
NaCl 
Glucose
Chloramphenicol
16 g/1 
10 g/1
5 g/1
1%, (v/v) 
25 (ig/ml
Low expression medium (LE) Tryptone 
Yeast Extract 
NaCl 
Glucose
Chloramphenicol
IPTG
16 g/1 
10 g/1 
5 g/1 
1%, (v/v) 
25 jig/ml 
0.5 mM
SOB medium Tryptone 
Yeast Extract 
NaCl 
KC1 
MgCl,
20 g/1 
5 g/1 
0.5 g/1 
2.5 mM 
20 mM
Super optimal catabolites (SOC) medium Tryptone 20 g/1
Yeast Extract 5 g/1
NaCl 0.5 g/1
KC1 2.5 mM
MgCl2 20 mM
Glucose 20 mM
pH 7.0
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2.1.4.2 Mammalian cell culture medium
All mammalian cell lines were routinely cultured in DMEM (Dulbecco's modification of 
Eagle's medium) supplemented with 10 % (v/v) foetal calf serum (FCS), 2 mM L-glutamine, 
and 25 (ig/ml gentamycin (referred to as DMEM). Subsequent variations of DMEM were 
used and are described in section 2.5.2.1.
2.1.5 Bacterial strains used
Liquid cultures were stored at -80°C with 15-20% (v/v) glycerol and at 4 ° C as streak agar 
plates (for no longer than one month).
Bacterial strain Source Comments
E. coli XL-1 Blue Stratagene Cultured in 2xTY broth
E. coli JM83 Stratagene Cultured in 2xTY broth
E. coli TGI Stratagene Cultured in 2xTY broth
ÆcoZ/TOPlOF’ Stratagene Cultured in 2xTY and SB broth
2.1.6 General buffer formulations
2.1.6.1 Phosphate buffered saline (PBS) wash buffer
One tablet (DA, Oxoid) was dissolved per 100 mis of distilled water according to the 
manufacturer’s instructions. When dissolved, prepared PBS contained 0.15 M NaCl, 2.5 mM 
potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium dihydrogen 
phosphate, and the pH was 7.4. This buffer will be referred to throughout as PBS.
2.1.6.2 PBS-Tween (PBS-T) wash buffer
Tween 20 surfactant (Sigma) was added to PBS to a final concentration of 0.05% (v/v) and 
mixed.
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2.1.6.3 PBS-TMdilution buffer
PBS-T was supplemented with 2 % (w/v) dried skimmed milk powder, and used for preparing 
antibody dilutions.
2.1.6.4 Blocking solution /  buffer
Dried skimmed milk powder was dissolved in PBS-T to give 5% (w/v) solution. This was 
used to block remaining absorption sites.
2.1.6.5 Tris-acetic acid-EDTA buffer (TAE)
A 50 X stock solution of TAE buffer was prepared in a final volume of 1 litre by dissolving 
242 g Tris, and addition of 57.1 ml glacial acetic acid followed by 100 ml of 0.5 M EDTA, 
with a pH of 8.0. All agarose gels were run in 1 X TAE by diluting the stock solution 1/50 
with ultra pure water.
2.1.6.6 Hepes Buffered Saline (HBS)
Hepes buffered saline (BIAcore running buffer) containing 50 mM NaCl, 10 mM HEPES, 3.4 
mM EDTA and 0.05% (v/v) Tween-20 was prepared by dissolving 8.76 g of NaCl, 2.56 g of 
HEPES, 1.27 g of EDTA and 500 jil of Tween 20 in 800 ml of distilled water. The pH of the 
solution was then adjusted to pH 7.4, by the addition of NaOH. The final volume was then 
made up to 1,000 ml. The solution was filtered through a 0.2 fim filter and degassed prior to
2.1.6.7 MES buffer
2-[N-Morpholino]-ethansulfonic acid (MES) buffer was prepared to a concentration of 5 mM, 
by dissolving 0.019g of MES in 15 ml of distilled water. The pH of the solution was adjusted 
to 5.8 by addition of NaOH. (For the production of KLH conjugates, this was supplemented 
with 0.9 M NaCl to aid solubility).
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2.2 Production of polyclonal antibodies to cephalexin
2.2.1 Antigen preparation
Coupling of the cephalexin to carrier protein was achieved using established EDC (1 -ethyl-3 - 
(3-dimethylaminopropyl) carbodiimide hydrochloride) / NHS (N-Hydroxysuccinimide) 
chemistry. EDC reacts with carboxylic acids to from highly active o-acylisourea 
intermediates that subsequently react with primary amines; NHS is used to stabilise the active 
intermediate produced by this reaction. Initially it was decided to activate the carboxyl group 
on the cephalexin molecule with subsequent addition of protein carrier (Activated Ester 
Coupling).
However, the carboxyl groups on the proteins were also activated followed by the addition of 
the cephalexin as a source of amine (Reverse Activated Ester Coupling). BSA (Bovine Serum 
Albumen), OVA (Ovalbumen), Thy (Thyroglobulin), KLH (Keyhole Limpet Haemocyanin), 
Biotin-Avidin, and Dextran conjugates with cephalexin were synthesised using the general 
coupling schemes that follow.
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Figure 2.1. Diagranimalic representation of generic reaction schemes used in the production 
of cephalexin conjugates. (A) The scheme in A is designated as cephalexin-activated 
coupling, where the carboxylic acid (-COOH) functional groups on the cephalexin molecule 
are activated using NHS / EDC and subsequently reacted with free amine (-NH2) groups 
present on the relevant protein (e.g. BSA) surface. B, (above) Shows the opposite process to 
that shown in (A), designated as protein-activated coupling, whereby carboxylic acid groups 
on the relevant protein surface are activated using NHS / EDC and subsequently reacted with 
free amines provided by cephalexin.
54
2.2.1.2 Preparation Cephalexin Conjugates (Cephalexin-activated ester coupling).
A 20 mg/ml solution of cephalexin was made up to a final volume of 4 ml with 0.2 M borate 
buffer, pH 8.5. Concentrations of EDC (N-ethyl-N-(dimethyl-aminopropyl) carbodiimide 
hydrochloride) and NHS (N-hydroxysuccinimide) were then added to give a final molarity of 
0.4 and 0.1 M, respectively, in the solution and allowed to react at room temperature without 
agitation for 10 min. Protein (BSA, OVA, THY) was prepared at a molar ratio of 1:100 to 
Cephalexin in 4 ml of 0.2 M borate buffer, pH 8.5, and added drop wise to the Cephalexin 
solution. This solution was allowed to react at room temperature for 2 h with mild stirring. 
The solution was dialysed against 50 volumes of PBS overnight at 4°C and further dialysed 
against 50 volumes of PBS at 4°C for 4 h.
2.2.1.3 Preparation o f Cephalexin Conjugates (Protein-activated coupling).
A 10 mg/ml solution of protein was made up to a final volume of 4 ml with 5 mM MES 
buffer, pH 6. Concentrations of EDC and NHS were then added to give a final molarity of 0.4 
and 0.1 M, respectively, in the solution and allowed to react at room temperature without 
agitation for 10 min. Protein (BSA, OVA, THY) was prepared at a molar ratio of 1:100 to 
Cephalexin in 4 ml of MES buffer, pH 6, and added drop wise to the Cephalexin solution. 
This solution was allowed to react at room temperature for 2 h with mild stirring. The 
solution was dialysed against 50 volumes of PBS overnight at 4°C and further dialysed 
against 50 volumes of PBS at 4°C for 4 h.
2.2.1.4 Preparation o f Cephalexin-KLH Conjugate.
Succinylated Keyhole Limpet Heamocyanin (KLH) (Sigma, research grade) was dissolved in 
5 mM MES buffer (0.9 M NaCl), pH 6, to give a 10-mg/ml solution of protein in a final 
volume of 1 ml. A stock solution of 10-mg/ml Cephalexin was made up in MES. 150 p.1 of 
this was added to the protein solution. From a 10-mg/ml stock solution of EDC a 100p.l 
portion was added to the solution containing the protein and cephalexin. The reaction mixture 
was vortexed and allowed to react at room temperature for 2 h with mild stirring. The 
solution was dialysed against 50 volumes of PBS overnight at 4°C and further dialysed 
against 50 volumes of PBS at 4°C for 4 h.
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2.2.1.5 Preparation o f Cephalexin-Biotin-Avidin Conjugate.
EZ-Link™ NHS-Biotin (N-Hydroxysuccinimidobiotin) purchased from Pierce was dissolved 
in 1 ml DMSO to give a 1-mg/ml solution; lOOfo.1 of this was reacted with a 20 molar 
equivalent of cephalexin dissolved in PBS, pH 7.4. The reaction mixture was allowed to react 
overnight at 4°C. The following day the reaction was further reacted with 1/10 molar 
equivalent avidin for 2 h at room temperature. The solution was dialysed against 50 volumes 
of PBS overnight at 4°C and further dialysed against 50 volumes of PBS at 4°C for 4 h.
2.2.2 Immunogen preparation and immunisation
All processes involving animals were licensed by the Department of Health and Children and 
care was taken to minimise the stress to the animals involved. Immunogen for the production 
of polyclonal antibodies consisted of a 1 mg/ml solution of Cephalexin-Bovine Serum 
Albumin (Ceph-BSA) conjugate in PBS and an equal volume of Freund’s complete adjuvant. 
This solution was vortexed until a stable emulsion was formed. New Zealand White female 
rabbits were injected subcutaneously at a number of sites with 1 ml of the emulsion. The 
immunisation was repeated 21 days later with Freund’s Incomplete adjuvant. Bleeds were 
taken from the marginal ear vein of the animals between 10 and 15 days after immunisation. 
Re-boosting and bleeding procedures were repeated until adequate antibody titre was 
obtained. Once sufficient titre was obtained the animals were sacrificed and the serum 
removed.
2.2.3 Purification ofpolyclonal antibody from whole serum
Purification of polyclonal antibody from rabbit serum was carried out by precipitation with 
saturated ammonium sulphate, followed by affinity purification using a protein G column.
2.2.3.1 Saturated ammonium sulphate precipitation
The ammonium sulphate precipitation of antibody from rabbit serum was carried out 
according to the method of (Hudson and Hay, 1989). Saturated ammonium sulphate (SAS) 
was prepared by dissolving 500 g of ammonium sulphate in 500 ml distilled water at 50°C, 
leaving the solution overnight at 4°C and adjusting the pH to 7.2. 10 ml of cold saturated 
ammonium sulphate (100%, w/v) was added drop-wise to an equal volume of rabbit serum on 
ice with gentle stirring. The mixture was allowed to stir at room temperature for 30 minutes,
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followed by centrifugation at 3,000 rpm for 20 minutes. The supernatant was discarded and 
the precipitate washed twice in 10 ml of 45% (w/v) ammonium sulphate. The washed pellet 
was dissolved in 5 ml of PBS and dialysed in 5 L of PBS overnight at 4°C to remove residual 
ammonium sulphate.
2.2.3.2 Protein G affinity chromatography
A 2 ml protein G-sepharose column was poured and equilibrated with 50 ml of PBS, pH 7.4, 
containing 0.3 M NaCl (running buffer). 2 ml of the dialysed ammonium sulphate rabbit 
immunoglobulin fraction was applied to the column and the flow rate adjusted to 1 ml/min. 
The sample was then re-applied to the column (twice) followed by washing the column with 
20 ml of PBS, pH 7.4, containing 0.5 M NaCl and 0.05% (v/v) Tween (wash buffer). Affinity 
captured-antibody was eluted with 0.1 M glycine/HCl, pH 2.2. 1 ml fractions were collected 
and immediately neutralised to pH 7.0 by addition of 100 pi of 1.5 M Tris/HCl, pH 8.7, to 
each fraction, in order to prevent denaturation of antibody. The optical density of each 
fraction was recorded at 280 nm, and those fractions containing protein were pooled and 
dialysed overnight in PBS at 4°C, and the preservative agent sodium azide added (0.05% (v/v) 
solution). The sample was aliquoted (0.5 ml fractions) and stored at -20°C.
2.3 Antibody characterisation
In general, antibodies were characterised using enzyme-linked immunosorbent solid-phase 
immunoassays, Sodium Dodecyl Sulphate Polyaciylamide Gel Electrophoresis (SDS-PAGE), 
Western blotting and Bicinchoninic acid (BCA) protein assays.
2.3.1 Solid-phase immunoassays
2.3.1.1 Enzyme-Linked Immunosorbent Assay (ELISA) for determination o f antibody titre
Nunc 96 well ELISA plates were coated with antigen (10-20 pg/ml of cephalexin-protein 
conjugate) for 1 hour at 37°C or overnight at 4°C. The plates were incubated at 37°C for 1 
hour, or at 4°C overnight and washed 3 times with PBS. The plates were then blocked with 
200 pi of a PBS-T 5% (w/v) blocking solution and incubated at 37°C for 1 hour and washed 
as before. Dilutions of antibody were prepared in dilution buffer (PBS-T) containing 1% 
(w/v) dried milk powder and 100 pi of each dilution added to the plates in triplicate. The 
plates were then incubated at 37°C for 1 hour, followed by 3 washes with PBS and 3 washes
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with PBS-T. A 1/2,000 dilution of secondary antibody (horse radish peroxidase (HRP)- 
labelled goat anti-rabbit antibody (polyclonal work) or HRP-labelled goat anti-mouse 
(monoclonal work)) was prepared in PBS-TM and 100 |_il of this solution added to the plates 
and incubated at 37°C for 1 hour. The plates were washed 3 times with PBS and 3 times with 
PBST, as before, and 100 (j.1 of freshly prepared o-phenylenediamine dihydrochloride (OPD) 
substrate added to each well. The absorbance was determined at 450 nm after 30 minutes 
using a Titertek Plate Reader Plus®. Antibody titres were taken as the lowest absorbance 
value that can be distinguished from background plus twice the standard deviation (SD).
2.3.1.2 Checkerboard ELISA for determination o f optimal concentrations o f immobilised 
conjugates
96-well plates were coated with varying antigen concentrations with each antigen 
concentration added to a different row on the ELISA plate. Plates were blocked, as described 
in section 2.3.1.1, with PBS containing 5% (w/v) dried skimmed milk and 100 fxl samples of 
antiserum were serially diluted in PBS-Tween containing 2% (w/v) milk (PBS-TM) added to 
each well and detected as in section 2.3.1.1.
2.3.1.3 Inhibition ELISA for antibody characterisation
Nunc ELISA plates were coated with antigen and blocked as described in section 2.2.3. 
Dilutions of free antigen (e.g. cephalexin or cross reactants) were made in PBS or whole milk 
and mixed with an equal volume of antibody. This mixture was incubated for 30 minutes at 
37°C. The plates were washed as before and 100 fil of each sample added to the plate in 
triplicate and incubated at room temperature for 1.5 hours with gentle mixing. Plates were 
washed three times with PBS and 3 times with PBS-Tween and 100 fil of 1/2000 dilution of 
HRP-conjugated goat anti-rabbit antibody in PBS-Tween containing 1% (w/v) Marvel added 
to each well. After incubation for 1 hour at 37°C, 100 |xl of OPD substrate was added to each 
well and the plates incubated for 30 minutes to 1 hour at 37°C. Absorbance was determined at 
450 nm. The results were plotted as a ratio (A/A0), where the absorbance for a given antibody 
and cephalexin standard concentration (A) was divided by the measured absorbance for the 
antibody with no free cephalexin (A0).
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2.3.2 Denaturing Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
Polyacrylamide gel electrophoresis was carried out, as described by Laemmli (1970), in the 
presence of SDS. The experimental apparatus (Atto dual minislab system) was set up 
according to the manufacturers’ guidelines. 12% (w/v) separating gels and 5% (w/v) stacking 
gels were normally used and prepared using following stock solutions as outlined in table 2.5:
(A) 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide.
Acrylamide 30 g
Bis-acrylamide 0.8 g
Dissolved in 100 ml dH20, mixed thoroughly and stored in the dark at 4°C.
(B) Separating gel buffer (4x) -1.5 M Tris-HCl, pH 8.8 containing 0.4% (w/v) SDS.
2 M Tris-HCl (pH 8.8) 75 ml
10% (w/v) SDS 4 ml
dH20  21 ml
Mixed thoroughly and stored at 4°C.
(C) Stacking gel buffer (4x) - 0.5 M Tris-HCl, pH 6.8 containing 0.4% (w/v) SDS.
1 M Tris-HCl (pH 6.8) 50 ml
10% (w/v) SDS 4 ml
dH20  46 ml
Mixed thoroughly and stored at 4°C.
(D) 10% (w/v) ammonium persulphate.
Ammonium persulphate 0.05 g
Dissolved in 500 (il of dH20  and mixed thoroughly and made fresh as
required.
The apparatus glass plates were washed thoroughly and wiped with acetone. Polymerisation 
of the separating gel acrylamide was catalysed by addition of ammonium persulphate solution
(D) and the accelerator TEMED (N, N, N', N'-tetramethyl-ethylenediamine) and the gel added 
to the space between the plates and covered with a layer of ethanol. Once the gel had 
polymerised, the ethanol was removed and the stacking gel was placed directly onto the
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separating gel. A plastic comb was placed in this gel to create the wells for sample 
application. Once the gel had fully polymerised, the plates were then placed in the 
electrophoresis apparatus, the comb was removed and the chamber and wells filled with lx 
electrophoresis buffer (25 mM Tris, 130 mM Glycine (electrophoresis grade), pH 8.3 and
0.1% (w/v) SDS).
5x Electrophoresis buffer (1L).
Tris-base (25 mM) 15 g
Glycine (130 mM) 72 g
SDS (0.1% (w/v)) 5 g
pH 8.3
It was mixed thoroughly and volume adjusted to 1 L in a volumetric flask and stored 
at R.T.
Table 2.5. Quantities of stock solutions used for the preparation of separating and stacking 
gels. (A) 30% (w/v) Acrylamide solution containing 29.2% (w/v) acrylamide and 0.8% (w/v) 
Bis-acrylamide; (B) 4X separating gel buffer consisting of Tris-HCl, pH 8.8 (1.5M) and SDS 
(0.4% w/v) diluted in distilled water; (C) 4X stacking gel buffer consisting of Tris-HCl, pH 
8.8, (0.5M) and SDS (0.4%, w/v) diluted in distilled water and (D) 100 mg/ml ammonium 
persulphate diluted in water.
Solution Resolving Gel Stacking Gel
Acrylamide (A) 5.0 ml 837^1
Distilled Water 2.5 ml 2.87 ml
Separating Gel Buffer (B) 2.5 ml -
Stacking Gel Buffer (C) - 1.25 ml
Ammonium Persulphate (D) 100 jxl 50^1
TEMED 10 (il 10 n-1
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Excess sample buffer is essential to maintain reduction of protein sulfhydryls and to prevent 
intra-molecular disulfide bond formation through oxidised cysteines. A 5x stock solution of 
sample buffer was prepared to give the following final concentrations: 60 mM Tris-HCl (pH 
6.8), 25% (w/v) glycerol, 2% (w/v) SDS, 14.4 mM 2-mercaptoethanol and 0.1% (w/v) 
bromophenol blue.
1 M Tris-HCl (pH 6.8) 0.6 ml
50% (v/v) Glycerol 5 ml
10% (w/v) SDS 2 ml
2- Mercaptoethanol 0.5 ml
1% (w/v) Bromophenol blue 1 ml
dH20 0.9 ml
Components were mixed thoroughly and stored in aliquots at -20°C.
Samples were mixed 5:1 with sample buffer and heated for 4-5 minutes at 100°C. Standard 
protein molecular weight markers, as outlined in table 2.6, were run in parallel with samples. 
A total sample volume of 20 (il was added to the respective wells on the gel. The power unit 
was run at 15 mA per gel until the sample had reached the bottom of the gel.
Gels were stained with Coomassie blue staining solution for 1-2 hours followed by destaining 
in 30% (v/v) methanol: 10% (v/v) acetic acid:60% (v/v) distilled water for 2-3 hours. 
Coomassie blue staining solution was prepared as follows:
Coomassie blue R-250 (Sigma) 1.25 g
Methanol 227 ml
dH20  227 ml
Glacial acetic acid 46 ml
The staining solution was mixed thoroughly and filtered through Whatman filter 
paper (grade 1) and stored in a dark bottle at R.T.
Destaining solution was stored at R.T. and typically prepared as follows:
Methanol 300 ml
dH20  600 ml
Glacial acetic acid 100 ml
Destaining solution was mixed thoroughly and stored at R.T.
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Table 2.6. Molecular weights of the protein standards used for SDS-PAGE and Western Blot 
analysis. The molecular weights of the Sigma wide range and Pierce Blue Ranger™ pre­
stained markers indicate the apparent molecular weights of each protein after staining.
Protein standard Sigma wide range marker Pierce blue ranger marker
Aprotinin 6.5 kDa -
a-Lactalbumin 14.2 kDa -
Lysozyme - 18 kDa
Trypsin Inhibitor 20 kDa 26 kDa
Trypsinogen 24 kDa -
Carbonic Anhydrase 29 kDa 32 kDa
Glyceraldehyde-3 - 
phosphate dehydrogenase
36 kDa -
Ovalbumin 45 kDa 48 kDa
Glutamic Dehydrogenase 55 kDa -
Albumin 66 kDa 85 kDa
Fructose-6-phosphate
Kinase
84 kDa -
Phosphorylase B 97 kDa 112 kDa
Galactosidase 116 kDa -
Myosin 205 kDa 208 kDa
2.3.3 Western blot analysis
Following electrophoresis, the polyacrylamide gel was placed on top of three sheets of 
Whatman filter paper pre-soaked in transfer buffer. A sheet of nitrocellulose membrane, also 
pre-soaked in transfer buffer, was carefully placed on top of the gel and any air bubbles 
removed by rolling a clean 10 ml pipette over the sheets. Three more sheets of pre-soaked 
filter paper were added on top of the gel and air bubbles removed. The proteins were 
transferred from the gel to the membrane using a Bio-Rad Semi-dry Transfer system for 20 
min at 20V at R.T.
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After transfer, the blotted membrane was washed 3 times with PBS (0.15 M NaCl, 2.5 mM 
potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium dihydrogen 
phosphate, pH 7.4), prior to overnight incubation in blocking buffer (PBS containing 5% 
(w/v) powdered skimmed milk). Following blocking, the blot was washed 3 times in PBS 
buffer and then incubated with primary antibody (at the appropriate dilution in dilution buffer
i.e. PBS-T containing 2% (w/v) skimmed milk powder) for 1.5 hours at room temperature 
while rocking. The blot was then washed 3 times in PBS and 3 times in PBS-T prior to 
incubation with enzyme-labelled secondary antibody (e.g. HRP-labelled goat anti-rabbit) 
diluted in PBS-T containing 2% (w/v) skimmed milk for 1.5 hours at R.T. The blot was 
washed 3 times in PBS-T then PBS. Following this the membrane was developed using 
appropriate substrate solution (i.e. 3,3',5,5'-Tetramethyl-Benzidine (TMB) for HRP-labelled 
and 5-bromo-4-chloro-3’-indolyphosphate / nitro blue tetrazolium chloride (BCIP/NBT) for 
alkaline phosphatase-labelled secondary antibodies). Colour development was allowed to 
proceed at room temperature until the desired bands were apparent. The reaction was then 
stopped by washing extensively with distilled water or by rinsing with lOOmM EDTA.
2.3.4 Bicinchoninic acid (BCA) assay for estimation ofprotein concentration
BCA reagents were provided as ‘made-up’ components in the BCA protein assay kit (Pierce). 
Solution ‘A’ comprised a mixture of sodium carbonate, sodium bicarbonate, Bicinchoninic 
acid and sodium tartrate in 0.1 M sodium hydroxide. Solution ‘B’ contained 4% (w/v) cupric 
sulphate. Working reagent (WR) was prepared by mixing solutions ‘A’ and ‘B’ in the ratio of 
50:1, respectively. Appropriate protein standards were prepared in an analogous buffer to 
unknown samples (e.g. PBS) at concentrations of 0, 25, 125, 250, 500, 750, 1000, 1500 and 
2000 fjg/ml. The assay was carried out by pipetting 25 jxl of each standard and unknown 
sample in triplicate into the wells of a 96-well plate. A 200 jxl aliquot of working reagent was 
added to each of the wells. The plate was covered with tin foil and incubated at 37°C for 30 
minutes. Following colour development the absorbance was read at 590 nm. Values obtained 
for each standard solution were used to construct a calibration curve by subtracting the blank 
(0 p.g/ml) measurement. That was subsequently used to estimate the total protein content of 
the unknown samples.
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2.4 Production of monoclonal antibodies to cephalexin
All mammalian cell cultures and reagents were manipulated aseptically in laminar air flow 
units and grown in a humidified 5 % (v/v) C 02 atmosphere, at 37°C. Somatic cell fusion was 
employed as a means of producing ‘immortal’ hybrid cell lines secreting specific antibody 
from pre-immunised murine B-lymphocyte and myeloma cells.
2.4.1 Immunogen preparation and Immunisation protocol for the production of 
monoclonal antibodies to Cephalexin
All processes involving animals were approved and licensed by the Department of Health and 
Children and care was taken to minimise the stress to the animals involved. Balb/C mice of 
age 5-8 weeks old were used for the production of monoclonal antibodies by immunisation 
with immunogens that were prepared as described previously (section 2.2.2). Three separate 
immunogens containing Thyro-Ceph., KLH-Ceph., and BSA-Ceph conjugates at a 
concentration of 1 mg/ml were used in the generic immunisation schedule described below:
Day 1: A 1-mg/ml solution of immunogen was prepared in PBS and mixed with an
equal volume of Freund's Complete Adjuvant (FCA). This solution was then 
vortexed to form an emulsion, and 150-200 (J.1 of the emulsion used to 
immunise mice by intra-peritoneal (i.p.) injection.
Day 21: Mice were re-immunised in the i.p. cavity (with a similar dose of the
immunogen, above in Freund's Incomplete Adjuvant (FICA) or PBS).
Day 28: Mice were bled from the tail vein, and the specific antibody titre determined.
Post-Day 28: Mice were boosted through the i.p. cavity with a similar mix of antigen and
FICA or PBS as per day 21.
Post-Day 28: The above immunisation and blood sampling sequence was continued until a
satisfactory antibody titre was recorded. Once the antibody titre was 
sufficiently high, the mouse was boosted by i.p. cavity injection with the 
respective immunogen.
The mouse was then sacrificed by cervical dislocation; the spleen was 
removed and used for subsequent monoclonal antibody fusion procedures.
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2.4.2 Mammalian cell culture
2.4.2.1 Preparation o f mammalian cell culture media
All cell lines were grown in DMEM (Dulbecco's modification of Eagle's medium) 
supplemented with 10 % (v/v) foetal calf serum (FCS), 2 mM L-glutamine, and 25 Mg/ml 
gentamycin (referred to as DMEM).
Three additional media preparations were prepared for somatic cell fusion procedures, (i) 
DMEM lacking foetal calf serum was prepared for use during somatic cell fusion procedures,
(ii) HAT (Hypoxanthine, Aminopterin and Thymidine) medium consisted of DMEM 
supplemented with 1 mM sodium pyruvate, non-essential amino acids (NEAA; 1 %, v/v), 100 
|xM hypoxanthine, 400 nM aminopterin, and 16 joM thymidine. This particular culture 
medium allowed for the selective growth of hybridoma cells post-fusion in the presence of 
Sp2/0 cells, which are unable to proliferate in HAT medium because they lack the requisite 
enzyme systems, (iii) DMEM supplemented with 1 mM sodium pyruvate, non-essential 
amino acids (1 %, v/v), 100 f.iM hypoxanthine and 16 |iM thymidine was also prepared 
(referred to as HT medium).
2.4.2.2 Recovery o f frozen cells
Cells were recovered from liquid nitrogen by rapidly thawing at 37°C, and transferring to a 
sterile universal containing 5 ml DMEM. The cells were then centrifuged at 2,000 r.p.m. for 
10 minutes, resuspended in fresh culture medium, transferred to a tissue culture flask and 
incubated at 37°C in a humidified 5 % (v/v) CO2 incubator. Prior to incubation, a 100 fj.1 
sample of the resuspended pellet was tested for cell viability using Trypan blue (section
2.5.2.3). Only cell preparations with > 90 % viability on recoveiy from frozen stocks were 
cultured further.
2.4.2.3 Cell counts and viability testing
All cell counts were made using an improved Neubaiier counting chamber. Viable cell counts 
were obtained by mixing 100 (xl of cell suspension with 20 (J.1 of a commercial 0.25 %, (w/v) 
isotonic Trypan blue solution (Sigma). The viable cell count was carried out within 5 minutes 
of the addition of Trypan blue as the solution is cytotoxic. A sample of this mixture was then 
used to perform the cell and viability count. Viable cells excluded the dye and remained
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white, whereas dead cells were stained blue. Cells were visualised under phase contrast on an 
inverted microscope at 40 X magnifications. All cells were pelleted from growth media by
centrifugation at 2,000 r.p.m. for 5 minutes unless otherwise stated.
2.4.2.4 Growth o f suspension cell lines
The Sp2/0 (ATCC CRL 1581) cell line was cultured in DMEM. The cells were sub-cultured, 
using a split ratio of 1:4, at approximately 70 % confluency. For sub-culturing, the cells were 
flushed off the surface of the flask using a Pasteur pipette, collected and centrifuged at 2,000 
r.p.m. The pellet was then resuspended in 4 ml of fresh culture medium. 1 ml of the 
resuspended pellet was then transferred to T-75 flasks containing 14 ml of fresh pre-warmed 
(37°C) DMEM.
2.4.2.5 Storage o f cell lines
Cells were harvested from the surface of a confluent T-75 flask by flushing the surface of the 
flask with a Pasteur pipette, and pelleted by centrifugation at 2,000 r.p.m. Pellets were 
resuspended in 3 ml of a 10 % (v/v) solution of DMSO (Dimethyl sulphoxide) in FCS and 1 
ml aliquots were transferred into 3 cryovials. A freezing-tray was used to gradually cool the 
cells, over a 3 hr. period, in the vapour-phase of liquid nitrogen. They were then immersed in 
the liquid-phase for long-term storage.
2.4.2.6 Mycoplasma screening
Cell lines were screened for Mycoplasma contamination in conjunction with the National Cell 
and Tissue Culture Centre (NCTCC), Dublin City University. Mouse myeloma cell lines used 
for somatic cell fusion procedures and selected hybridoma cell lines were cultured for 2 
weeks prior to screening in antibiotic-free media. This was to ensure that any intracellular 
antibiotic was removed. Cells were split at approximately 70% confluence and seeded at a 
low density to prolong contact with growth media. Conditioned medium was decanted and 
stored at -20°C for subsequent screening. Mycoplasma screening was carried out using 
Hoechst 33258 DNA-intercalating fluorescent dye. Uncontaminated cells show relatively 
strong fluorescence in the nuclei only, whereas cells that are contaminated are detected by 
cytoplasmic staining of the mycoplasmic DNA.
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2.4.3. Hybridoma production and isolation
2.4.3.1. Somatic cell fusion
Sp2/0 (ATCC CRL 1581) cells were grown for at least two weeks, prior to fusion. Cells 
were not grown above 50 % confluency, and were sub-cultured at a split ratio of 1:2 the day 
before fusion. On the day of fusion, the medium was poured off the Sp2/0 cells, and fresh 
DMEM lacking FCS (section 2.4.2.1) was added. Cells were resuspended and counted. The 
cells were stored at room temperature until required.
Lymphocytes, from an immunised mouse were harvested from the extracted spleen, 
resuspended in DMEM lacking FCS, and counted. The lymphocytes and Sp2/0 cells were 
mixed to give a cell ratio of approximately 5-10 lymphocytes per Sp2/0 cell. This cell 
mixture was pelleted by centrifugation at 1,250 r.p.m. and washed 4 times with 5 ml of 
DMEM lacking FCS.
All of the supernatant, from the final wash, was removed, except for 50-100 jj.1 (simply 
pouring off the supernatant sufficed). The cells were resuspended by tapping the outside of 
the centrifuge tube until the cell pellet was in suspension. The cell suspension was placed in 
an ice-water bath, and 1.5 ml of 50 % (v/v) PEG (polyethylene glycol, molecular weight 
1540 Da) previously cooled to 4°C, was added over a 1 minute period, with constant mixing. 
Mixing was continued for another 1.5 minutes. The centrifuge tube was removed from the 
ice-water bath, and enclosed in the palm of the hand, while adding 20 ml of pre-warmed 
(37°C) DMEM lacking FCS at a constant rate over a 5 minute period with continual slow 
swirling. The resulting suspension was placed at 37°C in a water bath for 15-20 minutes. 
Following this the suspension was centrifuged, at 1,000 r.p.m. for 10 minutes, and the cells 
resuspended at a cell density of 1.2xl06 cells/ml, in HAT medium supplemented with 5 % 
(v/v) Briclone (section 2.4.2.1). The suspension was plated (termed master plates), in 96 well 
plates, at 0.1 ml per well, and incubated for 7 days. On day 7, 75 jj.1 of fresh HAT medium 
supplemented with 5 % (v/v) Briclone was added to each well. Wells were then fed as 
required.
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2.4.3.2 Screening for specific monoclonal antibody production
100 jxl of ‘spent’ hybridoma supernatant was removed from each of the master plate wells, 
and replaced with 100 |il fresh DMEM supplemented with 5 % (v/v) Briclone. The 'spent' 
hybridoma medium was then screened for specific antibody production by conventional 
ELISA, as described in section 2.3.1.1. Positive wells from the initial screening were then 
transferred to 24-well plates, 12-well and subsequently to 6-well plates for cloning by limiting 
dilution. Positive populations were continuously monitored in displacement inhibition assays, 
as described in section 2.3.1.3.
2.4.3.3 Cloning ofhybridomas secreting cephalexin-specific antibodies
Post-fusion cells from wells that tested positive in the screening ELISA were expanded in 
HAT medium, from 96-well plates, to 24-well plates, 6-well plates and finally to T25 flasks. 
Cells were cloned by limiting dilution when they had reached 50 % confluency. Briefly, cells 
were resuspended, and diluted to a concentration of 100 cells/ml in HT supplemented with 5 
% (v/v) Briclone. 100 jj.1 aliquots were added to wells in fresh 96-well plates yielding 
approximate cell densities of 10 cells per well. After 7 days, the plates were examined 
microscopically and wells containing single colonies were noted. On days 10-12 screening for 
positive wells proceeded, using an ELISA, as per section 2.3.1.1, with neat medium from the 
wells, as the test sample. Only cells that demonstrated inhibition in the presence of free 
cephalexin in ELISA assay formats were expanded further. Positive wells were expanded, as 
already described, and re-cloned at 1 cell/well seeding densities. Finally, another round of 
cloning was carried out in DMEM containing 10 % (v/v) FCS, NEAA (1 %, v/v), and 1 mM 
sodium pyruvate i.e. lacking HT and Briclone supplements, at a 0.5 cell/well seeding density. 
Positive single colonies were considered to be monoclonal at this stage.
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2.5 Production of recombinant single chain Fv (scFv) antibodies to cephalexin
2.5.1 Production of murine scFv antibody libraries
Recombinant single chain variable fragment (scFv) production provides an alternative source 
of high affinity cephalexin-specific antibodies. Recombinant antibodies can be expressed in 
large quantities in E. coli and easily purified via engineered affinity tags, such as the 
polyhistidine tag or the Flag peptide tag. Antibody phage display has the advantage of a direct 
link between DNA sequence and protein function allowing modifications in the primary 
antibody sequence, (Hoogenboom et al., 1998). This makes it possible to manipulate the 
genetic sequence (genotype) of antibodies and, hence, their characteristics (e.g. affinity and 
specificity). The link between the antibody genotype and phenotype (i.e. the expressed 
antibody protein) facilitates the enrichment of desired antibodies by panning with appropriate 
antigen.
2.5.2 General molecular biology-based techniques
2.5.2.1 Agarose gel electrophoresis for DNA characterisation
DNA was analysed by running on agarose gels (containing 0.5 ng/ml ethidium bromide for 
staining of DNA) in a horizontal gel apparatus. Gels were prepared by dissolving agarose 
(typically ranging between 0.7-1.2% (w/v)) in lx  TAE buffer by heating and 0.5 |ig/ml 
ethidium bromide added to the cooled gel prior to setting. Following this gels were placed in 
the electrophoresis apparatus and 1 x TAE added as the running buffer. A 5X loading dye 
incorporated into each sample (1 j.il dye + 5 p.1 sample) to facilitate loading and monitoring of 
samples unless red Taq (Sigma) PCR products were run. Maxi gels were frequently run at 100 
volts for 1 hour or until the loading dye reached the end of the gel while mini gels were 
frequently run at 40-80 volts. Gels were then visualised on a UV transilluminator and 
photographed using a UV image analyser.
2.5.2.2 Purification o f PCR reaction products from agarose gels
DNA (i.e. PCR product) was purified from agarose gels using the Wizard® PCR prep DNA 
purification kit (Promega). PCR products were typically run on a 1% (w/v) low melt agarose 
gel containing 0.5 jig/m 1 ethidium bromide (section 2.5.2.1). The desired base pair band 
fragments (e.g. approximately 400 bp for variable heavy and light chain antibody genes) were 
excised from the gel with a sterile scalpel and the DNA purified from the low melt agarose
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according to manufacturers’ guidelines. The excised gel samples were incubated at 70°C in a 
water bath/heating block causing the agarose to melt within 5 minutes. 1 ml of resin was 
immediately added and mixed thoroughly by pipetting for 15 seconds. For each PCR 
preparation a plunger from a 5 ml syringe was attached to a Wizard Mini-column and the 
resin was slowly pushed through. The column was then washed with 2 ml of 80% (v/v) 
isopropanol. The column was centrifuged for 2 minutes at 14,000 rpm to remove any residual 
buffers. The mini-column was placed in a fresh 1.5 ml micro-centrifuge tube and 20 fj.1 of 
molecular grade ultra pure water (upH20 ) was applied to the mini-column and allowed to 
incubate for 1 minute at R.T. The column was centrifuged at 14,000 rpm for 20 seconds to 
elute the DNA, samples were and stored at -20°C until required.
2.5.2.3 Purification o f plasmid DNA
Plasmid DNA purification was performed using the Wizard® Plus SV miniprep DNA 
purification kit (Promega). A single E. coli colony containing plasmid (e.g. E.coli XLl-Blue 
containing pAKlOO phagemid vector, kindly donated by Andreas Pluckthun, University of 
Zurich, Switzerland) was picked from a stock agar streak plate and used to inoculate 5 ml of 2 
x TY supplemented with 30 (J.g/ml tetracycline. The culture was grown overnight at 37°C with 
vigorous shaking. The cells were then pelleted by centrifugation for 5 min at 4000 rpm. The 
supernatant was carefully decanted and the pellet thoroughly resuspended in 250 jxl 
resuspension buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA and 10 /¿g/ml RNase A) and 
transferred to a sterile 1.5 ml microcentrifuge tube. Cell lysis solution (250 jxl of 0.2 MNaOH 
and 1% (w/v) SDS) was added to the resuspended cells and mixed by inverting 4 times. The 
resulting mixture was incubated at R.T. for 5 minutes prior to the addition of 10 fil of alkaline 
protease solution and further mixing by inverting the tube 4 times and incubation for 5 
minutes. Alkaline protease was added in order to inactivate endonucleases and other proteins 
released during cell lysis that can adversely affect the quality of DNA. 350 |il of neutralisation 
solution (Buffer containing 4.09 M guanidine hydrochloride, 0.759 M potassium acetate and
2.12 M glacial acetic acid, pH 4.2) was added and again mixed by inverting the tube 4 times. 
The resulting mixture was centrifuged at 14,000 rpm for 10 minutes at R.T. The cleared lysate 
(supernatant) was carefully decanted into a spin column in a fresh 1.5 ml tube and centrifuged 
at 14,000 rpm for 1 min at R.T. The column ‘flow-through’ was discarded from the 1.5 ml 
tube and 750 jxl of wash solution (162.8 mM potassium acetate, 22.6 mM Tris-HCl, pH 7.5, 
and 0.109 M EDTA) pre-diluted with 95% (v/v) ethanol as per manufacturers’ guidelines, 
was added. The spin column was re-inserted in the microcentrifuge tube and centrifuged at 
14,000 rpm for 1 min at R.T. and the ‘flow-through’ discarded again. The wash procedure
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was repeated using 250 |xl of wash solution and centrifuged at 14,000 rpm for 2 minutes The 
‘flow-through’ was again discarded. The spin column was transferred to a fresh sterile 1.5 ml 
microcentrifuge tube and the plasmid DNA finally eluted by adding 100 fxl of ultra-pure 
molecular grade water to the column, followed by centrifugation at 14,000 rpm for 1 min at 
R.T. The volume collected in the 1.5 ml tube was kept for further analysis and the spin 
column discarded. DNA was stored at -20°C until required.
2.5.2.4 Ethanol precipitation o f DNA
DNA was routinely precipitated by ethanol precipitation as a means of concentrating samples 
and crude rapid purification. Typically, 1/10th the sample volume of 3 M sodium acetate 
buffer, pH 5.2, was added (i.e. 5 jxl sodium acetate for a 50 (il PCR reaction product). PCR 
product was transferred to a 1.5 ml microcentrifuge tube and mixed with the appropriate 
volume of sodium acetate buffer. This was followed by the addition of 2x the original sample 
volume of cold (stored at -20°C) 100% (v/v) ethanol (i.e. 100 jxl ethanol for a 50 (xl PCR 
reaction product). The mixture was placed at -20°C for at least 2 hours (mostly overnight) and 
centrifuged at 14,000 rpm for 15 minutes at 4°C. The supernatant was carefully removed 
using a pipette and the remaining ethanol evaporated by incubation in a 37°C water bath. The 
resulting pellet was resuspended using the desired volume of molecular grade upH20  and 
stored at -20°C until required.
2.5.2.5 Quantification o f DNA
DNA quantification was carried out on an agarose gel with a quantitative molecular weight 
markers (Promega, 100 bp Molecular Weight Markers, Bioline, Hyperladder quantification 
markers), The Promega 100 bp markers 500 bp fragment was used as a reference for 
densiometric quantitation, as 5 fil contains 150 ng of the 500 bp fragment and 50 ng of the 
other molecular weight fragments. Supplementary means of estimating the concentration of 
DNA samples was carried out using UV spectroscopic analysis. Samples were typically 
diluted (1/50), transferred to a dedicated quartz cuvette and the absorbance measured at 260 
nm. The concentration (|ig/ml) of DNA was calculated using the following formula:
[DNA] = Dilution factor (e.g. 50) x 50 x Absorbance
1000
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2.5.2.6 Preparation o f chemically competent E. coli cells
Chemically competent cells were prepared as previously described by Inoue et al. (1990). 
Stocks of E. coli JM83 and XL1 blue were streaked on 2xTY agar and incubated at 37°C 
overnight. Approximately 10-12 large colonies were removed from the plate and inoculated 
into 250 ml of SOB medium in a 2L baffled flask. The culture was grown at 18°C with 
vigorous shaking (200-250 rpm) until an OD60o of 0.6 was reached. The culture was then 
placed on ice for 10 minutes before being transferred to two pre-cooled 250 ml centrifuge 
tubes and spun at 4,000 rpm at 4°C for 5 minutes in a Beckman J2-21 centrifuge. The pellets 
were resuspended in 40 ml of ice-cold TB buffer (10 mM Pipes, 15 mM CaCl2, 150 mM KC1, 
pH adjusted to 6.7 with KOH and 55 mM MnCl2, sterile filtered and stored at 4°C), placed on 
ice for 10 minutes, pooled and centrifuged as before. The cell pellet was gently resuspended 
in 20 ml of ice-cold TB buffer and DMSO added slowly with gentle swirling to a final 
concentration of 7% (v/v). After incubation in an ice bath for 10 minutes the cell suspension 
was dispensed in 1 ml aliquots into microcentrifuge tubes. The cells were then flash frozen in 
liquid nitrogen and stored at -80°C.
2.6.2.1 Preparation o f high efficiency electrocompetent E. coli cells
Electrocompetent TOPIOF’ E. coli were prepared using a modified version of the protocol 
described by Barbas et al. (2001). In order for cells to be electrocompetent, E. coli must have 
a high resistance i.e. low ionic strength. This was achieved by repeatedly washing mid-log 
phase E. coli in low-salt buffers and eventually resuspending them in the same buffer 
supplemented with 10% (v/v) glycerol prior to flash freezing in liquid nitrogen at -80°C. 
TOPIOF’ cells were streaked on LB agar plates supplemented with 30 |ug/ml tetracycline 
(Tet.) and incubated inverted at 37°C overnight. Single colonies were picked and used to 
inoculate 15 ml of pre-warmed (37°C) SB containing 30 (ig/ml Tet. in polypropylene tubes 
(50 ml falcon tubes). Cultures were grown at 37°C overnight with shaking (250 rpm). 2.5 ml 
of overnight culture was used to inoculate two 2 L baffled culture flasks containing 500 ml 
SB broth supplemented with 0.4% (v/v) glucose, 10 mM MgCl2 and 30 (.ig/ml Tet. The 2 L 
flasks containing cultures were grown at 37°C with shaking (250 rpm) until OD of 0.8 at 
600nm was achieved. The cultures were then placed on ice in a 4°C environment for 15 min. 
All further steps were carried out as rapidly as possible and manipulated with pre-chilled 
pipettes in a cold room environment (4°C). The chilled cultures were decanted into two pre­
chilled 500 ml centrifuge tubes and centrifuged at 4000 rpm for 10 min at 4°C. Supernatant 
was decanted and the pellets were resuspended in 25 ml of pre-chilled 10% (v/v) glycerol 
solution. After resuspending, both cultures were combined and added to 500 ml centrifuge
72
tube bringing the volume up to approximately 500 ml with glycerol solution followed by 
centrifugation as before. Pellets were resuspended in 500 ml 10% (v/v) glycerol solution and 
centrifuged a further two times. The pellet was then thoroughly resuspended in 25 ml glycerol 
solution and transferred to a pre-chilled 50 ml falcon tube and centrifuged at 3500 rpm for 15 
min at 4°C. Most of the supernatant was carefully poured off until the pellet began to slide out 
of the tube. The remaining wet pellet was resuspended thoroughly and approximately 300 jil 
aliquots were placed in pre-chilled 1.5 ml sterile microcentrifuge tubes and immediately flash 
frozen in liquid nitrogen. Cell preparations were stored at -80°C until required (for no longer 
than 6 months).
2.5.3 Isolation o f murine antibody variable heavy (Vg) and light (Vj) chain genes from  
immunised mice
2.5.3.1 Immunisation procedure o f BALB/c mice for the production o f single chain Fv (scFv) 
antibody fragments to cephalexin.
Solutions of 1 mg/ml cephalexin conjugates were prepared in PBS and added to an equal 
volume of Freunds’ Complete adjuvant (FCA). This solution was vortexed until a stable 
emulsion was formed. 5-10 week old BALB/c mice were immunised subcutaneously with a 
total volume of 250 fil over several sites, as described in section 2.4.1. Further intra-peritoneal 
cavity immunisations were carried out after 21 days using Freunds’ Incomplete adjuvant 
(FLA). Tail bleeds from immunised mice were taken 7 days later and the antibody titre against 
cephalexin determined as per section 2.3.1.1. Mice were re-boosted and the bleeding 
procedure repeated until an adequate serum antibody titre was obtained. The animals were 
then re-immunised 7-10 days prior to sacrifice. The mice were sacrificed by cervical 
dislocation and the spleens removed.
2.5.3.2 Total RNA extraction from the spleens o f BALB/c mice
The spleen from an immunised mouse (immunised with various cephalexin conjugates) was 
removed aseptically and placed into a pre-weighed sterile universal. The spleen was weighed 
and 1 ml of Trizol reagent per 50 mg of spleen added. It was then homogenized, using a 
sterile homogeniser (Ultra-Turrax ®, model) for the mechanical disruption of tissues and 
cells. The apparatus was previously sterilised and desiccated, at 180°C overnight. The 
homogenized sample was dispensed into 1 ml aliquots and placed in sterile 1.5 ml centrifuge 
tubes. These were then left for 5 minutes at room temperature before the addition of 200 fil of
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chloroform to each tube. The tubes were shaken for 15 seconds and incubated again at room 
temperature for 2-3 minutes. After incubation the tubes were centrifuged at 14,000 rpm for 15 
minutes at 4°C. Three layers were observed, a lower red phenol/chloroform phase, a protein 
inter-phase and a colourless liquid upper phase containing the RNA. Transferring the aqueous 
phase to a fresh tube and adding 0.5 ml of isopropyl alcohol per tube precipitated the RNA. 
Samples were incubated at room temperature for 10 minutes and then centrifuged at 14,000 
rpm for 10 minutes at 4°C. Small brown pellets were observed at the side of each tube. The 
supernatant was removed and the pellet washed by re-dissolving in 1 ml of 75% (v/v) ethanol 
per tube by gentle pipetting and inversion. Each tube was then centrifuged at 10,000 rpm for 5 
minutes at 4°C, the ethanol decanted and the pellet dried at 37°C for 10 minutes. Each pellet 
was redissolved in 50 (il molecular grade (i.e. ‘nuclease-free’) ultra pure H20  and pooled 
together in a fresh sterile 1.5 ml microcentrifuge tube.
2.5.3.3 Reverse transcription o f mouse spleen mRNA
PCR can be performed directly from RNA but it is more successful to synthesize 
complementary DNA (cDNA) from total RNA for use in PCR. Complementary DNA was 
synthesized using a Promega cDNA synthesis kit containing random hexamer primers and 
oligo dT primers. Both primer sets i.e. random and hexamer were used as it is possible that 
the mRNA poly A tail could be sheared during the extraction process. Thus the use of the 
oligo dT primer could potentially reduce the amount of viable cDNA synthesized. The PCR 
reaction was set up as follows:
Component Stock conc. Conc. in 20ul X Iv X6
MgCl2 25mM 5mM 4 1^ 24 p.1
1 OX Buffer 10X IX 2 (4.1 12 |il
dNTP mix lOmM ImM 2 (il 12 fil
RNase Inhib. 40U/fxl lU/fj.1 0.5 fxl 3 nl
Primer 0.5fxg/(xl 0.2 pg/rxn* 0.4 nl 2.4 nl
AMVRT 25U/^1 15U/rxn* 0.6 jj.1 3.6 fil
Sterile H20 Made up to 20 fxl including RNA 7.5 nl 45 (il
RNA Varied 7-10 |ig RNA/rxn* 3 (xl 18 fj.1
T Volume for one reaction (XI) or six reactions (X6) 
* total concentration per reaction
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All reaction components, except enzymes, were placed on ice and left to thaw slowly. 
Enzymes were only removed when required and immediately kept at -20°C after use, in order 
to preserve activity. A 6X master mix was made up and the required volume of enzymes 
added before pipetting the mixture in to pre-labelled eppendorf tubes. Finally, the required 
volume of total RNA was added and mixed by pipetting.
2.5.4 Amplification of antibody light and heavy chain genes
2.5.4.1 PCR Primers
The listed PCR primers were obtained from Sigma-Genosys Ltd and designed to be compatible 
with the pAK vector system described by Krebber et al. (1997).
Variable light chain back primers
LB 1 5 'gccatggcggactacaaaGAYATCCAGCTGACTCAGCC3'
LB2 5'gccatggcggactacaaaGAYATTGTTCTCWCCCAGTC3'
LB3 5'gccatggcggactacaaaGAYATTGTGMTMACTCAGTC3'
LB4 5 'gccatggcggactacaaaGAY ATT GTGYTRACACAGTC3'
LB5 5'gccatggcggactacaaaGAYATTGTRATGACMCAGTC3'
LB6 5'gccatggcggactacaaaGAYATTMAGATRAMCCAGTC3'
LB 7 5' gccatggcggactacaaaGAYATTC AGATGA YDCAGTC3'
LB8 5 'gccatggcggactacaaaGAY A TYC AG ATG AC AC AGAC3'
LB9 5'gccatggcggactacaaaGAYATTGTTCTCAWCCAGTC3'
LB 10 5'gccatggcggactacaaaGAYATTGWGCTSACCCAATC3'
LB 11 5 'gccatggcggactacaaaGAY ATTSTRATGACCCARTC3'
LB 12 5'gccatggcggactacaaaGAYRTTKTGATGACCCARAC3'
LB 13 5' gccatggcggactacaaaGAY ATTGTG ATGACBCAGKC3'
LB 14 5'gccatggcggactacaaaGAYATTGTGATAACYCAGGA3'
LB 15 5'gccatggcggactacaaaGAYATTGTGATGACCCAGWT3'
LB 16 5' gccatggcggactacaaaGAY ATTGTGATGAC ACAACC3'
LB17 5'gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3'
LBX 5'gccatggcggactacaaaGAIGCTGTTGTGACTCAGGAATC3'
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Variable light chain forward primers
LF1 5 'ggagccgccgccgcc(agaaccaccaccacc)2 ACGTTTG ATTTCCAGCTTGG3'
LF2 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG3'
LF4 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3'
LF5 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG3'
LFA, 5'ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG3'
Variable heavy chain back primers
HB1 5'ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTTC3'
HB2 5'ggcggcggcggctccggtggtggtggatccGAGGTBCAGCTBCAGCAGTC3'
HB3 5'ggcggcggcggctccggtggtggtggatccCAGGTGCAGCTGAAGSASTC3'
HB4 5'ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3'
HB5 5'ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3'
HB6 5'ggcggcggcggctccggtggtggtggatccCAGGTYCARCTGCAGCAGTC3'
HB7 5'ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC3'
HB8 5'ggcggcggcggctccggtggtggtggatccGAGGTGAASSTGGTGGAATC3'
HB9 5'ggcggcggcggctccggtggtggtggatccGAVGTGAWGYTGGTGGAGTC3'
HB 10 5'ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC3'
HB11 5'ggcggcggcggctccggtggtggtggatccGAKGTGCAMCTGGTGGAGTC3'
HB 12 5'ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3'
HB 13 5'ggcggcggcggctccggtggtggtggatccGAGGTGCARCTTGTTGAGTC3'
HB 14 5'ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3'
HB 15 5'ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3'
HB16 5'ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG3'
HB 17 5 'ggcggcggcggctccggtggtggtggatccCAGGTCCAACTVCAGC ARCC3'
HB 18 5'ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC3'
HB 19 5'ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC3'
Variable heavy chain forward primers
HF1 5 'ggaattcggcccccgaggcCGAGGAAACGG TGACCGTGGT3'
HF2 5 'ggaattcggcccccgaggcCGAGGAGACTGTGAG AGTGGT3'
HF3 5 'ggaattcggcccccgaggcCGC AG AGAC AGTGACCAGAGT3'
HF4 5'ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT3'
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The concentration of stock primers varied. However, 0.1 nmol concentrations of the forward 
and reverse primers were used per reaction.
2.5A.2 Components o/PCR reaction for amplification of variable region light (Vi) and heavy
(Vfi) chain antibody genes
ComDonent Stock concentration Concentration in 50 ul
Forward Primers varied 0 .1  nmol of each primer/reaction
Reverse Primers varied 0 .1 nmol of each primer/reaction
10X Buffer 10 X IX
MgCl2 25 mM 1.0 mM
dNTP 20 mM 0.4 mM
Ultrapure water to 50 fil including Taq and DNA
cDNA varied 6 -8  jig of cDNA/50 pi reaction
Taq polymerase 5 U/fil 5 U/reaction (multiplex)
2.5.4.3 PCR conditions for amplification o f antibody light and heavy chain genes
Typical thermal cycling conditions were as follows:
94°C X 5 min ‘Hot-Start’
94°C X 1 min 
63°C X 30 sec 
58°C X 50 sec 
72°C X 1 min 
Repeat X 7 cycles
94°C X 1 min 
63°C X 30 sec 
72°C X 1 min 
Repeat X 24 cycles 
72°C X 10 min 
All ramping rates were at 4°C/sec.
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2.5A.4 Components o f Splice by overlap extension (SOE)-PCR
Agarose gel-purified (section 2.5.2.2) light and heavy chain genes (each approximately 400 
bp) were spliced together and amplified to produce 800 bp fragments by SOE PCR.
SOE Primers
Single chain back (scback): 5 'ttactcgcggcccagccggccatggcggactaccccg3'
Single chain forward (scfor): 5 'ggaattcggcccccgag3'
SOE-PCR reaction components for amplification and splicing of antibody light and heavy 
chain genes
Component Stock concentration Concentration in 50 ul
10 X buffer 10X 1 X
MgCl2 25 mM 1.0 mM
dNTP 20 mM 0.4 mM
Ultrapure water to 50 (J.1 including Taq, DNA and scfor and scback
VH varied 10  ng/reaction
vL varied 10  ng/reaction
SCfor varied 0.05 nmol /reaction
SCback varied 0.05 nmol/reaction
Taq polymerase 5 U/jj.1 5 U/reaction
SOE-PCR buffer compositions: buffer A (7.5 mM MgCl2, pH 8.5); buffer B (10 mM MgCl2, 
pH 8.5); buffer C (12.5 mM MgCl2, pH 8.5); buffer D (17.5 mM MgCl2, pH 8.5); buffer E 
(7.5 mM MgCl2, pH 9.0); buffer F (10 mM MgCl2, pH 9.0); buffer G (12.5 mM MgCl2, pH 
9.0); buffer H (17.5 mM MgCl2, pH 9.0); buffer I (7.5 mM MgCl2, pH 9.5) and buffer J (10 
mM MgCl2, pH 9.5).
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SOE-PCR conditions for amplification of joined antibody light and heavy chain genes
92°C X 1 min 
45°C X 50 min 
72°C X 1 min 
Repeat X 5 cycles
Add 0.05 mM scfor and scback primers: 
5 U Tag Polymerase/rxn
92°C X 1 min 
6 8°C X 30 sec 
72°C X 1 min 
Repeat X 25 cycles 
All ramping rates were at 4°C/sec.
2.5.4.5 Preparation and purification o f pAKlOO vector using Wizard miniprep system 
(Promega).
A single colony of E.coli XL 1-Blue containing pAKlOO phagemid vector (all vectors were 
kindly donated by Andreas Pluckthun, University of Zurich, Switzerland) was picked from a 
stock agar streak plate and used to inoculate 5 ml of 2 x TY supplemented with 30 (xg/ml 
tetracycline. The culture was grown overnight at 37°C with vigorous shaking. Purification of 
the pAKlOO phagemid vector was carried out using the Wizard miniprep system, as described 
in section 2.5.2.3.
2.5.4.6 Digestion o f pAKlOO and antibody light and heavy chain genes SOE PCR products
Digestion of pAKlOO and SOE products was performed using Sfil restriction enzyme. The 
pAKlOO phagemid vector requires digestion with Sfil restriction enzyme prior to ligation 
with the combined light and heavy chain gene SOE-PCR products. Antibody light and heavy 
chain gene SOE products were also digested with Sfil, for subsequent ligation into pAKlOO. 
Two units of Sfil enzyme was used to cut 30-50 ng/reaction SOE product or 50-100 
ng/reaction pAKlOO vector at 50°C overnight in a reaction volume of 10 fil.
79
2.5.4.7 Ligation o f antibody light and heavy chain genes into the pAKl 00 vector
Agarose gel-purified SOE products (section 2.5.2.2) were ligated into the Sfil digested 
pAKlOO plasmid vector using a reaction mixture containing DNA ligase (Promega), reaction 
buffer, SOE Vi/VH gene constructs and pAKlOO digests, at a ratio of 1.5:1, and molecular 
grade upH20 , to give a final volume of 10 pi. The reaction mixtures were incubated at 15°C 
overnight and DNA purified using ethanol precipitation (section 2.5.2.4). Following this the 
DNA was used to transform E.coliXLl-Blue chemically competent cells.
2.5.4.8 Preparation o f high efficiency chemically competent cells
High efficiency chemically competent E. coli XL-1 Blue and JM83 cells were prepared as 
previously described in section 2 .5.2.6.
2.5.4.9 Transformation o f E.coli XLl-Blue chemically competent cells with pAKlOO vector 
containing light and heavy chain genes and measurement o f transformation efficiencies
High efficiency competent E. coli XLl-Blue cells were thawed on ice. Cells were mixed by 
gentle tapping and transferred into two 15 ml polypropylene tubes (one tube was for the 
experimental transformation and the other tube was for the positive control transformation). 
The contents of the tubes were stirred gently and incubated on ice for 10 min, swirling gently 
at 2 min intervals. 0.1-50 ng of pAKlOO phagemid vector, containing light and heavy chain 
SOE-PCR product as insert was added to one of the tubes and swirled gently. The commercial 
(Invitrogen) control vector (1 pi of pUC18; 10 pg/pl) was added to the second tube and also 
swirled. Both tubes were then incubated on ice for 30 min. Cells were heat-pulsed for 30 sec 
in a water bath at 42°C, followed by incubation on ice for 2 min. 0.8 ml of LB medium, pre­
warmed at 37°C for 10 min, was then added and the tubes incubated at 37°C for 1 h with 
shaking at 225-250 rpm. pAklOO transformants were plated out on LB agar supplemented 
with 25 (j.g/ml chloramphenicol and 1% (v/v) glucose. Control transformants were plated out 
on LB agar supplemented with 20 jxg/ml of ampicillin. Both sets of plates were allowed to 
grow overnight inverted at 37°C. Transformed colonies were washed and scraped off the agar 
plates using sterile LB broth and used as library stocks. Concentrated library stocks were 
suspended in LB medium supplemented with 15% (v/v) glycerol and flash frozen in liquid 
nitrogen and stored at -80°C.
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2.5.5 Isolation o f scFv antibodies to cephalexin
2.5.5.1 Rescue o f scFv displaying phage
50 ml of non-expression (NE) medium (2xTY broth containing 1% (w/v) glucose and 25 
jug/ml chloramphenicol) was inoculated with 10 0  fil of cells from a stock library antibody 
library. The culture was shaken at 37°C until the O.D.550 = 0.5, at which point it was incubated 
for 10 minutes at 37°C without shaking. 10n pfu of helper phage (VCSM13) and 25 fxl of 1M 
IPTG solutions were added to the culture, followed by incubation for 15 minutes at 37°C 
without shaking. The culture was then diluted in 100 ml of low-expression (LE) medium (NE 
medium containing 0.5 mM IPTG) and then shaken for 2 hours at 26°C to allow phage 
production. After 2 hours 30 (i.g/ml kanamycin was added to the culture followed by 
incubation at 26°C with shaking (250 rpm) for a further 8 hours. Phage particles were 
purified and concentrated using PEG/NaCl precipitation and a phage titre carried out.
2.5.5.2 PEG/NaCl Precipitation
150 ml of the E. coli XL-1 blue/library was transferred to a sterile Sorvall 250 ml centrifuge 
tube and centrifuged at 10,000 rpm for 4°C for 10 minutes. Approximately 30 ml of 
autoclaved PEG/NaCl (36.52g NaCl and 50g PEG 10,000 in 250 ml H20) solution was added 
to the supernatant, mixed and incubated at 4°C (on ice) for at least one hour. The mixture was 
then centrifuged at 10,000 rpm at 4°C for 30 minutes. The pellet was re-suspended in 40 ml of 
sterile ultra-pure H2O and 8 ml of PEG/NaCl solution. The solution was then mixed and 
incubated at 4°C for 20 minutes. The mixture was then centrifuged at 10,000 rpm at 4°C for 
20 minutes. The supernatant was removed and the pellet was re-centrifuged at 7,000 rpm at 
4°C for a further 10 minutes. When all remaining supernatant had been removed, the pellet 
was re-suspended in 2 ml of sterile filtered PBS. The phage were then centrifuged at 4,000 
rpm for 4°C for 10 minutes to remove any bacterial debris (pellet) and supernatant decanted 
into a fresh 1.5 ml tube. The concentrated phage was retained and stored at 4°C (short-term) 
or at -80°C (long-term) in a 15% (v/v) glycerol solution.
2.5.5.3 Phage titre
5 ml of 2xTY containing 30 ^ig/ml tetracycline was inoculated with a single colony of XL-1- 
blue overnight at 37°C. The culture was then diluted 1/100 in 5 ml of 2xTY with 30 jag/ml 
tetracycline and left to grow shaking at 37°C until O.D.550 = 0.5-0.6 . It was then allowed stand
81
at 37°C for 15 minutes without shaking. Serial dilutions (ranging from 101 to 10'11) of phage 
were then prepared using the bacterial culture (180 pi E.coli XL-1 blue + 20 |il phage) and 
incubated for 30 minutes at 37°C without shaking. 100 pi of each dilution was spread on 
2xTY agar plates containing 1% (w/v) glucose and 25 fig/ml chloramphenicol. The plates 
were allowed to grow overnight at 37°C. The colonies were counted in order to calculate the 
titre of the stock phage.
2.5.5.4 Selection o f antigen binders by bio-panning using Nunc immunotubes with 
immobilised cephalexin conjugate
To facilitate specific scFv-displaying phage selection, immunotubes were coated overnight at 
4°C with various cephalexin conjugates (e.g. thyroglobulin, bovine serum albumin, 
ovalbumin). This was then blocked with blocking solution i.e. PBS with 5% (w/v) dried 
skimmed milk powder and incubated for 1 hour at 37°C. Tubes were then washed five times 
with PBS-Tween and five times with PBS. 1 ml of library phage (1011 phage/ml) particles 
were added to 3 ml of PBS-T, containing 2% (w/v) powder milk. This was allowed to 
incubate, while gently shaking, in the immunotube for 2 hours at room temperature. After 
washing lOx PBS-T and lOx PBS, bound phage were eluted from the tube by adding 800 |xl 
0.1 M glycine/HCl, pH 2.2, for 10 minutes. This was then neutralised using 48 (.il of 2 M Tris. 
A phage titre was then carried out as previously described in section 2.5.5.3, to determine the 
amount of phage recovered from each panning round. The phage titre agar plates were stored 
at 4°C for use in the phage ELISA.
2.5.5.5 Re-infection o f phage-displaying scFv
5 ml of 2xTY containing 30 (ig/ml tetracycline was inoculated with 50 (xl of E. coli XL-1 blue 
stock were grown overnight at 37°C. The culture was then diluted 1/100 in 5 ml of 2xTY 
containing 30 pg/ml tetracycline and grown while shaking until the O.D.55o= 0.4-0.5. It was 
then allowed to stand for 10 minutes at 37°C. 700 pi of eluted phage, from the panning step, 
was added to the culture and allowed stand at 37°C for 30 minutes. This culture was then 
shaken at 37°C for 1 hour before being plated out on 2xTY agar plates containing 25 pg/ml 
chloramphenicol and 30 (xg/ml tetracycline. It was then grown overnight at 37°C.
82
2.5.5.6 Screening o f individual phage-displaying scFv clones by ELISA
96 well culture plates were filled with 200 pl/well of NE medium containing 30 pg/ml 
tetracycline and 25 pg/ml chloramphenicol. Single colonies were picked from the phage titre 
plates and transferred into each well, leaving 2 wells free as controls. The clones were 
allowed to grow, while shaking at 150 rpm overnight at 37°C. These were designated master 
plates and frozen with in media supplemented with 15% (v/v) glycerol. A second copy set of 
plates was prepared with 180 pl/well of NE medium. 20 pi from each well on a master plate 
were transferred to the corresponding well on the second plate and incubated at 37°C while 
shaking for approximately 6-8 hours. 25 pi of solution X (5.75 ml 2xTY, with 1% (w/v) 
glucose, 25 pg/ml chloramphenicol, 1.5 mM IPTG and 5 x 109 phage/ml) were added to each 
well after 5 hours. The culture was then allowed to stand for 30 minutes at 37°C followed by 
shaking at 150 rpm for 1 hour. The plate was then centrifuged at 4000 rpm for 10 minutes. 
The supernatants were removed by inversion and the media was replaced with 200 pi of 
solution Y (20 ml 2xTY, 25 pg/ml chloramphenicol, 30 pg/ml kanamycin, 1% (w/v) glucose 
and 1.5 mM IPTG). The plate was then grown overnight shaking at 150 rpm at 26°C. An 
ELISA plate was coated with the appropriate cephalexin conjugate overnight at 4°C. The 
following day the culture plates were centrifuged at 4000 rpm for 10 minutes and 75 pi of the 
supernatant was used for the phage ELISA. The coated ELISA plates were blocked using 5% 
(w/v) milk marvel in PBS. The plates were then washed 3 times with PBS and 75 pi of 
supernatant from the culture plates were added to the corresponding wells on the ELISA 
plates. 25 pi of 5% (w/v) milk marvel-PBS was then added in on top of each well and mixed 
gently. The phage were left to bind for 2 hours at room temperature and then washed with 
PBS-Tween. 100 pl/well of a 1/1000 dilution of rabbit anti-fd bacteriophage antibody was 
added and the plate was incubated for 1 hour at 37°C followed by HRP-labelled goat anti­
rabbit IgG (1/2000 dilution). A non-inoculated well and non-transformed bacterial culture 
inoculated well i.e. containing no phagemid-scFv constructs, were used as negative controls. 
This was incubated for 30 min at 37°C and OPD substrate was used. The plates were read at 
450 nm after 30 minutes.
2.5.5.7 Preparation o f bacterial glycerol stocks
Bacteria cells were grown in 2xTY media containing the appropriate antibiotic at 37°C until 
the O.D6oo was 0.5-0.8. The cultures were then spun at 4,000 rpm for 10 minutes and the 
pellet resuspended in 2xTY containing 20% (v/v) glycerol to a volume of 1/4 the original
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culture volume. 0.5 ml aliquots were transferred to 1.5 ml sterile microcentrifuge tubes and 
flash frozen with liquid nitrogen. Cell stocks were stored at -80°C.
2.5.5.8 Expression o f soluble scFv antibodies from E. coli harbouring the pAK400 vector 
with scFv gene inserts
Enhanced soluble expression pAK400 vector was digested using Sfil restriction enzyme as 
described in section 2.5.4.6. SOE Vl/Vh gene constructs, also digested using Sfil, were 
ligated with linear pAK400 vector as outlined in section 2.5.4.7. Ligation reaction product 
was used to transform chemically competent E. coli JM83 cells. Transformed cells were 
grown in 2xTY media containing 25 |ig/ml chloramphenicol and 30 |Ag/ml tetracycline at 
37°C until the O.D.6oo = 0.5-0.8. Expression of the scFv gene product was induced by the 
addition of 1 mM IPTG and incubated for a further 4-5 hours at 30°C with constant agitation. 
The cultures were later centrifuged at 4,000 rpm for 15 minutes and supernatant analysed as 
described in section 2.5.5.9. The remaining cell pellets were resuspended in PBS (0.15 M 
NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium 
dihydrogen phosphate, pH 7.4) to a volume of 1/10* that of the original culture volume and 
sonicated for 45 seconds at an amplitude of 40 using a microtip Vibra Cell™ sonicator to lyse 
the bacterial cell walls. The cell debris was removed by centrifugation at 4,000 rpm for 5 
minutes, followed by further centrifugation at 14,000 rpm for 10 minutes. The supernatant 
(cell lysate) was then analysed by ELISA, as described in section 2.5.5.9.
2.5.5.9 ELISA for the determination o f soluble scFv
A screening ELISA was carried out with scFv antibody growth medium supernatants and cell 
lysates as described in section 2.3.1.1. In brief, dilutions of scFv antibody media or cell 
lysates were added to the wells of cephalexin conjugate-coated immunoplates and 
sequentially detected using two different secondary antibodies. A rabbit anti-histidine 
polyclonal was used followed by HRP-labelled goat anti-rabbit for the detection of bound 
scFv antibodies. In addition a mouse anti-FLAG monoclonal antibody was used and 
subsequently detected by HRP-labelled goat anti-mouse antibody. Colour was developed by 
the addition of OPD substrate solution.
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2.5.6 Production o f scFv antibody from hybridoma cell line secreting monoclonal 
cephalexin-specific antibody
2.5.6.1 Preparation o f VH and VL genes from hybridoma cells
Cephalexin-specific antibody secreting hybridoma cell lines were produced by mammalian 
somatic cell fusion as described in section 2.4.3.1. Monoclonality was achieved using 
successive rounds of cloning by limiting dilution. Cell clone (CTh5) secreting specific anti­
cephalexin antibody was used in the development of a single chain variable fragment (scFv) 
antibody fragment. CTh5 hybridoma cells were recovered from liquid nitrogen frozen stocks 
(section 2.4.2.2), transferred to a T25 culture vessel and incubated at 37°C in a humidified 5 
% (v/v) C 02 incubator. Prior to incubation, a 100 (j.1 sample of the resuspended cells were 
tested for cell viability using Trypan blue staining (section 2.4.2.3). Only cells with > 90 % 
viability on recovery from frozen stocks were cultured further. Cells were allowed to grow 
until 70% confluent in T25 flasks, pelleted by centrifugation at 2,000 rpm for 10 min and 
resuspended in 2 ml fresh DMEM. 1 ml portions were transferred to two T75 culture flasks 
containing 14 ml DMEM. Flasks were incubated as before until they reached confluence and 
subsequently the cells were harvested. The cell pellets were pooled and centrifuged at 2,000 
rpm for 10 min, and total RNA extracted using 1 ml Trizol reagent, as described in section
2.5.3.2.
2.5.6.2 Amplification o f Vh and VL chain genes
Amplification of variable H and L chain genes was carried using a modified version of the 
protocol described by Krebber et al. (1997). Heavy and light chain sequence primer mixes 
omitting the lambda light chain primers (CTh5 antibody was found to be of IgG2a isotype 
containing a kappa light chain), were used in separate PCR reactions. The reactions were 
carried out using, components as listed in section 2.5.4.2 and reaction conditions (section
2.5.4.3).
2.5.63 Components o f Splice by overlap extension (SOE)-PCR
Heavy and light chain genes each approximately 400 bp were run on agarose gel and purified 
(section 2.5.2.2). Purified fragments were spliced together and amplified to produce 800 bp 
fragments by SOE-PCR. Reactions were set up using the components and conditions as 
described in section 2.5.4.4.
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2.5.6.4 Preparation o f pAKlOO vector containing SOE gene insert
The pAKlOO phagemid vector was purified (section 2.5.4.5) and both vector and SOE-PCR 
purified products were digested using Sfil restriction enzyme digests as outlined in section 
2.5.4.6. The agarose gel-purified (section 2.5.2.2) SOE and linear pAKlOO vector products 
were ligated using DNA ligase (Promega) as described previously (section 2.5.4.7). The 
ligation DNA was purified and concentrated using ethanol precipitation (section 2.5.2.4). The 
resulting product was used to transform E.coli TOPI OF’ electrocompetent cells that were 
prepared as outlined in section 2.5.2.7.
2.5.6.5 Transformation o f E.coli TOPIOF’ electrocompetent cells with pAKlOO vector 
containing CTh5 light and heavy chain genes and measurement o f transformation efficiencies
Electro-transformations were carried out using a gene pulser apparatus (Bio Rad) set up at 25 
|j.F, 2.5 kV and 200 Q (Barbas et al., 2001). Electrocompetent E. coli TOPIOF’ cells were 
thawed on ice. A 5 p.1 aliquot of purified ligation product in a 1.5 ml microcentrifiige tube 
and 0.2 cm electroporation cuvette were placed on ice for 10 min. 50 jil of thawed cells was 
added to the ligation product mixed by pipetting, transferred to the pre-chilled cuvette and 
held on ice for 1 min. The cuvette was placed in the gene pulser apparatus and electroporated 
using the above conditions. It was then was flushed with 1 ml and then 2 ml portions of SOC 
medium at R.T. The combined 3 ml SOC medium wash was transferred to a 15 ml 
polypropylene tube and incubated at 37°C for 1 hour with shaking at 250 rpm. After this 
incubation period, 7 ml of SB medium was added. 1, 10, and 100 jxl volumes of the 
transformants were plated on LB agar supplemented with 25 jJg/ml chloramphenicol and 1% 
(v/v) glucose to ascertain the transformation efficiency. A Positive control (pUC18) 
transformation carried out using 1 pi of pUC18 (10 p.g/p.1, Invitrogen) vector. Control 
transformants were plated out on LB agar supplemented with 20 pg/ml of ampicillin. Both 
sets of plates were allowed to grow overnight inverted at 37°C. Transformed colonies were 
harvested from the agar plates and used as stocks. These stocks were suspended in 15% (v/v) 
glycerol, flash frozen in liquid nitrogen and stored at -80°C.
2.5.6.6 Isolation o f CTh5 scFv antibody to cephalexin
A total of 400 individual colonies were picked from transformation efficiency streak LB agar 
plates (prepared as per section 2.5.6.5) and used to inoculate the wells of sterile microtitre 
plates containing 200 |ul/well of NE medium containing 30 |ig/ml tetracycline and 25 fxg/ml
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chloramphenicol. The plates were incubated overnight at 37°C, while shaking at 150 rpm. 
These were designated master plates and stored frozen (-80°C) in growth media supplemented 
with 15% (v/v) glycerol after a copy set of plates was prepared with 180 pl/well of NE 
medium. The NE medium was inoculated with 20 pi from each corresponding well on the 
relevant master plate. The copy plates were incubated with shaking at 37°C for approximately 
6-8 hours. 25 pi of solution X (5.75 ml 2xTY, with 1% (w/v) glucose, 25 pg/ml 
chloramphenicol, 1.5 mM IPTG and 5 x 109 helper phage/ml) was added to each well after 5 
hours. The culture was then allowed to stand for 30 minutes at 37°C followed by shaking at 
150 rpm for 1 hour. The plate was then centrifuged at 4000 rpm for 10 minutes. The 
supernatants were removed by inversion and the media was replaced with 200 pi of solution 
Y (20 ml 2xTY, 25 pg/ml chloramphenicol, 30 fig/ml kanamycin, 1% (w/v) glucose and 1.5 
mM IPTG). The plate was then grown overnight shaking at 150 rpm at 26°C. An ELISA plate 
was coated with the appropriate cephalexin conjugate overnight at 4°C. The following day the 
culture plates were centrifuged at 4000 rpm for 10 minutes and 75 pi of the supernatant was 
used for the phage ELISA. The coated ELISA plates were blocked using PBS-T (0.15 M 
NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium 
dihydrogen phosphate, 0.05% (v/v) Tween 20, pH 7.4) containing 5% (w/v) dried skimmed 
milk powder for 1 hour at 37°C and washed 3 times with PBS. To each corresponding ELISA 
screening plate well was added 75 pi of supernatant from the culture plates. 25 pi of 5% (w/v) 
milk marvel-PBS was then added in to each well and mixed gently. Phage supernatants were 
left to bind for 2 hours at room temperature with gentle rocking followed by 3x washes with 
PBS-T. 100 pl/well of a 1/1000 dilution of rabbit anti-fd bacteriophage antibody was added 
to each well and plates incubated for 1 hour at 37°C. The plates were washed 3x PBS-T and 
3x PBS, followed by addition of HRP-labelled goat anti-rabbit IgG (1/2000 dilution) and 
incubation for 1 hour at 37°C. Plates were washed as before and the OPD substrate added. 
The absorbance of each well was read at 450 nm after 30 minutes.
2.5.6.7 Soluble expression o f CTh5 scFv
Soluble scFv was expressed as outlined in section 2.5.5.8.
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2.5.6.8 Purification o f soluble His-tagged scFv by immobilised metal affinity 
chromatography (IMAC)
A 1 ml aliquot of Ni+-NTA agarose resin (QIAgen) was added to a 20 ml universal tube and 
equilibrated with 20 ml of running buffer (PBS-T with 1% (v/v) Tween-20, 500 mM NaCl 
and 10 mM p-mercaptoethano 1). The solution was centrifuged at 4000 rpm for 10 minutes and 
the supernatant (running buffer) removed. Sonicated cytoplasmic extracts (2-3 ml) containing 
His-tagged recombinant protein were added to the pellet (Ni r-NTA resin) and mixed for 1-2 
hours at room temperature on a rocking platform. The mixture was then centrifuged at 4000 
rpm for 10 minutes and the supernatant (unbound material) removed. The pellet (resin with 
bound protein) was washed 3 times with 20 ml of running buffer. The proteins were eluted 
with 2-3 ml of sodium acetate buffer, pH 4.5, and neutralised with 2 M Tris buffer, pH 8.8. 
Purified proteins were stored at -20°C. This represents a generic protocol for IMAC-based 
scFv purification.
2.6 Production of mutant phage-display libraries
Following isolation and characterisation the wild type (WT) scFv gene construct was excised 
and used as template for random intra-gene digestion with RQ1 RNase-Free DNase 1 
endonuclease (Promega) and subsequent error-prone PCR, in order to produce mutant WT 
phage-display libraries. WT gene fragments were used as ‘self primers’ in a PCR for re­
amplification of the gene construct. The product of this PCR (fragments ranging from 600- 
800 bp) was amplified by SOE-PCR, as previously described, using with scfor and scback 
primers. Multiple 50 jxl volume SOE-PCR reactions were carried out to amplify a large 
amount of WT gene, yielding an 800 bp (approximately) band. The reaction product was run 
on agarose gel subsequent to purification. Each purified product was pooled and concentrated 
using ethanol precipitation so as to produce a concentrated working stock.
2.6.1 DNase 1 endonuclease digests optimisation
The DNase 1 concentration (U/rxn), WT DNA concentration (pg/pl) and digest time were 
optimised for the reaction so as to yield 50 bp fragments. The final digestion reaction 
consisted of 1 jul (1 U/jil) DNase, 2 pi buffer (400 mM Tris-HCl, pH 8, 100 mM MgS04 and 
10 mM CaCl2). The total reaction volume was made up to 20 |il with molecular grade H20 and 
initiated by adding 5 pg/rxn WT SOE-PCR product. The reaction was allowed to proceed at 
R.T. for 5 minutes and stopped using 1 p. EDTA (20 mM, pH 8) followed by DNase 
inactivation by placing in a water bath at 65°C for 10 minutes. The digest products was
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analysed on a 1% (w/v) agarose gel and fragments were purified and concentrated using 
ethanol precipitation (section 2.5.2.4).
2.6.2 PCR o f  DNase 1 digestion products
Purified DNase 1 digest product (fragments approximately 50 bp) was used as template for 
PCR reactions to re-construct scFv genes. PCR reaction components and conditions were as 
follows:
Component Stock concentration Concentration in SO
Digested fragments varied 300 ng
10 X buffer 10 X 1 X
MgCl2 25 mM 1.0 mM
dNTP 20 mM 0.4 mM
Taq polymerase 5 U/jj.1 5 U/reaction
H20  to 50 (xl including Taq, DNA, sCfor and sCback per rxn.
PCR conditions for amplification of digested light and heavy chain genes
95°C X 2 min ‘Hot-start’
Add 5 U Taq Polymerase/rxn 
95°C X 30 min 
50°C X 1 min 
72°C X 1 min
Repeat X 35 cycles 
72°C X 6 min 
All ramping rates were at 4°C/sec.
The PCR product was analysed on a 1% (w/v) agarose gel, purified and concentrated using 
ethanol precipitation (section 2.5.2.4).
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2.6.3 Error-prone PCR o f reconstructedfragments
Two separate reactions were set up using reconstructed scFv genes with sCfor and scback 
primers, designated Rl* and R2*. The reaction components were as follows:
Rl*
Component Stock concentration Concentration in 50 ul
Reconstructed fragment varied 300 ng
5 X buffer A 5 X 1 X
dNTP 20 mM 0.4 mM
SCfor varied 0.05 nmol /reaction
SCback varied 0.05 nmol/reaction
Taq polymerase 5 U/p.1 5 U/reaction
H20  to 50 pi final volume including Taq, DNA, scfor and scback
PCR buffer A (7.5 mM MgCl2, pH 8.5).
R2*
Component Stock concentration Concentration in 50 ul
Reconstructed fragment varied 300 ng
5 X buffer A 5 X IX
dNTP 20 mM 0.4 mM
MnC12 25 mM 0.5 mM
SCfor varied 0.05 nmol /reaction
SCback varied 0.05 nmol/reaction
Taq polymerase 5 U/^ ,1 5 U/reaction
H20  to 50 fj.1 final volume including Taq, DNA, scfor and scback
PCR buffer A (7.5 mM MgCl2, pH 8.5).
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2.6.4 Preparation o f pAKlOO vector containing SOE R l * and R2* gene constructs
The pAKlOO phagemid vector was purified (section 2.5.4.5) and both vector and Rl* and 
R2* SOE-PCR ethanol-purified products were digested using Sfil restriction enzyme digests, 
as outlined in section 2.5.4.6. The agarose gel-purified (section 2.5.2.2) Rl*, R2* fragments 
and linear pAKlOO vector were ligated using DNA ligase (Promega) (section 2.5.4.7). The 
ligation mixes were purified and concentrated using ethanol precipitation (section 2.5.2.4). 
The resulting products were used to transform E.coli TOPI OF’ electrocompetent cells (section 
2.5.2.7), and to construct mutant Rl * and R2* phage-display mutant library stocks.
2.6.5 Selection o f cephalexin binders by panning of mutant R l * and R2* phage libraries
Both mutant phage-scFv libraries (i.e. Rl* and R2*) were subjected to three rounds of 
panning with immobilised conjugates, as described in section 2.5.5.4, with additional phage 
elution using a 100 ng/ml solution of free cephalexin in PBS-T containing 2% (w/v) dried 
skimmed milk powder. A 1 ml solution of free cephalexin was added to each immunotube 
and incubated for 30 min at 37°C. This solution was then decanted and used to infect E. coli 
in the exponential growth phase (section 2.5.5.5). After eluting phages with cephalexin, any 
remaining bound phages were eluted using glycine solution, as per section 2.5.5.4. 
Subsequently, eluted phage fractions were used to infect E. coli XL1 blue. Phage-scFv clones 
were then screened as before (2.5.5.6).
2.7 Development of SPR-based immunoassay using a BIAcore 3000TM biosensor
Analysis was carried out on a BIAcore 3000™ instrument using a carboxymethylated dextran 
(CM5) sensor chips. The running buffer for all BIAcore experiments was HBS buffer, pH 7.4, 
containing 10 mM HEPES, 150 mM NaCl, 3.4 M EDTA, and 0.05% (v/v) Tween 20. The 
running buffer was filtered (pore size of 0.45 fxm) and degassed using a filtration apparatus 
(Millipore sintered glass filtration unit) immediately before use.
2.7.1 Preconcentration studies
In order to optimise the conditions needed for the immobilisation of desired proteins on the 
sensor chip surface, an initial preconcentration step, resulting from electrostatic binding of 
protonated amine groups on the biological component to negatively charged carboxyl groups on 
the chip surface, was performed. Preconcentration is in essence an optimisation of the buffer pH 
so that it falls below the isolectric point (pi) of the protein (i.e. cephalexin-protein conjugate)
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and facilitates the maximum binding of the protein through electrostatic interactions. Therefore, 
protein solutions were prepared in 10 mM sodium acetate at a range of different pHs and these 
solutions passed over an underivatised chip surface, with the degree of electrostatic binding 
monitored. The pH at which the highest preconcentration of protein onto the underivatised 
surface was observed was chosen as the pH for immobilisation.
2.7.2 General cephalexin-protein conjugates immobilisation conditions
The carboxymethylated dextran matrix was activated by mixing equal volumes of 100 mM 
NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) 
carbodiimide hydrochloride), and injecting the mixture over the sensor chip surface for 7 
minutes at a flow rate of 5 n 1/minute. The desired protein to be immobilised was diluted in 10 
mM sodium acetate at the optimised pH with a typical concentration of 50-100 |J.g/ml. This 
solution was then injected over the derivatised chip surface for 60 minutes at 2 ^minute. Un­
reacted NHS groups were capped, and non-covalently bound protein removed by injection of 1 
M ethanolamine hydrochloride, pH 8.5, for 5 min.
2.7.3 Direct cephalexin immobilisation conditions
The carboxymethylated dextran matrix was activated by mixing equal volumes of 100 mM 
NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) 
carbodiimide hydrochloride), and injecting the mixture over the CM5 sensor chip surface for 
16 minutes at a flow rate of 5 ^1/minute. The surface was converted to amine functionality by 
injecting ethylene diamine (1M pH 8.5 with HC1) for 20 minutes at a flow rate of 5 (il/min. 
Immediately afterwards a 200 (ig/ml cephalexin solution dissolved in equal volumes of 100 
mM NHS (N-hydroxysuccinimide) and 400 mM EDC (BIAcore amine coupling kit) was 
injected over activated surface for 40 minutes at a flow rate of 5 pl/min. Un-reacted sites on 
the chip surface were capped, and non-covalently bound material removed by two sequential 
injections of 1 M ethanolamine hydrochloride, pH 8.5, for 5 min at a flow rate of 10 pl/min.
2.7.4 Regeneration studies
To assess the stability of immobilised cephalexin and conjugate surfaces, a known 
concentration of antibody was passed over the chip surface, and the surface regenerated by 
passing over various concentrations of NaOH and HC1 ranging in concentration from 1-30 
mM. This cycle of regeneration was usually completed for greater than 50 cycles, and the
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binding signal measured to assess the stability and suitability of the immobilised surface for 
the development of a sensitive and reproducible assay.
2.7.5 ‘Spiked* whole milk sample preparation
A 5 mg portion of cephalexin hydrate was weighed out and diluted in 1 ml whole milk (well 
known brand locally purchased). The cephalexin milk solution was incubated at 37°C for 10 
min and vortexed. Serial dilutions of stock cephalexin were prepared accordingly. Each of the 
samples to be assayed was placed in a water bath at 95°C for 3 min (Gustavsson, 2003) 
followed by centrifugation at 14,000 rpm at R.T. for 15 min. The aqueous phase was gently 
removed using a 200 pi pipette and diluted 1:2 with the appropriate antibody dilution.
2.7.6 Inhibition assay fo r  the detection o f cephalexin using anti-cephalexin antibodies
The cephalexin-thyroglobulin conjugate was immobilised on a CM5 sensor chip (TCC) 
surface as described in section 2.7.2 while cephalexin was directly immobilised to the CM5 
sensor chip surface (DIC) as outlined in section 2.7.3. Each of the antibodies studied (i.e. 
polyclonal, monoclonal, and scFv) were diluted in HBS, PBS-T and prepared whole milk 
assay diluents. The antibody dilutions were optimised to yield a response ranging from 100- 
500 response units (RU). For each antibody both TCC and DIC chip surfaces were evaluated. 
Antibodies were passed across the TCC and DIC chip surfaces following pre-incubation with 
a range of cephalexin solution concentrations (i.e. from 100,000 ng/ml to 5 ng/ml) for 20 min 
at R.T. Each of the antibody-cephalexin standard samples were mixed thoroughly by 
inverting several times placed in the BIAcore 3000 auto-sampler and randomly passed over 
the appropriate sensor surface (in triplicate). The mean response (RU) was calculated and 
expressed as a ratio of RU/RU0, where the ‘spiked’ sample response (RU) was divided by the 
response with no free cephalexin (RU0).
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Chapter 3
Production of polyclonal antibodies to cephalexin and 
the development of ELISA-based assay for the detection
in milk
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3.1 Polyclonal antibody production
The aim of the work described in this chapter was the production, purification and 
characterisation of polyclonal antibodies to cephalexin. The production of cephalexin-protein 
(i.e. thyroglobulin-, bovine serum albumin (BSA)-, ovalbumin-cephalexin) conjugates, and 
their subsequent use in the production of polyclonal antibodies to cephalexin is presented. 
Polyclonal antibodies produced were evaluated in the development of an enzyme-linked 
immunosorbent assay (ELISA) for the detection of cephalexin in PBS and whole milk sample 
matrices.
3.1.1 Introduction to polyclonal antibody production
The need for a rapid and reliable assay for the determination of cephalosporin antibiotics has 
already been described in chapter 1. European laws clearly set out Maximum Residue Limits 
(MRL’s) for this class of compounds. The work presented in this thesis deals with cephalexin, 
a first generation semi-synthetic cephalosporin. Current analysis techniques are based on 
microbiological, receptor or enzyme-based screening methods that are inexpensive and 
broadly sensitive to a range of different antimicrobials but lack specificity. Confirmatory 
testing may also be carried out using chromatographic methods. High Performance Liquid 
Chromatography (HPLC) and Liquid chromatography (LC) are the most commonly used 
method for the specific determination of P-lactams in milk, as they are both sensitive and 
specific (Schenck et al., 1998 and Samanidou et al., 2003). However, LC/HPLC techniques 
involve extensive sample clean up when analysing complex biomatrices like milk (Fedeniuk 
and Shand, 1998). They also require trained operators, are expensive and require bulky 
equipment. Immunoassays may offer greater advantages in comparison to the microbial 
screening assays and HPLC/LC, as they are relatively inexpensive, sensitive, robust and 
highly specific. They also facilitate portability with assay transfer onto lateral flow devices or 
‘biochips’ for field-testing or on farm testing.
Antibodies or Immunoglobulins (Igs) are produced by an organism's immune system as part 
of the humoral immune response. Upon initial exposure, mature B-lymphocytes present in the 
secondary lymphoid organs (e.g. spleen, lymph nodes) of the particular organism produce 
antibodies with multiple specificities (Chapter 1). Antibodies produced are specific to 
relatively small regions on the antigens surface, referred to as the epitopes or antigenic 
determinants. In the production of antibodies, antigens may be of various different chemical
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classes ranging from biological to non-biological molecules. The relative molecular mass of 
the target antigen plays an important role in the subsequent immune response, as if it is 
relatively small molecular weight (<5,000 Da) for example, illicit drugs or some hormones, it 
may not be recognised by the organism’s immune system. Such compounds are termed 
haptens. In antibody production this obstacle is overcome by coupling the hapten of interest to 
larger protein carrier. Antibodies will be produced that are specific to the desired hapten and 
also the carrier protein. Bovine serum albumin (BSA), ovalbumin (OVA), thyroglobulin 
(THY), and non-protein polymers e.g. dextran, are generally used for coupling to haptens to 
elicit an immune response. Antibodies are produced and circulated within the blood of the 
organism; such antibody populations are heterogeneous in nature, derived from multiple 
parental B-cells and are termed as polyclonal (i.e. mixture of antibodies reactive to many 
different epitopes).
Polyclonal antibodies can be raised quickly and at relatively low cost to the producer when a 
sufficient supply of target analyte is available. This is in contrast to the expense and expertise 
required for traditional hybridoma and recombinant antibody production techniques 
(Stapleton et al., 2003). One of the main challenges when producing antibodies against 
haptens (e.g. cephalexin) is the need to conjugate such small molecules to larger ones (e.g. 
protein), so as to elicit an immune response and generate antibodies. Polyclonal antibody 
production techniques offer a relatively cheap and easy way to assess the potential immune 
response to a particular conjugated hapten. Once a serum titre is obtained against conjugated 
hapten, the antibody binding to free (i.e. un-conjugated) hapten may be evaluated in inhibition 
or competitive ELISA formats. There are potential drawbacks to using polyclonal antibody 
production techniques, depending on the desired application. These include, the facts that 
there is a finite supply of homogenous antibody populations, by their very nature they possess 
multiple epitope specificities and production varies from animal to animal, leading to 
problems with quality.
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3.2 Results
Cephalexin-protein and cephalexin-dextran conjugates were synthesised using various 
carbodiimide-coupling strategies, as shown in section 2.2.1. Initially, this involved activating 
the carboxyl group on the cephalexin molecule, and subsequent reaction with amine groups 
on the relevant protein (designated cephalexin-activated ester coupling, figure 2.1 (A)). 
However, cephalexin conjugates produced by this method lacked stability. It was observed 
that cephalexin-protein conjugates produced by activating the carboxyl groups on the protein 
and subsequent reaction with the amine functional group on the cephalexin (designated 
protein-activated ester coupling, figure 2.1 (B)) showed increased stability.
Cephalexin (Ceph)-protein conjugates were characterised by indirect checkerboard ELISA 
(section 2.3.1.2) using a cephalexin-specific polyclonal antibody, previously described by 
Dillon et al (2003a), that was generously donated by Dr. Aart van Amerongan (designated 
AVAab). This was carried out to confirm the cephalexin had been covalently linked to the 
respective carrier protein. Figures 3.1 and 3.2 show typical results obtained for checkerboard 
ELIS As using Bovine Serum Albumen (BSA) and ovalbumin (Ova) - Ceph conjugates, with 
AVAab anti-cephalexin polyclonal antibody.
3.2.1 Characterisation o f cephalexin-carrier protein conjugates
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Figure 3.1. Results obtained from a checkerboard ELISA using various coating 
concentrations (11.5 ng/ml, 115 ng/ml, 1.15 fig/ml, and 11.5 jig/ml) of the BSA-cephalexin 
(BSA-Ceph) conjugate detected with varying dilutions of the AVAab polyclonal anti­
cephalexin primary antibody. HRP-labelled goat anti-rabbit secondary antibody was used for 
the detection and the absorbance measured at 450 nm with OPD as substrate. Wells coated 
with 1 mg/ml BSA dissolved in PBS were used as negative controls. Each point represents the 
mean of two measurements.
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Figure 3.2. Results obtained from a checkerboard ELISA using various coating 
concentrations (11.5 ng/ml, 115 ng/ml, 1.15 pg/ml, and 11.5 (xg/ml) of the Ovalbumin- 
cephalexin (Ova-Ceph) conjugate detected with the AVAab polyclonal anti-cephalexin 
primary antibody. HRP-labelled goat anti-rabbit secondary antibody was used for detection 
and the absorbance measured at 450 nm with OPD as substrate. Wells coated with 1 mg/ml 
ovalbumin dissolved in PBS were used as negative controls. Each point represents the mean 
of two measurements.
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The protein concentrations of the cephalexin-conjugates were determined using a BCA 
(Bicinchonic acid) protein assay kit (Pierce) according to manufacturers’ guidelines. BCA 
assays were carried out, as described in section 2.3.4. The protein concentration of each 
conjugate was estimated by constructing a calibration curve with relevant protein standards 
(i.e. BSA for BSA-Ceph conjugate). A typical result of a BCA assay carried out for 
thyroglobulin-cephalexin conjugate is shown in figure 3.3. UV photometric spectroscopy was 
used to give putative evidence that the cephalexin had covalently bound to protein, by 
comparison of the spectra for the individual components of the reaction (i.e. cephalexin and 
protein) and the relevant conjugates post dialysis (section 2.2.1.2). However, it was observed 
that the cephalexin molecule has a broad absorbance peak from 290nm to 200nm thus 
masking the protein absorbance maximum at 280nm.
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Figure 3.3. Plot of the results obtained from a typical BCA assay standard curve. The 
calibration curve was constructed to estimate the concentration of a thyroglobulin-cephalexin 
conjugate (Thyro-Ceph) and was prepared using thyroglobulin protein standards ranging from
0 ug/ml to 2,000 (ig/ml. 25 jaI of each standard was added to the wells of a 96-well plate and 
colour developed by the addition of 200 |il of working reagent. Following incubation at 37°C 
for 30 min the absorbancies were read at 590 nm. Each point represents the mean of two 
measurements.
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3.2.2.1 Immunogen preparation and immunisation
A 1 mg/ml solution of BSA-Ceph conjugate diluted in PBS was added to an equal volume of 
Freund’s Complete adjuvant (FCA). The immunogen was prepared and immunisation carried 
out as described in section 2.2.2. Once a sufficient titre was obtained (> 1/100,000) the animal 
was sacrificed and the serum removed.
3.2.2.2 Serum titre o f polyclonal anti-serum against thyroglobulin-cephalexin conjugate
An indirect titre ELISA, as described in section 2.3.1.1, was used to determine IgG antibody 
titre. Serum was obtained from whole blood by centrifugation and serially diluted in PBS-T 
containing 2% (w/v) dried skimmed milk powder. 96 well plates were coated with a 13.2 
jig/ml thyroglobul in-cephalexin conjugate and the serum dilutions were added in to the wells 
triplicate. The antibody titre for the purposes of this work was defined as the highest dilution 
that yielded a response distinguishable from the background plus three standard deviations. 
The polyclonal anti-serum demonstrated sufficiently high titre (> 1/100,000) as can be seen in 
figure 3.4 (A). A similar titre ELISA was carried out using cephalexin dextran (Ceph-Dex) 
conjugate and coating a 96-well plate with 1:1,000 and 1:10,000 dilutions of Ceph-Dex and 
carrying out the rest of the assay as above, with serial dilutions of serum ranging from 1:400 
to 1:204,800. The rabbit was sacrificed and the terminal-bleed taken for subsequent antibody 
purification and characterisation.
3.2.2 Production and purification o f polyclonal antibody (designated anti-CephPl) to
cephalexin.
101
o
"sf
Oo
§
tQcfi
1.3
1.1
0.9
0.7
0.3
0.1
100
1 ----1-- 1— X-V'X I 1----------------------1-1-1-1— r I T T  I----------------------1------- 1-1------------- 1— r ■ T T I  J---I--------------1-1-1 I I I I  I
1000 10000 100000 1000000 
Serum dilution
Figure 3.4. (A) Determination of antibody titre to cephalexin using an indirect ELISA 
(section 2.3.1.1), A 96-well Nunc immunoplate was coated with 13.2 |xg/ml thyroglobulin- 
cephalexin (Thyro-Ceph) conjugate and serial dilutions of crude rabbit serum from 1/200 to 
1/102,400, diluted in PBS-TM dilution buffer (section 2.1.6.3), were added. Three wells were 
coated with 10 |ig/ml thyroglobulin and, following addition of 1/200 serum diluted as above, 
were used as a negative control. Each point represents the mean of three measurements.
102
1.2
Serum dilution
Figure 3.4. (B) Determination of antibody titre to cephalexin using an indirect ELISA 
(section 2.3.1.1). A 96-well Nunc immunoplate was coated with 1:1,000 and 1:10,000 
dilutions of cephalexin dextran conjugate (Dex-Ceph) conjugate and serial dilutions of crude 
rabbit serum from 1/400 to 1/204,800, diluted in PBS-TM dilution buffer (section 2.1.6.3), 
were added. Three wells were coated with 10 jxg/ml non-conjugated dextran and, following 
addition of 1/200 serum diluted as above, were used as a negative control. Each point 
represents the mean of three measurements.
103
3.2.2.3 Purification of polyclonal anti-serum
The crude rabbit serum was initially purified using saturated ammonium sulphate (SAS) 
precipitation, as described in section 2.2.3.1. Following dialysis against PBS the SAS-purified 
fraction was applied to a protein-G affinity chromatography column (section 2.2.3.2). The 
partially purified SAS precipitated antibody was passed through the column twice. The SAS 
portion was allowed to run through the column, by gravity, to maximise IgG binding to the 
protein-G immobilised phase via the Fc region. The column was then extensively washed so 
as to remove any non-specific impurities. A 0.1 M glycine solution, pH 2.2, was then used to 
elute the IgG fraction. Eluted fractions were subsequently neutralised with 2 M Tris base. A 
total of 16 fractions were taken and aliquots of each were transferred to a quartz cuvette and 
the absorbance at 280 nm was determined. Fractions with the highest absorbance values at 
280 nm, as determined from figure 3.5, were pooled and dialysed overnight at 4°C against 
PBS.
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Figure 3.5. Elution profile of the protein-G column purified fractions for the SAS precipitated 
rabbit anti-CephPl polyclonal serum. Antibody was eluted from the column using a 0.1 M 
glycine solution, pH 2.2, and neutralised with a 2 M Tris base, pH 8. A total of 16x 1 ml (A 
small aliquot of each fraction was transferred to a quartz cuvette) fractions were collected. 
The total protein content of each fraction was determined by measuring the absorbance at 280 
nm. Fractions 1-4 were pooled and dialysed overnight at 4°C against two 5L portions PBS to 
ensure complete buffer exchange.
105
3.2.2.4 Characterisation o f polyclonal antibody purification by SDS-PAGE, Western blotting 
and ELISA.
The purity of the anti-CephPl antibody was analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing conditions and subsequent 
Western blotting analysis, probing with an anti-rabbit horseradish peroxidase (HRP)-labelled 
secondary antibody, as detailed in sections 2.3.2 and 2.3.3, respectively. The SDS- 
polyacrylamide gel picture (figure 3.6) shows the serum, SAS precipitate, and protein G- 
purified fractions. The affinity-purified antibody appears as two separate bands on the SDS- 
PAGE gel with approximate molecular weights of 50kDa and 25 kDa, representing the heavy 
and light chains, respectively. The heavy chain may be seen in the Western blot (figure 3.7). 
However; the light chain was not detected on the western blot as an HRP-conjugated goat 
anti-rabbit IgG (Fc) specific antibody was used. The activity of the purification fractions (i.e. 
serum, SAS precipitate and protein-G purified) was analysed using a screening ELISA 
(section 2.3.1.1) the result of which showed minimal loss of activity during purification 
(figure 3.8).
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Figure 3.6. Denaturing SDS-PAGE gel of the polyclonal antibody following purification. The 
serum, SAS, and protein G-purified samples of the anti-cephalexin polyclonal antibody were 
loaded from left to right, respectively. Lane M, represents Blue Ranger pre-stained standard 
molecular weight marker, obtained from Pierce (Table 2.6); Lane 1 is the crude serum diluted 
1:20 in PBS; Lane 2 is the SAS (saturated ammonium sulphate precipitate) diluted 1:2 in 
PBS; Lane 3 is neat protein-G affinity-purified pooled fractions. Heavy chain and light chain 
domains are highlighted at approximately 50 kDa and 25 kDa, respectively.
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Figure 3.7. Western blot analysis of polyclonal antibody preparations following transfer from 
denaturing SDS-PAGE. The serum, SAS, and protein G-purified samples for anti-cephalexin 
polyclonal antibody were loaded, as in figure 3.6. Lane M, represents Blue Ranger pre-stained 
standard molecular weight marker, obtained from Pierce (Table 2.6); Lane 1 is the crude 
serum diluted 1:20 in PBS; Lane 2 is the SAS (saturated ammonium sulphate precipitate) 
diluted 1:2 in PBS; Lane 3 is neat protein-G affinity-purified pooled fractions. Heavy chain 
domain is highlighted at approximately 50 kDa. Following transfer to nitrocellulose 
membrane (section 2.3.3) heavy chain was detected, as highlighted above, using a HRP- 
labelled goat anti-rabbit IgG specific antibody, with subsequent addition of TMB substrate 
system. Light chain was not visualised as the HRP-labelled goat anti-rabbit IgG secondary 
antibody was Fc specific.
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Figure 3.8. Antibody titres of serum, SAS and protein-G purified fractions using an indirect 
ELISA (section 2.3.1.1). A 96-well Nunc immunoplate was coated with 13.2 jig/ml 
thyroglobulin-cephalexin (Thyro-Ceph) conjugate and serial dilutions of crude rabbit serum, 
SAS precipitate and protein-G purified polyclonal antibody fractions. The dilutions ranged 
from 1/200 to 1/102,400, and were prepared in PBS-TM dilution buffer (section 2.1.6.3). 
Three wells were coated with 10 fig/ml thyroglobulin and following addition of 1/200 serum, 
diluted as above, were used as negative control. Each point represents the mean of three 
measurements.
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3.2.3 Development of ELISA for the detection of cephalexin using polyclonal antibody 
(anti-CephPl)
3.2.3.1 Checkerboard ELISA for determining the optimal conjugate coating concentration 
and antibody dilution.
An indirect checkerboard ELISA was used to determine the optimal coating dilution of 
conjugate (described in section 2.3.1.2). Varying dilutions of a 1.32 mg/ml stock solution of 
thyroglobulin-cephalexin conjugate were prepared in PBS (pH 7.4) and coated on a 96 well 
microtitre plate. Dilutions of the protein G-purified mti-CephPl antibody were added to each 
of the conjugate dilutions. The results were plotted (Figure 3.9). The optimal coating 
concentration of thyroglobulin-cephalexin conjugate was found to be 1.32 fxg/ml. The optimal 
polyclonal antibody (anti-CephPl) dilution, which gave the greatest change in absorbance per 
change in antibody dilution, was determined to be 1/1,500. These conditions were used in the 
development of an inhibition ELISA for the detection of free cephalexin.
3.2.3.2 Development o f an inhibition ELISA for the detection o f cephalexin hydrate in spiked 
PBS and whole milk sample matrices.
Inhibition assays for the detection of cephalexin hydrate were developed in spiked PBS and 
‘spiked’ whole milk samples using the affinity-purified anti-CephPl polyclonal antibody. The 
optimal conjugate coating concentration and protein-G purified polyclonal antibody dilution 
(section 3.2.3.1) were used initially to develop an inhibition assay for the detection of 
cephalexin in ‘spiked’ PBS-T buffer containing 2% (w/v) skimmed milk powder. The Thyro- 
Ceph coating concentration used for subsequent inhibition assay development was 1.3 (ag/ml 
and an antibody dilution of 1/1,500. Standard ‘spiked’ solutions of cephalexin hydrate were 
prepared by serial dilution of a 1 mg/ml stock solution (1:2) in the appropriate sample matrix 
(i.e. PBS-T 2% (w/v) skimmed milk powder (section 2.1.6.3) and whole milk) and incubating 
as described in section 2.3.1.3. The cephalexin standard and antibody mixtures were then 
added to the microtitre plate and incubated at room temperature with gentle mixing. 
Following incubation, the rabbit anti-CephPl polyclonal was detected with an HRP- 
conjugated goat anti-rabbit antibody (section 2.3.1.3). The inhibition assay carried out in 
PBS-T 2% (w/v) had a limit of detection for free cephalexin of approximately 30 ng/ml 
(taking the limit of detection to be the background (i.e. A0) plus three standard deviations). 
The Ao represents the relevant antibody dilution and no free cephalexin. The absorbance (A) 
for each ‘spiked’ sample was expressed as a ratio of the A0 (i.e. antibody with no free
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cephalexin). The assay was subsequently carried out using whole milk as diluent for the 
standard cephalexin concentrations. The limit of detection was found to be 20 ng/ml. Inter- 
and intra-day variability studies were carried out using the optimised assay conditions.
Antibody Dilution
Figure 3.9. Results obtained from a checkerboard ELISA to determine the optimal conjugate 
coating concentration. A 96 well plate was coated using various concentrations of 
thyroglobulin-cephalexin (Thyro-Ceph) ranging from 0 |4.g/ml to 132 ng/ml. A 1 mg/ml 
solution of non-conjugated thyroglobulin (Thyro) was used as a negative control. The wells 
were subsequently blocked with PBS containing 5% (w/v) skimmed milk powder. Following 
this, serial dilutions of protein-G purified polyclonal antibody prepared in PBS-TM dilution 
buffer, were added. The anti-cephalexin polyclonal antibody was detected with HRP-labelled 
goat anti-rabbit polyclonal antibody (Sigma) and absorbance measured at 450 nm using OPD 
substrate.
I l l
3.2.3.3. Intra-day assay variability studies o f rabbit anti-cephalexin polyclonal (anti-CephP 1) 
antibody in PBS.
An inhibition ELISA format (section 2.3.1.3) was used in the development of an assay for the 
detection of free cephalexin hydrate in spiked phosphate buffered saline (PBS, 0.15 M NaCl,
2.5 mM potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium 
dihydrogen phosphate, pH 7.4). A 96 well microtitre plate was coated with a 1.3 pg/ml 
solution of thyroglobulin-cephalexin conjugate and blocked with a 5% (w/v) solution of milk 
marvel. Standard solutions of cephalexin hydrate were prepared in PBS and mixed with anti- 
CephPl polyclonal antibody. The linear range of detection was from 1.9 to 3906 ng/ml. The 
polyclonal anti-cephalexin antibody and standard cephalexin mixtures were incubated at 37°C 
for 30 min and then added to the wells of a microtitre plate. A HRP-conjugated goat anti­
rabbit antibody was used to detect the presence of rabbit IgG after the plate was washed 
initially with PBST and then with PBS. To carry out intra-day variability studies, five sets 
(i.e. five separate plates) of cephalexin hydrate standards were prepared and incubated with 
antibody prior to being assayed on the same day. Each concentration point was prepared in 
triplicate on each plate. The intra-day assay results were plotted (figure 3.10) and a limit of 
detection for the assay was found to be 20 ng/ml. The coefficients of variation (CV’s) were 
determined as a measure of the assay’s precision, by expressing the standard deviation as a 
percentage function of the mean A/A0 value. The A/A0 was determined by dividing the 
absorbance mean for each concentration point by the absorbance mean of the A0 (i.e. the 
absorbance obtained with antibody and no free antibiotic). CV’s for the intra-day assay 
ranged from 2.85% to 9.80% (Table 3.1).
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Figure 3.10. Inhibition ELISA assay calibration curve for rabbit anti-cephalexin polyclonal 
(arAi-CephP 1) antibody. A four-parameter equation was fitted to the intra-day data set using 
BIAevaluation 3.1 software. The mean A/Ao represents the mean of five sets of data. The 
mean absorbance for each standard cephalexin concentration (A) is divided by the 
background, i.e. antibody with no free cephalexin (Ao). For each of the five replicates, each 
point was carried out in triplicate. The linear range of detection was found to be from 1.9 to 
3906 ng/ml. The limit of detection (LOD) was estimated by taking three standard deviations 
away from the background (A0). The LOD for the assay was 20 ng/ml.
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Table 3.1. Calculated coefficients of variation for the rabbit anti-cephalexin polyclonal (anti- 
CephPl) antibody intra-day assay in PBS. The calculated mean A/A0 values and standard 
deviation for each concentration point are shown.
Concentration of 
cephalexin
(ng/ml)
Calculated mean A/Ao ± 
S.D.
CV’s
%
3906.3 0.633 ± 0.053 8.4
1953.1 0.672 ± 0.030 4.5
976.6 0.707 ±0.038 5.3
488.3 0.723 ± 0.071 9.8
244.1 0.781 ± 0.039 5.0
122.1 0.840 ± 0.066 7.9
61.0 0.874 ± 0.039 4.4
30.5 0.911+0.062 6.8
15.3 0.952 ± 0.048 5.1
7.6 0.970 ± 0.037 3.9
3.8 0.984 ± 0.032 3.3
1.9 1.002 ±0.029 2.9
3.2.3.4. Inter-day assay variability studies o f rabbit anti-cephalexin polyclonal (anti-CephP 1) 
antibody in PBS.
Inter-day assay variability studies were carried out for the anti-CephPl polyclonal antibody in 
‘spiked’ PBS. Five sets of standards were set up across a concentration range of cephalexin 
as described for the intra-day assay. The variability study was carried out by repeating the 
polyclonal inhibition assay five times, over five consecutive days (Findlay et al., 2000). The 
limit of detection for the assay was estimated by subtracting three standard deviations from 
the background (A0). The inter-day assay for the detection of cephalexin hydrate was found to 
have a limit of detection of 20 ng/ml (figure 3.11), with CV’s ranging from 4.9% to 13.7% 
(Table 3.2).
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Figure 3.11. Inhibition ELISA assay calibration curve for rabbit anti-cephalexin polyclonal 
(anti-CephPJ) antibody. A four-parameter equation was fitted to the inter-day data set using 
BIAevaluation 3.1 software. The mean A/A0 represents the mean of five sets of data. The 
mean absorbance for each standard cephalexin concentration (A) is divided by the 
background, i.e. antibody with no free cephalexin (A0). For each of the five replicates, each 
point was carried out in triplicate. The limit of detection (LOD) was estimated by taking three 
standard deviations away from the background (A0). The LOD for the assay was 20 ng/ml.
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Table 3.2. Calculated coefficients of variation, mean A/A0 values and standard deviations for 
the rabbit anti-cephalexin polyclonal antibody inter-day assay, carried out in PBS.
Concentration of 
cephalexin 
(ng/ml)
Calculated mean A/A0 ± 
S.D.
CV’s
%
3906.3 0.513 + 0.025 5.0
1953.1 0.582 + 0.048 8.3
976.6 0.617 ± 0.060 9.8
488.3 0.643 ± 0.088 13.7
244.1 0.705 ± 0.080 11.3
122.1 0.748 ± 0.074 9.9
61.0 0.787 ± 0.078 9.9
30.5 0.835 ± 0.073 8.7
15.3 0.887 + 0.059 6.7
7.6 0.926 + 0.065 7.0
3.8 0.930 + 0.050 5.5
1.9 0.990 + 0.048 4.9
3.2.3.5. Inter-day assay variability studies o f anti-cephalexin polyclonal antibody in whole 
milk.
An inhibition ELISA (section 2.2.5), was developed to determine the free cephalexin levels in 
‘spiked’ whole milk samples. A pint of a well-known brand of whole milk was purchased. 
This was stored at -20° C in 20.5 ml aliquots that were thawed and ‘spiked’ with cephalexin, 
as required. A 96 well microtitre plate was coated with a 1.3p,g/ml solution of thyroglobulin- 
cephalexin conjugate and blocked with a 5% (w/v) solution of milk marvel in PBS (0.15 M 
NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen phosphate and 18 mM sodium 
dihydrogen phosphate, pH 7.4). Five sets of standards, across a concentration range of 
cephalexin, were prepared in the whole milk and mixed with antibody diluted to 2 x the 
working dilution, also diluted in whole milk. The assay was carried out as described 
previously. The inter-day assay results were plotted (figure 3.12) and the limit of detection 
for the assay was found to be 20 ng/ml. The CV’s for the intra-day assay ranged from 3.8% to 
14.6% as shown in table 3.3.
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Figure 3.12. Inhibition ELISA assay calibration curve for rabbit anti-cephalexin polyclonal 
(anti-CephPl) antibody. A four-parameter equation was fitted to the inter-day data set using 
BIAevaluation 3.1 software. The assays were carried out in using cephalexin ‘spiked’ whole 
milk. The mean A/Ao represents the mean of five sets of data. The mean absorbance for each 
standard cephalexin concentration (A) is divided by the background, i.e. antibody with no 
free cephalexin (Ao). For each of the five replicates, each point was carried out in triplicate. 
The limit of detection (LOD) was estimated by taking three standard deviations away from 
the background (A0). The LOD for the assay was 20 ng/ml.
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Table 3.3. Calculated coefficients of variation of inter-day assay study for the rabbit anti­
cephalexin polyclonal antibody assay carried out in whole milk. The calculated mean A/A0 
values and standard deviation for each concentration point are shown.
Concentration of 
cephalexin 
(ng/ml)
Calculated mean A/A« ± 
S.D.
CV’s
%
3906.3 0.502 ± 0.063 12.6
1953.1 0.518 + 0.076 14.6
976.6 0.536 ±0.043 8.0
488.3 0.580 ± 0.063 10.8
244.1 0.658 ± 0.094 14.3
122.1 0.735 ± 0.094 12.7
61.0 0.763 ± 0.099 13.0
30.5 0.858 ± 0.074 8.6
15.3 0.911 ±0.069 7.6
7.6 0.940 ± 0.068 7.2
3.8 0.988 ± 0.043 4.4
1.9 1.004 ±0.038 3.8
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3.2.4. Cross-reactivity studies o f the rabbit anti-cephalexin polyclonal (anti-CephPl) 
antibody.
Cross reactivity studies were carried out with various related P-lactam compounds using an 
inhibition ELISA format. Since cephalexin is such a relatively small compound it is probable 
that the anti-cephalexin polyclonal antibody will cross-react with similar chemical structures. 
The extent of the cross reactivity and with which particular compound it occurs is critical to 
the performance of the immunoassay. Various related P-lactam antibiotic compounds 
including, cefazolin sodium salt, cephalosporin C zinc salt, cefuroxime sodium salt, oxacillin 
sodium salt, cefadroxil, amoxicillin tri-hydrate, cloxacillin sodium salt, 7-aminodesacetoxy 
cephalosporanic acid, cefoperazone sodium salt, (+)- 6 -aminopenicillanic acid, dicloxacillin 
sodium salt and cefotaxim sodium salt were chosen as potential cross reactants. The chemical 
structures of these compounds are outlined in table 3.4. The cross-reactivity characteristics of 
an immunoassay are invariably defined as the concentration of analyte that gives a 50% 
decrease (IC50) in the overall signal, from a concentration range of zero analyte (ICO) to the 
maximum concentration of analyte detected by the assay (IC100). The target analyte 
concentration at the IC50 is taken as a reference for calculating the percentage cross-reactivity 
(% CR) of a potential cross-reactant. For each potential cross-reactant an inhibition ELISA 
was carried out as described for the cephalexin immunoassay. The IC50 concentration of 
cephalexin was expressed as 100% of the cross-reactivity and each potential compounds IC50 
value was expressed as a percentage of this value using the following formula:
% cross-reactivity (CR) = Concentration of analyte at IC50 x 100
Concentration of cross-reactant at IC50
The immunoassays were carried out in whole milk as a sample matrix, the resulting calculated 
cross-reactivity for each of the compounds, listed in table 3.4, are shown in table 3.5. An 
overlay plot of each inhibition assay is for cephalexin and potential cross-reactant is shown in 
figure 3.13.
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Table 3.4. List of the potential cross-reactant (XR) structures tested in ELISA and the label 
assigned to each.
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Table 3.5. The calculated cross-reactivity (% CR) of selected p-lactam antibiotic compounds 
and the IC50 concentration of analyte (ng/ml) for the protein G-purified anti-CephPl 
antibody. The IC50 concentration of cephalexin was expressed as 100%, and the IC50 value 
for each potential cross-reactant was expressed as a percentage of this value. N/D means the 
concentration required to reach the IC50 value was too large (>1 mg/ml).
Compound Polyclonal IC50(Hg/ml) % CR (IC50)
Cephalexin 0.58 100.0
Cefadroxil 0.79 73.4
7-ADAC 6.18 9.4
Cefaperazone 87.90 0.7
Cephalosporin C 195.90 0.3
Cefotaxim 317.15 0.2
6-APA 401.60 0.1
Cefazolin 780.02 0.1
Oxacillin N/D —
Cloxacillin N/D —
Dicloxacillin N/D —
Cefiiroxime N/D —
Amoxicillin N/D —
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Figure 3.13. Overlay plot of selected polyclonal inhibition ELISA assay results using 
cephalexin, cefadroxil, cefoperazone, cephalosporin C and 7-ADAC. The assays were carried 
out using anti-CephPl polyclonal antibody (section 2.3.1.3). The A/A0 represents the 
absorbance for each antibody and standard compound concentration (A) divided by the 
antibody alone, i.e. with no free compound (A0). For each point above measurements were 
carried out in triplicate.
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3.3. Discussion
This chapter describes the production and characterisation of polyclonal antibody to 
cephalexin. Cephalexin was conjugated to Bovine serum albumin (BSA-Ceph), ovalbumin 
(Ceph-Ova), thyroglobulin (Thyro-Ceph) and dextran (Dex-Ceph), as described in sections
2.2.1.2 and 2.2.1.3. Cephalexin-carrier conjugates were characterised by non-competitive 
ELISA (section 2.3.1.2) using a cephalexin-specific polyclonal antibody (designated AVAab) 
that was kindly donated by Dr. Aart van Amerongan. The non-competitive ELISA using 
AVAab was carried out to confirm the cephalexin had been covalently linked to the respective 
carrier protein and was still in a detectable configuration. Figures 3.1 and 3.2 show typical 
results obtained for checkerboard ELIS As using Bovine Serum Albumen (BSA) and 
ovalbumin (Ova) -Ceph conjugates, with AVAab anti-cephalexin polyclonal antibody. Ceph- 
BSA conjugate was used in the preparation of immunogen for the production of cephalexin- 
specific polyclonal antibody (Hermanson, 1996).
The polyclonal antibody was purified using saturated ammonium (SAS) precipitation, 
followed by protein-G affinity chromatography from rabbit serum. The protein concentration 
of protein-G affinity purified fractions was monitored by UV spectroscopy (figure 3.5). The 
purity of antibody preparation was assessed by SDS-PAGE (section 2.3.2) analysis and 
Western blotting (section 2.3.3). The specific activity of the polyclonal antibody against 
Thyro-Ceph conjugate was monitored during the purification process by ELISA, in order to 
show there was no adverse affects on antibody activity during the purification.
It was found that the purified anti-CephPl polyclonal antibody recognised all of the 
cephalexin conjugates in a non-competitive ELISA format. Polyclonal antibody was 
subsequently used in the development of inhibition ELISA assay for the detection of free 
cephalexin in solution (i.e. un-conjugated cephalexin). The anti-CephPl polyclonal antibody 
binding to cephalexin-conjugate (synthesised using protein-activated ester coupling as 
described in section 2.2.1.3) was inhibited in the presence of free cephalexin. Cephalexin 
conjugates synthesised using the cephalexin-activated ester coupling were unstable (i.e. 
formed precipitate during storage). These conjugates, when used as immobilised surfaces in 
inhibition ELISA with the polyclonal anti-cephalexin antibody, yielded assays with poor 
reproducibility. The protein-activated thyroglobulin-cephalexin conjugate was chosen to 
develop an inhibition ELISA for the detection of cephalexin.
In determining the optimum coating concentration of conjugated cephalexin and polyclonal 
antibody dilution, a checkerboard ELISA (section 2.3.1.2) was performed with affinity
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purified polyclonal antibody and Thyro-Ceph conjugate. Initially an inhibition assay was 
developed, as described in section 2.3.1.3, using PBS to prepare cephalexin standards, 
following this cephalexin standards were prepared in whole milk (i.e. ‘spiked’ processed 
milk).
Cephalexin standards prepared in PBS and whole milk were used for the intra- and inter-day 
inhibition assay variability studies. The best comparative linear range of detection for the 
inhibition ELISA was found to be from 1.9 ng/ml to 3906 ng/ml. Intra- and inter-day assay 
variability studies in PBS had limits of detection (LOD) of be 20ng/ml. The LOD’s were 
below the required European Union maximum residue limit (MRL), currently set at lOOng/ml 
for cephalexin in milk samples, as set out in EEC council regulation No 2377/90. Inter-day 
assay variability studies carried out in cephalexin ‘spiked’ whole milk (homogenised and 
pasteurised) showed the assay LOD was below the EU-MRL, at approximately 20 ng/ml for 
the inhibition assay. The limits of detection achieved for similar antibiotic compounds are 
comparable to those reported in this chapter using polyclonal antibodies.
Situ and Elliot (2005) reported a polyclonal immunoassay-based detection technique for the 
simultaneous detection of five banned antibiotic growth promoters. They developed the 
immunoassay for the detection of the antibiotics (i.e. bacitracin, spiramycin, tylosin, 
virginiamycin and olaquindox) in animal feedstuffs, thus a sample clean-up step was required. 
The minimal detectable concentrations (MDC) were 4 mg/Kg for olquindox, and 1 mg/Kg for 
bacitracin, spiramycin, tylosin and virginiamycin. These values correspond to 4,000 ng/ml 
and 1,000 ng/ml MDC in feedstuff extract, respectively. The polyclonal antibodies were 
generated in an analogous manner to that described in this chapter. Antibiotic-Human Serum 
Albumen (HSA) conjugates were produced and used as immunogen for each of the listed anti­
microbial drugs. However, the ELISA assay format used was different to that reported in this 
chapter. Wells of 96-well plates were initially coated with antibiotic-specific antibody 
followed by the addition of HRP-labelled antibiotic standards, which were used to compare to 
unknown samples. A corresponding reduction in the response (i.e. absorbance) was attributed 
to the presence of antibiotic in the sample.
The cephalexin assays developed in this chapter also compare favourably with other distinct 
detection methods, in terms of sensitivity. In addition to assay sensitivity, each different P- 
lactam antibiotic has different maximum residue limits (MRL’s) in milk, as set out by the EU, 
and therefore generic and broadly specific assay types are usually favoured. Current 
commercial antibiotic detection techniques vary in terms of their basic principles. Overall, 
they may be classified into four main types, microbial inhibition, receptor binding assays,
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antibody-based assays (ELISA) and enzymatic assays. The more traditional microbial 
inhibition tests such as the Bacillus stearothermophilus disc assay are broadly specific for the 
P-lactam antibiotics and non- P-lactam antibiotics (Gilbertson et al., 1995; Scannella et al., 
1997; Popelka et al., 2003). Microbiological assays for the detection of antibiotic residues in 
milk utilise the genus Bacillus because of its high sensitivity to the majority of antibiotics. A 
host of commercial tests approved for screening utilise this principle, including the Delvotest 
SP (DSM Food Specialities, Delft, The Netherlands)(Althaus et al., 2003). Such assays have 
good sensitivities to the p-lactam antibiotics on the whole, for example penicillin G, 
amoxicillin, ampicillin, cephapirin, and cetiofur can all be detected at or below their 
respective MRL’s. However, they lack the ability to distinguish between the various antibiotic 
compounds within distinct groups. The Delvo® SP which is the standard rapid method of 
detection (Irish government, Department of Agriculture and Food, DAF) has a quoted 
sensitivity to cephalexin of 40-60 ng/ml. The anti-CephPl polyclonal antibody developed in 
this chapter is specific, as demonstrated by the minimal cross-reactivity with similar P-lactam 
compounds and it is capable of detection below that limit. However, PBS and milk assays 
performed poorly in terms of assay reproducibility, with relatively high standard deviation 
between assay replicates and individual measurements.
Some studies have found such rapid screening methods (e.g. microbial inhibitor, enzymatic 
assays and receptor binding assays) to be problematic also, in so far as they may lead to false 
positive results. One study carried out by Andrew (2000), suggests that results from Delvotest 
SP, Penzyme, Charm, and CITE Snap screening assays showed an increase in false positives 
between two distinct breeds of cattle. They also suggest that milk fat, protein content, and 
somatic cell counts were all associated with an increase in false positive results. This 
highlights a need for more robust and specific detection systems. Confirmatory testing is may 
be carried out using chromatographic methods (i.e. HPLC). These techniques can be costly 
and require trained operators. In addition, they involve extensive sample pre-treatment 
(Schenck and Callery, 1998). Zhi et al. (2001) developed an integrated flow-through 
immuno-analysis system for the detection of cephalexin in raw milk. This system was based 
on a polyclonal antibody specific for cephalexin and had a limit of detection (LOD) of 1 
ng/ml. The system used a cephalexin-alkaline phosphatase conjugate in direct competition 
with analyte (i.e. cephalexin) in solution.
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Chapter 4
Production of monoclonal antibodies to cephalexin and 
the development of an ELISA-based assay for detection
in milk
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4.1 Monoclonal antibody production
The aim of this chapter was the production, purification and characterisation of monoclonal 
antibodies against the p-lactam antibiotic cephalexin and their application in an ELISA-based 
assay for the detection of cephalexin in milk. Monoclonal antibodies were produced by 
murine somatic cell fusion procedures, subsequently purified and characterised by SDS- 
PAGE and Western blotting. Monoclonal antibodies with the desired characteristics (i.e. 
cephalexin-specific with a limit of detection (LOD) below the MRL) were identified and used 
in the development of an inhibition ELISA for the analysis of cephalexin in ‘spiked’ PBS and 
whole milk sample matrices. Cross-reactivity of this antibody with similar p-lactam antibiotic 
compounds was evaluated using solid-phase immunosorbent assay (ELISA).
4.1.1 Production of monoclonal antibodies following in vivo immunisation
BALB/c strain mice were initially immunised with cephalexin conjugates and boosted 
periodically over a period of several weeks as described in section 2.4.1. Specific serum 
antibody levels or titres were measured (Kemeny, 1992a) from tail bleed samples using an 
indirect screening enzyme-linked immunosorbent assay (ELISA). Upon obtaining a sufficient 
serum antibody titre (> 1/50,000) the animal was sacrificed and the lymphocytes extracted 
from the spleen and used for the cell fusion procedure. The spleen was used as it contains the 
highest percentage of B-lymphocytes of the major murine lymphoid organs (Table 4.1). The 
myeloma cells used as the fusion partner were originally derived from BALB/c lineage mice 
and selected on the basis of their hypoxanthine-guanine phosphoribosyltransferase (HGPRT) 
deficiency. Two of the most commonly used myeloma cell lines are Sp2/0-Agl4 (Shulman et 
al., 1978) and X63/Ag8.653 (Brown and Ling, 1988), which were produced from a myeloma 
cell line following the injection of mineral oil into the peritoneal cavity of mice. Neither of 
these cell lines possesses the inherent genetic capacity to produce immunoglobulin. The 
technique employed the use of the HAT (Hypoxanthine, Aminopterin, Thymidine) selection 
system, described by Littlefield (1964). Myeloma cells that lack the enzyme hypoxanthine 
guanine phosphoribosyltransferase (HGPRT ") are incapable of proliferating in the presence 
of HAT-supplemented medium. This is because aminopterin blocks the de novo synthesis of 
purines and pyrimidines required for DNA synthesis. Cells that are HGPRT " are incapable of 
using the salvage pathways for DNA synthesis as they do not possess the requisite enzyme 
systems (Figure 4.2).
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Table 4.1. Sub-populations of B- and T- lymphocytes within the major murine lymphoid 
organs. (Adapted from Hudson and Hay, 1980).
Organ % T-Cells % B-Cells
Thymus 97 1
Lymph node 77 18
Spleen 35 38
Blood 70 24
Thoracic duct lymph 80 19
Spleenocytes are HGPRT+ and therefore are capable of DNA synthesis using the salvage 
pathway. However, spleenocytes do not grow well in culture and naturally die off after a short 
period of time. Thus, in growth medium supplemented with HAT only hybridomas (i.e. fusion 
hybrid product of myeloma and lymphocyte cells) will proliferate. Cell fusion procedures in 
this work were carried out using polyethylene glycol (50% w/v) (Zola and Brooks, 1995). 
This facilitates membrane fusion between adjacent cells. Subsequent fused cell division leads 
to chromosome mixing. The cellular product of a fusion process consists of a heterogeneous 
population of un-fused myeloma cells and spleenocytes, fused myeloma/myeloma, 
lymphocyte / lymphocyte and the desired myeloma / B-lymphocyte hybrids. Early 
identification and isolation of specific monoclonal antibody-secreting myeloma / B- 
lymphocyte fusion products is essential. This may be achieved using appropriate screening 
techniques in conjunction with various cloning methods, as discussed in sections 4.1.2.1 and
4.1.2.2, respectively.
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Figure 4.1. Overview of monoclonal antibody production by somatic cell fusion. B- 
lymphocytes are extracted from the spleen of a mouse immunised with the antigen of interest. 
The lymphocytes (HGPRT+) are subsequently fused with a compatible murine myeloma cell 
line using appropriate fusogen (e.g. polyethylene glycol). Myeloma cells are HGPRT " and, 
thus, only proliferate in vitro if they have successfully fused with B-lymphocytes.
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Figure 4.2. Principle of the HAT selection system. The main biosynthetic pathway for DNA 
synthesis is blocked by aminopterin (A). Cells possessing the requisite enzymes can 
synthesise nucleic acids using the salvage pathways, if provided with hypoxanthine (H) and 
thymidine (T). Cells lacking the enzymes hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT) or thymidine kinase cannot synthesise nucleic acids via the salvage pathway and 
die off.
130
4.1.2 Isolation o f desired hybridoma clones
4.1.2.1 Screening
The post-fusion cell mixture is typically cultured in 96-well culture vessels or master plates. 
The master plates contain a heterogeneous population of hybridomas i.e. secreting antibodies 
derived from different B-cells. Each of the hybridoma populations must be screened for 
specific antibody activity as early as possible using a suitable assay. A non-specific or non- 
secreting cell population can potentially outgrow hybridomas secreting the desired antibody, 
therefore, early identification and isolation is of paramount importance. Each hybridoma 
within a given well population can contribute anywhere between 0 & 100 % of the secreted 
antibody content. Enzyme-linked immunosorbent assay (ELISA) facilitates multiple 
screening of multiple wells and is the screening method of choice in many cases.
A direct ELISA format can be easily optimised and is suitable for initial screening of a very 
large number of wells. This was carried out by coating the antigen of interest onto an ELISA 
plate, adding test well supernatant (diluted in PBS-T to limit non-specific interactions) 
followed by an anti-species enzyme-labelled (e.g. HRP-labelled goat anti-mouse) secondary 
detection antibody. In the case of haptens (e.g. cephalexin), plates can be coated with 
conjugated hapten or non-conjugated hapten. Haptens may be directly linked to the surface of 
the ELISA plate via adaptor or linker molecules (Danilova, 1994). In this chapter, we used 
conjugated-cephalexin-coated plates for monoclonal antibody screening purposes. It is 
important to include adequate positive and negative controls to confidently identify hapten- 
specific antibodies, as opposed to carrier-specific antibodies within a given population. 
Ideally, a distinct hapten-conjugate from the one used for initial mouse immunisation should 
be used for screening of hybridomas, so as to limit the possibility of obtaining carrier specific 
antibodies. Initially supernatants were screened against cephalexin-activated Ova-Ceph 
conjugate followed by protein-activated thyroglobulin Thyro-Ceph conjugate, as outlined in 
Figure 4.3. The screening of hybridoma populations against Ova-Ceph conjugate was carried 
out as the Thyro-Ceph conjugate was used as immunogen. In addition, alternative functional 
groups on the cephalexin molecule were originally used for conjugate synthesis. The covalent 
attachment to the Thyro was via the primary amine and Ova via the carboxyl functional 
groups, on the cephalexin molecule. Hybridomas that were positive for both conjugates were 
selected for further analysis using inhibition displacement ELISA. The inhibition 
displacement ELISA format (section 2.3.1.3) is outlined in Figure 4.4. Such assay formats are 
favoured in the case of haptens because the monoclonal antibodies and antigen are allowed to 
interact in the solution phase.
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Figure 4.3. Schematic representation of the two stage initial hybridoma screening strategies 
employed for the identification of whole cephalexin molecule-specific antibodies. Firstly, 
hybridoma supernatant was screened against Ova-Ceph conjugate, prepared using the 
cephalexin-activated (above left) method i.e. where the covalent linkage to Ova was formed 
via the carboxylic acid functional group on the cephalexin molecule. Secondly supernatants 
were screened against protein-activated (above right) Thyro-Ceph conjugate, where the 
covalent bond between cephalexin and Thyro was formed using the primary amine functional 
group on the cephalexin molecule. This was carried out to maximise the potential of 
identifying antibodies specific to the whole cephalexin molecule by presenting alternative 
cephalexin epitopes.
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Figure 4.4. Schematic diagram of inhibition ELISA used to screen supernatants from 
hybridoma populations. (A) A 96 well plate was coated with cephalexin-protein conjugate 
(e.g. Thyro-Ceph); (B) The remaining adsorption sites are ‘blocked’ with a solution of 5% 
(w/v) milk marvel in PBS; (I) Supernatant containing monoclonal antibody was pre-incubated 
with free cephalexin standards for 30 minutes at 37°C in a 1.5 ml micro-centrifuge tube; (C) 
Pre-incubated samples are added to the 96 well plate; (D) The monoclonal antibody was 
detected with a horse radish peroxidase (HRP)-conjugated goat anti-mouse antibody; (E) 
HRP-substrate was added to 96 well plate and developed at R.T. and the absorbance 
measured at 450nm.
4.1.2.2 Cloning o f specific antibody-secreting hybridomas
Following identification of the specific antibody-secreting hybridoma populations, the 
hybridomas must be isolated from the heterogeneous cell mixture to achieve monoclonality. 
There are many possible methods for doing this, but the simplest method is cloning by 
limiting dilution. Cloning by limiting dilution involves the repeated dilution and specific 
selection of positive antibody secreting hybrids (Harlow and Lane, 1988). This entails seeding 
the mixed population of hybridomas over a range of dilutions calculated to maximise the 
chances of only one cell being distributed to a particular well. A mathematical approach 
indicates that were less than 63 % of the wells seeded with concentrations of < 1 cell/well, 
and Poisson distribution indicates (Lefkovitz, 1979; Eshhar, 1985) that each well will most
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likely contain a single clone. The tendency of cells to clump, however, means that this 
mathematical explanation is not the most appropriate. In order to ensure ‘monoclonality’, it is 
best to repeat the cloning procedure again for several rounds, after which the hybridoma can 
be statistically considered monoclonal (Lietske and Unsicker, 1985).
One of the main problems with seeding the cells at such low concentrations is the need to add 
feeder layers to increase the seeding efficiency. The use of conditioned growth media such as 
Briclone™ can obviate the need for such layers. Cloning in semi-solid agar is the principle 
alternative to limiting dilution. The medium allows the cells to easily divide and grow to 
produce a viable, defined colony, without permitting cells to break away and cause disperse 
colony development (McCullough and Spier, 1990). Isolated colonies can then be picked off 
the semi-solid agar with a pipette tip and transferred to fresh liquid media. A more direct 
approach to cloning is one that involves the use of a Pelteir controlled pipette (Wewetzer and 
Seilheimer, 1995) to select a single colony and transfer it to a new well of a microtitre plate. 
This method increases confidence that only single hybridoma cells have been seeded and 
reduces the cloning period significantly in comparison to the traditional methods. Hybridomas 
secreting specific anti-cephalexin antibody were cloned out by limiting dilution, as outlined in 
figure 4.5.
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Figure 4.5. Overview of the post-fusion production of monoclonal antibodies. ‘Spent’ media 
is removed from the master plates and subsequently screened for specific anti-cephalexin 
antibody activity by ELISA. Positive populations are then scaled up. Frozen stocks of the 
positive hybridoma populations are made at this stage. The population is then cloned out by 
limiting dilution and seeded onto 96 well plates. Several cycles of the above process were 
carried out to achieve ‘monoclonality’.
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4.2 Results
A total of three mice were immunised with immunogens prepared using Keyhole Limpet 
Heamocyanin (KLH)-cephalexin (i.e. lx mouse) and thyroglobulin-cephalexin (i.e. 2x mice) 
conjugates. Mice were immunised with respective immunogen, as outlined in section 2.4.1. 
The serum titre from each mouse was determined against an Ovalbumin-cephalexin (Ova- 
Ceph) conjugate using a non-competitive ELISA (section 2.3.1.1). The antibody titre has been 
classically described as the lowest dilution of sample that can be reliably detected at a 
predetermined cut-off (Ciclitira et al., 1986). The titre for the purposes of this research was 
defined as the antibody dilution at 1.5x the background response (i.e. naïve serum, termed 
Mouse Neg.).
The initial serum screening was carried out using an Ova-cephalexin conjugate as opposed to 
either conjugate used as immunogen (i.e. Thyro-Ceph or KLH-Ceph) so as to rule out the 
possibility of selecting for a carrier protein-specific antibody. Serum samples from each 
mouse (i.e. Mouse 1 (KLH-cephalexin immunogen), Mouse 2 and 3 (Thyroglobulin- 
cephalexin immunogen) were serially diluted in PBS-T and added to the conjugate coated 
plate. The serum titre for mouse 1, 2 & 3 was approximately 1/50,000, in contrast to a 
negative control mouse serum (Mouse Neg.). The control serum was obtained from a mouse 
not previously immunised and showed negligible binding even at a 1:200 serum dilution 
(Figure 4.6).
On the day of the fusion (day 0), the spleens were removed and the lymphocytes harvested 
and pooled. After the somatic cell fusion (section 2.4.3.1) procedure, the cellular fusion 
product was seeded onto the wells of 96 well plates, at a density of 1.2 x 106 cells/ml and 
incubated for 8 days (termed master plates). The conditioned media (supernatant) from wells 
containing healthy colonies was removed for screening on day 8 post-fusion. Anti-cephalexin 
antibodies were screened for using an indirect non-competitive ELISA format. Post-fusion 
hybridoma populations are considered to be heterogeneous in nature (derived from different 
B-cells). Positive hybrid populations are propagated by incrementally seeding larger tissue 
culture vessels and subsequently isolated by cloning by limiting dilution. Cell dilutions were 
manipulated to achieve 1 or 0.5 cell/well seeding densities depending on the stability of the 
particular hybridoma cell line. A total of 11 positive wells were selected for scaling up to 24- 
well, 6-well and tissue culture flasks. An outline of the screening strategy employed is 
presented in figure 4.3.
4.2.1 Monoclonal antibody-producing hybridoma production, isolation and screening
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The results of a typical initial master plate hybridoma supernatant screen are shown in figure 
4.7. Hybridoma cell populations that yielded a high response, in terms of absolute absorbance, 
were selected from each master plate for further propagation, in order to obtain a functionally 
expressed and sufficiently high affinity antibody to cephalexin. Antibody binding was to the 
conjugated form of cephalexin at this stage. Ceph-conjugate, adsorbed onto the well surface, 
may present a dissimilar or mask the epitope to that of soluble antigen (i.e. cephalexin). 
Therefore, in order to characterise antibody binding to non-conjugated cephalexin, inhibition 
displacement ELISA (section 2.3.1.3.) were carried out.
The positive colonies detected in the initial screen were scaled up and subjected to four 
rounds of cloning by limiting dilution, as described in section 2.4.3.3. Positive cell 
populations were continuously screened by ELISA during the cloning process, to monitor 
cephalexin-specific antibody-secreting hybridomas. Following cloning out, hybridoma 
supernatant titres were ascertained, using an ELISA plate coated with thyroglobulin- 
cephalexin conjugate. In addition to this, the supernatants were screened against thyroglobulin 
(10 pg/inl in PBS, 0.15 M NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen 
phosphate and 18 mM sodium dihydrogen phosphate, pH 7.4) and PBS supplemented with 
skimmed milk powder (section 2.1.6.4) as negative controls. This is shown in figure 4.8. No 
significant binding was observed with the negative controls. Crude supernatant dilutions for 
each clone were determined from this result and used to carry out preliminary inhibition 
assays using a series of free cephalexin concentrations, ranging from 1.9 to 500,000 ng/ml 
(Figure 4.9).
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Figure 4,6. Plot of the results of a titre ELISA using mouse sera against a 10 pg/ml coating 
concentration of Ova-cephalexin conjugate. Mouse 1 was immunised with KLH-Cephalexin. 
Mouse 2 and mouse 3 were immunised with thyroglobulin-cephalexin. Mouse 3 was chosen 
for fusion after two boosts with thyroglobulin-cephalexin prior to removal of the spleen. 
Mouse (Neg) represents the response obtained from a non-immunised mouse serum.
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Figure 4.7. The results of a typical indirect screening ELISA using post-fusion master plate 
cell population supernatants. Supernatant was removed from the 96 well tissue culture plates 
containing post-fusion hybridoma cell populations and added to another 96 well plate coated 
with 10 fig/ml Ova-Ceph conjugate. Hybridomas in wells H5 and H ll showed the highest 
absorbance values (1.7 and 0.4 at 450 nm) for this particular master plate and were selected 
for scaling up and cloning by limiting dilution. The binding of murine IgG antibody to Ova- 
Ceph conjugate coated wells was detected using HRP-conjugated goat anti-mouse IgG 
secondary antibody. Wells A10 -  A12 were used as negative control. Each well was coated 
using PBS and blocked with 5% (w/v) skimmed milk powder in PBS-T.
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Figure 4.8. Results from an ELISA to determine the titre of monoclonal antibodies produced 
by positive clones C6, B6, and Dl. After four rounds of cloning by limiting dilution, 
supernatant from culture vessels containing each clone was screened against a thyroglobulin- 
cephalexin conjugate. 96-well immunoplates were coated using Thyro-Ceph (1.3 jig/ml) and 
thyroglobulin (10 pg/ml). The thyroglobulin-coated wells comprised negative control (Nl). In 
addition, the supernatant was also screened against a 5% (w/v) skimmed milk blocking 
solution (negative control (N2)).
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Figure 4.9. An overlay plot of the results from preliminary inhibition ELISAs using 
supernatant from positive cephalexin-conjugate-binding hybridoma clones D l, B6 and C6. 
Each assay was carried out using a thyroglobulin-cephalexin conjugate at a coating 
concentration of 1.3 pg/ml and the appropriate supernatant dilution (1/1,000 for C6, 1/1,500 
for B6 and Dl clones) The optimum supernatant dilutions for each clone were obtained from 
the results of the titre experiment (figure 4.8) and were taken as the dilution at half the 
maximum absorbance.
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4.2.2 Antibody isotyping
The most promising clones (C6 and B6) in terms of cell line stability and antibody 
characteristics were picked after being fully cloned out. Hybridoma supernatants (diluted 1:2 
in PBST) were added to an immunoplate coated with a 1.3 pg/ml thyroglobulin-cephalexin. 
Following incubation and washing, diluted supernatant from the positive hybridoma 
populations was added and antibody subsequently detected using alkaline phosphatase (AP)- 
conjugated goat anti-mouse isotype-specific secondaiy antibodies (Immunokontact). Results 
show the positive clones (C6 and B6) to be type IgG2a containing a kappa ( k )  light chain 
(Figure 4.10). Since both C6 and B6 hybrids were originally derived from the same master 
plate well, prior to cloning by limiting dilution and have similar inhibition assay 
characteristics it is highly probable that they are homologous. After determining the antibody 
isotype, C6 hybrid cell line was propagated and used to produce antibody for purification and 
assay development (from herein designated anti-CephMl).
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Figure 4.10. Isotype-specific ELISA for monoclonal antibody from positive cell populations 
C6 and B6. Hybridoma supernatant was screened using alkaline phosphatase (AP) conjugated 
goat anti-mouse isotype specific secondary antibodies and P-nitophenyl phosphate substrate 
system. The absorbance was recorded at 405 nm. Results indicate the isotype of the 
monoclonal anti-cephalexin antibody clones (wati-CephMl) to be IgG2a, containing a kappa 
light chain. The absorbance for DMEM growth media showed no significant response to any 
of the secondary antibodies used (DMEM media).
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4.2.3 Antibody purification
Various techniques are available for the purification of monoclonal antibodies from tissue 
culture media. Invariably antibodies are purified using SAS precipitation (section 2.2.3.1) and 
affinity column chromatography. Protein A and G (section 2.2.3.2) covalently linked to 
sepharose are convenient affinity matrix for the affinity selection of various IgG isotypes. 
Recombinant forms of protein A & G are currently available which have reduced affinity to 
contaminating albumin proteins. Prior to affinity purification antibody containing supernatant 
may be concentrated by ultra-filtration to counteract relatively low expression into and 
concentrations in growth media. Low concentration yields of monoclonal antibody may be 
improved by using alternative in vitro production techniques. In general, in vitro cultured 
cells have two basic requirements, a constant supply of gaseous and water soluble nutrients 
and a means of removing toxic metabolites (e.g. ammonium ions and lactic acid) from 
surrounding culture medium. Various techniques address these needs in different ways. 
Overall, the choice of method will be dictated by the quantity and purity of the monoclonal 
required (Peterson, 1998). For the purposes of this research (i.e. small scale antibody) 
production, a static hybridoma suspension system was employed. In this technique, nutrients 
are provided by diffusion which requires continuous monitoring and exchange of growth 
media. Typically, depending on the particular growth characteristics of the cell line in 
question, yields of 5-50 (xg/ml of antibody are achievable.
Supernatant from the anti-CephMl hybridoma cells was collected by continuously culturing 
cells in DMEM media and concentrated 10-fold using a stirred ultra-filtration cell. The 
concentrate was then applied to a protein-G sepharose affinity column, as described in section
2.2.3.2. The purification fractions were characterised by denaturing SDS-PAGE gel analysis 
and Western blotting, as described in sections 2.3.2 and 2.3.3, respectively. The results of the 
SDS-PAGE and Western blotting indicate that the antibody was successfully purified. The 
results are shown in figures 4.11 and 4.12, respectively. Heavy and light antibody polypeptide 
bands at approximately 50 kDa and 25 kDa can be clearly seen in both SDS-PAGE and 
Western blot. There were no detectable contaminants in the eluted antibody fraction.
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Figure 4.11. Results of a denaturing SDS-PAGE gel of the protein-G purified samples. The 
concentrated (lOx) flow through, column wash, and protein G-purified samples for anti- 
CephMl monoclonal antibody were loaded from left to right respectively. Lane M, represents 
wide range standard molecular weight markers, obtained from Sigma (Table 2.6); Lane 1 is 
the concentrated flow through diluted 1:20 in PBS; Lane 2 is the column wash diluted 1:2 in 
PBS; Lane 3 is neat protein-G affinity-purified pooled fractions. Heavy chain and light chain 
domains are highlighted at approximately 50 kDa and 25 kDa respectively.
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Figure 4.12. Results of Western blot analysis following transfer of the monoclonal 
purification samples from SDS-PAGE gel. The concentrated (lOx) flow through, column 
wash, and protein G-purified samples for anti-CephMl antibody were loaded from left to 
right respectively. Pierce Blue ranger ™ pre-stained protein molecular weight standards were 
used. Lane M, represents Pierce Blue ranger standard molecular weight marker (Table 2.6); 
Lane 1 is the concentrated flow through diluted 1:20 in PBS; Lane 2 is the column wash 
diluted 1:2 in PBS; Lane 3 is the neat protein-G affinity-purified fraction. Heavy chain and 
light chain domains are highlighted at approximately 50 kDa and 25 kDa, respectively. 
Heavy and light antibody chains were detected, as highlighted above, using HRP-labelled 
goat anti-mouse IgG whole molecule specific antibody.
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4.2.4 Development o f assay for the detection o f cephalexin using monoclonal antibody
Potential conformational changes arising from partial denaturation by passive adsorption onto 
hydrophobic microtitre wells was not envisaged to be problematic as cephalexin was 
covalently attached to protein surface and it is relatively small and inflexible,. The 
concentration of the adsorbed conjugate can play a vital role in the overall performance of the 
subsequent assay. Optimisation of the antigen coating and antibody concentration is of the 
utmost importance in the development of a solid-phase immunoassay. Potential problems may 
arise when the integrity of the adsorbed antigen is compromised (i.e. epitope masked) or the 
relative binding strength to the surface is not sufficient. The latter of the two generally arises 
from conditions where the concentration of protein (e.g. Thyro-Ceph) is higher than required, 
leading to saturation of the available surface spaces and weak inter-molecular (i.e. protein- 
protein) binding. Inter-molecular interactions are often weaker than those between treated 
surface and protein and results in the dissociation of ‘supposedly’ bound protein during the 
assay (Kemeny, 1992b).
Following protein G-purification of the anti-CephMl monoclonal antibody, it was then 
analysed using solid-phase immunoassay. A checkerboard ELISA, as described in section
2.2.4 was carried out to ensure that the purification process had no adverse effects on the 
ability of the antibody to recognise immobilised cephalexin conjugate and establish the 
optimal binding concentration of conjugate and purified monoclonal antibody for subsequent 
solution-phase binding studies i.e. inhibition displacement ELISA development.
A 96 well Nunc immunoplate was coated with varying concentrations of Thyro-Ceph in PBS. 
Following the blocking step, serial dilutions of protein G-purified anti-CephMl antibody 
prepared in PBS-TM were added to the appropriate wells. The resulting plot is shown in 
figure 4.13 and confirms that the purified antibody showed an increased titre, as expected. 
The monoclonal antibody retained binding capacity to adsorbed thyroglobulin-cephalexin 
conjugate.
Purified monoclonal anti-CephMl was evaluated for use in an assay for the detection of 
soluble cephalexin in whole milk. Cephalexin hydrate, the residue of cephalexin treatment 
was used to prepare standards in PBS-T supplemented with 2% (w/v) skimmed milk powder. 
This was carried out to confirm inhibition of antibody in the presence of soluble antigen and 
as a comparative study for the ‘spiked’ whole milk assay. The increased complexity of whole 
milk could have had potentially negative effects on assay performance, which needed to be 
fully elucidated. Inhibition displacement ELISA using ‘spiked’ PBS-T and whole milk
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samples, as described in section 2.3.1.3. The antibody and conjugate concentrations used were 
determined from figure 4.13. Each assay was carried out using a 1/20,000 antibody dilution 
and 1.32 ng/ml solution of thyroglobulin-cephalexin coating concentration. Cephalexin 
standards ranging from 1.9 to 500,000 ng/ml were prepared in PBS-T and whole milk.
The resulting data was plotted using BIAevaluation software (version 3.1) and four-parameter 
equations fitted to each data set for analysis. The limit of detection for the assay was taken as 
the minimum inhibitory drug concentration which corresponds to the background (i.e. Ao) 
minus 3x standard deviations. The initial assays had limits of detection (LOD’s) of 90 ng/ml 
and 60 ng/ml in PBST (Figure 4.14) and whole milk (Figure 4.15), respectively. The 
percentage accuracies were calculated using the following formula: (Back calculated value -  
Experimental value/ Back calculated value) x 100 + 100. The mean response (A/A0), 
cephalexin concentration (ng/ml), back calculated values, percentage coefficient of variation 
(% CV) and percentage accuracy (% Accuracy) for the PBS-T and milk assays are presented 
in tables 4.2 and 4.3, respectively. An overlay plot of the PBST and milk assays using 
monoclonal antibody showed slight difference in the two sample matrices. The milk assay 
showed an apparent increased sensitivity at lower concentrations of free inhibitory cephalexin 
(Figure 4.15).
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Figure 4.13. Results obtained from a checkerboard ELISA to determine optimal conjugate 
coating concentration. Wells were coated with concentrations of Thyro-Ceph conjugate (132 
ng/ml, 13.2 ug/ml and 1.32 pg/ml). Wells were subsequently blocked with PBS containing 
5% (w/v) skimmed milk powder and protein G-purified monoclonal anti-CephMl antibody 
serially diluted (ranging from 1/400 to 1/204,800) in PBST-M was added. Each measurement 
was carried out in duplicate. Wells coated with zero pg/ml conjugate showed no significant 
binding to monoclonal antibody and enzyme-labelled species-specific secondary antibody.
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Figure 4.14. A typical inhibition ELISA in ‘spiked’ PBST using a 1/20,000 dilution of 
protein G-purified antl-CephMl (C6) and a 1.32 jig/ml solution of thyroglobulin-cephalexin 
coating concentration. Cephalexin standards were prepared in PBST by serial dilutions (1:2) 
ranging from 1.9 to 500,000 ng/ml. The linear range of detection was found to be from 61 to 
7812 ng/ml. The limit of detection (LOD) was calculated by taking 3 times the standard 
deviation from the background (A0), and was found to be 80 ng/ml.
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Table 4.2. Tabulated values for mean response (A/A0), cephalexin concentration (ng/ml) of 
‘spiked’ PBST sample, back calculated values, percentage coefficient of variation (% CV) 
and percentage accuracy (% Accuracy) obtained for the monoclonal antibody inter-day assay 
in ‘spiked’ whole milk. Back calculated values were obtained by fitting a four-parameter 
equation to the data set using BIAevaluation software (version 3.1).
Calculated A/A© ± 
S.D.
Concentration of 
cephalexin 
(ng/ml)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
0.03 ± 0.003 62,500 77,743.9 3.45 119
0.04 ±0.002 31,250 42,969.1 2.33 127
0.06 ± 0.002 15,625 17,896.5 1.65 112
0.11 ±0.004 7,812.5 7,898.0 3.65 101
0.19 ±0.001 3,906.3 3,401.1 0.46 85
0.28 ± 0.003 1,953.1 1,739.5 2.05 89
0.40 ± 0.004 976.6 934.4 2.37 95
0.48 ± 0.003 488.3 640.5 1.42 123
0.69 ± 0.008 244.1 227.2 3.32 92
0.80 ±0.005 122.1 116.8 1.89 95
0.90 ± 0.004 61.0 43.4 1.32 59
0.93 ± 0.007 30.5 25.3 2.11 80
0.94 ± 0.006 15.3 25.0 1.76 138
0.98 ± 0.003 7.6 7.0 0.77 91
0.98 ±  0.003 3.8 7.5 0.99 149
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Figure 4.15. A typical inhibition ELISA in whole milk for 1/20,000 dilution of protein G- 
purified anti-CephMl and a 1.32 solution of thyroglobulin-cephalexin coating
concentration. Cephalexin standards were prepared in whole milk ranging from 1.9 to
500,000 ng/ml. The linear range of detection was found to be 30 to 15625 ng/ml. Hie limit of 
detection for the assay was found to be 60 ng/ml by taking 3 times the standard deviation 
from the background (A0),
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Table 4.3. Values for mean response (A/A0), cephalexin concentration (ng/ml) of ‘spiked’ 
milk sample, back calculated values, percentage coefficient of variation (% CV) and 
percentage accuracy (% Accuracy) obtained for the inter-day assay in ‘spiked’ whole milk 
using anti-CephMl antibody. Back calculated values were obtained by fitting a four- 
parameter equation to the data set using BIAevaluation software (version 3.1).
Calculated A/Ao ± 
S.D.
Concentration of 
cephalexin 
(»g/ml)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
0.02 ±0.005 62,500 42,021.3 6.13 48
0.01 ± 0.003 31,250 45,572.7 4.34 131
0.05 ± 0.001 15,625 19,023.9 1.67 117
0.09 ± 0.002 7,812.5 10,558.9 2.09 126
0.20 ± 0.005 3,906.3 3,261.5 4.34 80
0.31 ±0.004 1,953.1 1,282.2 2.47 47
0.36 ± 0.002 976.6 908.8 1.49 92
0.41 ±0.001 488.3 674.7 9.36 127
0.53 ± 0.003 244.1 292.3 1.39 116
0.65 ± 0.009 122.1 131.1 4.26 106
0.76 ± 0.006 61.0 51.2 2.41 81
0.85 ± 0.005 30.5 21.2 2.06 56
0.89 ±0.005 15.3 12.5 1.93 78
0.90 ±0.011 7.6 9.4 4.38 119
0.93 ± 0.004 3.8 5.7 1.38 133
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Figure 4.15. An overlay plot of inhibition ELISA using anti-CephMl and ‘spiked’ PBST and 
whole milk samples. The monoclonal assay was capable of detection of cephalexin in 
‘spiked’ whole milk at the required maximum residue limit (MRL) of 100 ng/ml. The LOD 
for the inhibition assay was below this value and defined by taking 3 times the standard 
deviation from the background (A0). The LOD was found to be 60 ng/ml (1.7 x 10‘7 M), 
which corresponds to 6 ng/well.
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4.2.5 Cross-reactivity studies o f the murine anti-cephalexin monoclonal (anti-CephMl) 
antibody
As monoclonal antibody was raised using a different conjugate (i.e. Thyro-Ceph) and animal 
species to that used to produce polyclonal antibody (chapter 3), it was necessaiy to reassess 
the potential cross reaction with similar related compounds. The potential cross-reactivity of 
several related P-lactam antibiotics (table 3.4) to monoclonal antibody were evaluated using 
inhibition displacement ELISA format as previously described. Standards of each potential 
cross-reactant were prepared in whole milk and pre-incubated with monoclonal antibody prior 
to assay. The percentage cross-reactivity was determined as a ratio of the IC50 
concentrations, as detailed in section 3.2.4. An overlay plot of the resulting assays is shown in 
figure 4.16. The IC50 values for each cross-reactant and the calculated percentage cross­
reactivity (% CR) are listed in table 4.4.
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Figure 4.16. An overlay plot of inhibition ELISA in whole milk samples ‘spiked’ with the 
potential cross-reactant (as listed in above legend). The 1C50 concentrations were calculated 
by fitting a four-parameter equation using BIAevaluation software. Each point represents the 
mean of 3 measurements.
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Table 4.4. The tabulated results for the calculation for the percentage cross-reactivity (% CR) 
of monoclonal anti-cephalexin antibodies produced. The IC50 values were determined for 
each potential cross-reactant and expressed as a percentage of the IC50 concentration value 
obtained for the cephalexin assays.
Compound IC50 (fig/ml) %CR(IC50)
Cephalexin 0.74 100.00%
Cefadroxil 3.08 24.18%
Cefaperazone 13.23 5.62%
7-ADAC 245.58 0.30%
Cephalosporin C 320.38 0.23%
Cefotaxim N/D —
6-APA 311.39 0.24%
Cefazolin N/D —
Oxacillin 591.34 0.13%
Cloxacillin 125.98 0.59%
Dicloxacillin 506.66 0.15%
Cefuroxime N/D —
Amoxicillin N/D —
N/D = compounds showed no cross-reactivity with 
monoclonal antibody over the assay concentration range (max 
1 mg/ml)
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4.3 Discussion
In this chapter we report the production, purification and characterisation a monoclonal 
antibody against cephalexin. Thyro- and KLH-cephalexin conjugates were used to immunise 
balb/c mice. Mice were continuously boosted and serum antibody titres were determined 
using an enzyme-liked immunosorbent assay (ELISA). Typical antibody serum titres of 
1/50,000 were obtained (Figure 4.6) during the immunisation protocol. There was very little 
difference between the serum titres of each of the thyroglobulin-cephalexin immunised mice 
(i.e. mouse 2 & 3), however; both had higher serum antibody titres in comparison with the 
KLH-Ceph conjugate immunised mouse. The spleens were removed and the lymphocytes 
extracted for in vitro somatic cell fusion procedures.
One week post-fusion, supernatant was removed from the hybridoma populations and used in 
a screening ELISA strategy that it was reasoned would isolate antibody secreting clones with 
greater affinity to soluble un-conjugated cephalexin. The stringent screening of hybrids did 
however, as an expected consequence; result in a decreased number of positive clones post 
fusion. Hybridoma cell populations with the highest absorbance values were selected (Figure 
4.7) were scaled up and used in the development of an inhibition ELISA for the detection of 
cephalexin. After several rounds of cloning by limiting dilution, isolated monoclonal antibody 
secreting clones were characterised. An IgG2a-K (mti-CephMl) was isolated and purified. 
The antibody specificity was determined by screening against various cephalexin conjugates 
with relevant controls, and confirmation of soluble cephalexin specificity was monitored by 
carrying out inhibition ELISA. It was discovered that binding of monoclonal antibody to 
immobilised conjugated cephalexin was inhibited over a range of soluble cephalexin 
concentrations. The antibody specificity was further analysed using a range of closely related 
p-lactam compounds (Figure 3.4), overall the antibody was found to be highly specific to 
cephalexin. However, the percentage cross-reactivity observed using cefadroxil and 
cefoperazone, in conjunction with results of the polyclonal antibody (Chapter 3) indicate that 
the probable antibody epitope is comprised mainly of the aromatic ring containing side chain. 
The lack of significant cross reaction with the core cephem structure of 7-amindesacetoxy- 
cephalosporanic acid would also corroborate this hypothesis.
The use of various coupling chemistries has been shown to have a determinant effect on the 
resulting epitope when generating antibodies toward such relatively small haptens. Other 
workers have reported difficulties associated with the selection of antibodies to small 
molecular weight haptens during screening procedures, resulting in the selection of antibodies 
sharing a combined hapten-protein epitope (Danilova, 1994; Keating, 1998; Killard, 1998). In
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general the need to conjugate haptens for immunisation, selection and screening of antibodies 
and antibody fragments increases the likelihood of this problem (Moghadam el al., 2001). 
The method employed to conjugate the hapten should mimic as closely as possible the 
structural and electronic properties of the non-conjugated hapten (Brun et al., 2004).
Nagakura et al. (1990) suggested that monoclonal antibodies they produced toward 
cephalexin recognised at least three distinct epitopes. However, the cephalexin-protein 
conjugation production method they chose was also based on the alkaline hydrolysis, which 
opens the core beta lactam ring structure, hence, providing a molecular charge and structural 
conformation. The three different cephalexin-specific antibodies produced were IgM isotype. 
The antibodies were not evaluated in assay for the detection of cephalexin in milk. Nagakura 
et al. (1991) also produced monoclonal antibodies against ampicillin. One antibody (from 
clone Abp7) was found to be specific to ampicillin and cross-reacted to a significant degree 
with cephalexin. To the best of our knowledge this antibody was not used for detection of 
cephalexin.
Protein G-purified anti-CephMl showed inhibition in ELISA with standards of free 
cephalexin prepared in PBS-T and whole milk. The assays were linear over a range 61 ng/ml 
to 7812 ng/ml in PBS (figure 4.14) and 30 to 15625 ng/ml in whole milk (4.15). The limit of 
detection (LOD) for the inhibition assay was 60 ng/ml in whole milk prepared samples. The 
milk assay showed increased linearity which may be due to increased antibody solubility and 
stability in a more complex biological matrix. In comparison with available p-lactam testing 
kits available, in particular the Department of Agriculture and Food (DAF) approved 
standard, the Delvo® SP (Gistbrocades / DSM) microbial inhibition test, which has a stated 
sensitivity range of 40-60 ng/ml in milk, the sensitivity of the assay described in this chapter 
performs well. However, the anti-CephMl antibody specificity limits its application to the 
specific detection of cephalexin, as opposed to the broadly specific range of compounds 
detected by the Delvo® SP.
The lack of commercially available generic antibodies to antimicrobial compounds and the 
difficulty in generating such antibodies suggests that an assay incorporating several different 
antibodies would be the optimum approach for developing a multianalyte or broad specificity 
detection platform. Strasser et al. (2003) reported a semi-quantitative immunochemical rapid 
test for antimicrobials in milk using monoclonal antibodies. The method utilised several 
monoclonal antibodies raised against streptomycin, sulfadiazine, sulfamethazine and 
cloxacillin. The assay was capable of detecting the relevant antimicrobial in a multianalyte 
detection system in milk samples. They reported no observed matrix effects and very low
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limits of detection i.e. 3.2 ng/ml for streptomycin, 9.0 ng/ml for sulfadiazine, 7.0 ng/ml for 
sulfamethazine and 0.8 ng/ml for cloxacillin. A similar approach to simultaneous detection of 
antibiotics in milk was reported by Knecht et al. (2004). Monoclonal antibodies against 
penicillin, cloxacillin, cephapirin, sulfadiazine, sulfamethazine, streptomycin, gentamycin, 
neomycin, erythromycin and tylosin were used for the simultaneous detection of respective 
analyte in a microarray-based system or parallel affinity sensor array (PASA). Protein 
conjugates of the haptens were immobilised as spots on disposable chips and integrated 
within a flow cell. An inhibition displacement assay format like the one in this chapter was 
used. The PASA system described was capable of detecting penicillin G at its MRL (4 ng/ml) 
and the remaining analytes could be detected well below their respective MRL values in milk.
In conclusion, the assay described in this chapter is capable of the specific detection of 
cephalexin in ‘spiked’ pasteurised whole milk. The assay performance also permits the 
detection of cephalexin at the current EUMRL, for cephalexin in milk (100 ng/ml). The assay 
is also comparable with similar work published in this field. Cliquet et al. (2001) raised broad 
specificity monoclonal antibodies against ampicillin-protein conjugates. One particular 
monoclonal antibody was capable of detecting a range of P-lactam antibiotics (ampicillin, 
penicillin G, oxacillin, dicloxacillin and carbenicillin) at 50 ng/ml concentrations. However, 
cephalexin was not assayed in this work and the competition ELISA formats were carried out 
using PBS as a sample matrix. Jin et al. (2005) described the production of monoclonal 
against gentamycin for the analysis of residues in serum and milk samples. The antibody was 
found to be highly specific with no observed cross-reactivity with other aminoglycosides. In 
addition, they reported a lower limit of detection for the milk assay (0.5 ng/ml) in comparison 
with PBS and serum ‘spiked’ samples, which were 0.9 and 1.0 ng/ml, respectively. The main 
benefit of the antibody presented in this chapter is its specific nature. As a working diagnostic 
reagent it would however need to be complemented with other antibodies for the broad 
detection of P-lactam antibiotics.
The anti-CephMl antibody, described in this chapter, was used in the development of a 
Biacore 3000™ SPR-based biosensor (Chapter 6) inhibition assay for the detection of 
cephalexin in milk. The hybridomas cell line that expresses anti-CephMl monoclonal 
antibody was also used in the production of a recombinant antibody fragment (scFv) libraries 
(Chapter 5). Future work arising from this research could encompass the evaluation of 
different assay formats and detection of cephalexin in different target samples, for example 
bovine kidney tissue extracts.
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Chapter 5
Production and engineering of recombinant scFv 
antibodies to cephalexin
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5.1 Introduction
5.1.1 Recombinant antibody production
The aim of this chapter was the production and isolation of recombinant scFv antibodies 
specific to cephalexin, and their subsequent use in the development of an immunoassay for 
the detection of cephalexin in milk. An existing naïve human combinatorial phage-display 
library (BMV library) was panned for cephalexin specific scFv-phage using cephalexin 
conjugates. Pre-immunised murine phage-display libraries were synthesised and anti-CephMl 
(chapter 4) antibody producing hybridoma cell line derived phage-displayed scFv were 
produced using the optimised phage-display system reported by Krebber et al. (1997). The 
isolated wild type (WT) phage-scFv derived from hybridoma cell line (anti-CephMl), scFv 
was expressed as single entity (i.e. not as phage-scFv fusion), purified and characterised. The 
WT-scFv was subsequently used as a template for the production of a mutant phage-display 
library, using random mutagenesis techniques. Mutant phage-displayed cephalexin-specific 
scFv were identified and expressed in soluble form, purified and compared to original WT- 
scFv in terms of their sequence information and assay performance. Two improved mutant 
scFv clones (R1*-DE-C5 and R2*-DE-H3) were identified, purified and characterised.
5.1.2 The Krebber phage display system for production and isolation of specific single 
chain variable antibody fragments (scFv)
Phage-display has been successfully utilised as a means of producing antibody fragments (e.g. 
scFv) and fragment libraries. Libraries may potentially contain vast quantities of 
heterogeneous Ab fragments (McCafferty et al., 1990 and Winter et al., 1994). In general, 
phage-display methodologies utilise non-lytic filamentous bacteriophage fd to express 
(display) specific scFv or Fab Ab fragments as phage protein coat fusions (Emanuel et al., 
2000). This technique combines the infectivity of the phage with the specificity of the 
antibodies. The fd phage infects strains of E. coli containing the F conjugative (‘male’) 
plasmid DNA (Azzazy and Highsmith, 2002). Therefore, antibody genes may be ligated into 
truncated-phage plasmids (i.e. phagemids), subsequent to transformation of E. coli and rescue 
of phage. Phage-displaying antibodies on their surface are then selected and enriched for 
analyte binding from the antibody population along with the genes encoding them.
Krebber et al. (1997) describes an optimised protocol for the generation of recombinant 
antibodies using a variety of genetic sources (e.g. hybridoma cell lines and lymphocytes). An 
overview of the major steps involved using the Krebber system is presented in figure 5.1. The
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genetic source material may be immunised (immune) or a non-immunised (naïve libraries). 
The Krebber standardised method for the display of murine scFv antibody libraries was 
optimised for robustness, vector stability, tight control of scFv-gene IE expression, and 
primer usage for amplification of heavy and light chain genes. The initial step in the process 
involves the cloning of antibody variable heavy and light chain antibody genes from a pool of 
genetic source material. A genetic source material rich in antibody genes (e.g. spleenocytes or 
hybridoma cell line), is used for RNA extraction, subsequent to cDNA synthesis using reverse 
transcription polymerase chain reaction (RT-PCR). The cDNA is then used as template pool 
for the amplification of antibody variable heavy (Vh) and light (VL) chain genes. The Krebber 
system reported a more complete set of murine primers for the amplification of all potentially 
known VH, V*, and Vi sequences reported on the Kabat database (Kabat et al., 1991) and 
extended primer sets, as described by Kettleborough et al. (1993); 0rum et al. (1993) and 
Zhou et al. (1994). In addition, VL back primers have been engineered to encode a short 
FLAG peptide tag, which is located at the N-terminus of VL chains.
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Figure 5.1. General schematic for production of phage display libraries, stepwise from initial 
extraction of mRNA, from either mixed populations of hybridomas or B-cells taken from the 
spleen of a pre-immunised animal. Both heavy and light chain cDNA are synthesised by 
Reverse Transcription PCR (RT-PCR) and annealed together using splice by overlap 
extension PCR. The combined H and L chain cDNA is then ligated into a phagemid vector 
and transfected into super-competent bacterial cells (e.g. XL1 blue). The scFv fragment is co­
expressed with phage coat protein and preferentially packaged into phage particles using a 
helper phage (e.g. M13-K07).
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The amplified VH and VL genes are assembled using a splice-by-overlap-extension 
polymerase chain reaction (SOE-PCR) as described by Horton et al. (1989). This system 
facilitates the directional cloning of scFv gene constructs by utilising a rare (i.e. in terms of 
restriction sites) restriction enzyme (Sfi 1) with an engineered series of compatible vectors 
(pAK 100-600). The Sfi 1 restriction enzyme recognises eight bases in total, interrupted by a 
sequence of five unrecognised (N) nucleotides:
5'- GGCCN*NNNNGGCC-3'
3'- CCGGNNNN*NCCGG-5'
The benefit of such a rare restriction site is that its presence in potential antibody gene 
sequences is highly improbable. Restriction sites were engineered to have two distinct ‘sticky’ 
ends that facilitate cloning of scFv genes in a directional manner.
The vector series also contain tetracycline (tetA and tetR) resistance cassettes (approximately 
2000 bp) in between two Sfi 1 restriction sites (Figures 5.2 and 5.3) that allow the linear 
digested vector to be easily identified and purified. In general, truncated phage plasmid 
vectors (phagemids) consist of double stranded DNA, encoding a phage coat protein (e.g. 
pill). They also contain an antibiotic resistance gene, an origin of replication and a promoter 
sequence (e.g. lacZ) (Garrard et al., 1991 and Krebber et al., 1997). The pAKlOO phagemid 
vector which was optimised for phage-display contains a chloramphenicol (cam) resistance 
cassette, to aid in the selection of transformed E. coli, a phage origin of replication (FI ori), a 
bacterial origin of replication (ColEl) as well as lac operon regulatory genes for the tight 
control of expression. The Vh and VL chains for the scFv of interest may be integrated into 
pAKlOO phagemid upstream of a myc affinity tag which is intersected by an amber stop 
codon (*), to facilitate the soluble expression of scFv in non-suppressor cells (e.g. E. coli 
JM83).
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Figure 5.2. Diagram showing the pAKlOO phagemid vector containing tetracycline (tetA and 
tetR) resistance cassette (approximately 2000 bp) in between two Sfi 1 restriction sites. The 
scFv gene may be ligated in frame into the vector in place of the tetracycline resistance 
cassette upstream of the region encoding a myc detection tag, the phage coat protein gill 
(250-406) followed by an amber codon (*). The pAK vectors also contains a pelB sequence, 
which adds an amino acid sequence to direct scFv-glll fusion proteins to the periplasmic 
membrance in E. coli, subsequent to phage packaging. In addition pAKlOO contains a 
chloramphenicol (cam) resistance cassette, to aid in the selection of transformed E. coli, a 
phage origin of replication (FI ori), a bacterial origin of replication (ColEl) as well as lac 
operon regulatoiy genes for the tight control of expression.
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Figure 5.3. Diagram of the pAKlOO related vectors that facilitate the introduction of 
modifications that allow for easier purification, enhanced soluble expression, dimérisation 
and enzyme-labelled dimérisation. All the pAK series of vectors contain tetracycline (letA 
and tetK) resistance cassette (approximately 2000 bp) in between two Sfi 1 restriction sites 
(restriction site sequence shown above). The scFv gene may be ligated in frame into the 
pAK300 and 400 vectors that facilitate soluble expression. The pAK400 contains a modified 
ribosomal binding sequence (i.e. Shine-Dalgamo, SDT7g10) that results in enhanced protein 
expression. The pAK500 vector allows for dimérisation of antibody and pAK600 allows 
dimérisation and in vivo labelling with alkaline phosphatase (AP) for the direct detection of 
expressed scFv.
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Transcribed antibody fragments may be fused at the N-terminus of the mature gene III protein 
(McCafferty et al., 1990), as in the Krebber-based system (Figure 5.4), or at the N-terminus 
of a truncated pin lacking the first two N-terminal domains (Barbas et al., 1991 and Garrard 
et al., 1991). The coat protein-antibody fusion protein is expressed and then incorporated into 
new phage particles within the E. coli by the superinfection with helper phage (e.g. M13K07, 
VCS-M13, Hyperphage) (Rondot et al., 2001) to package the DNA into phage particles. The 
pAKlOO phagemid is designed for low level expression which is of paramount importance 
when dealing with phage-displayed libraries. Therefore, it is not a suitable vector for the 
large-scale production of soluble scFv. The Krebber system has the pAK400 engineered 
compatible vector to counter this. The pAK400 (Figure 5.3) is designed for the enhanced 
soluble expression and purification of antibody fragment by the incorporation of a Shine- 
Dalgarno (SDT7g10) sequence. Other pAK series vectors facilitate purification and the 
introduction of modifications to scFvs. The scFv may be expressed as a dimer using the 
pAK500 and as a dimer with in vivo enzyme labelling (alkaline phosphatase) for direct 
detection using pAK600.
Figure 5.4. (A) The wild-type (WT) bacteriophage with mature gene-3-protein (gUIp) 
protein, consisting of the C-terminal (CT), N2 and N1 terminal domains in contrast with 
glllp-scFv fusion containing phage produced using the Krebber protocol. (B) Phage- 
displaying scFv as a glllp protein fusion on its surface; the scFv antibody fragments are fused 
at the N1-terminus of the mature gene III protein.
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5.2 Resulte
5.2.1 Panning of a naïve human synthetic recombinant antibody library for anti­
cephalexin-specific clones
A naïve human recombinant antibody library (BMV library) obtained from Cambridge 
Antibody Technology (CAT) was panned using immunotubes coated with a cephalexin-BSA 
conjugate. A total of four rounds of panning were carried out, as described in section 2.5.5.4, 
using the BSA-cephalexin conjugate. No positive cephalexin-specific phages-scFv antibodies 
were obtained after screening of phage using ELISA (section 2.5.5.6). Some workers have 
described the isolation of hapten-specific scFv using human naïve phage-display libraries 
(Moghaddam et al., 2001 and 2003) but also recognise that it is potentially problematic. 
Factors affecting the probability of isolating a hapten-specific scFv from human naïve 
libraries include the library source, panning strategy and hapten-conjugates. Another study 
(Van Wyngaardt et al., 2004) using haptens showed that naïve semi-synthetic combinatorial 
phage-display libraries produced using chickens generated large antibody diversity with 
hapten binding capability.
5.2.2 The production of scFv phage-display libraries against cephalexin using the 
Krebber system.
The Krebber optimised phage-display library protocol was used to develop two libraries using 
mice immunised with cephalexin conjugates. Libraries developed from immunised hosts have 
a distinct advantage over naïve libraries, especially in the case of haptens, as the host immune 
system is primed towards specific antigen before library production proceeds.
5.2.2.1 Phage-display library production
Initially Balb/c mice were immunised and boosted with cephalexin conjugates. Mouse A and 
B were immunised using cephalexin activated BSA and protein-activated cephalexin-Ova 
conjugate (sections 2.2.1.2 and 2.2.1.3), respectively, in Freund’s adjuvant. The serum titre 
from each mouse was analysed by ELISA (section 2.3.1.1) against thyroglobulin-cephalexin 
conjugate, at a concentration of 1 ng/ml. Serial dilutions of mouse serum prepared in PBS-T 
were added to Thyro-Ceph-coated immunoplates and detected using HRP-labelled rabbit anti­
mouse secondary antibody. The antibody titre for the purposes of this work was defined as the 
highest dilution that yielded a response distinguishable from the background plus three 
standard deviations. Figure 5.5 shows that the serum antibody titres for two mice was
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1/50,000 for BSA-cephalexin (mouse I) conjugate and Ova-cephalexin (mouse 2). The mice 
were re-boosted one week prior to sacrifice and extraction of RNA from spleen (section
2.5.3.2).
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Figure 5.5. Plot of the results obtained from an ELISA to determine the anti-cephalexin 
antibody titre, using the serum obtained from the mouse 1 (immunised with BSA-cephalexin) 
and mouse 2 (immunised with OVA-cephalexin). Serum samples from both mice were 
screened against thyroglobulin-cephalexin conjugate-coated plates at a concentration of 1 
Hg/ml and negative control surface thyroglobulin at a coating concentration of 1 pg/ml. 
Negative control serum represents the serial dilutions of naïve mouse serum added to 
cephalexin-thyroglobulin-coated wells. No significant binding to thyroglobulin-coated wells 
was observed. The mice were boosted once more prior to sacrifice and spleen removal.
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The spleens from mouse 1 and 2 were isolated under sterile conditions and the total RNA was 
extracted from the homogenized spleen tissue (section 2.5.3.2). The total RNA was used to 
synthesise cDNA with random hexamer, and oligo dT primers. Subsequently, using newly 
synthesised cDNA as template, heavy (VH) and light (VL) chain variable genes were amplified 
by PCR with the set of murine degenerate primers (section 2.5.4.1), as described by Krebber 
et al. (1997). Optimisation of the VH and VL chain amplification PCR was carried out using 
the Invitrogen PCR Optimizer™ kit. The kit covers a range of 300mM Tris-HCl and 75 mM 
ammonium sulphate buffers, differing in their respective MgCl2 concentrations and pH. The 
optimum buffer for the amplification of the heavy chain PCR for mouse 1 had 2.0mM MgCl2 
and pH of 8.5 whereas, VL amplification PCR product for mouse 1 was found to be 
unaffected by varying concentrations of MgCl2 at pH 8.5. The PCR products of the VH and VL 
gene amplification were analysed by gel electrophoresis (1% (w/v) agarose) and the expected 
bands, at approximately 400 bp, were observed for VL (375-402 bp) and VH (386-440 bp) 
(Figures 5.6 and 5.7, respectively).
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Figure 5.6. Picture of a typical 1% (w/v) agarose gel electrophoresis of buffer optimisation 
for mouse 1 heavy chain (VH) amplification PCR. Lane 1, Gibco lkb Plus DNA ladder; Lane 
2, buffer A; Lane 3, buffer B; Lane 4, buffer C; Lane 5, buffer D; Lane 6, buffer F; Lane 7, 
buffer J; Lane 8, buffer N. From this result buffer B was chosen to carry out subsequent heavy 
chain PCR amplifications.
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Figure 5.7. Picture of a typical 1% (w/v) agarose gel electrophoresis used during buffer 
optimisation for mouse 1, heavy (Vh) and light chain (VL) amplifications. Lane 1, Gibco lkb 
Plus DNA ladder; Lane 2, VH buffer A; Lane 3, VH buffer B; Lane 4, VH buffer C; Lane 5, VH 
buffer D; Lane 6, empty; Lane 7, VL buffer A; Lane 8, VL buffer B; Lane 9, VL buffer C; 
Lane 10, VL buffer D; Lane 11, Gibco 1 kb Plus DNA ladder. Buffer B was chosen to carry 
out subsequent Vh and VL PCR amplifications.
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The scFv gene constructs (Vl-(G4S)4-Vh) were synthesised using Splice-by-Overlap- 
Extension (SOE) PCR. The VH and VL chain PCR products were purified from a low melt 1% 
(w/v) agarose gel, as described in section 2.5.2.2. The amplified and purified VH and VL chain 
DNA for each mouse (1 & 2) were quantified with the 100 bp quantification marker 
(Promega) (Figure 5.8) and UV spectrophotometry.
Figure 5.8. 1% (w/v) Agarose gel pictures; A shows pooled VH and VL chain PCR products 
purified from an agarose gel. The fragments were run on the gel with Promega 1 OObp marker 
(standard band concentrations, 500 bp = 150 ng/5^1, all other bands contain 50 ng/5^1). Lane 
1, 100 bp Promega quantification ladder; Lane 2, heavy chain PCR product; Lane 3, light 
chain PCR product. The VH and VL chain stocks were prepared by pooling multiple PCR 
reactions following analysis on agarose gel (B). Lanes 1 & 10, Gibco 1 kb plus DNA ladder; 
Lanes 2-5, VH reactions; Lanes 6-9, VL reactions. The heavy and light chain pooled stocks 
were diluted to give a 10 ng/pl working stock for the subsequent SOE-PCR.
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The VH and VL chain DNA stocks were both diluted to give a 10 ng/(il working stock 
concentration and joined by SOE-PCR (section 2.5.4.4). Splice by Overlap Extension (SOE) 
PCR was optimised using the Invitrogen PCR Optimizer™ kit buffer E (7.5 mM MgCl2, pH 
9.0) and sCfor and scback primers (Krebber et al., 1997). This yielded predicted bands at 
approximately 800 bp, as shown in figure 5.9.
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Figure 5.9. Picture of a 1% (w/v) agarose electrophoresis gel of SOE-PCR buffer 
optimisation reactions using mouse Vh and Vl chain genes. Lane 1, Gibco 1 kb Plus DNA 
ladder; Lane 2, SOE reaction in buffer A product; Lane 3, SOE reaction in buffer B; Lane 4, 
SOE reaction in buffer E; Lane 5, SOE reaction in buffer F; Lane 6, SOE in buffer F; Lane 7, 
SOE reaction in buffer I; Lane 8, buffer J; Lane 9, Gibco 1 kb Plus DNA ladder. Buffer E was 
chosen for further SOE-PCR reactions.
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Bacterial stocks of XL 1-blue (E. coli) containing pAKlOO phagemid vector were grown as 
overnight cultures. The pAKlOO was purified from cellular lysates as described in section 
2.5.2.3. Purified vector and SOE-PCR product preparations were digested using Sfi 1 
restriction enzyme (section 2.5.4.6) overnight at 50°C and the resulting products analysed 
using agarose gel electrophoresis. Cut pAKlOO vector showed the expected bands at -4000 
bp and ~2000 bp, representing linear phagemid and tetracycline resistance cassette, 
respectively (Figure 5.10). The cut vector and SOE-PCR were purified from agarose gel and 
ligated overnight at 15°C using DNA ligase (section 2.5.4.7).
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Figure 5.10. Picture of 1% (w/v) agarose electrophoresis gel of pAKlOO vector and SOE- 
PCR Sfi 1 restriction digest products; Lane 1, Gibco 1 kb Plus DNA ladder; Lanes 2 & 3, 
identical pAKlOO (containing Tet) digestions, o/n with Sfil; Lane 4, undigested pAKlOO 
(Tet) vector; Lanes 5 & 6, pAKlOO (containing an scFv insert) digested o/n with Sfi 1; Lane 
7, undigested pAKlOO (SOE product); Lane 8, SOE-PCR product for mouse 1, digested o/n 
with Sfi 1; Lane 9, undigested SOE-PCR product; Lane 10, Gibco 1 kb Plus DNA ladder.
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The ligation reaction products for mouse 1 and 2 derived genes were used in a subsequent 
transformation (2.5.4.9) of chemically competent XLl-blue (E. coli) cells prepared ‘in house’, 
as described in section 2.5.2.6. Selection of transformed cells containing the pAKlOO and 
insert was achieved by plating on NE (Non-Expression) media containing chloramphenicol at 
a concentration of 25pg/ml. The chloramphenicol resistance gene is encoded for on the 
pAKlOO vector. Therefore, any transformants that grow on the NE media plates 
supplemented with chloramphenicol were adjudged to contain the pAKlOO vector. The 
numbers of transformants were found to be 4.6 x 10 3 and 3.2 x 103 cfu/ml, for mouse 1 and 2, 
respectively. Stocks of the transformed XLl-blue cells were produced and used for 
subsequent phage production.
5.2.2.2 Panning o f phage-display libraries
Selection of specific scFv from phage-libraries involves the enrichment of specific binders by 
several rounds of panning with specific antigen. Alternative methods of panning and elution 
of specific phage-scFv were investigated. As the numbers of transformants for each library 
were relatively low, the libraries from mouse 1 and 2 were pooled. Phage particles were 
rescued and precipitated from bacterial stocks, as described in sections 2.5.5.1 and 2.5.5.2, 
respectively. The stock phages were panned using protein-activated thyroglobulin-cephalexin 
(Thyro-Ceph) immobilised conjugate for round one (section 2.5.5.4), followed by cephalexin- 
activated dextran-cephalexin conjugate for round two, and a third and final round of panning 
with Thyro-Ceph. Various phage elution strategies were used, including acidic phage elution 
(section 2.5.5.4), where bound phage were eluted from the coated immunotube by adding 800 
pi 0.1 M glycine/HCl, pH 2.2, for 10 minutes. This was then neutralised using 48 pi of 2 M 
Tris/HCl, pH 8.5. XLl-blue E. coli in exponential growth phase were infected with eluted 
phages from each round of panning.
An alternative strategy using triethylamine and XLl-blue E. coli for eluting bound phage 
particles from the coated immunotubes was used (Wind et al., 1997 and De Briun et al., 
1999). This method consisted of an initial elution of lower-affinity binding phage using XLl- 
blue cells in exponential growth phase. Following this remaining phages were eluted with 
triethylamine. The phages were then decanted into a solution of 1M Tris-HCl, pH of 7.5, for 
subsequent neutralisation. During each round of panning the phage particles are separated into 
two fractions, a low affinity phage fraction (i.e. XLl-blue elution) and a higher affinity phage 
fraction (i.e. 100 mM triethylamine). Each of the eluted phage stocks (i.e. low and high 
affinity) were screened and subjected to subsequent rounds of panning.
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A sample was removed after each round of panning from both the bacterial and triethylamine 
elution’s in order to carry out a titre of the phage. Following this, the eluted phage were either 
grown directly (i.e. in the case of the bacterial elution), or used to transfect exponentially 
growing XLl-blue E. coli (i.e. triethylamine elution), as outlined in section 2.5.5.5.
Following rounds of panning and elution prepared ‘polyclonal’ phages supernatants were 
screened for cephalexin specific phage-scFv by ELISA. In addition, a total of 183 random 
individual (‘monoclonal’) clones were picked and screened by phage ELISA (section 2.5.5.6). 
The phages were detected using a rabbit anti-fd bacteriophage antibody (Sigma), which was 
subsequently detected using an HRP-conjugated goat anti-rabbit secondary antibody. No 
cephalexin-specific phage-scFvs were obtained from immunised mice libraries. To ensure that 
the library clones contained the scFv gene constructs, random clones from round 3 panned 
stocks and untransformed (negative control) XL-1 blue E. coli were used in a PCR. The SOE 
sCfor and scback primers were used to amplify 800 bp scFv insert. The resulting products were 
run on a 1% (w/v) agarose gel and clearly showed 800 bp fragments were present in randomly 
picked clones (Figure 5.11).
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Figure 5.11. Picture of a 1% (w/v) agarose gel electrophoresis of the resulting SOE-PCR 
products of 2 random clones picked off a phage titre plate from the third round of panning. 
This experiment was to confirm the presence of vector (pAklOO) containing the scFv gene 
insert (800 bp fragment). Lane 1 & 5, Gibco 1 kb plus DNA ladder; Lane 2, SOE-PCR 
product for clone 1; Lane 3, SOE-PCR product for clone 2; Lane 4, SOE-PCR product using 
untransformed X-Ll blue cells as negative control.
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5.2.3 The production of scFv against cephalexin from hyhridoma cell line secreting 
monoclonal anti-CephMl antibody using the Krebber system.
The Krebber optimised phage-display library protocol was used to develop recombinant anti­
cephalexin scFv, using the anti-CephMl monoclonal antibody (Chapter 4) secreting 
hybridoma cell line.
5.2.3.1 The production o f a phage-scFv antibody fragment from anti-cephalexin monoclonal 
antibody-secreting hybridoma cell line using the Krebber system.
A phage-scFv specific to soluble cephalexin was obtained from the hybridoma cell line (Anti- 
CephMl). The protocol and vector series used were as previously described by Krebber et al. 
Initially, the hybridoma cell line developed in chapter 4 of this research was used as the 
source for total RNA extraction. Total RNA from the positive secreting cell line was used as a 
template for the synthesis of cDNA by RT-PCR, according to kit manufacturer’s guidelines 
(Promega kit). VH and VL chain genes were amplified (Figure 5.12) using the listed set of 
degenerate primers, omitting X light chain primers (anti-CephMl contains k  light chain), and 
purified prior to scFv gene construction by SOE-PCR (Figure 5.13).
1 2 3 4 5 6
Figure 5.12. Picture showing 1% (w/v) agarose gel electrophoresis of VH and VL chain 
amplification PCRs. Lanes 1 & 6, Gibco lkb Plus DNA ladder; Lanes 2 & 3, buffer A 
amplified hybridoma VH chain; Lanes 4 & 5, buffer A amplified VL. Both heavy and light 
chain amplification PCR reactions yielded discreet bands at approximately 400 base pairs 
(bp) as expected.
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Figure 5.13. Typical 1% (w/v) Agarose gel of SOE-PCR product. Lanes 1 & 5, Hyperladder I 
DNA marker (Bioline); Lanes 2, 3 & 4 are SOE-PCR product using buffer A and varying 
concentration ratios of VH and VL chain template. The SOE-PCR reactions yielded discreet 
bands at approximately 800 base pairs (bp) as expected.
The resulting SOE-PCR gene constructs were digested with Sfi 1 restriction enzyme along 
with fresh pAKlOO phagemid vector and subsequently ligated together. The Sfi 1 restriction 
digest products were gel purified (section 2.5.2.2) and analysed by agarose gel 
electrophoresis. The digested and undigested products were run in situ. Figure 5.14 shows the 
purified products of the Sfi 1 digested, pAKlOO phagemid vector and SOE scFv gene 
constructs. Chemically competent E.coli (XL1 blue) cells were transformed with ligation 
reaction product (section 2.5.4.9) that was concentrated 10-fold (ethanol precipitation, section 
2.5.2.4). Transformed cells were used for phage production and PEG concentration, as 
described in sections 2.5.5.1 and 2.5.5.2, respectively.
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Figure 5.14. Picture of 1.5% (w/v) agarose gel electrophoresis of previously Sfi 1 digested 
and gel purified hybridoma SOE-PCR product and linear pAKlOO phagemid vector. Lanes 1
& 5, Hyperladder I DNA marker (Bioline); Lanes 2 & 3, gel-purified linearised pAKlOO 
vector. Lane 4 shows purified Sfi 1 digested SOE-PCR product.
The prepared phage-scFvs from hybridoma cell line were then subjected to two rounds of 
panning. The initial number of transformants was 6 x 104 cfu. The stock phages were panned 
(section 2.5.5.4) using three different conjugates of cephalexin (Thyroglobulin (Tl), Bovine 
Serum Albumin (Bl) and cephalexin-biotin-strepavidin-magnetic beads (MagCeph)). Panned 
and eluted phages were screened using ovalbumin-cephalexin conjugate by phage ELISA. 
This was to rule out potential selection of carrier protein (i.e. Thyro or BSA)-specific phage- 
scFv. Individual clones were randomly picked from spread plates and used to inoculate sterile 
96-well plates containing media and screened individually (section 2.5.5.6). The transformed 
bacterial stocks from each round of panning were plated on 2xTY agar supplemented with 
chloramphenicol (resistance conferred by the presence of pAKlOO-scFv within the cell) and 
tetracycline (intrinsic resistance of the E.coli strain used) and used to determine the phage 
titre (section 2.5.5.3). Positive cephalexin binding phage-scFv clones were identified by 
ELISA, using ovalbumin-cephalexin and ovalbumin-coated plates. Results are shown in 
figures 5.15 and 5.16, for thyroglobulin-cephalexin panned and BSA-cephalexin panned 
phages, respectively.
(A)
Column number
(B)
Figure 5.15. This figure represents a total 93 clones from round two panning. (A) The clones 
were panned using thyroglobulin-cephalexin and screened against ova-ceph (100|ig/ml). (B) 
The same clones were also screened against unconjugated ovalbumin (lOO^g/ml). Clones 
picked for further characterisation are indicated with a star. Wells H10, H ll and H12 were 
negative control wells for A and B, in that they were not inoculated with phage-producing 
colonies but were subjected to the same addition of helper phage-containing media as other 
wells.
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Figure 5.16. This figure represents a total 93 clones from round two pamiing. (A) The clones 
were panned using BSA-cephalexin and screened against ova-ceph (100p.g/ml). (B) The same 
clones were also screened against unconjugated ovalbumin (100|j.g/ml). Clones picked for 
further characterisation are indicated with a star. Wells H10, H ll and HI 2 were negative 
control wells (A & B), in that they were not inoculated with phage-producing colonies but 
were subjected to the same addition of helper phage-containing media as other wells.
1 8 2
Four positive clones, picked from each conjugate (i.e. BSA- & Thyro-Ceph) round two pan 
stocks were further characterised. The clones were designated TP-A7, TP-F8, TP-G7, TP-G9, 
BP-A7, BP-C3, BP-C10, and BP-D5. Each clone was picked from master culture plates and 
used to inoculate 5 ml of growth media. Phage-scFvs were rescued as described in section
2.5.5.1. Prepared phage-scFvs were screened using phage ELISA (section 2.2.2.6) to 
determine the titre for each clone against ovalbumin-cephalexin-coated plates. The results of 
this experiment are shown in figures 5.17 and 5.18.
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Figure 5.17. This figure represents a plot of the results of phage ELISA using round two 
thyroglobulin-cephalexin-panned individual clones (TP-A7, TP-F8, TP-G7 and TP-G9) and 
immunoplates coated with ovalbumin-cephalexin conjugate (100 i^g/ml). Bound phage-scFv 
was detected using a rabbit anti-fd bacteriophage antibody followed by HRP-labelled goat 
anti-rabbit antibody. For each clone the supernatant was used following phage rescue.
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Figure 5.18. This figure represents a plot of the results of a phages ELISA using round two 
bovine serum albumin (BSA)-cephalexin-panned individual clones (BP-A7, BP-C3, BP-C10 
and BP-D5) and immunoplates coated with ovalbumin-cephalexin conjugate (100 (xg/ml). 
Bound phage-scFv was detected using a rabbit anti-fd bacteriophage antibody with 
subsequent addition of HRP-labelled goat anti-rabbit antibody. For each clone the supernatant 
was used following phage rescue.
In addition, prepared phage-scFvs from selected clones (BP-A7 & TP-G7) were used in 
inhibition ELISA with a set of cephalexin standards prepared in PBS-T. The assay was 
performed to confirm phage-scFv bound to free cephalexin (i.e. non-conjugated). The results 
of this are shown in figure 5.19.
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Figure 5.18. This figure represents a plot of the results of an inhibition ELISA using BP-A7 
and TP-A7 phage-scFv clones. The ELISA was carried using Thyro-Ceph-coated 96-well 
plate (lp.g/ml) and a 1:2 dilution of phage-scFvs pre-incubated with the appropriate free 
cephalexin standard. Bound phage-scFvs were detected with subsequent addition of rabbit 
anti-fd bacteriophage antibody followed by HRP-labelled goat anti-rabbit antibody. For each 
clone the supernatant was used following phage rescue.
5.2.3.2 The production and purification o f soluble scFv antibody fragment from anti­
cephalexin monoclonal antibody-secreting hybridoma cell line using the Krebber system.
The phage-scFv clones TP-A7 and BP-A7, described in the previous section (5.2.3.1), were 
chosen for the production of soluble scFv, by sub-cloning into the pAk400 vector for 
enhanced soluble expression. These clones showed the best inhibition ELISA results and were 
expressed as soluble scFv. The pAk400 containing tet resistance cassette and pAKlOO vectors 
containing scFv gene constructs were purified from overnight cultures of the relevant clone 
(section 2.5.2.3) and digested using Sfi 1 restriction enzyme. The digested products were run 
on an agarose gel electrophoresis apparatus. The results of this are shown in figure 5.19. The 
linear pAK400 vector (4,000 bp) and scFv gene (800 bp) were purified from the gel (section
2.5.2.2) and ligated using T4 DNA ligase (section 2.5.4.7). Linearised pAK400 vector (as a 
control) was ligated without addition of the scFv gene and both experimental and control 
ligation mixes were precipitated using sodium acetate (3M) and 100% (v/v) ethanol 
(supplemented with pellet paint to aid in identification), as described in section 2.5.2.4. The 
ligation products for TP-A7 and BP-A7 clones and controls were used to transform 
chemically competent E. coli (JM83) cells, as described in section (2.5.4.9).
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Figure 5.19. Picture of 1.5% (w/v) agarose gel electrophoresis using prepped pAKlOO vector 
(TP-A7 and BP-A7 clones); and prepped pAk400 Sfi 1 digest products. Lanes 1 & 6, 
Hyperladder IDNA marker (Bioline); Lane 2, TP-A7 Sfi 1 digest product, showing scFv gene 
(800 bp) and linearised pAKlOO (4,000 bp) bands; Lanes 3 & 5, show pAK400 Sfi 1 digest 
product, containing linear vector (4,000 bp) and tet resistance cassette (2,000 bp).
Individual colonies were picked from the pAK400 transformants for each original clone and 
used to inoculate cultures. Cultures were grown until the exponential phase was reached and 
subsequent soluble expression was induced using 1 mM IPTG (section 2.5.5.8). Cell lysates 
were prepared 4 hours and 20 hours post-IPTG induction and screened using an ELISA, as 
described in section 2.5.5.9. The results (Figure 5.20) of this experiment identified a positive 
scFv-expressing clone (designated wild type (CTh5)) from the original TP-A7 transformation 
and suggest longer post-IPTG induced expression incubation yields a larger amount of 
functional scFv antibody. The soluble scFv was detected using a combination of rabbit anti­
poly histidine followed by HRP-labelled goat anti-rabbit antibody.
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Figure 5.20. This figure represents a plot of the results of an ELISA using wild type clone 
cell lysates at 4 hours (WT T4 post-IPTG) and 20 hours (WT T20 post-IPTG) post-IPTG 
induction. Cell lysates were screened against thyroglobulin-cephalexin coated (1.3 (ig/ml) 
wells, and soluble scFv was detected using rabbit anti-poly Histidine tag antibody followed 
by HRP-labelled goat anti-rabbit antibody.
Cell lysates from the WT-scFv clone (before soluble expression was induced using IPTG, 0 
hours (TO), 4 hours (T4) post-IPTG and 20 hours (T20) post-IPTG induction) were analysed 
by denaturing SDS-PAGE analysis, as described in section 2.3.2. The results confirmed the 
appearance of an expected 30 KDa band after the cells had been exposed to IPTG (Figure 
5.21). Further confirmation that the band at approximately 30 KDa was a scFv was obtained 
by carrying out Western blotting analysis, as outlined in section 2.3.3. Following transfer onto 
nitrocellulose membrane the cell lysates were probed with rabbit anti-FLAG (peptide tag) 
polyclonal antibody. This was subsequently detected with a HRP-labelled goat anti-rabbit 
antibody and a TMB substrate system. The results of this experiment showed a distinct band 
at approximately 30 KDa that corresponded to the expected scFv band (Figure 5.22).
188
( ^ )  O '« ------scFv
Figure 5.21. SDS-PAGE gel picture from a time-course expression experiment using the wild 
type pAK.400 (WT CTh5) clone expression in Jm83 E.coli. The M lane contains Sigma Wide 
Range protein markers with the bands at 36 KDa and 29 KDa highlighted. Lane To represents 
the WT cell lysate (1:5 dilution in PBS) prior to addition of ImM IPTG and expression 
induction. T4 lane is 4 hours post-induction with the addition of ImM IPTG to culture media 
with the band representing the scFv encircled in red. The T20 lane represents the cell lysate 20 
hours post-induction with the addition of ImM IPTG, the bands representing the WT scFv are 
encircled in red.
M 1 2 M 1 2
Figure 5.22. SDS-PAGE gel (above left) and Western blot (above right) analysis pictures of 
WT CTh5 scFv pAK 400 (JM83) cell expression (T20) lysates. The scFv bands were detected 
on the Western blot using a rabbit anti-FLAG polyclonal antibody. This was subsequently 
detected with a HRP-labelled goat anti-rabbit antibody and a TMB substrate system. The M 
lanes contain Sigma wide range protein markers for the SDS-PAGE gel and Pierce Blue- 
ranger pre-stained protein molecular weight markers for the Western blot. Lane 1 was empty 
and lane 2 contained WT clone cell lysates 20 hours post-induction with the addition of ImM 
IPTG. The bands representing the WT scFv are encircled in red. The Western blotting 
analysis confirms that the picked clone was expressing soluble scFv.
Having identified and selected the WT CTh5 clone on the basis of its stable production of 
active scFv, it was necessary to optimise the purification from crude cell lysates and 
maximise the yield of pure and active scFv product. This would require a method that 
facilitated purification under native conditions to obtain optimum yield of correctly folded 
and active scFv. Immobilised metal affinity chromatography (IMAC) is a technique by which 
proteins or other molecules may be separated based on their ability to form coordination 
complexes with immobilised metal ions (Porath et al., 1975; Hermanson et al., 1992). Since 
the pAK400 expression vector incorporates a hexahistidine tag onto the C-terminal end of the 
scFv expression product, it provides a convenient method for detection and purification 
facilitated by complex formation between histidine residues and immobilised metal ion. In
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general, histidine residues are infrequent, amounting to approximately only 2 % of the amino 
acid content of globular proteins. In addition, only half of these residues are normally exposed 
on the protein surface (Ueda et al., 2003). Histidine residues are also advantageous in that 
they form relatively strong interactions with immobilised metal ions. The Ni-nitrilotriacetic 
acid matrix (NTA resin) currently supplied by Qiagen Ltd. (as Ni-NTA coupled to 
Sepharose®) is widely used for IMAC processes with hexahistidine tagged proteins (Figure 
5.23). Overall the purification technique involves binding of his-tagged proteins to an 
immobilised Ni-NTA affinity matrix, washing to remove non-specifically bound material and 
subsequent elution of the histidine tagged protein. WT CTh5 soluble scFv was purified using 
IMAC, as described in section 2.5.6.8.
with NTA binds 2 (NTA) matrix
adjacent His residues
Figure 5.23. Outline of the principle interactions between histidine tag proteins (shown in red 
above) and nickel- nitrilotriacetic acid (Ni-NTA) immobilised matrices. The Ni2+ metal ion 
has four chelating sites with the NTA resin and two available chelating sites for two adjacent 
histidine residues from a 6x histidine tagged protein (chelating sites shown in blue). The Ni- 
NTA resin is coupled to sepharose CL-6B, thus comprising the Ni-NTA (IMAC) purification 
reagent as supplied by Qiagen Ltd., widely used for the purification of hexahistidine tagged 
proteins.
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The WT CTh5 scFv was expressed, as outlined in section 2.5.5.8, and purified using I MAC 
with Ni-NTA (Qiagen Ltd.) reagent (described in section 2.5.6.8). SDS-PAGE and Western 
blot analysis were used to monitor the degree of purification and the functional scFv activity 
was assayed using ELISA. The SDS-PAGE analysis (Figure 5.24) showed that the 1MAC 
purification yielded a clean and distinct band at 30 KDa as expected. Subsequent Western 
blotting analysis (Figure 5.25) and probing with anti-FLAG antibody showed that the 
expression product was successfully purified from cell lysate, with bands appearing in the 
original pre-IMAC lysate and the post-IMAC elution. No scFv was detected in the column 
flow through or wash fractions. The cephalexin activity of the WT CTh5 scFv purification 
fractions (i.e. flow-through, wash, and elution fractions) was analysed using a screening 
ELISA, the results of which are shown in figure 5.26.
Figure 5.24. SDS-PAGE gel picture of IMAC Ni2'-NTA purified soluble scFv from WT 
CTh5 clone expression lysates (E. coli JM83). The M lane contains Sigma Wide Range 
protein markers with the bands at 36 KDa and 29 KDa, 24 KDa and 20.1 KDa highlighted. 
Lane 1 represents the WT CTh5 cell lysate (1:5 dilution in PBS) prior to IMAC purification. 
Lane 2 represents the WT CTh5 cell lysate (1:5 dilution in PBS) after two passes through 
IMAC column (Flow through). Lane 3 represents the column wash run off (neat). Lane 4 
represents WT CTh5 scFv eluate from IMAC column, showing the scFv band at 
approximately 30 KDa.
192
48.0 KDa
32.0 KDa
26.0 KDa
18.0 KDa
1 2 3 4 M
Figure 5.25. Picture of Western blot analysis of WT CTh5 clone expression and subsequent 
IMAC (Ni2+-NTA) purification fractions. The M lane contains Pierce Blue ranger pre-stained 
protein markers with bands at 48 KDa, 32 KDa and 26 KDa, and 18 KDa highlighted. Lane I 
represents the WT CTh5 cell lysate (1:5 dilution in PBS) prior to IMAC purification. Lane 2 
represents the WT CTh5 cell lysate (1:5 dilution in PBS) after two passes through IMAC 
column (Flow through). Lane 3 represents the column wash run off (neat). Lane 4 represents 
WT CTh5 scFv eluate from IMAC column, showing the distinct scFv band at approximately 
30 KDa.
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Figure 5.26. Typical result obtained for monitoring binding activity Ni2+-NTA agarose resin 
immobilised metal affinity chromatography WT CTh5 scFv purification. A 96-well plate 
coated with 6(j.g/ml thyroglobulin-cephalexin conjugate was blocked with PBS containing 5% 
(w/v) milk marvel. 100^1 aliquots of wild-type CTh5 supernatant (WT Super) (spent culture 
media) and each IMAC purification fraction, including column flow through (WT FT), wash 
(WT Wash), cleared cytoplasmic lysate (WT CL), and dialysed scFv IMAC eluate (WT 
Eluate) were added in duplicate to the 96-well plate and incubated. The scFv was 
subsequently detected with HRP-labelled monoclonal anti-poly histidine antibody, followed 
by addition of Sigma fast OPD substrate system. The normalised absorbance was calculated 
by taking the absorbance for each sample and subtracting background absorbance obtained 
from control surface (i.e. wells coated with thyroglobulin (6 ¿ig/ml) protein).
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The results of the SDS-PAGE, Western blotting and screening ELISA confirmed that the 
soluble scFv derived from WT CTh5 clone was successfully purified from crude cell lysates 
and that it retained binding activity to conjugated (Thyro-Ceph) cephalexin in ELISA. The 
purified scFv was used in the subsequent development of an ELISA for the detection of 
soluble cephalexin in ‘spiked’ whole milk samples.
5.1.3.3 The development o f an inhibition displacement ELISA using scFv antibody fragment 
from anti-cephalexin monoclonal antibody for the detection o f cephalexin in whole milk 
samples.
IMAC-purified WT CTh5 scFv antibody was used in the development of an ELISA for the 
detection of cephalexin in whole milk. Initially, the optimum secondary detection antibody 
and subsequent scFv dilution for use in the inhibition ELISA were determined. Plates were 
coated with a (protein-activated) thyroglobulin-cephalexin (1.3 (xg/ml), as described in section
2.3.1.1. Serial dilutions of scFv were added and separately detected with both secondary 
antibodies i.e. anti-Histidine and anti-FLAG antibodies, used at 1/1,000 dilutions. This 
showed that the anti-histidine antibody gave a greater response in terms of corrected 
absorbance in comparison to the anti-FLAG antibody. Anti-histidine secondary antibody was 
used in subsequent ELISA experiments.
An inhibition ELISA was carried out using IMAC-purified WT CTh5 scFv and a range of 
free cephalexin concentrations. The scFv was diluted (1:100) in whole processed milk with 
the appropriate cephalexin standard. The linear range of detection for the assay was found to 
be from 100 to 100,000 ng/ml approximately (Figure 5.27). The limit of detection (LOD) was 
calculated by taking 3x standard deviations from the background (A0), and was found to be
143.3 ng/ml. Results showed that the limit of detection of the assay, when carried out in 
‘spiked’ processed milk, was not sufficiently low enough to detect free cephalexin hydrate at 
the required EUMRL value of 100 ng/ml.
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Figure 5.27. This figure represents a plot of the results of an inhibition ELISA in ‘spiked’ 
whole milk samples, using IMAC-purified WT CTh5 scFv and a range of free cephalexin 
concentrations from 1 ng/ml to 1,000,000 ng/ml. The scFv was diluted (1:100) in whole 
processed milk with the appropriate cephalexin standard. The linear range of detection for the 
assay was from 100 to 100,000 ng/ml. The limit of detection (LOD) was calculated by taking 
3x standard deviations from the background (A0), and was found to be 143.3 ng/ml.
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5.2.3.4 Bioinformatic analysis o f wild type scFv antibody derived from anti-CephMl 
antibody-secreting cell line.
The wild type scFv gene construct was sequenced (Qiagen Genomic Services) using primers 
that were designed to anneal to sequence regions on the pAK400 vector (pAKfor: CGG CAG 
CCG CTG GAT TGT TAT TAC and pAKback: CAT TTT TCA CTT CAC AGG TCA AGC). 
A 1.5 ml microcentrifiige tube containing wild type clone stab culture was prepared. The stab 
culture and primer sequence information were sent to Qiagen for primer synthesis and 
subsequent sequence analysis. The resulting nucleic acid sequence was analysed using the 
Chromaslite200 software package, and the Expasy nucleic acid translation tool 
(http://www.expasv.org/tools/dna.html). Once the amino acid sequence had been obtained, it 
was inputted into the IgBlast search engine at the National Institutes of Health, National 
centre for Biotechnology information website (http://www.ncbi.nlm.nih.gov/igblast/') that 
finds and aligns homologous antibody amino-acid sequences. Figure 5.28 shows the resulting 
wild type amino acid sequence, the variable light and heavy chain CDR regions, glycine / 
serine peptide linker peptide and the hexahistidine tag are all highlighted as shown. Using this 
site the variable heavy chain complemetarity determining regions (CDR’s) were identified.
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Wild type scFv
* 20 * 40 *
<---------- VlCDR1-------->
GVGMADYKDIVLTQSPLSLPVSLGDQASISCRSSRNIVHSNGNTYLEWYLQKPGQSP
60 * 80 * 100 * 
<VlCDR2> <-VlCDR3->
KLLMYKVSNRLSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGG
120 * 140 * 160 *
<V
TKLEIKRGGGGSGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSLKLSCAASGFTFS
180 * 200 * 220 
HCDR1> <---------VhCDR2-------->
SYGMSWVRQTPEKTLEWVASISGGGNTYYPDSVKGRFTISRDNARNILYLQMSSLRS
* 240 * 260 *
<_— VhCDR3— ->
EDT AMYYC ARGLGYGKAFMDY WGQGTS VTV S S ASG ADHHHHHH-
Figure 5.28. Wild type amino acid sequence obtained using the Expasy DNA translation tool. 
The text highlighted in blue represents the particular number of the respective amino acid 
residue, where * represents ten residues. The complementarity determining regions (CDR) are 
highlighted in grey for both variable heavy and light chains. The 15 amino acid glycine serine 
repeat peptide linker and hexahistidine tag are highlighted in yellow. The variable heavy and 
light chain CDR regions were fully identified using the Kabat rules for identifying antibody 
CDR regions from linear amino acid sequences, which are summarised at the following 
website f http://www.nibic.idg.ac.uk/abeng/cdrs.htmh.
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The wild type scFv was also modelled in three dimensions using SWISS model and SWISS 
PDB viewer software (http://wwvY.ca.expasv.orE//S WISS-MQDEL.html). Figures 5.29 shows 
a picture of the wild type scFv ribbon model with variable heavy and light chain domains 
coloured red and blue, respectively, for convenience.
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Figure 5.29. Picture of wild type scFv model (top view, with respect to antigen binding site) 
obtained using the SWISS-Model bioinformatics website and PDB viewer software. The 
heavy and light chain framework regions are shown as ribbon structures, and are highlighted 
in red and blue, respectively. The CDR regions are shown using a space fill model with the 
corresponding heavy and light chain CDRs highlighted in different colours for ease of 
distinction.
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5.2.4 The production o f mutant scFv phage-display libraries using wild type scFv gene.
The wild type scFv-expressing clone previously found to be cephalexin-specific and displaced 
by soluble cephalexin was used as a template in the production of mutant phage-display 
libraries. Mutant libraries were produced using random mutagenesis and error-prone PCR 
techniques as described in section 2.6. The wild type clone was grown overnight at 37°C, the 
cells were then pelleted by centrifugation and the vector DNA was purified (section 2.5.2.3) 
and used as template in multiple copy PCR reactions (section 2.5.4.4). The PCR products 
were run on a 1% (w/v) agarose electrophoresis gel (Figure 5.30).
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Figure 5.30. Picture of 1% (w/v) agarose gel loaded with multiple SOE PCR reaction 
products. The SOE-PCR reactions were carried out using mini-prepped pAKlOO vector 
containing the wild type gene as template. Lane 1, Hyperladder I (Bioline) DNA marker; 
Lanes 2-7, multiple copies of the wild type PCR reaction.
The PCR products were pooled and concentrated using ethanol precipitation (section 2.5.2.4) 
and digested using DNase 1 endonuclease enzyme, as described in section 2.6.1. For the 
digest the optimised concentrations of the enzyme and PCR product were found to be 1 U/rxn 
and 4(ig/rxn, respectively. The reaction time was also carried out over defined time intervals 
before addition of enzyme stopping buffer (EDTA). The optimised time was found to be 5 
min. The products of the digest were analysed by agarose gel electrophoresis, as shown in 
figure 5.31.
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Figure 5.31. Picture of 1% (w/v) agarose gel loaded with undigested and DNase 1 digested 
wild type scFv gene (SOE PCR product). Samples were run on gel in order to assess the 
optimum digestion time. Lane 1, Hyperladder I (Bioline) DNA marker; Lane 2, undigested 
SOE PCR product stock; Lane 3, 0 min incubation at 37°C with DNase 1; Lane 4, Digest 
product after 5 min incubation; Lane 5, Digest product after 10 min incubation; Lane 6, 
Digest product after 15 min incubation with DNase 1.
All reactions were stopped after the allotted time using stop buffer as provided (section 2.6.1). 
Figure 5.31 demonstrates that the scFv gene (800 bp) was completely digested into smaller 
(50-1 OObp) fragments after 5 min incubation with the DNase 1 endonuclease enzyme. 
Following optimisation of the DNase 1 digest, multiple reactions were carried out and the 
reaction products pooled and concentrated using ethanol precipitation. The digested fragments 
were then used as primers for each other in an initial re-amplification (section 2.6.2). The 
product of this reaction varied in size from approximately 400-800 bp (Figure 5.32). The band 
at 800 bp was gel purified and used for error-prone PCR, as described in section 2.6.3.
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Figure 5.32. Picture of 1% (w/v) agarose gel loaded with re-amplified DNase 1 digestion 
product. The digested wild type scFv gene fragments were used as a mix of complementary 
primers and amplified, as described in section 2.6.2. Lane 1 was loaded with lkb DNA 
ladder; Lane 2 contained re-amplification PCR product of the DNase 1 digested products.
The error-prone PCR was carried out using two similar PCR reactions. However, one was 
performed using MgCl2 (i.e. Rl*, designated shuffle library) and the other using MnCl2 (i.e. 
R2*, designated error prone (EP) library), as described in section 2.6.3. To increase the 
potential introduction of mutations the PCR reactions were carried using 35 repeat cycles 
while using Red Taq (Sigma) which does not contain any proof reading capacity. Both PCR 
reactions yielded a discreet band at 800 bp, as shown in figure 5.33.
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Figure 5.33. Picture of 1% (w/v) agarose gel loaded with shuffle and error-prone PCR 
products. The PCR reactions (Rl* & R2*, section 2.6.3) were carried out using re-amplified 
wild type gene fragments as template. Lanes 1 & 4, Gibco lkb plus DNA ladder; Lane 2 was 
loaded with shuffle PCR product; Lane 3 contains error-prone (EP)-PCR product.
The shuffle and EP-PCR products were purified by ethanol precipitation (section 2.5.2.4) and 
ligated into pAKlOO vector after Sfi 1 restriction digest as described in section 2.6.4. The 
ligation products were used to transform electrocompetent E. coli (TOPIOF') as described in 
section 2.52.1. The electro-competent TOPIOF' E.coli cells were tested with commercial 
pUC18 plasmid and yielded a transformation efficiency of 109 transformants / jj.g pUC18 
plasmid DNA. The number of transformants obtained for each library (i.e. shuffle (Rl*) and 
error-prone (R2*)) was 1.4 x 107 and 2.3 x 106, respectively.
The Rl* and R2* mutant phage-display libraries were panned for anti-cephalexin phage 
(section 2.6.5). A two phase elution strategy was employed. This entailed elution of conjugate 
bound phage-scFv using soluble cephalexin to elute binders with a higher affinity for the 
soluble drug. Secondly the remaining phages were eluted using acid shock, as described in 
section 2.5.5.4. Both libraries were subjected to three rounds of panning using BSA- 
cephalexin and thyroglobulin-cephalexin conjugates. The results of a polyclonal phage 
ELISA for each round eluate fractions is shown in figure 5.34.
5.2.4.1 Bio-panning Shuffle and Error-prone mutant scFv phage-display libraries.
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Figure 5.34. The plotted results of a polyclonal phage ELISA using eluted phages from the 
first, second and third rounds of panning with Thyro-Ceph (TP). The eluted phages from the 
two libraries (i.e. Rl* and R2*) are shown as cephalexin eluate (DE) and glycine eluate (GE) 
fractions. The Rl * library eluted phages for the Thyro-Ceph panned rounds are represented in 
blue and green above for the drug elution and glycine elution fractions, respectively. The R2* 
library phages eluate for the panned rounds are shown in purple and red for the drug eluate 
and glycine eluate fractions, respectively. No significant binding was observed to 
thyroglobulin and blocking solution control surfaces.
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The cephalexin eluate (DE) and glycine eluate (GE) phages from the third round of panning 
for each library (i.e. Rl* and R2*) were used to infect E. coli in exponential growth phase. 
Individual colonies were picked from agar plates containing transformed colonies from each 
library and DE or GE eluate phages. The colonies were randomly picked from streaked agar 
plates and used to inoculate sterile 96-well plates containing media and screened individually, 
as described in section 2.5.5.6. Positive cephalexin binding phage-scFv clones were identified 
by ELISA. Results of individual phage ELISA for randomly picked individual clones from 
the Rl* library, drug (DE) and glycine (GE) eluted phages, are shown in figure 5.35. Phages 
were screened against thyroglobulin-cephalexin-coated (1.3 pg/ml) wells. Phage-scFv were 
detected using rabbit anti-fd-bacteriophage antibody, followed by HRP-labelled goat anti­
rabbit antibodies. The corresponding R2* library results are shown in figure 5.36. In all 
ELISAs the original wild type phage-scFv were screened in well H I2 as a positive control. 
The average absorbance for wild type phage-scFv on each plate ranged from 0.65 to 0.75, 
following colour development with Sigma fast OPD substrate system. The cut off point was 
set at an absorbance of 0.7 due to the large number of positive binders and the comparative 
value for the wild type phage. Thus, the wild type response is not visible on all of the 
resulting plots. The randomly picked free-drug eluted clones typically yielded a smaller 
percentage of positive clones when compared to the glycine-eluted clones for the shuffled 
mutant (Rl *) library as clearly seen in figure 5.35.
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Figure 5.35. This figure represents a total 186 randomly picked clones from round three 
shuffle (Rl *) mutant library, 93 clones were picked from each elution fraction (i.e. free-drug 
and glycine). (A) The 93 clones from the free drug eluted (DE) phage stocks; wells H10 & 
HI 1 were negative controls; well H I2 (highlighted in red above) contained original wild type 
phage-scFv. (B) The 93 clones (with controls as for A) from the glycine eluted (GE) phage 
stocks. The cut off was set at an absorbance of 0.7 because of the large number of positive 
clones.
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Figure 5.36. This figure represents a total 186 randomly picked clones from round three 
error-prone (R2*) mutant library, 93 clones were picked from each elution fraction (i.e. free- 
drug and glycine). (A) The 93 clones from the free drug eluted phage stocks; wells H10 & 
HI 1 were negative controls; well H12 (highlighted in red above) contained original wild type 
phage-scFv. (B) The 93 clones (with controls as for A) from the glycine eluted phage stocks. 
The cut off was set at an absorbance of 0.7 because of the large number of positive clones.
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A total of 22 positive phage-scFv-producing clones were picked from the free-drug and 
glycine-eluted fractions of each mutant library (Rl* and R2*). The clones were initially 
ranked on the basis of their respective absorbance in phage ELISA against cephalexin- 
conjugate-coated plates. Sample clones with low (<0.5), medium (<0.8) and high (<1.0) 
absorbance were picked from the positive stock pool for further characterisation so as to limit 
the possibility of omitting a high affinity clone on the basis that it was relatively poorly 
expressed.
Preliminary inhibition displacement ELISAs with a range of free cephalexin concentrations 
were carried out using plates coated with Thyro-Ceph. This was done in order to ensure that 
the cephalexin conjugate positive mutants were binding to the soluble cephalexin prior to 
further selection, expression and purification. The assays were used to give an indication of 
the effects (if any) on assay performance using the selected clones. Figures 5.37 and 5.38 
show the results of preliminary phage inhibition ELISA carried out for the clones picked from 
Rl * mutant library. As observed from the results, some of the mutant clones picked had a 
dramatically reduced affinity for the soluble cephalexin, in particular, the glycine-eluted (GE) 
A1 and Cl clones from the Rl* mutant library. The drug-eluted (DE) clones from the shuffle 
(Rl*) library i.e. C5 and G2 (Figure 5.37), showed an increased sensitivity to cephalexin in 
comparison to the original wild type phage-scFv.
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Figure 5.37. Plot of a preliminary inhibition displacement phage ELISA using selected clones 
from the cephalexin-eluted (DE) fraction of the shuffle (Rl*) library. In addition, by way of 
comparison, the original wild type phage-scFv (WT) was screened. The assay was carried out 
using Thyro-Ceph-coated immunoplates and prepared phage from each clone (diluted 1:2 in 
PBS-T). Clones C5 and G2 showed noticeable increased slopes in comparison to the wild 
type phage-scFv plot.
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Figure 5.38. Plot of a preliminary inhibition displacement phage ELISA using picked clones 
from the glycine-eluted (GE) fraction shuffle (Rl*) library. In addition, by way of 
comparison, the original wild type phage-scFv (WT) was screened. The assay was carried out 
using Thyro-Ceph coated immunoplates and prepared phage from each clone (diluted 1:2 in 
PBS-T). Clones Cl and A1 showed an apparent lowered affinity to cephalexin in comparison 
to the wild type phage-scFv.
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5.2A.2 Soluble expression, purification and characterisation o f recombinant mutant anti­
cephalexin scFv antibody fragments.
Six clones were picked for further characterisation on the basis of preliminary inhibition 
ELISA data. The six clones were picked from the positive drug-eluted stocks, three from each 
mutant library i.e. shuffle (Rl*) and error-prone (R2*). The scFv gene-containing pAKlOO 
vector for each clone was purified. The scFv gene constructs were excised using Sfi 1 
restriction enzyme prior to sub-cloning into the pAK400 vector for enhanced soluble 
expression. Crude cell lysates were prepared from the pAK400 transformants for each of the 
picked clones and screened initially using ELISA. They were compared to wild type cell 
lysates in terms of the relative amount of expressed functional scFv. Two nascent clones (Rl * 
DE C5 and R2* DE H3) were identified. They were selected for subsequent purification by 
immobilised metal affinity chromatography (IMAC), as described in section 2.5.6.8, prior to 
further characterisation and comparison with the original wild type.
The IMAC purification fractions were analysed using SDS-PAGE, Western blotting and 
ELISA. Figure 5.39 shows a picture obtained for an SDS-PAGE experiment. Crude cell 
lysates, Ni2+-NTA column flow through, wash and eluted fractions were run for each clone. 
The gel picture shows strong and distinctive bands at approximately 30 KDa as expected for 
each mutant clone, with minimal impurities. A Western blotting experiment was carried out 
following SDS-PAGE analysis in order to confirm the bands were histidine tagged scFvs. 
After transferring the bands from the SDS gel (section 2.3.3) the nitrocellulose membrane was 
probed using mouse anti-polyhistidine antibody, followed by HRP-labelled goat anti-mouse 
antibody. The colour was developed using TMB liquid substrate. Figure 5.40 shows a picture 
obtained from the Western blot analysis. Bands were observed in the crude lysate and IMAC 
column eluate fractions for both mutant clones at approximately 30 KDa.
211
1 2 3 4  5 6  7 8 9  10 11
C5 H3
Figure 5.39. An SDS-PAGE gel image of Ni2+-NTA immobilised metal affinity 
chromatography purification fractions from mutants R1 *DE C5 and R2*DE H3 using PBS-T 
(0.5M NaCl) containing lOmM imidazole, running buffer. Lanes 1 and 11 are Sigma wide- 
range protein markers; Lane 6 is empty; Lane 2, C5 clone lysate (diluted 1:5); Lane 3, 
Column flow through (FT) for the C5 (diluted 1:5); Lane 4, column wash (neat); Lane 5, C5 
IMAC column eluate (neat); Lane 7, H3 clone lysate (diluted 1:5); Lane 8, H3 column flow 
through (diluted 1:5); Lane 9, H3 column wash (neat); Lane 10, H3 eluate (neat). Strong 
distinct bands at approximately 30 kDa represent scFv protein, as confirmed by Western 
blotting analysis.
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Figure 5.40. A Western blot for mutant clones C5 and H3 IMAC purification fractions. The 
I MAC purification was carried out, as described previously, where fractions were run on a 
15% (w/v) SDS-PAGE gel and transferred to a nitrocellulose membrane using a semi-dry 
blotter. Lanes 1 and 11 represent Pierce Blue Ranger™ pre-stained protein markers; Lane 2, 
C5 lysate (diluted 1:5); Lane 3, column flow through (FT) for the C5 (diluted 1:5); Lane 4, 
column wash (neat); Lane 5, C5 IMAC column eluate using 100 mM sodium acetate, pH 4.5 
(neat); Lane 6 is empty; Lane 7, H3 clone lysate (diluted 1:5); Lane 8 H3 column flow 
through (diluted 1:5); Lane 9, wash for the H3 column (neat); Lane 10, H3 eluate using 
lOOmM sodium acetate, pH 4.5 (neat). The membrane was blocked using PBS-T 
supplemented with 5% (w/v) semi-skimmed milk powder. Subsequent scFv detection was 
carried out using 1:2,000 dilution of HRP-labelled monoclonal anti-poly histidine antibody. 
Colour development was achieved by the addition of TMB membrane substrate system. Both 
C5 and H3 scFv were detected (distinct bands at approximately 30 kDa) in the cleared lysates 
and IMAC eluate fractions.
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Figure 5.41. Result obtained for ELISA to monitor the binding activity of C5 and H3 scFvs 
to Thyro-Ceph-coated wells following Ni2+-NTA agarose resin IMAC-purification. A 96-well 
plate coated with 6pg/ml thyroglobulin-cephalexin conjugate, blocked with PBS containing 
5% (w/v) milk marvel. lOOfxl aliquots of each IMAC purification fraction, i.e. column flow 
through (FT) (diluted 1:2 with PBS-T), column washes (Wash) (neat), and dialysed scFv 
IMAC eluates (diluted 1:2 with PBS-T) were added in duplicate to the 96-well plate and 
incubated. The scFv was subsequently detected with HRP-labelled monoclonal anti-poly 
histidine antibody, followed by addition of Sigma fast OPD substrate system.
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5.2.4.3 Development o f an inhibition ELISA for the detection o f cephalexin using IMAC- 
purified scFv from mutant clones C5 and H3 and assay comparison with original wild type 
scFv.
The mutant scFv produced by clones C5 and H3 (section 5.2.4.2) were used in the 
development of an inhibition ELISA for the detection on soluble cephalexin hydrate. Initially, 
the IMAC-purified scFv titres for original wild type, C5 (from shuffle mutant library R1 *), 
and H3 (from error-prone mutant library R2*) clones were assessed (section 2.3.1.1) with 
iramunoplates (Nunc) coated with thyroglobulin-cephalexin conjugate (Figure 5.42).
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Figure 5.42. Results obtained for an ELISA to determine the scFv titre for wild-type (WT), 
C5 and H3 clone antibodies. The scFvs were screened against Thyro-Ceph (6 pg/ml) and 
thyroglobulin (T) - coated wells. From the plot the scFv dilution yielding an absorbance of 0.4 
at 450 nm was chosen for each scFv for subsequent inhibition displacement ELISA 
development. The WT dilution was 1:150, C5 was 1:300 and H3 scFv dilution was 1:200. 
Overall the mutant clones expressed a larger amount of functional scFv in comparison to WT 
(observation). Each point represents the mean value of three measurements (n=3).
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A control coating (thyroglobulin with no cephalexin attached) was used to rule out any non­
specific binding interactions. The results of this experiment (Figure 5.42) showed the mutant 
C5 scFv displayed the highest titre of the three tested antibody preparations. None of the scFv 
displayed any significant binding to the control surface. Inhibition ELISAs were carried out, 
as described previously (section 5.2.3.3). The results of each assay are shown in figure 5.43.
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Figure 5.43. Overlay plot of the results obtained from displacement ELISA assays using 
wild-type (WT), H3 and C5 soluble scFv. The graph shows the improved assay sensitivity 
using C5 and H3 compared to WT. The resulting data was used in BIAevaluation and four- 
parameter equation fitted to each data set, and used to back calculate concentrations, and 
determine the IC50 values. This revealed a 2 fold improvement in sensitivity for clone C5 
soluble scFv with respect to WT.
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The limits of detection (LOD) for each of the assays were determined by subtracting 3 times 
the standard deviation obtained from the background (AO, no free drug). The LOD achieved 
with C5 scFv in comparison with wild type scFv showed a 1.8 fold improved sensitivity, from 
an absolute value of 143.3 ng/ml for the original wild type scFv to 77.9 ng/ml for the mutant 
C5 scFv. Although the H3 scFv displayed an increased sensitivity to free drug at 
concentrations of >1000 ng/ml, as observed by a 1.2 fold increase in the IC50 (in comparison 
with wild type scFv), at lower drug concentrations the comparative sensitivity was poor, with 
an assay LOD of 327 ng/ml. The standard deviation observed for assay point using the H3 
scFv in ELISA was observably higher than for the original wild type and C5 scFv antibody 
fragments, which may suggest a lack of functional stability due to point mutations.
5.2.4.4 Sequencing and bioinformatics analysis o f mutant C5 and H3 scFv gene constructs.
The mutant scFv clones C5 and H3 gene constructs were sequenced, as described in section
5.2.3.4. In addition, isolated mutant clone A1 (from Rl* mutant library, glycine-eluted clones 
(GE)) was also sequenced. The A1 phage-scFv was previously found not to show competitive 
inhibition by free cephalexin (Figure 5.38), and was sub-cloned into pAK400 soluble 
expression vector prior to sequencing. The A1 clone was chosen for comparison, in order to 
assess potential mutations that may be detrimental to soluble cephalexin binding activity. All 
clones were sequenced from pAK400-containing E. coli (JM83) stab cultures with primers 
detailed in section 5.2.3.4.
The resulting nucleic acid sequences were translated into amino acid sequences using the 
Expasy translation tool (http://www.expasv.org/tools/dna.litmn. Subsequently the amino acid 
sequences were then co-aligned with the original wild type sequence (Figure 5.28) using the 
sequence alignment tool ('http://www.prodes.touloiise.infa.fi/mmalin). The resulting amino 
acid alignments for wild type (WT), C5 and H3 scFvs are shown in figures 5.44 (CDRs) and 
5.45 (structural framework regions). Regions where there are mutations are highlighted in red 
(C5) and blue (H3). Amino acid deletions are represented by asterisks (*).
The C5 mutant clone was modelled using the SWISS-Model web site described in section
5.2.3.4. Using the SWISS-Model PDB viewer software, the CDR regions were highlighted in 
an analogous manner to the wild type model (Figure 5.29). The specific CDR regions where 
amino acid sequence mutations observed were highlighted, as shown in figure 5.46.
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CDR hi WT- S Y G M S
C5- S y g m s
H3- S Y G M S
Al- S Y G M S
CDRh2 WT- S I S G G G N T Y Y P D S V K G
C5- S I S G G G N T Y Y P D S V K G
H3- S I S G G G N T Y Y P D S V K G
Al- S I S G G G N T Y Y P D S V K G
CDR h3 WT- G L G Y G K A F M D Y
C5- g | g y g k a f m d y
H3- G L G Y G K A F M D Y
Al- g l g y g k a f m | y
c d r l1 WT- R S S R N I V H S N G N T Y L E W
C5- R S S Q N I V H S N G N T Y L E W
H3- R S S Q N I V H S N G N T Y L E W
Al- R S S Q D I V H S N G N T Y L E W
c d r l2 w t - k v s n r l s
C5- K V S N R L S
H3- K V S N R L S
Al- K V S N R L S
c d r L3 w t - f q g s h v p
C5- F Q G S H V P
H3- F Q G S H V P
Al- F Q G S H V P
Figure 5.44. This represents the scFv heavy and light chain complementarity determining 
region (CDR) amino acid sequence alignments for the wild-type (WT), C5 and H3 clones. 
The WT complete amino acid sequence is shown in figure 5.28. The point mutations for clone
C5 and Al are highlighted in red. Clone H3 has complete CDR amino acid sequence
homology with the wild type. Mutations in the H3 clone are confined to scFv framework 
regions.
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Al -  D Y K D * V L M T Q T P L S L P  V S L G G Q  A S I S C
Framework L2
Framework L3 
WT-  
C5-  
H3-  
Al -
Framework Hi 
WT-  
C5-  
H3-  
Al -
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Al -  W V R Q T P E K T L E W V A
R F T I S R D N A R N I L Y L Q M S S L R S E D T A M Y Y C A R
R F T I S R D N A R N I L Y L Q M S S L R S E D T A M Y Y C A R
R F T I S R D N A R N I L Y L Q M S S L R S E D T A M Y Y C A R
R F T I S R D N A R N I L Y L Q M S S L R S E D T A M Y Y C A R
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H3- W G Q G T S V T V S S A S G A D  
Al -  W G Q G T S V T V S S A S G A D
Figure 5.45. Representation of the scFv heavy and light chain framework region (FR) amino 
acid sequences. The sequences were aligned for the wild-type (WT), C5 and H3 clones. The 
point mutations for clone C5 are highlighted in red, for H3 clone in turquoise and for A1 in 
yellow, deletions are represented by an asterisk [*]. Heavy and light chain regions are 
designated H or L subscript with the corresponding number shown.
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Figure 5.46. Picture of C5 scFv three dimensional model obtained using the SWISS-Model 
bioinformatics website and PDB viewer software. The heavy and light chain framework 
regions are shown as ribbon structures, and are highlighted in red and blue, respectively. The 
CDR regions are shown using a space fill model with the corresponding heavy and light chain 
CDRs highlighted in different colours for ease of distinction. Hie point mutations 
(highlighted by dashed black circle) in the heavy chain CDR1 (Purple) and CDR3 (blue) are 
shown.
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5.3 Discussion
In summary, the BMV human naive phage-scFv antibody library was panned with cephalexin 
conjugates. No soluble cephalexin-specifrc phages were isolated using this library. In the 
literature, there are reports of scFvs successfully isolated against hapten molecules using 
human naive libraries. The likelihood of isolating a hapten (e.g. cephalexin)-specific phage, 
however, depends a great deal on the library size and the particular one used. In the pursuit of 
a scFv against cephalexin, two phage display libraries were produced using the method 
described by Krebber et al. (1997). The two libraries were produced from pre-immunised 
Balb/C mice.
Serum antibody titres for the immunised mice were monitored using ELISA and the animals 
were sacrificed, their spleens removed, and the RNA extracted for library construction. Total 
RNA from both mice (i.e. 1 & 2) was used to synthesise cDNA by reverse-transcription PCR 
(RT-PCR). Random hexamer primers were used for the RT-PCR initially. The resulting 
cDNA was used as a template for the heavy and light chain amplification PCR using the 
established set of degenerate primers (section 2.5.4.1). Variable heavy and light chain PCR 
products were gel-purified and genes were constructed by SOE-PCR. The gene constructs 
were ligated into the pAK.100 phagemid vector and, subsequently, used to transform 
chemically competent E. coli (XL1 blue). The two phage display libraries produced contained 
4.6 x 103 and 3.2 x 103 transformants each. In comparison with phage-display libraries 
reported in the literature, the number of transformants obtained for both libraries was low 
(usually of the order of 108 or 109 transformants). However, it was decided to pan the libraries 
since they originate from immunised mice and should have greater numbers of cepahexin- 
specific antibodies, as a result. Some authors have reported the isolation of specific phage 
scFv form such small libraries produced from pre-sensitised sources (Daly, 2001; Dillon et 
al., 2003b; Leonard, 2003).
After several rounds of panning with various cephalexin conjugates, and investigating various 
bound phage elution strategies (Wind et ah, 1997 and De Briun et al., 1999) no scFv were 
isolated that recognised the soluble (i.e. non-conjugated) P-lactam antibiotic residue. Two 
random clones were picked from library stock agar plates and used along with un-transformed 
cells to ensure that the cells did indeed contain pAKlOO vector with scFv gene insert. The 
results of this experiment (Figure 5.11) showed that the library clones did contain the scFv 
gene construct. Although we can be sure the library clones did contain scFv gene constructs, 
the sequence diversity and hence the variety of binding function could not be fully 
enumerated without sequencing all the resulting transformants, which for the purposes of this
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work was impracticable. The lack of potential cephalexin-specific scFvs within the two 
libraries is most probably due to the small library sizes obtained. The transformation of 
bacterial cells is well recognised as a critical limiting factor in terms of obtaining large 
libraries. It was decided in future library production work to apply an alternative 
electroporation-based (section 2.5.6.5) transformation protocol, used in the production of 
mutant phage display libraries (section 5.2.4)
At this point another approach was taken to obtain a cephalexin-specific scFv antibody 
fragment. The hybridoma cell line produced in chapter 4 of this work was used as a genetic 
source for scFv production (section 5.2.3). Positive phage-scFvs were produced and identified 
(Figures 5.15 and 5.16) and picked clones bound free-cephalexin which was demonstrated in 
inhibition ELISA (Figure 5.18). The scFv gene construct was purified from one of the picked 
clones and sub-cloned into the pAK400 vector for enhanced soluble expression. The scFv was 
successfully expressed as a single entity (i.e. no longer as a glllp fusion protein) in E. coli 
(JM83) cells. The expression was induced with IPTG and scFv production was monitored by 
SDS-PAGE and Western blotting (Figures 5.21 and 5.23). The cephalexin-specific scFv 
(termed wild type) was successfully purified by Ni2+-NTA immobilised metal affinity 
chromatography (IMAC) and the purification process characterised using SDS-PAGE, 
Western blotting and ELISA.
Following isolation and purification of the wild type (WT) scFv by IMAC, an inhibition 
ELISA for the detection of cephalexin in ‘spiked’ processed milk samples was developed 
(section 5.2.3.3). The assay was not as sensitive as the parental monoclonal IgG antibody 
(Chapter 4) resulting in a limit of detection (LOD) of 143.3 ng/ml, compared to 60 ng/ml for 
the intact monoclonal IgG. It is probable that the reduced assay sensitivity may be due to 
avidity effects, going from a divalent intact IgG to a predominantly monovalent scFv. Kortt 
et al. (1994) suggest scFvs with 15 amino acid linker sequences are comprised mostly of the 
monomeric form. However, under certain concentration conditions (~5 mg/ml) they found 
that dimeric and, in some cases, larger multimeric aggregates were formed. In addition, 
freezing was found to enhance aggregate formation.
The wild type scFv gene was sequenced (section 5.2.3.4) and the complementarity 
determining regions (CDR) were identified using the National (US) centre for Biotechnology 
information Ig Blast tool (http://www.ncbi.nlm.nih.gov/igblast/). The wild type scFv gene 
sequence was found to be 98.3% homologous to the murine sequence number AJ231205 from 
the crl germline gene sequence (Thiebe et al., 1999), the heavy chain scored 95.8% 
homology with the Balb/c VH7183 gene family, as characterised by Williams et al. (2001). A
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model of the WT scFv protein was produced using the SWISS-Model protein modelling 
website, the SWISS-Model system and PDB software (Pietsch, 1995; Guex and Pietsch 1997; 
Schwede et al., 2003,).
The cephalexin-specific wild type (WT) scFv gene was isolated from the bacterial clone used 
to express the soluble scFv, and used as a template for random mutagenesis procedures (Coia 
et al., 2001; Korpimaki et al., 2002; Razai et al., 2005). Intra-gene sequence shuffle (Rl*) 
and error-prone PCR (R2*) phage-display libraries were constructed by ligation of mutated 
scFv gene constructs into the pAKlOO phagemid vector. The ligation products were used to 
transform E. coli TOPI OF' electrocompetent cells and the number of transformants obtained 
was of the order of 1.4 x 107 for Rl* and 2.3 x 106 for R2* libraries, respectively. The two 
libraries were panned using various cephalexin-conjugates. The conjugate bound phage-scFvs 
were initially competitively eluted by adding non-conjugated cephalexin and successively 
lowering the concentration followed by elution with glycine. The specific ‘polyclonal’ phage- 
scFv populations were more noticeably enriched over three rounds of panning using the free 
drug elution (DE) method (Figure 5.34). For example, in terms of absorbance, the response 
obtained for third round panned R2* drug eluted phages was 1.6-fold higher than the first 
round panned phages. The glycine-eluted phage for the same library (R2*) response for round 
one and three panned phage was the same.
Individual specific clones (i.e. ‘monoclonal’) were screened and positive phage-scFv 
identified by ELISA (Figures 5.35 and 5.36). In addition, binding of 22 selected clones to free 
cephalexin was observed in inhibition ELISA (Figures 5.37 and 5.38). Nascent phage-scFvs 
were singled out and sub-cloned into pAK400 vector for subsequent soluble expression. Two 
clones (C5 and H3) with the most promising improvements in terms of inhibition ELISA 
sensitivity were purified by IMAC chromatography. From the IMAC purification fractions 
were analysed by denaturing SDS-PAGE and Western blotting analysis (Figures 5.39 and 
5.40). The IMAC-purified mutant scFv antibody fragments were used in an inhibition ELISA 
for the detection of cephalexin hydrate in ‘spiked’ processed milk samples (section 5.2.4.3), 
in parallel with the original wild type scFv. The mutant C5 clone scFv displayed two-fold 
increased assay sensitivity in comparison with wild type. The mutant H3 scFv was not as 
sensitive at lower cephalexin concentrations, but it did have a lower IC50 value. In 
comparison with the wild type the mutant H3 scFv assay IC50 value represented a 1.2 fold 
decrease. The H3 clone had point mutations in the framework regions which may contribute 
to a greater stability. However, there were no observed mutations in any CDR regions when 
compared to the WT clone.
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Other workers have suggested that larger mutation rates are required to increase specificity 
(Saviranta et ah, 1998) by reducing cross reaction with similar target antigens. They 
described the production of a mutant anti-17P-estradiol Fab library using random mutagenesis 
techniques. They found that each mutant contained on average 24 amino acid changes. 
Drummond et ah (2005) suggest that a balance rate of mutation may be calculated to strike a 
balance between obtaining functional and unique clones.
The mutant clone C5 scFv ELISA limit of detection (LOD) was determined by subtracting 3 
times the standard deviation obtained from the background and achieved a 1.8 fold improved 
sensitivity, from an absolute value of 143.3 ng/ml for the original wild type scFv, to 77.9 
ng/ml for the mutant C5 scFv. The C5 scFv was the best scFv produced in terms of 
expression, functional stability and assay performance, capable of cephalexin detection below 
the 100 ng/ml EUMRL for milk. Harvey et ah (2006) reported the production and isolation of 
mutant scFvs with improved affinity and expression compared to original parental scFv. EP- 
PCR was used to incorporate mutations into the original gene sequence for a 
methamphetamine-specific scFv. Interestingly, they isolated scFv mutants with single amino 
acid point mutations in their VhCDRI and VHCDR3 regions compared to parent scFv, with 
higher affinity to methamphetamine (up to 3-fold higher) and improved expression in E. coli.
The C5 scFv amino acid sequence with observed mutations in the variable heavy chain CDR1 
and CDR3 regions (Figure 5.44) supports the established concept that the majority of antigen 
binding interactions are conferred by the variable heavy chain complementarity determining 
regions. In conjunction with this finding, the point mutations observed in the C5 and H3 
protein framework regions may go some way to explaining the observed improvement in 
bacterial host expression in comparison with the wild type scFv clone. The H3 scFv did 
contain many similar framework mutations (Figure 5.45) to the C5 scFv. However, clone H3 
scFv did not have analogous heavy chain CDR mutations and hence the assay improvement 
was not as considerable as for C5 scFv. The mutant clones had observably higher titres than 
the wild type. This may be attributed to increased expression of mutant clones or expression 
of more functional properly folded proteins.
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Chapter 6
Biosensor-based detection of cephalexin
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6.1 Biosensors an introduction
The IUPAC has previously introduced a more rigid definition of a biosensor (Thevenot et al., 
1999): i.e. “A biosensor is a self-contained integrated device which is capable of providing 
specific quantitative or semi-quantitative analytical information using a biological recognition 
element (i.e. antibody) which is in direct spatial contact with a transducer element. A 
biosensor should be clearly distinguished from a bioanalytical system, which requires 
additional processing steps, such as reagent addition. Furthermore, a biosensor should be 
distinguished from a bioprobe which is either disposable after one measurement, i.e. single 
use, or unable to continuously monitor the analyte concentration.” This definition excludes 
many devices that have been successfully developed, for example optically-based 
immunosensors and disposable enzyme electrodes for the detection of blood glucose levels, as 
they do not fulfil the criterion of continuous monitoring or have additional preparation steps. 
However, for the sake of clarity this chapter will consider biosensors which fulfil the more 
traditional criterion, the direct spatial combination of biological recognition and transduction 
into a readable signal.
Human senses allow us to extract information from our environments e.g. from our sense of 
smell to our sight. The fundamental principles of these senses is the initial detection of an 
analyte (e.g. odorous molecules, light) via receptors (Figure 6.1), that then transduce this into 
an electrical impulse via neurotransmitters that can be processed in the brain. A biosensor 
combines a biological component (e.g. antibody, enzyme, whole cell, DNA etc.) integrated 
with a transducing element that in turn changes an event (e.g. antibody-antigen binding) into a 
signal (e.g. electric, photonic), which may be further processed, usually by a computer.
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(A) Nerve Cell
Olfactory Membrane Brain
detection 
element
Transducer Signal processor
Figure 6.1. Human sense of smell signal path schematic (A) and the general biosensor 
schematic (B) with the corresponding elements labelled.
Since the first biosensor devices were reported in the 1960’s, much interest was generated and 
details of many different types of biosensor have been published in the literature (Cornell et 
al., 1997; Nice and Catimel, 1999; Preston and Me Fadden, 2001; Sanders et al., 2001; Vo- 
Dinh and Cullum, 2000a). There are a lot of potential variations in the choice of 
biocomponent and means of signal transduction available when developing a biosensor 
device. These are considerations that depend on the future application and performance 
criteria of the biosensor and its intended use in medical, industrial or environmental 
diagnostics. It may be possible to integrate any number of combinations of transducer and 
bio-component (Table 6.1), yielding a host of different possibilities.
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Table 6.1. The biological recognition and transducer elements that may be combined in 
Biosensor design.
Biological Elements Transducer Types
Whole Organisms Potentiometric
Tissues Amperometric
Cells Conductometric
Organelles Impedimetric
Membranes Optical
Enzymes Calorimetric
Enzyme Components Acoustic
Receptors Mechanical
Antibodies
Nucleic Acids
Modem antibody-based sensors have been developed utilising different optical phenomena as 
a means of detection and analysis for antibody-antigen interactions. There are many 
biosensors that rely on evanescent wave generation such as waveguide interferometers, 
resonant mirror (or frustrated total internal reflection (FTIR)), surface plasmon resonance 
(SPR), surface enhanced rayman scattering (SERS), and near field scanning optical 
microscopy (NSOM) (Attridge et ah, 1991; Liron et ah, 2002; Seydack, 2005).
In addition, many light-based biosensor technologies comprise of tapered optical fibres 
incorporating a bio-component. Most of the optical fibre devices reported utilise a 
fluorescence-based probe coupled to a biological recognition element. The technique was first 
developed for sub-micron fibre probes for chemical analysis (Tan et ah, 1992) and as a means 
of measuring refractive index changes using SPR (Ranot-Trioli et ah, 1996; Dorstalek et ah, 
1997; Homola and Hongbo, 2001). One particular antibody-based study utilised an antibody 
for the detection of benzo [a] pyrene tetrol (BPT), a marker for exposure to a known 
carcinogen, benzo [a] pyrene (BaP) (Vo-Dinh et ah, 1987). It was fabricated using a 
micropipette puller to taper the optical fibres. The outside of the fibre was coated with a 
uniform layer of silver, 200nm thick, and the uncoated tip of the fibre was silanised and 
covalently bonded to the anti-BPT antibody. The bio-sensing device showed increased 
sensitivity and response time, attributed to the small tip area and it had an absolute limit of 
detection for BPT of approximately 300 zeptomoles (10'21moles). Since the initial reports of 
this type of biosensor many researchers have applied the technology for the direct and indirect
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analysis of a host of different compounds using a variety of bio-components (Barker et al., 
1998; Cullum et al., 1999; Liu and Tan 1999; Vo-Dinh et al., 2000b).
SPR-based sensors (Quinn and O’Kennedy, 1999; Homola, 2003) have become an integral 
part of biomolecular interaction analysis. In particular the Biacore ™ systems have been 
extensively reported in the literature, with approximately 90% of the 1998-1999 commercial 
biosensor publications citing the use of a Biacore instrument (Rich and Myszka, 2000), which 
seems to be a prevalent trend to date. Biacore sensors have been successfully applied in 
conjunction with antibodies to the detection of whole cells (Leonard et al., 2003; Hearty, 
2004), proteins and peptides (Yribarren et al., 2003) and small molecules (i.e. haptens) 
(Brennan et al., 2003; Tiidos et al., 2003).
6.1.1 Surface plasmon resonance (SPR)-based signal transduction
SPR is a unique optical phenomena that has been successfully applied to optical-based 
sensing with numerous and varied applications. The initial historical applications of SPR were 
in the investigation of optical properties of thin metal films. Since then SPR has been 
incorporated into a variety of sensing devices, in particular biosensors, with great success. 
Many SPR-based sensors have been developed based on the ‘Kretschmann configuration’ 
(Kretschmann and Raether, 1968; Kretschmann, 1971), as shown in figure 6.2. SPR was used 
to probe changes in the refractive index (RI), within the evanescent field (EF) range. Thus, 
any physical event or change in mass that occurs on the surface of the sensor (e.g. antibody 
binding to antigen) changes the value for the refractive index and thus produce a measurable 
signal.
SPR may be achieved by varying the frequency of the incident light or by varying the angle of 
incidence of that light until there is a noticeable sharp drop in the overall intensity of the 
reflected light. The SPR condition is generated by evanescent field tunnelling of incident light 
energy into free electrons on the metal surface, thus creating plasmons. The incident p- 
polarised light is directed into the prism at an angle that is greater than the critical angle. 
Thus, incident light undergoes total internal reflection within the glass substrate (e.g. high 
refractive index media) when it is reflected at the boundary of the low refractive index 
material (i.e. sample medium). Hence, an evanescent field is generated normal to the sensor 
surface and decays exponentially into the sample medium. In effect the evanescent filed is 
sensitive to mass changes within a defined distance from the surface (200-300 nm), since 
refractive index changes are proportional to mass changes at the sensing surface. Using the 
apparatus set up in the Kretschmann geometry, for example, (Figure 6.2) transverse magnetic
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polarised light passing through the prism with a particular angle above the critical angle 
reflects from the thin metal film. Resonance is observed by monitoring the position of the 
reflectance minimum.
Glass Prism
p-Polariscd ligh Reflected Light
Evanescent Wave
J 50 nm Metal surface
Figure 6.2. The basic ‘Kretschmann configuration’ apparatus setup for the monitoring of SPR 
optical phenomena. The SPR condition is generated by evanescent field tunnelling of incident 
light energy into free electrons on the inert thin metal surface («50 nm thickness). When the 
incident p-polarised light is directed into the prism at an angle (0) that is greater than the 
critical angle it undergoes total internal reflection within the glass substrate (e.g. high 
refractive index media) when it is reflected at the boundary of the low refractive index 
material (i.e. sample medium). Thus an evanescent field is generated normal to the sensor 
surface and decays exponentially into the sample medium.
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There are now a host of commercially available devices based on SPR signal transduction. 
Biacore™ AB (Uppsala, Sweden) has numerous automated instruments including, the 
Biacore™ 1000/2000/3000 series. The Biacore systems utilise SPR using the principles 
outlined in figure 6.3. Texas Instruments have also manufactured a waveguide-based SPR 
biosensor, the Spreeta™. They generally consist of several basic elements including, sensor 
chips, an optical detection unit, and integrated micro fluidics with appropriate control 
software. Other commercially available SPR-based biosensors include, the IAsys instrument 
(NeoSensors), the BIOS-1 system (Windsor Scientific Ltd), and the AnaLight Bio 200 
(Farfield sensors Ltd.). SPR-based biosensor systems offer robust and reliable analysis 
techniques and have been extensively used for antibody characterisation and assay 
development. SPR biosensors comprise the majority of published material with regard to 
antibodies and their application in the detection of a variety of hapten compounds.
This chapter describes the use of the Biacore™ 3000 SPR-based real-time biosensor for the 
evaluation of anti-cephalexin polyclonal (Chapter 3), monoclonal (Chapter 4) and 
recombinant single chain Fv (scFv) antibodies (Chapter 5) in the development of a semi- 
quantitative inhibition assay for the detection of cephalexin hydrate, in milk. Conjugated and 
un-conjugated cephalexin was immobilised onto carboxymethylated dextran (CM5) Biacore 
chips, and evaluated in terms non-specific binding and assay performance with each anti­
cephalexin antibody.
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p-Polarised light Optical detection 
Unit
Running buffer flow nalyie binding immobilised ligand
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Figure 6.3. Diagrammatic representation of the Biacore SPR-based biosensor working 
principles. The SPR angle (— 0spri) with immobilised ligand is altered by the binding of 
target analyte to give 0Spr2 (—-). The ‘real-time’ difference between the SPR angles (A0Spr) is 
plotted as arbitrary response units (— RU) against time in seconds (s). The association and 
dissociation rates may be determined for the ligand and analyte binding.
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6 .2 Results
6.2.1 The production o f immobilised cephalexin-thyroglobulin conjugate sensor surface.
The Biacore 3000 SPR-based biosensor was used in conjunction with carboxymethylated 
dextran (CM5) sensor chips, as described in section 2.7. Immobilisation of thyroglobulin- 
cephalexin conjugate was carried out by initial CM surface ‘preconcentration’ (section 2.7.1) 
followed by covalent attachment of cephalexin-thyroglobulin using NHS/EDC-mediated 
chemistry.
6.2.1.1 Preconcentration studies using a carboxymethylated dextran (CM5) chip and 
thyroglobulin-cephalexin conjugate.
The underivatised CM5 sensor chip surface has a net negative charge, therefore, in order to 
maximise the immobilisation of protein ligands, it is essential to maximise the electrostatic 
attraction between surface and ligand in solution. This is achieved by using low ionic strength 
buffers (e.g. 10 mM sodium acetate) that facilitates maintaining the protein ligand at a pH 
value below its isoelectric point (pi), thus giving the protein a net positive charge. Studies 
were carried out using 10 mM sodium acetate buffer at a range of low pH values so as to 
maximise or ‘preconcentrate’ the amount of conjugate (i.e. in terms of response units (RU)) 
electrostatically associated to the negatively charged CM5 chip surface. The optimum pH of 
10 mM sodium acetate buffer was found to be 3.9, as shown in figure 6.4, which gave the 
maximum response of 10,000 RU.
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Figure 6.4. Cephalexin-thyroglobulin (20 pg/ml) was passed over a CM5 chip surface in 
lOmM sodium acetate buffer at a flow rate of 10 pl/min for 2 min, in order to facilitate 
electrostatic association between the negative charged dextran surface and the charged 
conjugate. Sodium acetate buffer (10 mM) with pH values ranging from 3.5 to 4.2 were used. 
After each injection of conjugate a regeneration step was required to remove residual 
conjugate. A regeneration solution of 5 mM NaOH was used to remove electrostatically 
associated conjugate. The sodium acetate buffer, with pH of 3.7, gave the largest response 
units (~10,000 RU). This progressively decreased as the pH increased.
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6.2.1.2 Immobilisation o f Thyro-Ceph conjugate and thyroglobulin to the CM5 sensor chip 
flow cell surface and binding studies using polyclonal antibody.
Following the determination of the optimum immobilisation buffer by ‘preconcentration’, the 
thyroglobulin-cephalexin conjugate and thyroglobulin itself (as a control surface) were 
immobilised onto two separate flow cells on the same sensor chip (section 2.7.2). Initially for 
the cephalexin conjugate, the CM5 chip surface was activated using 0.05 M NHS / 0.2 M 
EDC and followed by an injection of 50 pg/ml solution of the conjugate dissolved in the 
appropriate sodium acetate buffer (10 mM, pH 3.7). Any remaining un-reacted sites 
(‘activated’ carboxylic acid groups) were then ‘capped’ by passing a solution of 1M 
ethanolamine, pH 8.5 across the chip surface. Figure 6.5 shows a typical immobilisation 
sensorgram for thyroglobulin-cephalexin. The total amount of conjugate immobilised in terms 
of response units was approximately 14,000 (RU).
In order to assess the newly synthesised Thyro-Ceph (TCC) immobilised flow cell surface 
(section 2.7.2), cephalexin-specific polyclonal antibody (Chapter 3) diluted in PBS-T was 
injected over it and two control surfaces. Non-conjugated thyroglobulin protein was also 
immobilised, as described (section 2.7.2), yielding a final immobilised thyroglobulin response 
of 13,360 RU (Figure 6.6). This flow cell comprised control surface one. The polyclonal 
antibody was simultaneously injected over an unmodified carboxymethylated dextran flow 
cell surface, comprising control surface two. The sensorgrams obtained for the TCC, control 
one and two surfaces were plotted and are presented in figure 6.7. No significant binding 
response was observed (<5 RU) for the negative control surfaces, as expected compared to a 
binding response of 220 RU using polyclonal (anti-CephPl) antibody and the TCC flow cell 
surface.
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Figure 6.5. Sensorgram of thyroglobulin-cephalexin immobilisation (above top) and each of 
the corresponding main steps (A, B, C) are the schematically represented (above bottom). The 
carboxyl groups on the carboxymethylated dextran matrix surface (CM5) were activated 
using EDC and NHS (A), hence forming intermediate NHS ester groups (B). This was further 
reacted with thyroglobulin-cephalexin conjugate-containing amine groups (C). The surface 
was then treated with 1 M ethanolamine in order to remove electrostatically associated 
conjugate and block or ‘cap’ any unreacted carboxyl groups on the chip. A total of 14,000 RU 
of conjugate was covalently bound to the flow cell sensor surface.
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Figure 6.6. Sensorgram of unconjugated thyroglobulin immobilisation highlighting each of 
the main steps on the sensorgram (A, B, C) The carboxyl groups on the carboxymethylated 
dextran matrix surface (CM5) were activated using EDC and NHS (A), hence forming 
intermediate NHS ester groups (B). This was further reacted with thyroglobulin protein 
solution (50 pg/ml), thus forming covalent bonds with primary amine groups present on 
protein and EDC-activated sensor surface (C). The surface was then treated with 1M 
ethanolamine in order to remove electrostatically associated protein, and block or ‘cap’ any 
un-reacted carboxyl groups on the chip. A total of 13,360 RU of protein was covalently bound 
to the flow cell sensor surface.
237
RU
300
200 ___  Thyroglobulin-Cephalexin / \
1 0 0  ------- Thyroglobulin , 20 RU
_ __________ _____________________________________________________y
CM Dextran
0, -100 
</> c o
8 -200 
oc
-300
-400
-500
-600
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170
Time s
Figure 6.7. Overlay sensorgram plots of the response obtained using a CM dextran (—), 
immobilised thyroglobulin (—), and immobilised thyroglobulin-cephalexin surfaces (—). The 
dotted line represents the experimental baseline. A 1:100 dilution of anti-cephalexin 
polyclonal antibody diluted in PBS-T was injected over each surface at a flow rate of 5 pl/min 
for duration of 2 minutes. The response units (RU) for each sensorgrams have been 
normalised to zero. The immobilised thyroglobulin-cephalexin conjugate gave the greatest 
response (220 RU) as expected. Responses of <5 RU were obtained for each negative control 
surface.
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6.2.1.3 Evaluation o f immobilised thyroglobulin-cephalexin conjugate surface stability by 
successive binding and regeneration using anti-cephalexin antibodies.
In order to assess the immobilised cephalexin-conjugate surface stability, polyclonal antibody 
(Chapter 3, mti-CephPl) was repeatedly bound and surface regenerated. Initially, the 
regeneration solution was optimised from a range of sodium hydroxide and hydrochloric acid 
solutions (30 mM 1 mM), as described in section 2.7.4. The 5 mM sodium hydroxide was 
found to be optimum for the regeneration of the immobilised conjugate surface following 
binding of anti-CephPl polyclonal antibody. A total of 50 antibody binding and surface 
regeneration cycles were carried out using 5 mM NaOH to remove bound polyclonal 
antibody. There was veiy little (4.5%) loss of surface activity over the course of the 
regenerations as can be seen in figure 6.8. After >200 regeneration cycles (observation, data 
not shown) the immobilised thyroglobulin-cephalexin surface activity was still below the 
acceptable loss of activity limit, of 20% (Wong et al., 1997). This confirms its stability and 
applicability.
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Figure 6.8. Regeneration studies of immobilised thyroglobulin-cephalexin surface polyclonal 
anti-cephalexin antibody binding. There was a 4.5% overall loss of surface binding activity 
over 50 regenerations from initial binding response of 278.8 RU to final polyclonal binding 
response of 265.9 RU. The surface showed minimal surface activity loss.
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6.2.2 The production of a directly immobilised cephalexin-CM5 sensor chip surface.
In addition, to the immobilised conjugate (thyroglobulin-cephalexin) surface (TCC), 
cephalexin was also directly immobilised to a CM5 sensor chip surface. The directly 
immobilised cephalexin (DIC) flow cell was prepared as described in section 2.7.3. Initially, 
preconcentration studies were carried out using sodium acetate buffer across a range of acidic 
pH values (pH 3-> 6.6) in order to obtain sufficient attraction between the negatively charged 
CM dextran surface and the cephalexin in solution. The isoelectric point (pi) of cephalexin 
ranges from 4.5 -  5 approximately in water (www.rxlist.com). At prolonged exposure to 
alkaline pH (>7) the |3-lactam ring will readily hydrolyse to form the biologically inactive 
forms. Therefore, only acidic pH buffers were used in pre-concentration studies. No 
observable ‘pre-concentration’ was observed (data not shown) across the above pH range. 
There was an apparent repulsion between soluble cephalexin and the un-modified CM5 chip 
surface. In order to circumvent this it was decided to alter the CM5 chip surface chemistry in 
order to maximise the electrostatic attraction to soluble cephalexin and hence the 
immobilisation efficiency. The CM5 chip surface was chemically altered in terms of net 
charge and binding functionality (i.e. -COOH -NH2) by reacting with ethylene diamine 
(1M, pH 8.5), as described in section 2.7.3, and cephalexin was covalently attached through 
its carboxylic acid functionality (Figure 1.4) by subsequent NHS/EDC-mediated chemistry. 
The resulting immobilisation sensorgram and an outline of the chemistries involved are 
shown in figure 6.9.
A similar reference flow cell was prepared as described for the DIC cephalexin flow cell. 
However, the cephalexin was omitted. This flow cell surface was prepared for use as a 
negative control and for ‘real-time’ reference subtraction which is facilitated using the 
Biacore 3000 control software. In order to obtain an accurate estimate of the amount of 
surface activity (Figure 6.9) the response obtained for the control or reference subtraction 
flow cell, as shown in figure 6.10, (447.6 RU) was subtracted from the 982.8 RU value 
observed for the DIC cephalexin flow cell. This yielded a response value of 535.2 RU. This 
value was much lower in comparison to cephalexin-protein immobilisation. It was expected, 
however, due to the relative molecular mass difference between the conjugated and free 
cephalexin.
The DIC test and control surfaces were used in binding studies using anti-cephalexin 
antibodies at various concentrations in order to confirm antibody binding and identify any 
potential non-specific interactions.
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Figure 6.9. Chemistry schematic (top) and sensorgram (bottom) for the direct immobilisation 
of cephalexin on a CM5 Biacore sensor chip (DIC). (A) shows the initial activation of the 
CM5 chip surface using 100 mM NHS / 400 mM EDC for 16 min at a flow rate of 5 pl/min. 
Following activation, the surface was subjected to a 20 min pulse with a 1 M pH 8.5 ethylene 
diamine solution at 5 pl/min (B), so as to convert the surface to amine functionality (C). 
Cephalexin hydrate (200 pg/ml), dissolved in 100 mM NHS / 400 mM EDC, was then 
injected over the surface for 40 min at 5 pl/min (D). The surface was then ‘double-capped’ 
using two 5 min injections of 1 M ethanolamine hydrochloride, pH 8.5, at a flow rate of 10 
pl/min, resulting in a final response of 982.8 RU.
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Figure 6.10. Sensorgram for the direct immobilisation control flow cell surface CM5 Biacore 
sensor chip (DIC). (A) Shows the initial activation of the CM5 chip surface using 100 mM 
NHS / 400 mM EDC for 16 min at a flow rate of 5 ¿il/min. Following activation, the surface 
was subjected to a 20 min pulse with a 1 M ethylene diamine, pH 8.5, solution at 5 fj.l/min
(B), so as to convert the surface to amine functionality (C). A 100 mM NHS / 400 mM EDC 
solution was then injected over the surface for 40 min at 5 ¿il/min (D). The surface was then 
‘double-capped’ using two 5 min injections of 1 M ethanolamine hydrochloride, pH 8.5, at a 
flow rate of 10 nl/min, resulting in a final response of 447.6 RU.
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The directly immobilised cephalexin (DIC) flow cell surface, prepared as described in section 
6.2.1.3, was evaluated for cephalexin-specific antibody binding. Protein G-purified 
monoclonal and polyclonal anti-cephalexin antibody dilutions were prepared in sterile-filtered 
HBS and injected over DIC and reference control flow cells for 1 min at a flow rate of 10 
|il/min. A flow rate of 10 (il/min was used for throughout unless otherwise stated. The surface 
was regenerated using a 5-20 mM sodium hydroxide solution, depending on the antibody 
used and sample buffer (i.e. HBS, milk). The results showed that monoclonal (Figure 6.11) 
and wild type recombinant scFv antibodies (Figure 6.12) bound to the DIC with veiy little 
binding to the reference flow cell surface. Recombinant antibody was in the form of 
unpurified supernatant from wild type scFv-expression culture media. Hence, these results 
confirm that the directly immobilised cephalexin was still recognised by each of the 
antibodies.
In contrast the protein G-purified polyclonal antibody preparation (Figure 6.13) showed large 
non-specific binding to the control flow cell surface, comprising, on average, 70% of the 
overall response. This was an unexpected result, as it was reasoned that the DIC chip surface 
would reduce all non-specific binding with all antibody preparations in HBS and milk running 
buffers in comparison with the conjugate immobilised chip surface. There was minimal non­
specific interaction between polyclonal anti-cephalexin antibody and the un-modified CM5 
dextran and immobilised thyroglobulin surfaces (Figure 6.7). The reduction in non-specific 
interactions was observed, however, using monoclonal and recombinant anti-cephalexin 
antibodies.
6.2.2.1 Binding studies using monoclonal, polyclonal and recombinant single chain Fv
(scFv) anti-cephalexin antibodies on a directly immobilised cephalexin (DIC) sensor chip.
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Figure 6.11. Overlay plot of protein-G purified monoclonal anti-cephalexin antibody binding 
sensorgrams for directly immobilised cephalexin flow cell (blue), control flow cell (grey) and 
the ‘real-time’ reference subtraction (red). Antibody was injected over the surface in order to 
ensure it bound to the directly immobilised cephalexin. The protein-G purified monoclonal 
antibody was diluted 1:20 in HBS and injected (A = injection start) over each surface for a 1 
min pulse. (B = injection finish). Immediately following antibody association a standard 
report point response difference of 333 RU was measured. The surface was regenerated using 
three 30 s injections (starting at points C, E, & G) of 20 mM NaOH. The points D, F & H 
represent the end of each 30 s regeneration pulse.
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Figure 6.12. Overlay plot of wild type scFv anti-cephalexin antibody expression culture 
media (supernatant) binding sensorgrams for directly immobilised cephalexin flow cell (blue), 
control flow cell (grey) and the ‘real-time’ reference subtraction (red). Antibody was injected 
over the surface in order to ensure it bound to the directly immobilised cephalexin. The wild 
type supernatant was diluted 1:5 in HBS and injected (A = injection start) over each surface 
for a 1 min pulse. (B = injection finish). Immediately following antibody association a 
standard report point response difference of 258 RU was measured. The surface was 
regenerated using a 30 s injection (starting at point C) of 40 mM NaOH. D represents the end 
of the 30 s regeneration pulse.
245
RU
o><flc
oa
(A<u
DC
■aa>
<a
E
Time
Figure 6.13. Overlay plot of protein-G purified polyclonal anti-cephalexin antibody binding 
sensorgrams for directly immobilised cephalexin flow cell (purple), control flow cell (grey) 
and the ‘real-time’ reference subtraction (red). Antibody was injected over the surface in 
order to ensure it bound to the directly immobilised cephalexin. The protein-G purified 
polyclonal antibody was diluted 1:100 in HBS and injected (A = injection start) over each 
surface for a 1 min pulse. (B = injection finish). Immediately following antibody association a 
standard reference-subtract response of 117 RU was measured. The DIC flow cell signal was 
381 RU (purple line). However, the response observed with the reference flow cell was 263 
RU (grey line). This comprised approximately 70% of the overall signal. The surface was 
regenerated using a 30 s injection (starting at point C) of 10 mM NaOH. D represents the end 
of the 30 s regeneration pulse.
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Following demonstration of binding of each antibody preparation (i.e. polyclonal, monoclonal 
and recombinant), diluted in PBS-T, to DIC and TCC chip surfaces, an evaluation of the 
interactions between prepared milk samples and immobilised sensor surfaces (i.e. TCC and 
DIC) was carried out. Mammalian milk is highly complex and generally composed of water, 
protein, carbohydrate, fat and a variety of vitamins and minerals. Therefore, the potential for 
non-specific interactions with a mass-sensitive biosensor device (e.g. Biacore 3000) must be 
critically evaluated in order to develop a viable assay. The milk used in this work was a well 
known brand of full-fat processed (i.e. pasteurised and homogenised) milk purchased from 
the DCU campus shop. In order to assess the potential non-specific interactions with 
immobilised control and cephalexin CM5 flow cells (i.e. TCC and DIC chips), various milk 
sample preparation steps were carried out. Blank milk samples (i.e. no cephalexin added) and 
‘spiked’ milk samples were prepared, as described in section 2.7.5, prior to injection over 
each sensor chip surface.
One set of the milk samples was prepared by removing the fat content (termed de-fatted). A 
second set of milk samples was placed in a water bath at 95° C for 3 min (Gustavsson, 2003) 
followed by centrifugation at 14,000 rpm at R.T. for 15 min to remove fat and whey protein 
(termed de-fatted and de-wheyed). Milk binding studies were carried out using prepared 
processed milk samples (i.e. de-fatted milk and de-wheyed / de-fatted milk) by injecting each 
sample set over the relevant sensor chip surface (i.e. DIC / TCC and relevant control 
reference flow cells) in parallel for one min and the response recorded (Figure 6.14). Any 
residual bound material was easily removed with a 30 s injection of 20 mM NaOH. Four 
replicate measurements were carried out and an average response was plotted for each sample 
preparation method, as shown for the DIC chip in figure 6.15. The non-specific binding 
observed for milk sample preparations with both flow cell surfaces (DIC and reference flow 
cells) were minimal and are better illustrated in figure 6.15. The maximum non-specific 
binding response was obtained for the de-fatted milk samples (40-45 RU). There was little 
difference in binding between DIC and reference flow cell surfaces for the de-fatted de- 
wheyed sample. Diluting the de-fatted de-wheyed sample had minimal effect on the response 
obtained. Undiluted (neat) and diluted 1:2 (prepared samples with PBS-T) average responses 
for de-fatted de-wheyed sample ranged from 5->10 RU (Figure 6.15).
6.2.2.2 Binding studies using prepared milk samples with cephalexin conjugate (TCC) and
directly immobilised cephalexin (DIC) sensor chip surfaces.
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Figure 6.14. (A) Overlay plot of sensorgrams obtained for each of the prepared processed 
milk samples containing no antibody (de-fatted milk, de-wheyed and de-fatted milk) injected 
over directly immobilised cephalexin and negative control (i.e. reference) flow cell surfaces. 
Initially the surface was pulsed with the 5 mM NaOH regeneration solution. The net 
refractive index change (i.e. response) using the de-fatted and de-wheyed milk is significantly 
lower than the de-fatted milk samples as expected. (B) Above highlights the non-specific 
interactions with both surfaces (DIC and reference flow cells) were minimal.
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Figure 6.15. Plot of the mean (n = 4) responses obtained for each of the prepared processed 
milk samples containing no antibody (de-fatted milk; de-fatted milk and de-wheyed; de-fatted 
and de-wheyed diluted 1:2 with PBS-T) injected over directly immobilised cephalexin and 
negative control (i.e. reference) flow cell surfaces. Each surface was pulsed with 20 mM 
NaOH to remove any residual material. The highest non-specific binding response was 
observed for the de-fatted milk samples (40-45 RU). There was little difference in binding 
between both flow cell surfaces, and the de-fatted de-wheyed neat and diluted 1:2 prepared 
samples with PBS-T (ranged from 5->10 RU).
In comparison with the immobilised thyroglobulin-cephalexin conjugate surface prepared in 
section 6.2.1.2, the directly immobilised cephalexin flow cell surface showed a significant 
decrease, (~ 90% and 95% signal reduction) for defatted and de-fatted / de-wheyed milk 
samples, respectively. The DIC flow cell surface had approximately 11-fold less non-specific 
binding than the conjugate (TCC) flow cell (i.e. 40 RU obtained for DIC and 440 RU 
obtained for TCC using de-fatted milk) (Figure 6.16).
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Figure 6.16. Plot of the mean (n=4) responses obtained for each of the prepared processed 
milk samples containing no antibody (de-fatted milk; de-wheyed and de-fatted milk; de-fatted 
and de-wheyed diluted 1:2 with PBS-T) injected over the immobilised thyroglobulin- 
cephalexin conjugate (TCC) directly immobilised cephalexin (DIC) flow cell surfaces. Each 
surface was pulsed with 20 mM NaOH to remove any residual material. The figure shows the 
decreased non-specific binding of milk components to the DIC and reference flow cells in 
comparison with the immobilised cephalexin conjugate surface. The Y-error bars shown 
indicate the standard deviation for each point.
250
6.2.3 The development and validation o f a Biacore 3000-based inhibition assay fo r  the 
detection o f  Cephalexin hydrate-‘spiked’ PBS and processed milk.
The Biacore biosensor 3000 has a number of advantages over conventional detection 
technologies, in that all analyses are carried out in ‘real time’ with no need for labelling, the 
system is automated, relatively rapid and facilitates multiple analyses using a single chip. 
SPR-based sensors in general essentially detect mass changes. Therefore, the specificity of 
the antibody used must be determined and all potential sources of non-specific interactions 
must be ruled out. Biacore-based assays for the detection of small molecules or haptens are 
invariably developed using an inhibition assay format. An inhibition assay format, as outlined 
in figure 6.17, was employed for each antibody and immobilised chip surface (i.e. 
thyroglobulin-cephalexin and directly immobilised cephalexin CM5 chips) described in this 
chapter. A range of cephalexin standards were prepared and injected over the relevant sensor 
surface. The response obtained for each measured sample was plotted as a ratio of the 
standard cephalexin concentration (RU) and the zero cephalexin (RU0) sample.
251
Antibody and free cephalexin injected 
over Cephalexin-immobilised C M 5 chip 
surface
Antibody and free cephalexin injected 
over ethylene diamine-modified CM 5 
chip surface
TCC- Analytical test surface
Antibody and free cephalexin injected 
over Thyroglobulin-cephalexin - 
im mobilised C M 5 chip surface
TCC- Control surface
Antibody and free cephalexin injected 
over Thyroglobulin-immobilised CM 5 
chip surface
=  Thyro-Ceph conjugate
r
« p  -  Thyroglobulin
= Ethylene diamine linker
Figure 6.17. Schematic outline of the inhibition format used in the development of a Biacore 
3000 SPR-based biosensor assays for the detection of cephalexin hydrate ‘spiked’ samples. 
Anti-cephalexin antibodies were pre-incubated with a range of free cephalexin standards, 0.1 
mg -> 0 mg (RU0), and injected over DIC (above top) and TCC (above bottom) analytical and 
control surfaces and the response recorded.
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As outlined in figure 6.17, anti-cephalexin antibodies were pre-incubated with a range of free 
cephalexin concentrations (section 2.7.6) and injected across the DIC or TCC flow cells and 
corresponding control surfaces. This assay format was employed with immobilised conjugate 
(TCC) and directly immobilised (DIC) cephalexin CM5 chip surfaces, as discussed 
previously (section 6.2.2.1). The degree of inhibition was inversely proportional to the 
observed response and each particular known free cephalexin concentration point was plotted 
as a ratio of its response (RU) divided by the response with no or 0 mg/ml free cephalexin, 
(denoted as RUo).
The Biacore inhibition assay was developed initially using ‘spiked’ PBS-T as a sample matrix 
prior to carrying out the analysis for cephalexin in processed whole milk. The antibody 
dilutions were optimised to give the largest possible signal (RU), yet still at a sufficiently low 
concentration to be the limiting factor of the assay (i.e. yielding a typical response between 
200-300 RU). The anti-CephPl polyclonal antibody (1:100 dilution) was pre-incubated with a 
range of free cephalexin standards for a 20 min period. The antibody and free cephalexin 
mixtures were then injected across the immobilised thyroglobulin-cephalexin surface in 
triplicate and the response recorded. Figure 6.18 shows a typical overlay plot taken from a set 
of replicate (triplicate) measurements using the TCC chip experimental and reference flow 
cell surfaces and polyclonal (anti-CephPl) antibody reported in chapter 3.
Similar studies were carried out using the DIC chip experimental and reference flow cells. 
Monoclonal antibody (anti-CephMl) was pre-incubated with a range of cephalexin standards 
prepared in PBS-T and were then injected over both flow cells. The results of this are shown 
in figure 6.19. On-line reference subtraction, where reference (i.e. treated with same 
chemistry as DIC surface with no cephalexin added) flow cell 3 was subtracted from DIC 
surface on flow cell 4. This was applied using the Biacore control software. Each surface was 
subjected to a 30 s injection of 20 mM NaOH after each measurement in order to regenerate 
the surface. The overlaid sensorgrams (Figures 6.18 & 6.19) were differentially coloured with 
the corresponding cephalexin standard concentration shown. There was a proportional 
decrease in response for each consecutive increase in concentration of soluble cephalexin.
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Figure 6.18. Overlay plot showing the decreasing response units (RU) per increase in the 
concentration of free cephalexin using the polyclonal antibody (anti-CephPl) on the 
immobilised thyroglobulin-cephalexin (TCC) flow cell surface. The baseline for each point 
was normalised to 0 RU. (A) Shows an initial drop, due to a refractive index change. (B) The 
subsequent increase due to the anti-CephPl antibody binding to the immobilised 
thyroglobulin-cephalexin surface. The plateau (C) shows the decreasing amount of antibody 
bound to the chip surface (RU) with increasing concentrations of cephalexin.
254
250
200
150
§| 100
o2
50
-100
100 150
Concentration o f  
cephalexin (ng/m l)
—  0 
— 1 
—  10 
—  100 
—  1,000 
10,000 
—  100,000 
—  1000,000 
—  N o  Antibody or drug
200 250
Time (s)
Figure 6.19. Overlay plot showing the decreasing response units (RU) per increase in the 
concentration of free cephalexin using the monoclonal antibody on the directly immobilised 
cephalexin (DIC) flow cell surface. The baseline for each point was normalised to 0 RU. 
Cephalexin standards were pre-mixed with anti-CephMl monoclonal antibody subsequent to 
injection over the DIC and reference surface. The sensorgrams represent the response 
difference between the DIC and reference flow cells. Following each injection of antibody 
and free drug the surfaces were regenerated using 20 mM NaOH.
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6.2.3.1 Comparative study o f monoclonal antibody-based inhibition assay using 
thyroglobulin-cephalexin (TCC) and directly immobilised cephalexin (DIC) sensor chip 
surfaces.
The TCC and DIC prepared sensor chip surfaces were evaluated in terms of inhibition assay 
performance. This was carried out using monoclonal mti-CephMl antibody (Chapter 4), and 
a range of cephalexin standards prepared in PBS-T. A range (i.e. 1:10 serial dilutions) of 
standards was prepared in order to cover a broad concentration range for each of the 
cephalexin-specific antibodies. Assays were carried out as described in section 2.7.6, using 
pre-treated ‘spiked’ milk samples (section 2.7.5). Results from milk control experiments 
using the TCC and DIC surfaces (Figure 6.16) had already indicated that there was a 
significant reduction in the background response using the DIC as opposed to the TCC chip. 
In order to further evaluate both DIC and TCC chips it was necessary to assess the inhibition 
assay performance using the two immobilised sensor chip surfaces. Inhibition assays carried 
out using the anti-CephPl on the TCC chip (Figure 6.18) and mti-CephMl on the DIC chip 
(Figure 6.19) had indicated that both surfaces facilitated the development of inhibition assays. 
As observed, there was a proportional drop in response for a range of free cephalexin 
concentrations using each chip surface. However, inhibition assays carried out using 
monoclonal mti-CephMl antibody showed increased assay sensitivity at the lower 
concentrations of free cephalexin (Figure 6.20) using the DIC, as opposed to the TCC sensor 
chip.
Assays developed in processed milk samples with the DIC chip (data not shown) showed 
significantly reduced standard deviation values for each replicate measurement in contrast to 
the TCC chip. The larger standard deviations obtained using the TCC may be as result of the 
fact that a larger fraction (i.e. at worst 50%) of the response obtained was due to non-specific 
binding with the reference flow cell on the TCC sensor chip. Therefore it had an intrinsically 
lower signal to noise ratio. It was reasoned that the DIC chip would be the more reliable 
surface to develop a reproducible Biacore biosensor-based assay for the detection of 
cephalexin in milk.
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Figure 6.20. Overlay plot of Biacore inhibition assays using monoclonal mti-CephMl 
antibody. All cephalexin standards were prepared in PBS-T buffer. The standards were pre­
incubated with antibody at R.T. for 15 min and injected across the surface (i.e. thyroglobulin- 
cephalexin (TCC) immobilised and directly immobilised cephalexin (DIC) flow cells). Each 
point represents the mean of three measurements, where the background response was 
subtracted from the experimental response. The TCC sensor surface (blue) begins to level off 
at 50 ng/ml, in contrast, the DIC sensor surface (red) does not begin to plateau until 10 ng/ml. 
The standard deviation (SD) for each point (n = 3) is highlighted.
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6.2.3.2 The development o f Biacore-based inhibition assay for the detection o f cephalexin in 
milk using polyclonal monoclonal and recombinant antibodies and a directly immobilised 
cephalexin (DIC) sensor chip surface.
Inter-day assay reproducibility studies were carried out by performing each assay over a 3- 
day period (n = 3 for each individual point per assay) according to Wong et al. (1997). Four- 
parameter equations were fitted to each data set in order to construct calibration curves and 
obtain assay recoveries (i.e. back calculated values) using Biaevaluation software. Assay 
limits of detection were taken to be the background (i.e. RU0, antibody with no soluble 
cephalexin) minus three standard deviations. The coefficient of variation and percentage 
accuracies were calculated using equation 6.1 and equation 6.2, respectively.
Equation 6.1.
Accuracy (%) = Experimental concentration of Cephalexin -  Back calculated value
Back calculated value *100+ 100.
Equation 6.2.
Coefficient of Variation (%) = Standard deviation
Mean (RU/RU„)
Initially, polyclonal (anti-CephPT) antibody was evaluated in the development of Biacore- 
based assay for the detection of cephalexin in milk. Protein G-purified polyclonal anti­
cephalexin antibody (Chapter 3) diluted in HBS buffer was found to bind non-specifically to 
the directly immobilised (DIC) reference flow cell (section 6.2.2.1, figure 6.13). The 
inhibition assay results (Figure 6.21) showed that a proportion of the protein G-purified 
polyclonal antibody was inhibited from binding to the immobilised cephalexin over a defined 
range of soluble cephalexin concentrations. However, a significant proportion of the response 
was due to non-specific binding (Figure 6.22) of the polyclonal and the milk sample matrix. 
Thus high individual standard deviation values were obtained, and hence, the assay exhibited 
intrinsically poor reproducibility and sensitivity. The limit of detection for the assay (i.e. 
based on three times the standard deviation subtracted from the mean RU0) was 156 ng/ml. 
The standard deviation value obtained for the RUo was ± 8.3 RU.
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Figure 6.21. Graph representing the Biacore ‘spiked’ milk inhibition assay using polyclonal 
(anti-CephPl) antibody. De-fatted and de-wheyed ‘spiked’ milk was pre-incubated with 
antibody (1:100 working dilution) at R.T. and subsequently injected over the directly 
immobilised sensor chip (i.e. reference and cephalexin flow cells) utilising the online 
reference subtraction function to obtain data points. Each point represents the mean (n = 4) 
response (RU) divided by the response with no free cephalexin present (RU0). Measurements 
were carried out in triplicate. The standard deviation values obtained for each replicate data 
point were unacceptably large. The residual values shown above represent the ‘closeness of 
fit’ of the data set to the four-parameter calibration curve. The limit of detection for the assay 
was calculated by taking 3 times the standard deviation from the mean RU0 and was found to 
be 156 ng/ml.
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Figure 6.22. Bar plot of the mean response values obtained for the Biacore ‘spiked’ milk 
inhibition assay using polyclonal (anti-CephPT) antibody. The mean response for each flow 
cell is illustrated above. The directly immobilised cephalexin flow cell (red) shows the 
proportional decrease as the concentration of cephalexin increases. The mean response to the 
reference flow cell (blue) demonstrates little fluctuation across the range of cephalexin 
concentrations tested. The results illustrated the large degree of non-specific interactions 
observed using the anti-cephalexin polyclonal antibody. This contributes to the large standard 
deviations observed for each individual measurement in milk.
Similar inhibition assay development studies were carried out using the monoclonal (Chapter 
4, mti-CephMl), wild type (WT) scFv, mutant C5 and H3 scFv antibodies described in 
chapter 5 of this thesis. Inter-day assay reproducibility studies were performed on the 
optimised inhibition assays. Assays were carried out on three consecutive days (Wong et al., 
1997). Protein G-purified monoclonal anti-cephalexin antibody was diluted in de-fatted and 
de-wheyed milk as described previously. The milk was ‘spiked’ with a range of cephalexin
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concentrations from 0~> 100,000 ng/ml. Each sample preparation was assayed in triplicate on 
each separate day and the mean RU/RU0 for each day determined. For the monoclonal 
antibody, a four-parameter equation was fitted to the data set, as shown in figure 6.23. The 
limit of detection for the assay was 72 ng/ml. The mean response (RU/RUo), back calculated 
values, percentage coefficients of variation (CV) and accuracies are shown in table 6.2.
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Figure 6.23. Biacore inhibition inter-day assay studies using monoclonal avti-CephMl 
antibody. The limit of detection (LOD) taken as the background minus 3 times standard 
deviations and was 72 ng/ml. Thus the monoclonal antibody-based inhibition assay provides a 
suitable analytical method for the detection of cephalexin below its respective MRL (100 
ng/ml) in milk samples.
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Table 6.2. Values obtained for the Inter-day Biacore inhibition assay in ‘spiked’ milk samples 
with monoclonal (anti-CephMl) antibody. Back calculated values were obtained by fitting a 
four-parameter equation to the data set using Biaevaluation software. The percentage 
accuracy and CV’s were calculated using equations 3.1 and 3.2.
Response
Rll/RUo*100±
S.D.
Concentration of 
Cephalexin 
(ng/ni!)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
7.37 ± 0.48 100,000 91,996.3 6.55 91
12.93 ± 0.49 20,000 20,319 3.80 101
31.74 ± 1.62 4,000 4,035.4 5.11 101
65.05 ± 1.46 800 804.8 2.24 101
78.91 ± 0.28 400 370.4 0.36 92
87.25 ± 1.80 160 189.9 2.06 115
93.80 ± 1.30 80 78.8 1.38 97
97.63 ± 1.49 32 25.2 1.52 72
99.28 ± 1.29 6.4 5.4 1.30 82
2 6 2
For each scFv antibody (e.g. WT, C5 & H3), the assays were carried out in an analogous 
manner. However, intra-day studies were used. Assays were carried out in triplicate within a 
single day and four-parameter equations fitted to the data sets. The results for the WT assay 
are shown in figure 6.24. The limit of detection for the assay was 111 ng/ml. The mean 
response (RU/RU0), back calculated values, percentage coefficients of variation (CV’s) and 
accuracies are shown in table 6.3. The mutant C5 and H3 scFv antibody-based assays results 
are plotted in figures 6.25 and 6.26, respectively. The back calculated values, percentage 
CV’s and accuracies are shown in tables 6.4 (C5 scFv) and 6.5 (H3 scFv). The C5 clone scFv 
gave the best assay performance in terms of detection limit in milk samples, with a LOD of 
84 ng/ml, and therefore, is a suitable assay for detection of cephalexin in milk below the 
defined MRL.
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Figure 6.24. Biacore 3000 inter-day assay studies plot using the WT scFv antibody. The 
assay was carried out in whole milk on a directly immobilised chip. The calculated mean 
RU/RUo*100 values are plotted against each of the cephalexin concentration points. Each 
point is a mean representation of 9 measurements. The assay limit of detection (i.e. 
background minus 3 times the standard deviation) was 111 ng/ml.
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Table 6.3. WT scFv Biacore 3000 inhibition assay carried out in whole milk on a directly 
immobilised chip. The calculated mean RU/RUo values, standard deviations and coefficients 
of variation for each concentration point are shown.
Response 
RU/RUo* 100 ± 
S.D.
Concentration of 
Cephalexin 
(ng/ml)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
11.63 ±0.82 100,000 122,895.2 7.06 81
15.59 ±0.33 20,000 19,198.6 2.14 104
29.48 ± 0.42 4,000 3,975.2 1.44 101
60.28 ± 0.07 800 809.9 0.12 98
87.29 ± 0.03 160 151.9 0.04 105
95.35 ± 0.27 32 40.2 0.29 80
98.56 ±1.40 6.4 2.6 1.42 146
98.67 ±3.45 1.3 1.4 3.46 92
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Figure 6.25. Results of a Biacore 3000 inhibition displacement assay carried out in ‘spiked’ 
whole milk samples. The assay was carried out using the C5 mutant scFv antibody. The assay 
was carried out in whole milk on a directly immobilised cephalexin chip. The calculated mean 
RU/RU0*100 values are plotted against each of the cephalexin concentration points. Each 
point is a mean representation of 9 measurements with the respective residuals shown in the 
lower portion of the figure. The assay limit of detection (i.e. background minus 3 times the 
standard deviation) was 84 ng/ml.
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Table 6.4. C5 mutant scFv Biacore 3000 inhibition assay carried out in whole milk on a 
directly immobilised chip. The calculated mean RU/RU0 values, standard deviations and 
coefficients of variation for each concentration point are shown. Some values could not be 
calculated, due to poor fit to the calibration curve (—).
Response
RU/RU0*100±
S.D.
Concentration of 
Cephalexin 
(ng/ml)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
13.68 + 0.45 100,000 76,214.2 3.28 131
15.86 + 0.94 20,000 22,256.1 5.94 90
27.14 + 0.67 4,000 3,956.4 2.47 101
54.47 + 0.05 800 801.5 0.10 100
83.69 ± 1.85 160 159.2 2.21 101
95.89 + 3.21 32 33.4 3.35 96
99.43 ±0.81 6.4 — 0.81 —
98.67 + 3.45 1.3 5.9 2.03 22
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Figure 6.26. Biacore 3000 displacement inhibition assay plot of the H3 scFv antibody assays. 
The assay was carried out in whole milk on a directly immobilised chip. The calculated mean 
RU/RU0*100 values are plotted against each of the cephalexin concentration points. Each 
point is a mean representation of 9 measurements. The assay limit of detection (i.e. 
background minus 3 times the standard deviation) was 146 ng/ml.
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Table 6.5. H3 scFv Biacore 3000 inhibition assay carried out in whole milk on directly 
immobilised chip. The calculated mean RU/RU0 values, standard deviations and coefficients 
of variation for each concentration point are shown. ‘Low’ represents a point at which the 
experimental RU/RU0 value does not intersect the four-parameter fit and thus no back 
calculated value could be obtained. Some values could not be calculated, due to poor fit to the 
calibration curve (—).
Response
RU/RU0*100±
S.D.
Concentration of 
Cephalexin 
(ng/ml)
Back Calculated 
value (ng/ml)
%
CV's
%
Accuracies
12.42+1.30 100,000 79,956.2 10.48 125
15.82 ±2.77 20,000 22,744.3 17.54 88
30.54 ±2.86 4,000 3,934.9 9.36 102
58.79 ±2.94 800 775.1 5.00 103
80.97 ± 1.79 160 193.1 2.22 83
96.65 ±3.50 32 6.6 3.62 484
97.86 ±2.81 6.4 — 2.87 —
94.82 ±9.26 1.3 21.3 9.77 6.1
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An overlay plot (Figure 6.27) of the three resulting calibration curves obtained for the WT, 
C5 and H3 mutant scFvs was constructed to highlight the improved linear range of the C5 
mutant in comparison to the WT and H3 mutant scFvs. The C5 mutant proved to be the most 
sensitive scFv antibody to cephalexin spiked samples, having a limit of detection of 84 ng/ml. 
The mutant H3 clone assay suffered from poor reproducibility, with relatively high standard 
deviation values recorded for each point. In addition to intra-day assay studies, inter-day 
assay studies were also carried out using C5 mutant scFv, extra assay points were also added 
to the range of cephalexin ‘spiked’ standards. The resulting calibration plot of this experiment 
is shown in figure 6.28 and calculated values in table 6.6.
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Figure 6.27. Overlay plot of the Biacore 3000 displacement inhibition assays for the IMAC- 
purified WT, C5 and H3 clone scFvs. The assays were carried out using ‘spiked’ whole milk 
samples on a directly immobilised cephalexin chip. The calculated mean RU/RU0*100 values 
were plotted against each of the cephalexin concentration points.
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Figure 6.28. Biacore inhibition inter-day assay studies using the IMAC-purified C5 clone 
scFv anti-cephalexin antibody. The assay was carried out, as described previously, but 
including additional measurement points. The limit of detection (LOD) taken as the 
background minus 3 times the standard deviation and was 84 ng/ml. Thus, the C5 mutant 
clone scFv assay is suitable for the detection of cephalexin below its respective MRL (100 
ng/ml) in milk.
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Table 6.6.
with C5 scFv antibody. Back calculated '» to p  were 
equation to the M  set using Biaevaluation software. The 
were calculated usingequations 6.1 and 6.2.
% a four-parameter
e accuracy and CV’s
Response
RL7Rl0*lUO±
S.D.
CDfiCcntration of 
Cepli alexin 
(ng/ml)
L!ai:k Calculated 
value (ng/ml)
%
CV's
%
Accuracies
10.00 ±0.92 100,000 58,577.1 10.01 170
11.83 ± 1.01 20,000 30,309.9 7.82 66
28.92 ± 2.25 4,000 3,650.4 8.59 110
55.33 ±3.01 800 833.5 5.30 96
70.04 ± 2.69 400 386.2 3.70 104
82.33 ± 1.22 160 173.7 1.42 92
91.22 ±0.69 80 72.2 0.77 111
96.43 ± 1.66 32 28.4 1.73 113
99.34 ± 1.71 6.4 9.2 1.74 70
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6.3. Discussion
This chapter describes the development of specific assays for the detection of cephalexin in 
milk using a Biacore 3000™ system. One of the first demonstrations of the use of Biacore 
systems to detect foreign substances in food (Steresjo et al., 1995) utilised polyclonal 
antibodies raised against sulfamethazine. The assay was successfully applied to the detection 
of sulfamethazine in HBS, raw and skimmed milk spiked samples. In this research, CM5 
sensor chips were used in the production of immobilised cephalexin-thyroglobulin (TCC) and 
directly immobilised cephalexin (DIC) surfaces. Thyroglobulin-cephalexin was covalently 
immobilised to the carboxymethylated-dextran surface (CM 5) Biacore chip flow cell surface 
at a level of 14,000 RU. The reference flow cell for the TCC sensor chip consisted of 
immobilised thyroglobulin (13,360 RU). The stability of the immobilised TCC surface was 
evaluated by carrying our successive antibody binding and regeneration cycles. The DIC 
sensor chip surface yielded 983 RU during the immobilisation of cephalexin. The reference 
flow cell for the DIC chip consisted of a flow cell exposed to the exact same chemistries with 
the exception of cephalexin. The DIC reference flow cell yielded a response of 448 RU, 
therefore, the net directly immobilised cephalexin was taken as equivalent to 535 RU. The 
TCC, DIC and relevant control surfaces were evaluated in terms of antibody-binding and non­
specific interactions with milk as a sample matrix prior to assay development.
Milk sample pre-treatment was also investigated as a means of reducing the background 
response observed when using a complex sample matrix. The milk was fractionated into lipid 
and aqueous phases by initial centrifugation at 13,000 rpm and the aqueous phase decanted 
and used for analysis (termed ‘de-fatted’). This pre-treatment step resulted in a slightly lower 
non-specific binding response against both TCC and DIC flow cells (Figure 6.16). An 
additional sample pre-treatment step involving heating samples in a water bath at 95°C for 3 
min and then centrifugation at 13,000 rpm for 15 min (termed ‘de-fatted’ and ‘de-wheyed’). 
This sample treatment further reduced the non-specific binding with TCC and DIC flow cell 
surfaces. The milk sample pre-treatment method employed was a modified version of that 
reported by Gaudin et al. (2001) and Gustavsson (2003). The DIC sensor surface and milk 
sample pre-treatment resulted in an average 95% decrease in non-specific response in 
comparison with the TCC surface. The directly immobilised cephalexin flow cell surface was 
found to have the lowest background response to milk samples in comparison with the 
thyroglobulin-cephalexin immobilised (TCC) flow cell surface.
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The polyclonal anti-CephPl (Chapter 3), monoclonal anti-CephMl (Chapter 4) and 
recombinant scFv antibodies (WT, C5 & H3, Chapter 5) were used to develop an inhibition 
assay for the detection of cephalexin. The inhibition assay format (Figure 6.17) was chosen 
due to the relative small molecular weight of the target analyte in this case (i.e. cephalexin). 
Inhibition assays are generally reported in the literature when using SPR-based biosensor 
devices for the detection of low molecular weight analytes. Initial polyclonal and monoclonal 
antibody assays showed, as expected, proportional decreases in response to TCC and DIC 
flow cells with subsequent increases in soluble (or free) cephalexin (Figures 6.18 & 6.19). A 
comparative study using both DIC and TCC sensor chip surfaces and monoclonal antibody 
was carried out in order to assess any potential difference in inhibition assay performance 
between the two surfaces. The assays were carried out in an identical manner for both 
surfaces using monoclonal antibody and cephalexin-‘spiked’ PBS-T. The results of this 
further suggested, in conjunction with non-specific interaction analysis, that the DIC sensor 
chip was the optimal format for further assay development. The inhibition assay using 
polyclonal mti-CephPl antibody was unexpectedly found to have intrinsically high variation 
with a large degree of binding to the reference flow cell. Online reference subtraction was 
employed in assay development and highlighted the fact that a large percentage (<50% at 
worst) of polyclonal response was non-specific in nature (Figure 6.22). This high non-specific 
response was only observed using protein G-purified polyclonal antibody. The apparent 
‘sticky’ nature of the purified polyclonal antibody contributed to the high relative standard 
deviation and in turn the higher estimation of the limit of detection in comparison with its 
performance in the ELISA-based assay (20 ng/ml).
Monoclonal anti-CephMl antibody described in chapter 4 of this thesis was also used to 
develop a Biacore inhibition assay for the detection of cephalexin in milk. Inter-day assay 
variability studies were carried out using protein G-purified monoclonal and ‘spiked’ milk 
that had been pre-treated by ‘de-fatting’ and ‘de-wheying’. In contrast to the polyclonal 
antibody-based assay, minimal non-specific interaction (<2%) was observed with reference 
flow cell surface. The limit of detection was below the defined MRL value at 72 ng/ml 
(Figure 6.23). The monoclonal assay was reproducible and had low coefficients of variation 
(<10%), in addition the calculated percentage accuracies (i.e. sample recovery) were 
acceptable over the concentration range of standards (Table 6.2).
Other beta-lactam antibiotic Biacore-based detection techniques have been reported in the 
literature with varying degrees of success in terms of sensitivities. Gaudin et al. (2001) 
reported a polyclonal antibody-based assay for the detection of penicillin residues in milk 
using the Biacore X system. The assay was not capable of detecting cephalosporins among
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other beta-lactams, due to the antibodies used. The authors do, however, suggest that the 
particular antibody is the limiting factor in applying such biosensor systems to the analysis 
beta-lactam antibiotics in biological matrices. The antibody (polyclonal anti-ampicillin) 
binding response to open and closed ring ampicillin was different due the unstable nature of 
some beta lactam antibiotic ring structures (may be readily opened by hydrolysis, enzymatic 
or chemical means). This is particularly true of ampicillin, which they used to directly 
immobilise onto Biacore CM5 chip surface. The assay sensitivity was dependant on the 
particular antibody binding response to open and closed forms of the antibiotic.
A generic beta-lactam Biacore-based detection approach was taken by Cacciatore et al. 
(2004). They report the use of immobilised digoxigenin antibody, a penicillin binding protein 
(PBP2x*) to form complexes with a range penicillin and cephalosporins and a digoigenin- 
labelled (DIG-Amp) ampicillin conjugate. An inhibition assay format was used where sample 
was pre-incubated with PBP2x*, followed by incubation with DIG-Amp. In the presence of 
free beta-lactam there would be a decrease in the binding of PBP-DIG-Amp complex to the 
immobilised digoxigenin antibody. This method was successful for detecting a wide range 
beta-lactam antibiotics at quoted MRL values in milk samples. These included 
benzylpenicillin, ampicillin, amoxicillin, cloxacillin, cephalexin, and cefoperazone.
IMAC-purified recombinant antibodies (WT, C5, H3) described in chapter 5 were also used 
in the development of a Biacore inhibition assay for the detection of cephalexin. The optimum 
scFv in terms of assay performance was found to be the one expressed by mutant C5. This 
corroborates the findings for comparative ELISA-based assays, as described in chapter 5, 
section 5.2.4.3. The WT and H3 scFvs were capable of detecting cephalexin over a range of 
concentrations, yet had limits of detection (111 & 146 ng/ml, respectively) above the defined 
MRL of 100 ng/ml for cephalexin in milk. This was best illustrated in the overlay plot of the 
three different assays, as shown in figure 6.27.
The monoclonal and mutant C5 scFv (Figure 6.28) antibody-based inhibition assays presented 
in this chapter offer a reliable analytical method for the specific detection of cephalexin 
hydrate in ‘spiked’ processed milk. The limits of detection (LOD) of the monoclonal and C5 
scFv antibody-based assays were found to be 72 ng/ml (Figure 6.23) and 84 ng/ml 
respectively. The detection limits for the monoclonal and C5 scFv antibodies are 
approximately equivalent to those described for the ELISA assays (60 ng/ml and 78 ng/ml 
respectively). The detection limits for each assay are below the required sensitivity as set out 
by the European Union maximum residue limit (MRL) of 100 ng/ml for cephalexin in milk 
(EEC council regulation No 2377/90).
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Chapter 7
Overall conclusions
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7.1 Overall conclusions
The purpose of this work was to develop an assay for the detection of the P-lactam antibiotic 
residue, cephalexin, in milk. Initial studies focused on the production and characterisation of 
polyclonal antibody to cephalexin, as described in chapter 1. Cephalexin-based protein 
conjugates were produced and characterised by non-competitive ELISA using a cephalexin- 
specific polyclonal antibody (designated AVAab) that was kindly donated by Dr. Aart van 
Amerongan. The non-competitive ELISA using AVAab was carried out to confirm the 
cephalexin had been covalently linked to the respective carrier protein and was still in a 
detectable configuration. A polyclonal antibody was produced that bound free and conjugated 
cephalexin. This confirmed that the cephalexin conjugates produced were satisfactory 
immunogens for the production of cephalexin-binding antibodies.
The polyclonal antibody was purified using saturated ammonium (SAS) precipitation, 
followed by protein-G affinity chromatography from rabbit serum. The purity of antibody 
preparation was assessed by SDS-PAGE analysis and Western blotting. It was found that the 
purified anti-CephPl polyclonal antibody recognised all of the cephalexin conjugates in a 
non-competitive ELISA format. Polyclonal antibody was subsequently used in the 
development of an inhibition ELISA assay for the detection of free cephalexin in solution (i.e. 
un-conjugated cephalexin). The anti-CephPl polyclonal antibody binding to cephalexin- 
conjugate was inhibited in the presence of free cephalexin. Initially an inhibition assay was 
developed using PBS to prepare cephalexin standards, following this cephalexin standards 
were prepared in whole milk (i.e. ‘spiked’ processed milk).
The best comparative linear range of detection for the inhibition ELISA was found to be from 
1.9 ng/ml to 3906 ng/ml. Intra- and inter-day assay variability studies in PBS had limits of 
detection (LOD) of be 20ng/ml. The LOD’s were below the required European Union 
maximum residue limit (MRL), currently set at 100ng/ml for cephalexin in milk samples, as 
set out in EEC council regulation No 2377/90. Inter-day assay variability studies carried out 
in cephalexin ‘spiked’ whole milk showed the assay LOD was below the EU-MRL, at 
approximately 20 ng/ml for the inhibition assay. The limits of detection achieved were 
comparable to other reported methods for antibiotic residue detection.
The Delvo® SP which is the standard rapid method of detection (Irish government, 
Department of Agriculture and Food, DAF) has a quoted sensitivity to cephalexin of 40-60 
ng/ml. The anti-CephPl polyclonal antibody described in this chapter is specific, as 
demonstrated by the minimal cross-reactivity with similar P-lactam compounds and it is
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capable of detection below that limit. However, PBS and milk assays performed poorly in 
terms of assay reproducibility, with relatively high standard deviation between assay 
replicates and individual measurements. In addition, there was a finite supply of homogenous 
antibody population which would limit its application in such assays.
Chapter 4 described the production, purification and characterisation a monoclonal antibody 
against cephalexin. The spleens of previously immunised mice were removed and the 
lymphocytes extracted for in vitro somatic cell fusion procedures. Hybridoma cell populations 
secreting antibody with the highest absorbance values were selected, scaled up and used in the 
development of an inhibition ELISA for the detection of cephalexin. An IgG2a-K antibody 
subtype (anti-CephMl) was isolated and purified. It was discovered that binding of 
monoclonal antibody to immobilised conjugated cephalexin was inhibited over a range of 
soluble cephalexin concentrations. The antibody specificity was further analysed using a 
range of closely related (3-lactam compounds and was found to be highly specific to 
cephalexin. However, the percentage cross-reactivity observed using cefadroxil and 
cefoperazone, in conjunction with results of the polyclonal antibody (Chapter 3) indicate that 
the probable epitope consists mainly of the three double bonded oxygens and the aromatic 
ring-containing side chain. The lack of significant cross reaction of both anti-CephPl and 
anti-CephMl antibodies with the core cephem structure of 7-amindesacetoxy-cephalosporanic 
acid indicated this to be the case.
Protein G-purified anti-CephMl showed inhibition in ELISA with standards of free 
cephalexin prepared in PBS-T and whole milk. The assays were linear over a range 61 ng/ml 
to 7812 ng/ml in PBS and 30 ng/ml to 15625 ng/ml in whole milk. The limit of detection 
(LOD) for the inhibition assay was 60 ng/ml in whole milk prepared samples. The milk assay 
showed increased linearity which may be due to increased antibody solubility and stability in 
a more complex biological matrix. The anti-CephMl antibody specificity limits its application 
to the specific detection of cephalexin, as opposed to the broadly specific range of compounds 
detected by the Delvo® SP. The lack of commercially available generic antibodies to 
antimicrobial compounds and the difficulty in generating such antibodies suggests that an 
assay incorporating several different antibodies is the optimum approach for developing a 
multianalyte detection technique. In conclusion, the assay is capable of the specific detection 
of cephalexin in ‘spiked’ pasteurised whole milk. The assay performance also permits the 
detection of cephalexin at the current EUMRL, for cephalexin in milk (100 ng/ml). The main 
benefit of the monoclonal antibody (anti-CephMl) is its specific nature. If used as a working 
diagnostic reagent it would however need to be complemented with other antibodies for the 
detection of a broad range of P-lactam antibiotics.
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Recombinant scFv antibody production and engineering techniques based on phage-display 
methodologies were used, as described in chapter 5. In summary, the BMV human naive 
phage-scFv antibody library was panned with cephalexin conjugates and two immunised 
phage display libraries were produced (Krebber et al., 1997). No scFv were isolated that 
recognised the soluble (i.e. un-conjugated) (i-lactam antibiotic residue. Results indicated 
showed that the immune library clones did contain scFv gene construct. However, the 
sequence diversity and hence the variety of binding function was most probably too small. 
This could not be fully enumerated without sequencing all the resulting transformants, which 
for the purposes of this work was impracticable. The lack of potential cephalexin-specific 
scFvs within the two libraries may be due to the small library sizes obtained.
The hybridoma cell line produced in chapter 4 of this work was used as a genetic source for 
scFv production. Positive phage-scFvs were produced, identified and bound free-cephalexin, 
as demonstrated in inhibition ELISA. The scFv gene construct was purified from one of the 
picked clones and sub-cloned into the pAK400 vector for enhanced soluble expression. The 
expression was induced with IPTG and scFv production was monitored by a SDS-PAGE and 
Western blotting. The cephalexin-specific scFv (termed wild type) was successfully purified 
by Ni2+-NTA immobilised metal affinity chromatography (IMAC).
Following isolation and purification of the wild type (WT) scFv by IMAC, an inhibition 
ELISA for the detection of cephalexin in ‘spiked’ processed milk samples was developed. 
The assay was not as sensitive as the parental monoclonal IgG antibody (Chapter 4) resulting 
in a limit of detection (LOD) of 143.3 ng/ml, compared to 60 ng/ml for the intact monoclonal 
IgG. It is probable that the reduced assay sensitivity may be due to avidity effects, going from 
a divalent intact IgG to a predominantly monovalent scFv.
The wild type scFv gene was sequenced and the complementarity determining regions (CDR) 
were identified using the National (US) centre for Biotechnology information Ig Blast tool 
(http://www.ncbi.nlm.nih.gOv/igblast/~). The wild type scFv gene sequence was found to be 
98.3% homologous to the murine sequence number AJ231205 from the crl germline gene 
sequence (Thiebe et al., 1999), the heavy chain scored 95.8% homology with the Balb/c 
VH7183 gene family, as characterised by Williams et al. (2001). A model of the WT scFv 
protein was produced using the SWISS-Model protein modelling website, the SWISS-Model 
system and PDB software (Pietsch, 1995; Guex and Pietsch 1997; Schwede et al., 2003).
The cephalexin-specific wild type (WT) scFv gene was used as a template for random 
mutagenesis procedures (Coia et al., 2001 and Korpimaki et al., 2002; Razai et al., 2005).
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Intra-gene sequence shuffle (Rl*) and error-prone PCR (R2*) phage-display libraries were 
constructed by ligation of mutated scFv gene constructs into the pAKlOO phagemid vector. 
The ligation products were used to transform E. coli electrocompetent cells. The number of 
transformants obtained was of the order of 1.4 x 107 for Rl* and 2.3 x 106 for R2* libraries, 
respectively. The two libraries were panned and conjugate bound phage-scFvs were initially 
competitively eluted by adding un-conjugated cephalexin followed by elution with glycine.
Nascent phage-scFvs were singled out and sub-cloned into pAK400 vector for subsequent 
soluble expression. Two clones (C5 and H3) with the most promising improvements in terms 
of inhibition ELISA sensitivity were purified by IMAC chromatography. IMAC-purified 
mutant scFv antibody fragments were used in an inhibition ELISA for the detection of 
cephalexin hydrate in ‘spiked’ processed milk samples (section 5.2.4.3). The mutant C5 clone 
scFv displayed two-fold increased assay sensitivity in comparison with wild type. The mutant 
H3 scFv was not as sensitive at lower cephalexin concentrations, but it had a higher titre and a 
lower IC50 value compared to original wild type (1.2 fold lower).
The comparative (wild type and C5 mutant) amino-acid sequence point mutation (section 
5.2.4.4) for the CDRHi consisted of the replacement of a serine (S) with an asparagine (N) 
residue. The two residues are polar and hydrophilic. However, for the CDRh3 point mutation a 
wild type leucine (L) was replaced by a glutamine (Q) residue. This represents a change from 
a non-polar hydrophobic (L) to a polar hydrophilic (Q) based residue. From sequencing 
results it was found that the H3 clone had point mutations in the framework regions. 
However, there were no observed mutations in any CDR regions when compared to the WT 
clone. The C5 scFv amino acid sequence had point mutations in the variable CDRHi and 
CDRH3 regions. This supports the established concept that the majority antigen binding 
interactions are conferred by the variable heavy chain complementarity determining regions. 
The mutant clone C5 scFv ELISA limit of detection was found to be 1.8 fold lower from a 
value of 143.3 ng/ml for the original wild type scFv, to 77.9 ng/ml for the mutant C5 scFv. 
The C5 scFv was the best scFv produced in terms of expression, functional stability and assay 
performance, capable of cephalexin detection below the 100 ng/ml EUMRL for milk.
The polyclonal (Chapter 3), monoclonal (Chapter 4) and recombinant scFv (Chapter 5) 
antibodies produced in this work were used to develop assays for the detection of cephalexin 
in milk using a BIAcore 3000™ system. In this research, CM5 sensor chips were used in the 
production of immobilised cephalexin-thyroglobulin and directly immobilised cephalexin 
surfaces. The TCC, DIC and relevant control surfaces were evaluated in terms of antibody 
binding and non-specific interactions with milk as a sample matrix prior to assay
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development. Milk sample pre-treatment was also investigated as a means of reducing the 
background response observed when using a complex sample matrix. Sample treatment 
further reduced the non-specific binding with TCC and DIC flow cell surfaces. The milk 
sample pre-treatment method employed was a modified version of that reported by 
Gustavsson (2003). The DIC sensor surface and milk sample pre-treatment resulted in an 
average 95% decrease in non-specific response in comparison with the TCC surface. The 
directly immobilised cephalexin flow cell surface was found have the lowest background 
response to milk samples in comparison with the thyroglobulin-cephalexin immobilised 
(TCC) flow cell surface.
The inhibition assay format (Figure 6.17) chosen was generally reported in the literature when 
using SPR-based biosensor devices for the detection of low molecular weight analytes. A 
comparative study using both DIC and TCC sensor chip surfaces and monoclonal antibody 
inhibition assays performance between the two surfaces suggested, in conjunction with non­
specific interaction analysis, that the DIC sensor chip was optimum for further assay 
development. The inhibition assay using polyclonal anti-CephPl antibody was found to have 
intrinsically high variation with a large degree of binding to the reference flow cell. Online 
reference subtraction was employed in assay development and highlighted the fact that a large 
percentage («50% at worst) of polyclonal response was non-specific in nature (Figure 6.22). 
This high non-specific response was only observed using protein-G purified polyclonal 
antibody. The apparent ‘sticky’ nature of the purified polyclonal antibody contributed to the 
high relative standard deviation and in turn the higher estimation of the limit of detection in 
comparison with its performance in the ELISA-based assay. The polyclonal antibody was not 
applicable to developing a reproducible assay using this system.
Inter-day assay variability studies using aati-CephMl monoclonal antibody, in contrast to the 
polyclonal antibody-based assay, showed minimal non-specific interaction (<2%) was 
observed with DIC reference flow cell surface. The limit of detection was below the required 
MRL value at 72 ng/ml. The monoclonal assay was reproducible and had low coefficients of 
variation (<10%), in addition the calculated percentage accuracies (i.e. sample recovery) were 
acceptable (i.e. within 20% of actual value) over the concentration range of standards.
IMAC-purified recombinant antibodies (WT, C5, H3) described in chapter 5 were also used 
in the development of a BIAcore inhibition assay for the detection of cephalexin. The 
optimum scFv in terms of assay performance was found to be the one expressed by mutant 
C5. This corroborates the findings for comparative ELISA-based assays, as described in 
section 5.2.4.3. The WT and H3 scFvs were capable of detecting cephalexin over a range of
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concentrations, yet had limits of detection (111 & 146 ng/ml, respectively) above the MRL 
for cephalexin in milk of 100 ng/ml. The monoclonal and mutant C5 scFv antibody-based 
inhibition assays developed in this work offer a reliable analytical method for the specific 
detection of cephalexin hydrate in ‘spiked’ processed milk. In addition, the mutant libraries 
produced may offer a potential source of specific scFv antibodies to different P-lactams.
Future work arising from this research, and currently underway, is the incorporation of the 
antibodies described into novel assay formats including the development of fluorescent-based 
arrays. The application of such arrays in a ‘user-friendly’ portable sensing device for ‘on-site’ 
measurement of antibiotic levels in individual cows is currently being investigated. This work 
involves a multidisciplinary collaboration between biologists, physical chemists, physicists 
and engineers. It highlights the need for teams of experts for the generation of ‘state-of-the- 
art’ nanotechnology-based devices that can have significant impacts on animal and human 
health. It is envisaged that such a device will facilitate more stringent control on the use 
antibiotics hence should limit their potential to enter the food chain via bovine milk and 
associated products.
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Appendix 1
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Council Regulation (ECC) No 2377/90 
O f the 26th June 1990
laying down a community procedure for the establishment of maximum residue limits of 
veterinary medicinal products in foodstuffs of animal origin 
(O J L 224,18.8.1990, p l4)
adapted fro m  ANNEX 1 
List o f pharmacologically active substances for which maximum residue limits have been fixed
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues
Other
provisions
TM 91 Cefacetrile Cefacetrile Bovine 125 (ig/kg Milk
For intra­
mammary 
use only
▼M71 Cephalexin Cephalexin Bovine
200 ng/kg 
200 ng/kg 
200 ng/kg 
1000 ng/kg 
100 ng/kg
Muscle
Fat
Liver
Kidney
Milk
TM 100 Cefalonium Cefalonium Bovine 20 jig/kg Milk
▼M87 Cefapirin
Sum of cephapirin and 
Desacetylcephapirin
Bovine
50 |ig/kg 
50 ng/kg 
100 ng/kg
Muscle
Fat
Kidney
